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Abstract 
Human metapneumovirus (hMPV) is a newly described respiratory virus belonging to the 
Paramyxoviridae family, first identified in respiratory samples of children with acute 
respiratory tract infection (ARTI). Since its discovery hMPV has been associated with 
AR TI worldwide, however, important questions remain as to the contribution of hMPV to 
respiratory illness, and its impact on public health. 
Extensive surveillance of hMPV within different populations of the United Kingdom (UK) 
demonstrates it is an important cause of ARTI in the elderly, and influenza like illness 
(ILl) in people of all ages in the community. Furthermore it is a frequent cause of 
hospitalisation in young children. 
Recombinant baculovirus expressed hMPV nucleocapsid protein (N) proved to be a useful 
source of antigen for the development of an hMPV specific ELISA. Analysis of age 
stratified sera from the UK indicates that a majority of children are infected by the age of 6 
years with primary infections occurring throughout infancy. Virtually all adults have 
detectable levels of hMPV antibody; however, reinfection with hMPV is common, raising 
questions concerning acquisition and duration of immunity. 
Sequence analysis of the attachment glycoprotein (G), shows a high degree of nucleotide 
and amino acid variation and extensive glycosylation. Frequent nucleotide insertions or 
deletions result in frame shift mutations which can drastically alter the appearance of the 
protein and often results in premature termination. Antibody recognition of hMPV G is 
likely to be highly strain specific and dependent on the extent of glycosylation, suggesting 
an involvement of G in immune evasion. 
Phylogenetic analysis of hMPV G gene sequence shows that whilst a large degree of 
variation exists within this gene, strains circulating within the UK are genetically similar to 
strains circulating elsewhere in the world, and similar strains circulate throughout different 
years and populations within the UK. 
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Chapter 1 
General Introduction 
Chapter 1 - General Introduction 
1.1. Newly identified or emerging viruses 
Over the past 30 years the number of newly emerging, re-emerging or identified viral 
pathogens has risen considerably in both humans and animals. Viral pathogens are of a 
particular concern to human and animal health· because of their enormous contribution to 
burden of disease, the limited availability of antiviral treatments, their rapid adaptability to 
environmental change, acquisition of antiviral resistance, and the potential for zoonotic 
transmission. 
The underlying causes for the emergence of new viruses are due to generalized social 
changes (urbanization, IV drug use and sexual practices), ecosystem disturbance (increased 
human mobility, civil unrest, deforestation, and hunting), economic and commercial trends 
(intensive farming, farming practices, global trade, and exotic meat trade), medical 
interventions (organ transplant, blood transfusion, antibiotics and antivirals) and climatic 
change (global warming) (Kuiken et al., 2003a). As a result many viral pathogens, for 
example; HIV; SARS coronavirus; Ebola; Marburg; West Nile virus and Avian Influenza, 
have expanded their host range or ability to transmit to new species. 
Other new viruses however, have arisen, or rather; have been discovered as a result of 
improved diagnostic efforts in the search for previously unidentified etiological agents or 
in the hunt for host reservoirs of newly emerging diseases. These new viruses are therefore 
often classed as newly identified (having been present in the host species for a number of 
years) rather than newly emerging (human coronavirus NL63(van der Hoek et al., 2004), 
human metapneumovirus (hMPV)(van den Hoogen et al., 2001), and human coronavirus 
HKUl(Woo et al., 2005)). The most recent of which is human bocavirus (hBoV) a newly 
identified parvovirus associated with LRTI (Allander et al., 2005). 
Both newly emergmg and newly identified VIruses are of great importance and 
investigations into these new agents are vital for evaluating their potential threat to a 
species or population, their contribution to burden of disease, and potential benefit of 
antiviral or vaccine development. 
1.2. Acute respiratory tract infections 
Acute respiratory tract infections (ARTI) m humans are one of the leading causes of 
morbidity and mortality worldwide, and as such have enormous economical implications 
1 
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(Monto, 2002). A wide range of viruses, bacteria and fungi are associated with respiratory 
illness, and therefore an accurate diagnosis of infection is vital for correct patient 
management, and the implementation of preventative strategies such as vaccination. 
Despite this however more than 50% of patients with ARTI each year are not assigned a 
cause (Louie et aI., 2005, Zambon et aI., 2001). This may be attributed to diagnostic 
limitations, lack of recognition by existing detection methodologies and by still unknown 
pathogens. 
A large number of viral pathogens from a number of virus families have been associated 
with respiratory illness including the Adenoviridae, Coronaviridae, Orthomyxoviridae, 
Paramyxoviridae and Picornaviridae families (Table 1.1). 
Table 1.1 Characteristics of selected human respiratory viruses. 
Virus famil~ Viruses Genome Virion Structure 
Adenoviridae Adenovirus a Double stranded Non- enveloped 
DNA 30-42Kb Icosahedral 
capsid 
Coronaviridae NL63, 229E, OC43, Single stranded Enveloped 
SARS positive sense RNA Helical capsid 
27-32Kb 
Orthomyxoviridae Influenza Ab, Band C Segmented negative Enveloped 
sense RNA 12-15 Kb Helical capsid 
Paramyxoviridae Parainfluenza virus C Single stranded Enveloped 
Respiratory syncytial negative sense RNA Helical capsid 
• d 13-16Kb VIrus 
Picornaviridae Human rhinoviruses e Single stranded Non-enveloped 
E . f positive sense RNA Icosahedral nteroviruses 
7.2-8.4 Kb caEsid 
Footnotes: (a): At least 51 serotypes are known. (b): Divided into further subtypes. (c): 4 subtypes known. 
(d): 2 Subtypes known. (e): More than 100 serotypes are known. (t): More than 71 serotypes are known 
Many of the newly emerging or newly identified viruses over the past 30 years belong to 
these families and have been associated with respiratory tract infections (RTI) in humans. 
The focuses of this thesis is on the recently identified respiratory pathogen, human 
metapneumovirus (hMPV). At the start of this research very little was known about hMPY 
but over the past 5 years there has been a great deal of work on this virus. This introduction 
gives an overview of Human metapneumovirus and the different aspects of work that have 
been reported since its discovery. 
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1.3. The newly identified human metapneumovirus (hMPV) 
In 2001 human metapneumovirus (hMPV) was identified by van den Hoogen et al in the 
Netherlands (van den Hoogen et aI., 2001). HMPV was detected in nasopharyngeal 
aspirates taken from 28 epidemiologically unrelated children over a 20 year period 
presenting with RTI using a combination of cell culture isolation, electron microscopy, and 
random polymerase chain reaction (PCR) techniques. HMPV has since been reported 
worldwide. Although newly identified, serological evidence of hMPV infections dating 
back to 1958 has been reported indicating hMPV has been present in the human population 
for at least the last 50 years (van den Hoogen et aI., 2001), viral isolation over the past 10 
to 20 years has also been reported in Europe and North America (Boivin et aI., 2002, van 
den Hoogen et aI., 2001) . 
HMPV has been associated with ARTI in people of all ages, but is especially prevalent in 
young children, where 1-25% of respiratory tract infections have been associated with 
hMPV. Seroloprevalence studies indicate that virtually all children have been infected by 
the age of5- 10 years (Ebihara et aI., 2003, van den Hoogen et ai., 2001, Wolfet ai., 2003). 
The detection of hMPV in people of all ages suggests that despite universal infection in 
childhood repeated infections occur throughout life. This is likely to be due to 
incompletely protective immune responses and virus diversity (Peret et ai., 2002). 
HMPV has a seasonal distribution typical of a majority of respiratory viruses. In temperate 
countries most cases are reported during the winter and spring months, whilst in sub-
tropical countries peak activity occurs in the spring and early summer. Phylogenetic 
analysis shows that there are two lineages of hMPV; A and B, each with at least 2 sub-
lineages (AI, A2 and BI, B2) (Bastien et ai., 2003, Mackay et ai., 2004). It has recently 
been reported that an additional A sub-lineage (A3) may exist (Huck et aI., 2006). The two 
subtypes of hMPV have been shown to co-circulate at the same time in the same 
geographical locations. As yet there is no evidence to suggest that these subtypes are 
associated with differences in severity of disease. A more detailed discussion regarding 
hMPV epidemiology is presented in chapter 3 of this thesis. 
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Based on sequence homology and gene order hMPV was placed as the first human member 
of the mefapneumovirus genus of the subfamily Pneumovirinae, of the family 
Paramyxoviridae as illustrated in Figure 1. 
1.4. The Paramyxoviridae Family 
The Paramyxoviridae contain some of the most infectious viruses known for both humans 
and animals such as measles, mumps, distemper, Newcastle disease, parainfluenza (PIV), 
and respiratory syncytial virus (RSV), Paramyxovirus infections are therefore extremely 
costly in terms of burden of disease in both animals and humans and subsequent economic 
impact. Over the last decade several new members of the family in addition to hMPV have 
been identified mostly in animals such as snakes (Franke et aI., 2001), fish (K vellestad et 
aI., 2003), shrews (Tidona et aI., 1999), and pigs(Philbey et aI., 1998). Others such as the 
Nipha and Hendra viruses have been found in both animals and humans and shown to 
cause serious respiratory and neurological illness (Chua et aI., 1999, Murray et ai., 1995). 
The Paramyxiviridae belong to the order of Monoegaviriales along with the Filovoviridae, 
which include the Marburg and Ebola like viruses, Rhabdoviridae which includes the 
lassaviruses such as rabies, and Bornaviridae whose sole member is the borna disease 
virus. The Paramyxiviridae are divided in to 2 subfamilies the Paramyxovirinae, which 
contains 5 genera, and the Pneumovirinae, which contains 2 genera (Figure 1.1) (Blichen-
Osmond, 2001 onwards). The classification of these viruses is based on morphological 
criteria, genome organisation, biological activities of the viral proteins, and sequence 
relationships. 
4 
Chapter 1 - General Introduction 
Paramyxoviridae 
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Paramyxovirinae 
/ 
Respirovirus 
hPIVI 
hPIV3 
SeV 
Rubulavirus 
SV5 
MuV 
hPIV2 
/ 
Avulavirus 
NOV 
/ Henipahvirus 
! 
HeV 
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hPIV 4 ,-'1 Morbillivirus 
! 
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... ,/ 
) 
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J 
/ 
,/ 
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Pneumovirinae 
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Pneumovirus 
hRSV 
bRSV 
PVM 
Metapneumovirus 
APV (TRTV) 
hMPV* 
Figure 1.1: Schematic representation of Paramyxoviridae taxonomy. Abbreviations: 
hPIV: human parainfluenza, SeV: Sendai virus, SV5: Simian virus 5, MuV Mumps virus, CDV: 
Canine distemper virus; PDV porcine distemper virus; HeV: Hendra virus; NiV: Nipah virus; 
NDV: Newcastle disease virus; RSV: respiratory syncytial virus; PVM: Pneumovirus of mice; 
APV: Avian Pneumovirus; TRTV: Turkey Rhinotracheitis virus hMPV: Human Metapneumovirus 
(8 lichen-Osmond, 2001 onwards). 
1.4.1. The Pneumovirinae Subfamily 
The Pneumovirinae subfamily contains two genera, the Pneumoviruses for which human 
respiratory syncytial virus (hRSV) is the prototype and the Metapneumovirus for which 
avian pneumovirus (APV) is the prototype, which are described below. Where the term 
Human Pneumovirinae is used it refers to hMPV and hRSV. 
1.4.2. Avian Pneumovirus (APV) 
APV is the closest genetic relative to hMPV and is the only other member of the 
metapneumovirus genera. APV is the cause of severe respiratory infection in turkeys and 
was first identified in South Africa in the 1970s (Buys & Preez, 1980), but has since been 
found world wide in a range of birds such as chicken, ducks (Shin et aI., 2002, Toquin et 
aI., 1999), ostrich (Cadman et aI., 1994), geese and pheasant (Gough et aI., 1988). To date 
there are 4 subtypes of APV (A to D). Subtype C is most closely related to hMPV(van den 
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Hoogen et aI., 2001). APV C outbreaks occur mainly in the spring and autumn and the 
spread of disease to domestic poultry has been associated with migratory birds (Shin et aL 
2000). For industry this disease has devastating consequences and as such has been the 
focus of much research on the detection, prevention and treatment of the disease (Cook, 
2000, Cook & Cavanagh, 2002, Njenga et aI., 2003). The close genetic relationship of 
hMPV and APV C suggests that hMPV may have appeared in the human population as a 
result of zoonosis. Juvenile turkeys experimentally infected with hMPV however did not 
support virus replication. Together with data showing serological evidence of hMPV in the 
human population for at least the past 60 years this suggests any zoonotic event that may 
have occurred will have happened over 60 years ago (van den Hoogen et aI., 2001). 
1.4.3. Human Respiratory Syncytial Virus (hRSV) 
hRSV belongs to the pneumovirus genus and is the closest human virus relative to hMPV 
(van den Hoogen et aI., 2001). hRSV was first isolated in 1956 from a symptomatic 
chimpanzee (Blount et aI., 1956), and shortly after from infants with respiratory 
disease(Chanock et aI., 1957). hRSV is prevalent world wide and is now known to be the 
most important cause of lower respiratory tract infection (LR TI) in young children with 
90% having been infected by the age of 2 years (reviewed by (Collins et aI., 2001). There 
are 2 groups of hRSV A, and B, which co-circulate primarily during the winter and spring 
months. Some reports suggest that viruses belonging to different groups differ in 
pathogenicity, however other reports have contradicted this (Hornsleth et aI., 1998, 
McIntosh et aI., 1993, Walsh et aI., 1997). Reinfection with homologous and heterologous 
strains of hRSV occurs frequently throughout a person's lifetime but are usually limited to 
the upper respiratory tract. However hRSV may cause pneumonia in elderly and 
immunocompromised individuals (Collins et aI., 2001). 
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1.5. Pneumovirinae structure 
G 
N 
P 
RNA 
Figure 1.2 Schematic of the Pneumovirus particle adapted from (Easton et aI., 2004). The 
Proteins of the RNP complex (N, P, Land M2-I) associate with the genomic RNA to form a helical 
structure. THE RNP complex is surrounded by the matrix protein and a lipid envelope in to which 
the viral glycoproteins G, F and SH are inserted. 
Visualisation of Pneumovirinae virions by electron microscopy (EM) shows virus particles 
that have an irregular spherical or filamentous shape of approximately 150 to 300nm in 
size. Virions consist of a nucleocapsid core displaying helical symmetry. The core of the 
virion consists of the RNA genome which is associated with the nucleocapsid (N) protein, 
phosphoprotein (P), polymerase (L), and M2-1 proteins which form the ribonucleoprotein 
(RNP) complex. A lipid bi-Iayer envelope derived from the host cell plasma membrane 
surrounds the virions. Inserted into the envelope are 3 virally encoded transmembrane 
glycoproteins; the attachment glycoprotein (G), the fusion protein (F), and the small 
hydrophobic protein (SH) which are organised on the envelope surface and appear as short 
surface projections of approximately II-20nm in length by EM. Residing between the 
RNP complex and the lipid envelope is the viral matrix protein (M) which interacts with 
both the RNP complex and the internal regions of the surface glycoproteins (Collins et aI. , 
2001). 
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1.6. Genome structure and organisation 
The hMPV genome consists of a single negative strand of RNA approximately 13kb in 
length. It contains 8 genes, which encode for 9 proteins, based on homology with hRSV 
and APV. From 3' to 5' these are the nucleocapsid protein (N), phosphoprotein (P), matrix 
protein (M), fusion protein (F), M2 which encodes for the transcription elongation factor 
(M2-1), and the RNA synthesis regulatory factor (M2-2), small hydrophobic protein (SH), 
attachment glycoprotein (G), and the large polymerase protein (L) (van den Hoogen et aI., 
2001). The 3' and 5' ends of the genome encode regulatory sequences termed the leader 
and trailer sequences. The 3' leader sequence in the genome sense RNA directs replication 
and transcription, while the 5' end trailer sequence (3' in anti genome sense) directs 
replication. At the start of each transcribable gene there is a gene start signal (GS), at 
which transcription initiates, and at the end a gene end sequence (GE), at which point 
transcription terminates (Collins et aI., 2001 , Easton et aI., 2004) 
hMPV13Kb 
3 '1 N Hr----p ---'H M ~L..--_F ---,H M2 ~ SH ~I.-.-_G ---'~I...--_L_--,~5' 
hRSV 15kB 
3 ' -1 NSI ~L-..N_S2.......J~IL-._N --I~L. _p---'~L-..M---ILI_SH---L..-I _G ~~L _F--.J~L-.Ml---"I:!..I __ L_----1r 5' 
Figure 1.3 Schematic of hMPV and hRSV genome organisation. 
There are a number of notable differences between the genomes of hMPV and hRSV, 
which separate them in to their different genera. The ftrst is that hRSV contains two non-
structural genes; NS-l and NS-2 at the 3' end of the genome. These genes are thought to 
playa role in antagonising host antiviral interferon responses (Bossert & Conzelmann, 
2002, Spann et aI., 2005), and the lack of these in hMPV may be associated with the 
typically milder course of illness and the difficulties in isolating hMPV in cell culture. The 
gene order also differs between the two genera. As shown in Figure 1.3 the F and M2 
genes of hMPV are located closer to the 3' end of the hMPV genome than in hRSV. This 
may affect the relative quantities of the different proteins produced during infection due a 
transcription gradient, which occurs in all single stranded negative sense RNA viruses. The 
hRSV genome also contains an overlapping open reading frame in the M2 and L genes that 
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is not present in hMPV. Thirdly the length of the putative open reading frames (ORF) 
differs between members of the Pneumovirinae, as shown in Table 1.2. 
Table 1.2 Lengths in amino acid residues of the putative ORFs of hMPV, hRSV and 
APVC 
Virus Amino acid length 
N P M F M2-1 M2-2 SH G L 
hMPV 394 294 254 539 187 71 183 236 2005 
hRSV 391 241 256 574 194 90 64 298 2165 
APVC 394 294 254 537 184 71 175 585 2005 
1. 7. Virus proteins 
1.7.1. The Ribonucleoprotein (RNP) Complex 
The 3 major proteins of the RNP complex N, P and L are the minimum trans-acting 
requirements for Pneumovirinae (proteins required for efficient first round replication in 
the reverse genetics system), and co-localise with the RNA genome in cytoplasmic 
inclusions of infected cells to form the RNP complex (Grosfeld et aI., 1995, Teng & 
Collins, 1998, Yu et aI., 1995). 
1.7.2. The N Protein 
The N proteins of the Paramyxoviridae form an integral part of the RNP complex and is an 
essential for transcription and replication (Grosfeld et aI., 1995, Teng & Collins, 1998, Yu 
et aI., 1995). It binds to viral genomic and anti-genomic RNAs to form an RNAse resistant 
nucleocapsid and is thought to be responsible for giving the genome its helical structure 
(Bhella et aI., 2002, Easton et aI., 2004, Fooks et aI., 1993, Meric et aI., 1994). The N 
protein ofhMPV contains 394 amino acids with an estimated molecular mass of 43.5KDa, 
consistent with that of other Pneumovirinae (Barr et aI., 1991, van den Hoogen et aI., 
2002). It is highly conserved showing 98-100% amino acid homology between hMPV 
strains within the same lineage, and 94-96% between lineages and shares 69-89% amino 
acid identity with different members of the APV, and 42-44% with hRSV (Bastien et aI., 
2003). 
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1.7.3. The P protien 
The P proteins of the Paramyxoviridae also form part of the RNP complex and is also 
essential for transcription and replication (Grosfeld et aI., 1995, Teng & Collins, 1998, Yu 
et aI., 1995). The P protein of hMPV is the major phosphorylated species and is comprised 
of 294 amino acids, with a predicted molecular mass of 32.5KDa (van den Hoogen et aI., 
2002). The P proteins of the Pneumovirinae exist as homo-dimers and tetramers, and the 
oligomerisation domain for hRSV P has been mapped to a short amino acid stretch in the 
central part of the protein (Castagne et aI., 2004). Phosphorylation of P is thought to be 
important for its various functions; although exactly how and why remains to be 
elucidated. Cellular kinase 2 has been shown to mediate the phosphorylation of specific 
serine residues in the hRSV P protein, however phosphorylation patterns differ when using 
this enzyme in vitro indicating other kinases or factors may be involved (Villanueva et ai., 
1994). 
Within each lineage of hMPV, P displays 94.6-100% amino acid homology and 51.6-
85.7% between lineages with a majority of amino acid changes occurring at the amino 
terminal of the protein (Bastien et aI., 2003). There is a significant level of sequence 
divergence between the hMPV P protein and those of other members of the 
Pneumovirinae. The most closely related is that of APV C, which shares 68% amino acid 
homology. The central region of hMPV P (171-226aa) however represents a highly 
conserved domain present in the P proteins of all pneumoviruses, and as such a greater 
level of amino acid identity exists; 80-880/0 and 63-68% with avian and mammalian 
pneumoviruses respectively (Bastien et aI., 2003). HMPV P also contains a large number 
of charged amino acids at the carboxyl terminal, another common feature of 
pneumoviruses (van den Hoogen et aI., 2002). 
When expressed alone in insect cells or E.coli the N protein of hRSV and other 
Paramyxoviridae form nucleocapsid like structures around non-specific cellular RNAs 
(Meric et aI., 1994). When co-expressed with hRSV P however, soluble N-P complexes 
form which can be co-immunoprecipitated, and non-specific encapsidation is inhibited. It 
has been suggested therefore that N-P complexes form prior to nucleocapsid assembly, 
where P acts as a chaperone for N, preventing non-specific binding to cellular RNAs 
(Castagne et aI., 2004, Curran et aI., 1995). The carboxyl terminal of both hRSV Nand P 
has been shown to be vital for their interaction; however other regions may be involved. 
The role of P phosphorylation in N-P interactions still requires clarification. The formation 
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of hRSV N-P complexes in E.coli is very efficient despite the lack of phosphorylation 
(Castagne et aI., 2004). However, a 40% reduction in the formation of N-P complexes is 
observed using a reverse genetics system in which the major phosphorylation sites of 
hRSV P were mutated (Lu et aI., 2002). However, structural differences at these mutated 
sites may account for the reduction in N-P interactions as oppose to a lack of 
phosphorylation. 
1.7.4. The Large (L) Polymerase Protein 
The L protein is the major component of the viral RNA dependent RNA polymerase 
complex, and as such is essential for transcription and replication (Grosfeld et aI., 1995, 
Teng & Collins, 1998, Yu et aI., 1995), and thought also to be responsible for mRNA 
methylation and capping (Colonno & Stone, 1975, Ogino et aI., 2005). L is the largest of 
the hMPV proteins containing 2005 amino acids, and shares 64% amino acid identity with 
APV -A and 44% with hRSV (van den Hoogen et aI., 2002). There are 6 conserved 
domains within the L proteins of the Monoegaviriaies, containing 4 core motifs that are 
highly conserved in all viruses of this order including hMPV (van den Hoogen et aI., 
2002). 
1.7.5. The Transcription Elongation Factor (M2-1) 
The first open reading frame of the M2 gene encodes the M2-1 protein, which associates 
with the RNP complex. The M2-1 gene of hMPV encodes a 187 amino acid protein that 
shares 84% homology with that of APV -C (van den Hoogen et aI., 2002). All the M2-1 
proteins of Pneumovirinae including hMPV contain a conserved CyslHis zinc finger- like 
motif that is thought to be essential for its function. M2-1 is an RNA binding protein that 
interacts with the Nand P proteins of the RNP complex. The function of M2-1 has been 
determined for hRSV through the use of mini genome systems, where it acts as a 
transcription elongation factor necessary for the full processivity of the viral polymerase 
(L) and enhances the read-through of intergenic regions, promoting the expression of genes 
distal to the 3' end of the genome (Collins et aI., 1996). Unlike the M2-1 protein of hRSV 
however M2-1 is not essential for the growth of hMPV in vitro, but was required for 
detectable levels of growth in vivo (Buchholz et aI., 2005). 
1.7.6. The RNA Synthesis Regulatory Factor (M2-2) 
The second open reading frame of the hMPV M2 gene encodes the putative RNA synthesis 
regulatory factor (M2-2). The function ofM2-2 has only been reported for hRSV, in which 
11 
III 
Chapter 1 - General Introduction 
mutants lacking this protein replicated more slowly in cell culture and were highly 
attenuated in vivo. Mutants resulted in a reduced production of full length genomic RNA, 
whilst the production of mRNAs was increased. This indicates that M2-2 acts as a 
regulatory factor switching the polymerase complex from transcriptional to replicational 
mode (Bermingham & Collins, 1999). HMPV mutants lacking M2-2 were also highly 
attenuated in vivo, but were capable of replicating in vitro (Biacchesi et aI., 2005, 
Buchholz et aI., 2005). 
1.7.7. The Matrix Protein (M) 
The M protein is associated with the cytoplasmic face of the plasma membrane of infected 
cells. M has been shown to interact with the RNP complex to inhibit transcription of the 
viral genome during the late stages of infection, and facilitates assembly of the virion by 
bringing together the RNP complex and viral envelope proteins. It has been reported that 
the M protein of hRSV can be found in the nucleus of the infected cells during the early 
stages of infection where it may inhibit host cell transcription (Ghildyal et ai., 2003). 
During the later stages of infection RSV M is present mainly in the cytoplasm of the cell 
where it associates with plasma membrane lipid rafts containing the viral surface 
glycoproteins, this acts as a platform for virion assembly and budding (Ghildyal et aI., 
2003, Ghildyal et aI., 2005, Ghildyal et aI., 2002) . The M protein of hMPV contains 254 
amino acids and shows a high level of amino acid identity with that of APV (76-87%), but 
only 37-38% with hRSV. All pneumoviruses contain a conserved hexapeptide at position 
14-19 that is also found in hMPV (van den Hoogen et at., 2002). 
1.7.8. The Fusion (F) Protein 
The F protein of hRSV has been shown to mediate viral penetration in to the host cell 
following attachment by fusing the virion envelope and the host cell plasma 
membrane(Walsh & Hruska, 1983). At the later stages ofhRSV infection F is expressed on 
the surface of the infected cell where it can fuse the membranes of neighbouring cells to 
form syncytia, a characteristic that gives hRSV its name. 
hRSV F is synthesised as a full-length inactive precursor, Fo, which trimerises in the rough 
endoplasmic reticulum (ER). Once in the trans-golgi network each protein is cleaved at 2 
furin sites into its active form, which is comprised of 2 hetero subunits; F 1 and F2, which 
remain linked via disulphide bonds. This cleavage results in liberating the hydrophobic 
fusion peptide (Zhao et aI., 2000). Although hRSV F is sufficient for the formation of 
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syncytial, the co-expression of G and SH has been shown to increase its efficiency 
(Heminway et al., 1994). 
The F protein of hMPV contains 539 amino acids with a predicted molecular mass of 
58.4Kda (van den Hoogen et aI., 2002). The F protein of hMPV is highly conserved and 
displays 98-100% amino acid homology within subgroups, and 94-95.5% homology 
between subgroups. The F protein of hMPV shares 81-82% amino acid identity with that 
of APVC, but only 30-43% identity with hRSV (Bastien et ai., 2003). The F protein of 
hMPV contains the two heptad repeats which have been shown to be necessary for viral 
fusion in other paramyxoviruses (Baker et ai., 1999, Ghosh & Shai, 1999), and 3 potential 
N-linked glycosylation sites, which are conserved also in APV F proteins(van den Hoogen 
et aI., 2002). 
Being a surface protein F is one of the major antigenic determinants of pneumovirinae, and 
the high level of amino acid homology of the F protein of a particular virus means 
antibodies generated against F are generally cross-protective for the different strains of the 
virus in experimental animals (Skiadopoulos et ai., 2004). Detection of F antibody has 
been used in serological assays(Ishiguro et aI., 2005, Leung et aI., 2005, Skiadopoulos et 
aI., 2004). The ability of hRSV and hMPV to cause repeated infections therefore is 
thought to lie partly with the other major surface antigen the G protein. 
1.7.9. The Small Hydrophobic (SH) Protein 
The SH proteins of Pneumoviruses are small integral membrane proteins for which the 
function is unknown. It is a type II membrane protein that is anchored at the amino 
terminal, with the carboxyl terminal orientated extracellulariy. Several forms of SH are 
detected in hRSV infected cells, SHo, a full length non glycosylated species; SHg, a full 
length species containing a single N linked carbohydrate side chain; SHp, a full length 
species containing an N-linked side chain modified by polylactosaminoglycan, and SHt a 
non glycosylated species derived from the second methionine in the same ORF (Collins et 
aI., 2001, Olmsted & Collins, 1989). All forms oligomerise to form pentomers. Whether 
different forms of SH exist during hMPV infection is yet to be determined. The deletion of 
SH in both hMPV and hRSV reverse genetics systems has shown that the protein is 
dispensable in vitro, and in some cell lines provides a growth advantage for hRSV, but was 
attenuated in the upper but not lower respiratory tract of mice and primates (Biacchesi et 
aI., 2005, Biacchesi et aI., 2004, Bukreyev et aI., 1997, Techaarpornkul et aI., 2001). 
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1.7.10. The Attachment Glycoprotein (G) 
The designation of the t h gene of the hMPV genome as the attachment glycoprotein gene 
was due to similarities in the properties of the predicted protein, and that ofhRSV G (van 
den Hoogen et aI., 2001), identified as the attachment protein, since antibodies specific to 
hRSV G blocked cell binding (Levine et aI., 1987). However, it has been demonstrated 
using reverse genetics that the G protein of hMPV is not essential for growth in vitro or 
vivo using a hamster model (Biacchesi et aI., 2004) calling in to question its role in 
receptor binding. Furthermore, in contrast to hRSV G, hMPV G elicits only low levels of 
neutralizing antibody (Skiadopoulos et aI., 2006). 
The G protein of hMPV is 236 amino acids in length. This is considerably shorter than that 
of hRSV A and B, which are 298 and 299 amino acids respectively and for which there is 
only 15.6% and 15.2% amino acid homology with hMPV G respectively. The G protein of 
APV C is almost twice its length at 435 amino acids and shares only 19% amino acid 
homology with hMPV G (Bastien et aI., 2004, van den Hoogen et aI., 2002) 
As with hRSV and APV the G protein of hMPV shows a high degree of nucleotide and 
ammo acid variation both within and between lineages (61 % and 33% 
respectively)(Bastien et aI., 2004). This high degree of amino acid variation may contribute 
to the viruses' ability to evade host immune responses and cause repeated infections 
throughout life. The extent of variation in the G protein of strains circulating in the UK and 
world wide is investigated in chapter 4 of this thesis where a more detailed discussion can 
be found. 
G is a type II transmembrane protein containing a hydrophobic region at the N-terminus 
which serves as both a signal peptide and transmembrane anchor. The remaining two thirds 
of the protein is orientated externally. Within this external region of the hRSV and APV G 
proteins there is a conserved region containing a number of motifs, to which neutralising 
antibodies are directed and is therefore thought to contain the receptor binding site. Four 
conserved cystine residues are also present in hRSV; 2 either side of this conserved region. 
Disulphide bonds between these cysteine residues create a cystine loop in which the 
conserved region is present (Melero et aI., 1997). The hRSV G proteins has been shown to 
form homo oligomers of up to 3 G molecules (Collins & Mottet, 1992, Melero et aI., 
1997). HRSV mutants lacking this cysteine loop region, however, showed little difference 
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to wild type virus in terms of the kinetics or efficiency of virus replication in vitro, or in 
the upper respiratory tract of mice, however, a 3-10 fold reduction of the mutant virus was 
observed in the lower respiratory tract (Teng & Collins, 2002). 
In contrast hMPV G contains only 1 cysteine residue and as yet no conserved region has 
been identified in the external region, suggesting potential differences in the structure of 
the protein and its potential binding site. 
The G proteins of all Pneumovirinae contain a large number of potential 0- linked 
glycosylation sites at serine and threonine residues. For hRSV up to 60% of the molecular 
weight of the mature form of G has been shown to be due to the presence of carbohydrate 
(Wertz et aI., 1989). Glycosylation has been shown to playa role in immune evasion of 
hRSV, by masking epitopes and contributing to the antigenic variance of the protein 
(Melero et aI., 1997). The hMPV G ORF also contains up to 5 potential N-linked 
glycosylation sites. The predicted MW of the polypeptide backbone of hMPV G protein is 
26KDa (van den Hoogen et aI., 2002). For hRSV G this is approximately 32KDa. The 
addition of N-linked sugars has shown to increase this to 45KDa, and O-linked sugars to 
approximately 80 to 90KDa (Wertz et aI., 1985, Wertz et aI., 1989). 
The amino acid sequence also reveals a high proline content of 8.5%. The unusually high 
potential for O-linked glycosylation and the high abundance of proline residues in the G 
proteins of pneumovirinae has also been observed in mucins, host glycoproteins present in 
mucus of the respiratory, gastrointestinal and reproductive tracts (van den Hoogen et aI., 
2002, Wertz et aI., 1985). 
The G protein ofhRSV is also synthesised in a secreted form due to initiation of translation 
at the second methionine codon in the same ORF and lacks the entire transmembrane and 
signal peptide region (Hendricks et aI., 1987). The production of a secreted G in hMPV is 
yet to be shown, however a second AUG is present in the same ORF located immediately 
downstream of the transmembrane region. The secreted G protein of hRSV is thought to 
play an important role in immune evasion by mopping up neutralizing antibody and 
reducing inflammatory responses (Arnold et aI., 2004, Hendricks et aI., 1987). It has also 
been demonstrated that soluble hRSV G retains its ability of cell receptor binding, the 
addition of which to hRSV infected cells inhibits virus spread (Escribano-Romero et aI., 
2004). 
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1.S. Virus replication cycle 
The replication of Paramyxoviridae takes place in the cytoplasm of the host cell. An over 
view of the life cycle is shown in Figure 1.4 . 
N 
.. 
~(-) 
.. 
............... (+) 
P L M F G SH 
• \ I 
~(+) 
~(-) .. ' .' . 
ER Golgi 
Figure 1.4 Schematic representation of the pneumovirinae life cycle. Adapted from 
(Lamb & Kolakofsky, 2001).N: Nucleocapsid; P:Phospoprotein; L:Large polymerase; M: Matrix; 
F: Fusion; G: attachment glycoprotein; SH: small hydrophobic protein. ER: endoplasmic reticulum; 
Golgi: Golgi apparatus. 
1.8.1. Virus attachment and penetration 
Attachment of pneumoviruses to the host cell is thought to be mediated via the G protein. 
As described above however through the use of reverse genetics it has been demonstrated 
that the G proteins of RSV and hMPV are required for growth in vivo, but are dispensable 
for growth in vitro indicating alterative mechanisms for attachment may be available by 
the F protein in vitro (Biacchesi et ai., 2005, Biacchesi et aI., 2004, Karger et aI., 2001 , 
Techaarpornkul et aI., 2001 , Teng & Collins, 1998). The host cell receptor for hMPV and 
hRSV is yet to be determined; however hRSV has been shown to bind to certain cellular 
glycosaminoglycans (GAGs) such as those containing heparin sulphate or condroitin 
sulphate B (Feldman et aI., 2000, Feldman et aI., 1999, Hallak et aI., 2000a, Hallak et aI. , 
2000b, Krusat & Streckert, 1997, Martinez & Melero, 2000, Shields et aI., 2003). 
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The pneumovirinae enter the host cell by fusion of the host cell plasma membrane with the 
envelope of the virion. The fusion event is mediated by the Fusion (F) protein at neutral 
pH. Whilst fusion by hRSV can be mediated by F alone, there is evidence indicating that 
SH and G may enhance the fusion process (Heminway et aI., 1994). After membrane 
fusion the nucleocapsid dissociates from the matrix protein by an unknown mechanism and 
is released into the cytoplasm of the cell, where transcription and replication of the viral 
genome occurs. 
1.8.2.Pneumovirinae Transcription 
The current model of transcription and replication for Pneumovirinae is consistent with 
that for all non-segmented negative sense viruses and occurs entirely in the cytoplasm of 
the infected cell. 
The polymerase complex (N, P and L) attaches to the genome at the leader sequence at the 
3' end of the genome, and initiates transcription at the gene start (GS) signals located at the 
beginning of each transcribable gene. The polymerase complex continues along the 
genome synthesising the mRNA strand until the gene end (GE) signal is reached at which 
point transcription is terminated. Following the GE signal Pneumovirinae genomes contain 
a run of U residues, which marks the position at which the mRNA is polyadenylated and 
released from the genome-polymerase complex. During the transcription process the 
nascent mRNA is also methylated, allowing the gene to be translated by host cell 
ribosomes, located either on the endoplasmic reticulum, or by free ribosomes in the 
cytoplasm, depending on the nature of the protein product (Collins et aI., 2001, Easton et 
ai., 2004). 
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Figure 1.5: Schematic representation of the Pneumovirinae transcription process. 
At the GE sequence approximately only 50% of the active polymerase molecules are able 
to remain attached and move along the genome without transcribing until they reaches the 
next GS signal upon which transcription reinitiates, at the next GE signal the same process 
occurs where approximately 50% of the polymerase will remain attached and go on to 
transcribe the next gene, the remaining 50% will dissociate from the genome. The 
dissociated polymerase translocates back to the leader sequence at the 3' end where it can 
reattach and initiate transcription of the fITst gene. The polymerase is unable to reattach at 
any other location other than the 3 'leader sequence. This means that the genes proximal to 
the 3' leader sequence are transcribed more frequently than those, which are located at the 
5' end resulting in a transcription gradient (Easton et ai., 2004, Krempl et ai., 2002). The 
association of the M2-1 protein with the polymerase complex during transcription inhibits 
dissociation of the polymerase from the genome, therefore allowing genes distal to the 3' 
end to be transcribed (Buchholz et ai. , 2005). 
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1.8.3. Genome Replication 
During replication the polymerase complex binds to the leader sequence at the 3' end of 
the genome, where synthesis of the anti-genome initiates (Fearns et ai., 2002). Once 
committed the polymerase continues to the end of the genome. The polymerase then uses 
the anti-genome as a template to synthesis genome. In order to do this the polymerase 
complex binds to the anti-genome 3' end, where the sequence complementary to the 
genome trailer sequence acts as a binding site for the polymerase, and promotes 
replication. 
-3'. lS H f H M H F H M2 H SB H G H I . ~ 5' 
• 
Pol Complex ~ 
+ 5' 3' 
~ 
3'-1 N H p H M H F H Ml H SH H G H L ~ 5' 
Figure 1.6: Schematic representation of Pneumovirinae genome replication 
1.8.4. Transcription versus Replication 
It is not yet clear how the polymerase switches between transcription and replication. The 
M2-2 protein has been shown to playa role, although how M2-2 functions is not known 
(Bermingham & Collins, 1999). In accordance with other members of the 
Monoegaviriaies, replication may also be dependent of RNA encapsidation, which requires 
ongoing protein synthesis. Therefore increasing levels of N protein expression may 
influence this switch, although there is conflicting data suggesting that the increase in N 
stimulates transcription rather than replication (Feams et aI., 1997, Lamb & Kolakofsky, 
2001). 
1.8.5. Virion Assembly 
The assembly of the nucleocapsid takes place in the cytoplasm where the components of 
the polymerase complex N, P and L associate with genomic RNA to form the helical RNP 
structure. Both genomic and antigenomic RNA is encapsidated, however mRNAs are not. 
It is therefore assumed that the 5' trailer sequence of genomic RNA and 5' leader of 
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antigenomic RNA contains a specific sequence for encapsidation (Easton et aI., 2004, 
Mink et aI., 1991). 
The second stage of virus assembly; the envelope takes place at the cell surface. The viral 
membrane proteins are synthesised in the ER. The folding of which involves numerous 
cellular enzymes. Once folded the proteins are transported out of the ER through the Golgi 
apparatus, where further maturation in the form of glycosylation or protein cleavage 
occurs. Mature forms of the proteins are transported to the plasma membrane where they 
exist in lipid rafts(Brown et ai., 2004, Collins & Mottet, 1992, Olmsted et aI., 1989, Rixon 
et ai., 2004). 
The third stage of virus assembly involves the association of the RNP with the surface 
glycoproteins which is thought to be mediated by the M protein. M is thought to interact 
with the cytoplasmic tails of the surface proteins during their passage through the Golgi 
apparatus(Ghildyal et ai., 2005, Ghildyal et aI., 2002, Marty et aI., 2004). M has also been 
shown to associate with the RNP complex in cytoplasmic inclusions present in infected 
cells near to the plasma membrane (Ghildyal et aI., 2002). Aggregation of M proteins 
bound to the RNP and glycoproteins brings the two components together resulting in 
progeny virions which bud from the surface of the cell. In polarised cells such as those 
lining the respiratory tract virus is released from the apical side into the airways (Roberts et 
aI., 1995). 
1.9. Clinical Manifestations 
HMPV has been associated with acute respiratory tract infections (ARTI) in people of all 
ages, with more severe disease occurring in young children, the elderly and 
immunocompromised individuals (Boivin et aI., 2002, Boivin et ai., 2003, Falsey et aI., 
2003, Pelletier et ai., 2002). 
Clinical features ofhMPV are virtually indistinguishable from those ofhRSV, although the 
course of illness is usually less severe(Boivin et aI., 2003). Symptoms include high fever, 
severe cough, difficulty breathing, and wheezing. The most commonly reported diagnosis 
associated with hMPV is bronchiolitis with or without pneumonitis (Boivin et aI., 2003). 
HMPV has also been associated with COPD and asthma exacerbations(Martinello et aI., 
2006, Rohde et aI., 2005, Williams et ai., 2005a). One study showed that as many as 14% 
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of hMPV cases triggered asthma exacerbations following infection in children with a 
medical history of asthma(Williams et aI., 2004). HMPV has also been detected in patients 
with otitis media (Schildgen & Simon, 2005, Suzuki et aI., 2005, Williams et aI., 2006). 
Hospitalization rates due to severe hMPV infections peak in children of 3-6months of 
age(Boivin et aI., 2003, van den Hoogen et ai., 2003). As with hRSV, children with 
underlying medical conditions are more prone to severe illness due to hMPV infection 
leading to increased rates of hospitalization in this group. One study in north America 
suggest that 25-33% of hMPV cases requiring hospitalisation occurred in children with 
underlying conditions, which ranged from cardiopulmonary problems to 
immunosuppression (Boivin et ai., 2002, Esper et ai., 2003). However the risk factors for 
severe hMPV infection have not been fully investigated. 
Co-infection of hMPV and hRSV were associated with increased severity of disease 
compared with hRSV alone. In this study 70% of infants hospitalised with hRSV 
bronchiolitis were also infected with hMPV, and 90% of those requiring mechanical 
incubation were co-infected (Greensill et ai., 2003, Semple et ai., 2005). During the recent 
SARS Coronavirus outbreak in 2003 hMPV was identified as the most common co-
pathogen and a possible synergistic effect on disease severity has been postulated, however 
synergistic effects were not found in Macaques co-infected with SARS CoY and hMPV, 
but this remains to be investigated further (Fouchier et ai., 2003, Kuiken et aI., 2003b, 
Kuiken et ai., 2004). 
HMPV infections in adults have been less well studied than those in children. However, a 
few studies have associated hMPV with influenza like illness and colds in healthy adults. 
HMPV was identified in 2% of adults in England with Influenza like illness (ILl) where no 
other viral pathogen was detected (Stockton et ai., 2002), and in 4.1 % of adult patients who 
attended the emergency room with community acquired pneumonia and chronic 
obstructive pulmonary disease (COPD) exacerbations over 2 winter seasons in Canada 
(Hamelin et ai., 2005a). In a retrospective study of 10 patients over 65 years of age 
hospitalised with an hMPV infection, 4 were diagnosed with pneumonitus and 2 died 
(Boivin et ai., 2002). 
HMPV has also been associated with the death of a child who suffered with a severe lower 
respiratory tract infection following a hematopoietic stem cell transplant(Cane et ai., 2003), 
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and an immunocompromised child who was repeatedly co-infected with both subtypes of 
hMPV (Pelletier et aI., 2002). A case of fatal encephalitis has also been associated with 
hMPV infection following the detection of hMPV RNA in the brain and lung tissue 
following post mortem (Schildgen et aI., 2005). 
1.10. Immune Response to pneumovirinae 
Protection against and recovery from pneumovirus infection is mediated largely by the host 
immune response. It has been shown that children with primary or acquired 
immunodeficiency diseases fail to clear hRSV infection and virus may be shed for several 
months, compared to immunocompetent children where clearance is achieved within 3 
weeks (Chandwani et aI., 1990) it is likely that this is similar for hMPV, the only study 
thus far to comment of viral shedding in children showed that virus could be detected by 
RT-PCR for up to 3 weeks in otherwise healthy children (Ebihara et aI., 2004). In 
immunocompromised adults, such as those having undergone bone marrow 
transplantation, serious hMPV and hRSV infections have also been reported, with many 
leading to death (Englund et aI., 2006, Englund et aI., 1988, Fouillard et aI., 1992, 
Harrington et aI., 1992). In studies of hRSV infection in mice, CTL and antibody responses 
both playa role in the eradication of virus from the respiratory tract. 
1.10.1. Antibody responses 
Post infection sera contains antibodies against the various structural proteins of the virion, 
which provides many opportunities for the development of sero-diagnostic assays, 
however typically only antibodies targeted towards the F or G proteins of pneumovirinae 
have been shown to neutralize virus in vitro. Recent work by Skiadopoulos et al (2006) 
however indicated that in contrast to other members of this subfamily only low levels of 
neutralizing antibody is generated against the hMPV G protein, and therefore the hMPV F 
protein appears to be the sole antigen against which protective antibodies are generated 
(Skiadopoulos et aI., 2006). 
Neutralizing antibodies targeted towards the F proteins of Pneumovirinae appear to target 
conformational epitopes, and have been mapped primarily to the F 1 subunit of the protein 
(Lopez et aI., 1993, West et aI., 1994). Antibodies generated against the F protein of 
hMPV have been shown to be reactive against both lineages (Skiadopoulos et aI., 2004). In 
contrast antibody recognition of hRSV G appears not to be dependent of conformational 
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epitopes (Martinez et aI., 1997), are often not reactive against viruses from both lineages, 
and are normally classified as group specific, which are more likely to recognise non-
glycosylated species of G, or strain specific, which are often dependent of the presence of 
glycosylation (Martinez et aI., 1997). It is not yet clear whether antibodies against hMPV 
G behave in a similar manner. 
New born infants possess maternally derived antibody against hRSV which offers 
protection against severe illness in a majority of individuals. These maternally derived 
antibodies however only offer a limited amount of protection and infection with hRSV still 
occurs (Glezen et aI., 1981, Ogilvie et aI., 1981). Antibodies are produced in high titre in 
older infants and young children where maternal antibody has declined. However in infants 
1-8 months of age only a limited antibody response is mounted due to immunological 
immaturity and suppressive effects of maternal antibody (Murphy et ai., 1986, Murphy et 
aI., 1988). 
Secreted IgA plays an important role in protecting against reinfection. However this does 
not last long following primary infection and often fails to neutralize virus (in 
vitro )(McIntosh et aI., 1978). Repeat infections induce higher levels of IgA which can be 
sustained for longer periods; however this remains only partially protective as adults 
continue to become symptomatically infected (Hall et aI., 1991, Walsh & Falsey, 2004). 
Serum antibody persists at much higher titres for longer; inefficient transuduction of IgG 
into the respiratory tract however means it offers little protection. 
1.10.2. Cellular immune response 
Clearance of human Pneumovirinae infection has been associated with an increase in CTL 
response. Nude mice infected with hRSV have been shown to persistently shed virus, 
which is cleared upon adoptive transfer of primed T cells (Cannon et aI., 1987). 
The N, M, SH, and F proteins of human Pneumovirinae have been shown to stimulates 
specific T cell responses(Cherrie et aI., 1992, Nicholas et aI., 1990). In contrast a CTL 
response against the G protein has not been detected (Bangham et aI., 1986, Cherrie et aI., 
1992) and this is reflected in the pattern of the T helper cell response which is biased 
towards Th-2, while that of F is biased towards a Th 1 response(Hancock et ai., 1996) 
.Overall pneumovirus infection is characterised as a Th-l response. 
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Infection of epithelial cells and macrophages of the respiratory tract with human 
Pneumovirinae induces transcriptional activation of cellular genes involved in 
inflammatory and immune responses. Increases in pro-inflammatory cytokines such as IL-
6, IL-8, TNF -u, and RANTES result in the recruitment and activation of macrophage, 
neutrophils, eosinophils CTLs and NK cells involved in viral clearance either by direct 
attack of infected cells or release of degradative enzymes. 
Abberant immune responses to hRSV are thought to be involved in the pathogenesis of 
hRSV infection in young babies, where narrow airways are easily obstructed as a result of 
inflammation and oedema (McIntosh & Fishaut, 1980, Murphy et aI., 1990) . Adverse 
immune responses have also been observed during vaccine development in which children 
vaccinated with a formalin inactivated hRSV suffered significantly more severe disease 
than unvaccinated children upon natural infection (Chin et ai., 1969, Kapikian et ai., 1969, 
Prince et aI., 1986). It is unknown whether immunopathogenesis is involved in the severity 
of hMPV infections. 
1.11. Pathogenesis 
A number of small animals (hamsters, cotton rats, mIce and ferrets) and primates 
(chimpanzees, cynomologous and rhesus macaques, and African green monkeys) have 
been evaluated for their susceptibility to hMPV and their ability to support viral replication 
in order to develop a model for the investigating of hMPV pathogenesis, antiviral 
compounds and vaccines (Alvarez & Tripp, 2005, Darniot et aI., 2005, Hamelin et ai., 
2005b, Kuiken et aI., 2004, van den Hoogen et aI., 2001, Williams et aI., 2005b). Virus 
replication has been reported in the upper and lower respiratory tracts of many of these, 
however, only BALB/c mice, cynomologous macaques and chimpanzees have been 
reported to display clinical symptoms (Alvarez et ai., 2004, Hamelin et aI., 2005b, Kuiken 
et aI., 2004, Skiadopoulos et aI., 2004, van den Hoogen et aI., 2001) . 
Studies conducted by Alvarez et al (2004) show hMPV replicates in a biphasic growth 
pattern in BALB/c mice with peak titres occurring at days 7 and 14. However, only 
monophasic replication has been reported by other groups with peak lung titres occurring 
on day 4 or 5 (Hamelin et aI., 2005b). 
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Alverez et al (2004) also reported that infectious virus could be recovered from the lungs 
of infected mice up to 60 days post infection, and genomic RNA could be detected by RT-
PCR up to 180 days pi. Other groups however have not reported the same length of viral 
persistence, (Hamelin et aI., 2005b) reported similar levels of virus replication, but could 
only recover 1 detect virus up to 3 weeks pi. 
The persistence of hMPV observed by Alvarez et al (2004) occurred despite the presence 
of neutralizing antibodies, which protected the mice from subsequent challenge. This same 
group went on to demonstrate that this persistence was associated with aberrant immunity, 
and impaired viral clearance, due to the delayed onset of CTL responses compared to that 
of hRSV in this same mouse model. Furthermore the depletion of T cells or NK cells 
resulted in increased levels of virus replication in the lungs (Alvarez & Tripp, 2005). 
Cotton rats, ferrets and Syrian golden hamsters have also been shown to support high titre 
replication of hMPV with peak virus lung titre occurring on days 4/5 pi and complete viral 
clearance within 2 weeks. The induction of neutralizing antibodies was also reported, 
which were protective against subsequent challenge in ferrets and hamsters but only 
partially protective in cotton rats (Hamelin et aI., 2005b, MacPhail et aI., 2004). 
In cynomologous macaques and African green monkeys peak lung titres were observed 
between days 4 to 7 pi with shedding lasting up to 11 days pi. Clinical symptoms were not 
noted in African green monkeys, however cynomologous macaques were reported to have 
had slight loss of appetite and rhinorrhea on the days of peak virus titre (Kuiken et aI., 
2004, MacPhail et aI., 2004). 
Using immunohistological techniques hMPV was detected primarily around the apical 
plasma membranes of ciliated epithelial cells in multi focal groups (adjacent cells). hMPV 
was not detected in goblet or basal cells of the respiratory tract nor in other tissues 
investigated (brain, heart, lung, liver) of infected animals (Hamelin et aI., 2005b, Kuiken et 
aI., 2003b, MacPhail et aI., 2004). 
Similar pathological changes were observed in the respiratory tracts of monkeys, cotton 
rats and BALB/c mice. Typically, the loss of cilia in the epithelium was noted to occur in 
multifocal lesions throughout the length of the respiratory tract from the larynx to the 
bronchiols, and some surrounding alveoli. Pulmonary inflammation was observed in these 
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animals with the translocation of neutrophils in the epithelium and sub-mucosa, with 
increased mucus production noted (Kuiken et aI., 2004, MacPhail et aI., 2004, Wyde et aI., 
2005). In BALB/c and cotton rats inflammation was associated with increases in cytokines 
such as IL-2, IL-8, IL-4 and IFNy. In BALB/c mice inflammatory changes were still 
present in the lungs more than 21 days pi (Wyde et aI., 2005). 
A number of studies have shown that for hRSV severe disease is associated with high 
levels of inflammatory cytokines and chemokines. Due to the similarity of the symptoms 
observed during hMPV and hRSV infections, it was therefore postulated that similar 
inflammatory responses may be induced during infection. Studies comparing the cytokine 
responses of these two viruses however have shown that hMPV is a much poorer inducer 
of inflammatory cytokines, compared to hRSV. In BALB/c mice hMPV induced lower 
levels of IL-1, IL-6, and TNFa compared to hRSV, but was a more potent inducer of 
granulocyte macrophage colony stimulating factor, INFa, and INFy (Damiot et aI., 2005). 
Similar findings were also observed by (Laham et aI., 2004), who analysed the cytokine 
responses of infants infected with hMPV and hRSV. As with the previous studies hMPV 
elicited significantly lower levels of inflammatory cytokines compared with hRSV (IL-12, 
TNFa, IL-1, IL-6, and IL-8). Furthermore the cytokine profiles of infants with hMPV 
requiring hospitalisation were no different to those who did not require hospitalization. 
This indicates that the symptoms elicited by hMPV are mediated via an independent 
mechanism to that ofhRSV. 
1.12. Vaccine Development 
Several different strategies for vaccine development against hRSV have been investigated. 
However, only a few have made it to clinical trials. The search for a hRSV vaccine has 
been hindered considerably by a study in which formalin inactivated hRSV tested in young 
children, resulted in enhanced disease upon natural infection. Concerns exist that a similar 
problem may be experienced with hMPV (Chin et aI., 1969, Kapikian et aI., 1969, Prince 
et aI., 1986). For hRSV however live attenuated vaccines appear to be the best approach, 
and no enhanced disease associated with these vaccine candidates has been reported. 
Reverse genetics systems provide useful tools for the development of such vaccines, where 
mutations can be engineered to suit specific needs. It is through the use of reverse genetics 
systems that a majority ofhMPV vaccine development has been focused. 
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Recombinant hMPV viruses lacking either the G (L\G) or G and SH (L\G+SH) genes 
replicated efficiently in vitro but displayed at least a 600 fold reduction in replication in the 
lungs of hamsters when administered intranasally. High levels of neutralizing antibodies 
however were induced, and the hamsters were protected upon challenge with wild type 
virus (Biacchesi et aI., 2004). More recently African green monkeys were also 
administered recombinant hMPV viruses lacking either G, SH or M2-2. Little effect on 
virus replication was observed with the L\SH virus, however both the L\G and L\M2-2 
viruses were highly attenuated with 3200fold, and 4000fold reductions in virus replication 
observed in the lower respiratory tract respectively. High levels of neutralizing antibodies 
were induced and the monkeys were protected upon challenge with wild type virus 
(Biacchesi et aI., 2005). L\G and L\M2-2 recombinant hMPV viruses therefore provide 
promising vaccine candidates. 
Chimeric VIruses generated through reverse genetics have also provided possible 
multivalent vaccine candidates. In one study recombinant hPIVl expressing the F gene 
from hMPV induced neutralizing antibodies in hamsters against both viruses and protected 
against both PIVI and hMPV during challenge with wild type viruses (Skiadopoulos et aI., 
2004). A similar study using a recombinant bovine PIV3 virus expressing the F proteins of 
hPIV3 and hMPV also induced neutralizing antibodies and protected against challenge 
with wild type hMPV and hPIV3 in hamsters and African green monkeys (Tang et aI., 
2005, Tang et aI., 2003). In both these studies it was noted that the hamsters were protected 
against both subtypes of hMPV indicating the F gene provide a substantial level of cross-
reactive neutralizing antibodies. 
In a different approach (Herd et aI., 2006) used predictive bioinformatics, peptide 
immunization, and functional T cell assays to identify cytotoxic T cell epitopes that would 
be recognised by mice. In this study several T cell epitopes were identified in the N, M2-2, 
SH and G proteins of hMPV. Vaccination of mice with the corresponding peptides reduced 
both viral titre and lung pathology. Increased T helper cell Type 1 responses were observed 
in the lungs and pulmonary lymph nodes measured by an increase in IL-12 and IFN-y. The 
epitopes identified in the G and SH proteins varied between subtypes, and therefore may 
be less suitable for vaccine development than the Nand M2-2 peptides, which represent 
conserved epitopes present in all subtypes of hMPV. 
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1.13. Antiviral Therapy 
Currently there are no drugs or compounds available for the treatment ofhMPV. A number 
of antiviral compounds however have been evaluated and are licensed for use against 
hRSV, and therefore tested for use against hMPV. 
Ribavirin, a nucleoside analogue of guanosine has been used for the treatment of hRSV 
pneumonitis in young children. In vitro studies have shown ribavirin has a similar level of 
antiviral activity against hMPV and hRSV (Wyde et aI., 2003). Moreover hMPV infected 
BALB/c mice had significantly reduced levels of hMPV virus replication in the lungs, and 
reduced pulmonary inflammation when treated with ribavirin (Hamelin et aI., 2006). In this 
same study glucocorticoids, which are powerful suppressors of innate immunity, were also 
evaluated. While no decrease in viral replication was observed in the lungs of mice treated 
with this drug, lung inflammation and weight loss were significantly reduced. The use of 
ribavirin, and glucocorticoids used separately or in combination may provide a powerful 
antiviral treatment against hMPV infection. 
NMS03, a sulphated sialyl lipid and heparin, another sulphated compound have also been 
shown to be effective against hMPV in vitro, especially when administered before or 
during viral attachment and penetration (Wyde et aI., 2004), also suggesting that hMPV 
may have a similar mode of attachment as hRSV. 
Intravenous immunoglobulins (lVIG), used for prophylactic treatment against hRSV, were 
also shown to inhibit the growth of hMPV in vitro (Wyde et aI., 2003), and may therefore 
be of some benefit in vivo. Indeed Alvaerez et al demonstrated that affinity purified a-
hMPV IgG when passively transferred in to nai've BALB/c mice reduced the levels of 
hMPV replication when challenged with virus. The humanised monoclonal antibodies 
targeted towards the hRSV F protein (palivizumab) have been shown to decrease the 
severity of lower respiratory tract infections for both subtypes of hRSV. These antibodies 
tested in vitro against hMPV had however no antiviral activity (Wyde et aI., 2003). Due to 
the conserved nature of the hMPV F gene, hMPV specific monoclonal antibodies targeted 
to this protein could be effective. 
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Recently antiviral activity through RNA interference (RNAi) has been studied. RNAi is a 
mechanism of sequence specific silencing through the formation of dsRNA molecules, and 
is well recognised as being instrumental in the antiviral responses of plants and insects. 
The introduction of virus specific small interfering RNAs (siRNA) into cells has been 
shown to be an effective therapeutic against mammalian viruses in vitro and vivo for a 
wide range of viruses (Barik, 2004, Bitko et aI., 2005, van Rij & Andino, 2006). In vivo 
studies targeting hRSV and PIV using an intranasal delivery system in BALB/c mice, 
showed reduced lung titres and pulmonary pathology (Bitko et aI., 2005), and may 
therefore also be effective against hMPV. 
1.14. Detection Methods 
One of the reasons that hMPV was not identified before 2001 is that growth of this virus in 
cell culture is particularly fastidious, requiring cell lines not commonly used in diagnostic 
laboratories, trypsin, and incubation periods of up to 3 weeks, often without the production 
of cytopathic effect (CPE). Some studies have reported the successful growth of hMPV in 
LLC-MK2, tertiary monkey kidney and Vero cells. CPE has been reported to occur more 
than 10-14 days post infection (pi) and varies from the formation of syncytia to focal 
rounding and cell destruction. 
The detection of viral antigens by immunofluorescence (IF) provides a rapid diagnosis for 
a wide range of possible pathogens and is used routinely in diagnostic laboratories. For 
hMPV, and many other pathogens however, IF has proved to be not as sensitive as other 
techniques such as reverse transcription - polymerase chain reaction (RT-PCR) (Casiano-
Colon et aI., 2003, Ebihara et aI., 2005). A number of block-based and real-time RT -PCR 
assays have been described which target mainly the L, P, N or F genes ofhMPV. 
A number of serological assays such as enzyme linked immunoabsorbance assays (ELISA) 
and IF against hMPV infected cells or hMPV recombinant proteins have been reported, but 
only provide a means of retrospective diagnosis. However are useful for confirmatory 
diagnosis and seroprevalence studies. 
29 
Chapter 1 - General Introduction 
1.15. Scope of this thesis 
As stated previously, at the start of this work very little of this information was known 
about hMPV in terms of its contribution to burden of disease and epidemiology, and still 
enormous gaps in our knowledge exist. This thesis aims to address the questions related to 
the epidemiology and prevalence ofhMPV in different populations within the UK. 
• What is the burden of illness due to hMPV infection? 
• When does it circulate? 
• What age group is most at risk of infection? 
• What illnesses is it associated with? 
• Which strains are circulating in the UK? 
• Is strain diversity important, and what drives it? 
By addressing these important questions we can ask whether hMPV vaccine production is 
worth while, and identify what factors should be considered in the pursuit of a suitable 
vaccine candidate. 
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2.1. Clinical Specimens Receipt and Analysis 
2.1.1. Routine Surveillance Samples 
Respiratory clinical samples, mainly combined nose and throat swabs or nasopharyngeal 
aspirates were taken from patents either in the community presenting with Influenza like 
Illness (aI), or hospitalised children presenting with acute respiratory tract infection. 
Swabs were put in to 2ml of virus transport medium (VTM) [VTM: 109 veal infusion 
broth, 2g bovine albumin fraction V, 400ml sterile distilled water, 0.8 ml gentamicin 
sulfate solution (50 mg/ml) and 3.2 ml amphotericin B (250 J.Lg/ml)], and posted to the 
HP A Colindale for analysis. Upon receipt, swabs were removed and 200J.lI of 250J.Lg/ml 
Amphotericin B Fungizone (Invitrogen) was added. 150J.lI of the sample was aliquoted in 
to 50J.lI of L6 extraction buffer (Severn Biotech). Aliquots and the remaining original 
sample were stored at -80°C until testing. 
Samples were processed, extracted and tested for influenza and respiratory syncytial virus 
fIrst as part of routine surveillance. The remaining cDNA was stored at -20°C until tested 
for hMPV. The samples were tested for hMPV by F gene PCR as described later was 
carried out in batches of 20, with the appropriate controls. 
2.1.2. Samples submitted for Severe acute Respiratory Syndrome (SARS) 
investigation 
Respiratory samples sent to the HP A Colindale for investigation in to the SARS outbreak 
from returning travellers in 2003 were processed in a category 3 laboratory. 150ul of 
sample was aliquoted in to 850ul of L6 lysis buffer (Severn Biotech). Aliquots and the 
remaining original sample were stored at -80°C until testing. Nucleic acid extraction was 
carried out using the manual Boom method described previously (Boom et al., 1990, 
Stockton et al., 1998) . cDNA was generated as described below and stored at -20°C until 
tested. 
2.1.3. Samples collected from immunocompromised patients 
An aliquot of the original patient sample taken and previously tested for other respiratory 
pathogens at the Royal Free Hospital, were sent on wet ice to Colindale HP A for hMPV 
screening by RT -PCR. 150J.lI of the sample was aliquoted in to 50J.lI of L6 extraction buffer 
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(Severn Biotech). Aliquots and the remaining original sample were stored at -80°C until 
testing. 
2.1.4. Serum Samples 
Serum samples were sent to the HP A Colindale by post and were aliquoted and stored at -
20°C until testing. 
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2.2. Mammalian Cell Culture Techniques 
2.2.1. Maintenance 
Mammalian cells (Table 2.2) were maintained on Minimum Essential Medium (MEM) 
(lX) liquid containing Earle's salts, and 25 mM HEPES (Invitrogen) supplemented with a 
final concentration of 10% Foetal Bovine Serum (Invitrogen), 2mM Glutamax I 
(Invitrogen), 50Jlglml Gentamicin (Invitrogen), and Ix MEM Non- Essential amino acid 
solution (Sigma). Cells were trypsonised with Trypsin EDT A (Invitrogen). 
2.2.2. Virus Growth from Clinical Samples 
Tissue culture tubes or 6 well plates were seeded with LLC-MK2 cells (Ix 106 Cells/ml for 
tubes and 1 x 106 Cells/well for plates) in growth medium (described above), and incubated 
at 37°C until cells were 80-100% confluent. Growth medium was removed and the cells 
washed twice in PBS. 200-500JlI of the clinical specimen was inoculated on to the cells 
and adsorbed at room temperature for 1 hour. The inoculum was removed and replaced 
with Iml of post inoculation media (Growth medium without the FBS, supplemented with 
IJlllml of 2.5% Trypsin (Biowhittica», and incubated at 33°C. Tubes were placed on a 
roller. Cells were monitored daily for CPE. On days 2 and 7 post inoculation 1 JlI of fresh 
trypsin was added to the medium. Cells were harvested by scraping the cells in to the 
medium and sonicating for 15 minutes on days 7 or 14 post inoculation or when CPE was 
evident. The harvested material was passaged on to a fresh monolayer of LLC-MK2 cells 
(80 - 100% confluent) in a tissue culture tube or 25cm3 tissue culture flask as described 
above. Some material was saved and analysed by hMPV PCR 1 described below. 
2.2.3. Production of hMPV Infected CelIs for Analysis by Immunofluorescence 
The hMPV isolates (Ix A subtype and Ix B subtype) used in this study to validate 
antiserum were kindly provide by Dr Alison Bermingham (HP A, Colindale), in the form of 
infected cell culture supernatant. The original clinical isolates originated from patients with 
ARTI in Northern Ireland, propagated oh RMK cells at Belfast HPA. 
Covers lips were placed in the bottom of each well of a 24 well tissue culture plate, and 
seeded with LLC-MK2 cells (5x105 cells/ well) in growth medium and incubated at 37°C 
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until cells were 80-100% confluent. Growth medium was removed and the cells washed 
twice in PBS. 250Jll of the hMPV isolate (unknown quantity of virus) was inoculated on 
to the cells and adsorbed at room temperature for 1 hour. The inoculum was removed and 
replaced with 1ml of post inoculation media (Growth medium without the FBS, 
supplemented with 1Jlllml of 2.5% Trypsin (Biowhittica», and incubated at 37°C 5%C02. 
Cells were monitored daily for CPE. On days 2, 7 and 14 post infection 1 Jll of fresh trypsin 
was added to the medium. 
On days 7, 14 or 21 post infection the medium was removed and the cells washed with 1 ml 
PBS then fixed with 80% ice cold acetone in PBS for 10 minutes at -20°C. The acetone 
was removed and the cells air dried at room temperature for 30 minutes. 
Cells were washed 3 times for 5 minutes with PBS containing 0.1 % (v/v) TWEEN 20, and 
blocked with 1% BSA (v/v) in PBS for 15 minutes. Cells were washed as before then 
incubated with 200Jll primary antibody (Rabbit a-hMPV N-FL or rabbit a-hMPV Total) 
diluted 1 :25 in PBS containing 0.1 % (v/v) TWEEN 20 and 1 % BSA (v/v) for 30 minutes at 
37°C. Cells were washed as before and incubated with Secondary FITC conjugated 
antibody (swine a-rabbit IgG FITC) diluted 1:40 in PBS containing 0.1% (v/v) TWEEN 20 
and 1 % BSA (v/v), 0.01 % Evans Blue counter stain and incubated for 30 minutes at 37°C. 
An FITC conjugated rabbit a-hMPV N-FL IgG was also evaluated for its use as a direct 
immunofluorescent agent. In this instance fixed cells were incubated with 200Jll of the 
conjugated antibody diluted 1 :25 in PBS containing 0.1 % (v/v) TWEEN 20, 1% BSA (v/v) 
and 0.01% Evans blue counter stain for 30 minutes at 37°C (The conjugate was kindly 
prepared by Dr Dhan Samuels at the HP A Colindale). 
Fluorescence was analysed using a Zeiss Axiovert 200 Inverted Microscope. Images were 
captured with a Zeiss AxioCam HRc and Axio vision software. 
2.2.4. Production of hMPV Infected CeUs for Analysis by Western Blot. 
6 well tissue culture plates were seeded with LLC-MK2 cells (Ix 106 Cells/well) in growth 
medium, and incubated at 37°C until cells were 80-100% confluent. Growth medium was 
removed and the cells washed twice in PBS. 500fll of the inoculum (described in 2.2.3) 
was adsorbed on to the cells at room temperature for 1 hour. The inoculum was removed 
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and replaced with 1 ml of post inoculation media (Growth medium without the FBS, 
supplemented with IJ..Ll/ml of 2.5% Trypsin (Biowhittica)), and incubated at 37°C 5%C02 
and monitored daily for CPE. On days 2 and 7 post inoculation 1 J..LI of fresh trypsin was 
added to the medium. On day 14 cells were harvested by scraping the cells in to the cell 
culture medium. The media was transferred to a 2ml microcentrifuge tube and the cells 
pelleted by centrifugation. The cell pellet was resuspended in Iml of Ix Nupage LDS 
sample lysis buffer (Invitrogen) and Ix Nupage Sample reducing agent (Invitrogen) 
containing DTT and heated for 10 minutes at 100°C. 20J..LI of the lysed sample preparation 
was resolved on a 4-12% Nupage Novex Bis-Tris acrylamide gels(I.5mm thick) 
(Invitrogen), for approximately 1 hour at 180V with 1 x MOPS or 1 x MES Buffer 
(Invitrogen) using the XC ell SureLock Mini Cell electrophoresis equipment (Invitrogen). 
Transfer onto nitrocellulose and detection was performed as described in 2.6.2. 
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2.3. Molecular Techniques 
2.3.1. PCR anti Contamination Precautions 
To prevent any carryover contamination, nucleic acid extraction and reverse transcription, 
PCR reaction mix set up, thermocycling, and gel analysis were all conducted in separate 
rooms each with its own dedicated equipment and clothing. All pippetting was carried out 
with filtered tips. Addition of primary products to a secondary round PCR mix was carried 
out in UV equipped PCR workstations (LabCaire; Scientific Laboratory Supplies). When 
large runs of samples were tested negative water controls were placed every 6 samples so 
carry over could be detected. Positive controls were at the end of every run. 
2.3.2. Nucleic Acid Extraction 
Total nucleic acid was extracted from 150J.lI volume of sample in 50J.lI of L6 Nucleic Acid 
Extraction Buffer (Severn Biotech Ltd) using the MagNA Pure LC automated system 
(Roche Diagnostics) in conjunction with the MagNA Pure LC Total Nucleic Acid Isolation 
kit (Roche Diagnostics) according to the manufacturers instructions. Total nucleic acid was 
eluted in a 100J.lI volume of elution buffer. 
2.3.3. cDNA Synthesis 
For reverse transcription 22.2J.lI of the total nucleic acid was added to 17.8J.lI reaction 
mixture to create a fmal concentration of 20mM Tris-HCL (pH8.4), SOmM KCL, 7.SmM 
MgCh (Invitrogen), 1.5 mM of each dNTP (Invitrogen), 5.3nglJ.lI of random heximer 
primer pdN6 (Pharmacia Biotech), 16units of RNasin (Promega), and 200units Moloney 
Murine Leukaemia Virus Reverse Transcriptase (Invitrogen). The reaction was incubated at 
room temperature for 10 minutes, 37°C for 50 minutes, 95°C for five minutes and 
quenched on ice, cDNA was then stored at -20°C. 
2.3.4. Primer Design 
Primers were designed using sequences available from the GenBank database available at 
(http://www.ncbLnlm.nih.gov/entrezlquery.fcgi). OLIGO primer analysis software was 
used to assess the TM and GC content, mispriming elsewhere in the hMPV genome, and 
hairpin or primer duplexes. Primers were checked against all other sequences using the 
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Nmsc Basic Local Alignment Search Tool available at 
(http://www.ncbLnlm.nih.govIBLASTD for potential cross reactivity with other genomic 
templates. 
2.3.5. PCR Optimisation 
All optimisation steps were performed changing only one parameter at a time. A number of 
different primers were tried in different combinations. A range of buffer conditions were 
tested (see below). Experiments varying the range of the annealing temperature were 
carried out on PTC - 225 gradient thermocycler (MJ Research). 
2.3.6. PCR Optimisation with the Stratagene Optiprime kit 
Five fJI of each buffer labelled 1-12 (Table 2.1) were aliquoted in to correspondingly 
labelled tubes. The following master mix was then made: 12.5fJI or Optiprime master mix, 
12.5fJI of dNTP mix (at 10mM each dNTP), 12.5JlI of each primer (50pmol/fJl), 125ul of 
cDNA, 1.5U Taq Polymerase. Forty five fJI of this mix was added to the 5JlI of each buffer. 
The tubes were incubated at 94°C for 1 minute followed by 35 cycles of 94°C for 1 
minute, 50°C for 1 minute, 72°C for 1 minute. Two JlI of the primary round product was 
added to another 5fJI of each corresponding buffer with 43fJI of the master mix, as above, 
and incubated as before. 
Table 2.1: Composition of Strata gene PCR optimisation buffers 
Buffer Number Tris-HCL MgCL2 KCL 
1 100mM pH 8.3 15mM 250mM 
2 100mM pH 8.3 15mM 750mM 
3 100mM pH 8.3 35mM 250mM 
4 100mM pH 8.3 35mM 750mM 
5 100mM pH 8.8 15mM 250mM 
6 100mM pH 8.8 15mM 750mM 
7 100mM pH 8.8 35mM 250mM 
8 100mM pH 8.8 35mM 750mM 
9 100mM pH 9.2 15mM 250mM 
10 100mM pH 9.2 15mM 750mM 
11 100mM pH 9.2 35mM 250mM 
12 100mM EH9.2 35mM 750mM 
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2.3.7. Agarose Gel Electrophoresis 
For PCR products I5J.lI was mixed with 2J.lI of Blue Juice (Invitrogen) and run on a 1.25% 
MP Agarose gel (Roche Diagnostics) in I x TBE (Invitrogen). The amplicons were 
visualised using ethidium bromide at Smgll (Invitrogen) and photographed using the Gel 
Doc 2000 System (BioRad). 
2.3.8. hMPV F Gene PCR 2 
The primers used are shown in Table 2.9 and were used at 50pmol. For the primary round 
PCR SJ.lI of cDNA was added to 40J.lI of the reaction mix containing Ix Optiprime Buffer 
10 (10mM Tris-HCL, I.SmM MgCh and 75mM KCI) and 2units Taq DNA polymerase 
(Invitrogen). Amplification using PTC-225 thermo cycler (MJ Research) consisted of I 
cycle at 94°C for 2 minutes followed by 40 cycles of 94°C for 1 minute, 58°C for I minute, 
72°C for 1 minute. Two J.lI of primary round product was added to the secondary round 
amplification mix, as described above with a fmal concentration of 0.2mM of each dNTP. 
Amplification consisted of 1 cycle at 94°C for 2 minutes followed by 35 cycles of 94°C for 
I minute, 52°C for I minute, 72°C for I minute. 
2.3.9. HMPV Attachment Glycoprotein Gene Amplification PCR for Sequencing 
The primers used are shown in Table 2.5 and were used at 25pmol. For the primary round 
PCR 5J.lI of cDNA was added to 20J.lI of the reaction mix containing Ix High Fidelity 
Buffer (60mM Tris-HCL, and I8mM Ammonium Sulphate) 0.2mM MgCh, O.2mM of 
each dNTP and I U Platinum Taq DNA polymerase High Fidelity (Invitrogen). 
Amplification using PTC-22S thermocycler (MJ Research) consisted of 1 cycle at 9SoC for 
2 minutes followed by 40 cycles of 95°C for 30 seconds, SOoC for 30 seconds, 72°C for 30 
seconds followed by and extension of 72°C for 10 minutes. Two J.lI of primary round 
product was added to 48J.lI of the secondary round amplification mix, as described above. 
Amplification consisted of 1 cycle at 9SoC for 2 minutes followed by 40 cycles of 9SoC for 
30 seconds, SSoC for 30 seconds, 72°C for 30 seconds followed by and extension of 72°C 
for 10 minutes. ISJ.lI of the second round product was analysed on a gel. Ifpositive 30Jll of 
the remaining product was rerun an a second gel for Gel purification as described below. 
39 
Chapter 2 - Materials and Methods 
------- ------ - ---- ------------------------------~---------
2.3.10. HMPV Nucleocapsid and Attachment Glycoprotein! protein fragments 
Amplification for Cloning 
The hMPV nucleocapsid and attachment glycoprotein gene or gene fragments were 
amplified by PCR from an hMPV positive clinical sample (Subtype A- by sequencing as 
described below). Twenty JlI of cDNA (as described above) was added to 80J.lI reaction 
mix containing a final concentration of 20mM Tris-HCL (pH8.4), 50mM KCI, and ImM 
MgCh and 3.6 units of taq polymerase (Invitrogen). The primers used are shown in Table 
2.6 and 2.7 and were used at 50pmol. Amplification using PTC-225 thermocycler (MJ 
Research) consisted of 1 cycle at 94°C for 2 minutes followed by 35 cycles of 94°C for 1 
minute, 51°C for 1 minute, 72°C for 1 minute. Amplicons were analysed by agarose gel 
electrophoresis as described above, and gel purified prior to cloning, as described below. 
2.3.11. Gel purification 
Gel Fragments were excised from the agarose gel using a clean scalpel. DNA was purified 
from the agarose using QIAquick gel extraction kit (Qiagen) according to the 
manufacturers instructions. 
2.3.12. Addition of 3' Deoxyadenosine Residues to Proof Reading Taq Polymerase 
Generated PCR Products. 
10JlI of the gel purified product was added to 10JlI reaction mix to give the fmal 
concentrations 0.2mM dATP, 20mM Tris-HCL (pH8.4), 50mM KCL, 7.5mM MgCh, 
1 unit Taq DNA polymerase (Invitrogen). Samples were incubated at 72°C for 10 minutes. 
2.3.13. Purification of PCR Products 
PCR Products were purified using a QIAquick PCR purification kit (Qiagen) according to 
the manufacturers instruction. 
2.3.14. ADI Sequencing 
The hMPV G ORF was sequenced using 3.2 pmol of primers indicated in Table 2.5. Using 
the ABI Big dye Terminator v3.1 Cycling sequencing kit (Applied Biosystems) according 
to the manufacturers instructions. Termination of the sequencing reaction was achieved by 
adding 2JlI of 125mM EDTA (Sigma) and 3ul of 3M sodium acetate (Sigma) to each 
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reaction. To clean up the reaction 50JlI of ice cold 100% ethanol (VWR international) was 
added and incubated at room temperature for 15 minutes. Samples were spun at 4°C 
13000rpm on a chilled micro centrifuge for 45 minutes. Ethanol was removed and the 
pellet washed with 70JlI of 70% ice cold ethanol. Excess ethanol was removed and the 
sample dried using a Savant DNA aped vac 120. Samples were analysed on the Applied 
Biosystems 377 DNA Sequencer XL (DBS genomics, University of Durham). 
2.3.15. Beckman Coulter Sequencing 
The partial F gene was sequenced using 3.2 pmol of primer indicated in Table 2.9. Using 
the Beckman Coulter CEQ 2000 Dye Terminator Cycling sequencing with Quick Start kit 
(Beckman Coulter) according to the manufacturers instructions. Termination of the 
sequencing reaction was achieved by adding 2J.lI of 100mM EDTA (Sigma), 2JlI of 3M 
sodium acetate (Sigma) and IJlI or 20 mg/ml glycogen (supplied with the kit) to each 
reaction. To clean up the reaction 60ul of ice cold 100% ethanol (VWR international) was 
added and spun at 4°C 13000rpm for 15 minutes. Ethanol was removed and the pellet 
washed twice more with 70JlI of 70% ice cold ethanol. Excess ethanol was removed and 
the sample dried using a Savant DNA aped vac 120. Samples were re-suspended in 40J.lI of 
sample loading solution supplied with the kit. Samples were analysed on a Beckman 
Coulter CEQ 8000 Genetic Analysis System. 
2.3.16. Sequence Analysis 
Output files from the sequencer were edited to remove questionable data from the ends of 
the sequences and exported. Files were imported in to SeqMan II (Lasergene, DNAStar) to 
compare forward, reverse and overlapping sequences to generate a consensus sequence. 
Consensus sequences we imported in to MegAlign (Lasergene, DNA Star) where they were 
placed in frame and aligned using the clustal W method for both nucleotide and amino acid 
sequences. 
2.3.17. Sequence and Phylogenetic Analysis 
Amino acid alignments of the different data sets were created using Clustal X, and applied 
to CODON Align with the corresponding nucleotide sequences in order to create in-frame 
nucleotide alignments. The in-frame nucleotide alignments were subsequently used for the 
generation of maximum likelihood trees using the program PAUP (4.1 Ob). The criterion 
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used for creating the trees was determined using the MODELTEST 3.7 (posanda and 
Crandall 1998) application within PAUP. Bootstrapping of maximum likelihood trees was 
impractical due to the large amount of computing time required. Maximum likelihood trees 
were therefore compared with bootstrapped neighbour joining trees. Where trees were 
congruent bootstraps are shown on the maximum likelihood trees. 
In-frame nucleotide alignments were used to calculate Transition: Transversion Ratios 
using the program PUZZLE, and Non-synonymous: Synonymous Ratios using the program 
MEGA 3.1. 
2.3.18. Synthesis of hMPV F gene RNA transcripts for analysis of hMPV F Gene 
RT -peR 2 sensitivity. 
RNA transcripts were prepared from the PTMl vector containing the hMPV F gene PCR 2 
target sequence cloned in frame with a T7 RNA polymerase promoter. The purified 
plasmid containing the insert was provided by Lucy Beasley and Dr Alison Bermingham, 
HP A Colindale. 
Prior to RNA synthesis the vector was linearised at the unique Sma! restriction site located 
downstream of the insert using the Smal restriction enzyme (NEB) according to the 
manufacturers instructions. The linearised plasmid was analysed by DNA gel 
electrophoresis and gel purified using the QlAquick gel purification kit (Qiagen) according 
to the manufacturers instruction. 
To generate the RNA transcripts, T7 RNA polymerase (Invitrogen) was used according to 
the manufacturers instructions. Briefly; O.lJ.lg of linearised plasmid was mixed with lJ.lI 
(50Units) of T7 RNA polymerase, 2J.lI of 5x T7 reaction buffer, 0.5J.lI of O.1M DTT, and 
IJ.lI ofa 4mM UTP, ATP, CTP and GTP mix. The reaction was made up to a fmal volume 
of 10111 with nuclease free water, and incubated at 37°C for 10 minutes. 
Plasmid DNA was removed by RNAse free DNase digest using the Turbo DNA free Kit 
(Ambion) according to the manufacturers instruction. Briefly; IJ.lI (2 Units) of turbo DNase 
was added to 10111 of the transcribed RNA, 5J.lI of the lOx Turbo DNase buffer and 34J.lI of 
nuclease free water. The reaction was incubated for 20 minutes at 37°C. A further llli (2 
Units) of turbo DNase was added and incubated as before. 10J.lI of the re-suspended DNase 
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inactivation reagent was added and incubated at room temperature for 2 minutes. The 
reaction was centrifuged at 10,000g for 3 minutes and the supernatant containing the RNA 
was transferred to a fresh tube. 
To further ensure full removal of plasmid DNA and the purity of the RNA the RNA was 
then purified using an RNeasy column (Qiagen) according to the manufacturers instruction 
and eluted in 30J.lI of nuclease free water. 
The concentration of RNA was measured using a spectrophotometer, and the copy number 
calculated using the following equation: 
Copies/ml of RNA = Concentration of RNA (g/ml)x Avogadro's number 
(Size of RNA transcript (bases))(330 x 1ntlbp) 
Where Avogadro's number = 6.022 x 1023 
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2.4. Cloning Techniques 
2.4.1. Bacterial Cell Culture and Medium 
Transformed E.coli were grown on Luria-Bertani Agar (LB, 1% tryptone, 0.5% yeast 
extract, 0.5% sodium chloride, 0.1 % glucose, 1 % difco agar in distilled water) plates 
containing 100fJ.g/ml ampicillin or 50fJ.g/ml kanamycin where appropriate and incubated at 
37°C overnight. 
Lurina-Bertani Broth (same as above without the 1% difco agar) containing IOOfJ.g/ml 
ampicillin or 50fJ.g/ml kanamycin where appropriate and incubated at 37°C overnight on an 
orbital shaker at 200rpm. 
All media reagents were made in the Colindale HP A media department, and were 
autoclaved at 15psi and 120°C for 20 minutes. 
2.4.2. TOPO Cloning 
Gel extracted or PCR purified PCR products (with 3' end deoxyadenosine residues) were 
cloned in to the TOPO T A pCR 2.1-TOPO cloning vector (Invitrogen) according to the 
manufacturers instruction. 
2.4.3. Ligation in to other Vectors Using Restriction Sites 
Different ratios of vector DNA: insert DNA (3: 1, I: I, 1:3 and I: 1 0, where 100ng of vector 
DNA was used in the 1: 1 ratio) were set up in 20fJ.I reaction volumes containing 400units 
of T4 DNA Ligase (New England Biolabs) and Ix T4 DNA ligase Buffer (50mM Tris-
HCL (pH7.5), 10mM MgCh 10mM dithiothreitol, ImM ATP, 25fJ.g/ml bovine serum 
albumin) and incubated overnight at 16°C. The ligation mix was transformed in to E.coli as 
described below. 
2.4.4. Transformation of E.coli 
Two fJ.I of plasmid DNA or Ligation mix were transformed in to One Shot Chemical 
competent Top 10 E. coli by heat shock according to the manufactures instructions 
(Invitrogen). 250fJ.I of SOC medium was added and incubated at 37°C for 1 hour on an 
orbital shaker at 200rpm. Cells were plated on to LB Plates containing the appropriate 
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selective antibiotic for the plasmid, as described above and pre-treated with 40fll of 40 
mg/ml X-gal (Invitrogen) where appropriate. 
2.4.5. Small Scale Purification of Plasmid DNA 
Cells containing the plasmid of interest were pelleted from a 2ml culture USIng a 
microcentifuge at 13000g and the plasmid DNA purified using the Qiaprep Spin Miniprep 
kit (Qiagen) according to the manufacturers instructions. 
2.4.6. Large Scale Purification of Plasmid DNA 
A 5 ml miniprep culture of E. coli containing the plasmid of interest with the appropriate 
selective antibiotic was incubated for 8 hours. A 1 :200 dilution of the miniprep culture was 
made to give a final 500ml volume with the appropriate selective antibiotic and was 
incubated over night at 37°C on an orbital shaker at 200rpm. Cells were pelleted by 
centrifigation at 6000rpm, and the media discarded. Plasmid DNA was purified using an 
Endofree Plasmid Maxi Kit (Qiagen). 
2.4.7. Restriction Digest Analysis 
Restriction digests were carried out using enzymes with their supplied buffers at a 1 x 
concentration (New England Biolabs) according to the manufacturers instruction. Usually 1 
unit of enzyme for every 1 Jlg of DNA in a 30ul reaction mix. Where double digests were 
carried out the optimal buffer was selected according to the manufacturers guidelines. 
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2.5. Recombinant Baculovirus and Insect Cell Culture Techniques 
2.5.1. Insect Cell Culture 
SF9 cells (Table 2.2) were maintained every 3 to 4 days in SF-900 II medium with L-
glutamine (Invitrogen) and supplemented to a final concentration of 2% FBS (Invitrogen) 
and 50Jlg/ml Gentamicin (Invitrogen). Cells were seeded at 5xl0s cells/mI in a 50ml 
volume in a 250ml Corning Erlenmyer flask (Sigma), and passaged every 3 to 4 days, not 
allowing the cells to reach densities above lXI07 cells/ mI. 
High 5 cells (Table 2.2) were maintained as above every 2 -3 days using serum free 
Express 5 medium (Invitrogen) supplemented with 0.2mM L-glutamine (Invitrogen). 
2.5.2. Preparation of Bacmid DNA 
20Jlg of purified Bacmid DNA (kindly supplied by Prof. Ian Jones, University of Reading) 
was linearised by restiction digest with BSU361, (for which there is a unique site within 
the bacmid DNA) with Ix NEB Digest buffer3 (50mM Tris-HCL, 100mM Nacl, 10mM 
MgCL2, ImM dithiothreitol, pH 7.9) with 1.2ng/JlI BSA and 60Units BSU 361 restriction 
endonuclease (New England Biolabs) in a total reaction volume of 80ul. The reaction was 
incubated 37°C for two hours followed by the addition of another 6JlI of BSU 361 and 
incubate for a further 2 hours at 37°C and inactivated at 80°C for 20 minutes. 
2.5.3. Generation of Recombinant Baculovirus 
A 6 well tissue culture plate was seeded with Sf9 cells at 1 x 106 cells/well in 2ml of 
growth medium and allowed to adhere for 30 minutes at room temperature. The growth 
medium was removed and the cells washed once and replace with serum and antibiotic free 
SF-900 II medium 
The transfection mix was made containing 1 f.lg of Bacmid DNA, 0.5Jlg of Transfer vector 
DNA containing insert, 8JlI of Reagent (Invitrogen) and made up to a final volume of 24f.l1 
with Nuclease free water (Promega) and incubated at room temperature for 15 minutes. 
One ml of serum! antibiotic free medium was added to the mixture. The entire transfection 
mixture replaced the medium on the cells and incubated for 16 hours at 28°C. The 
transfection mixture was replaced with 2 ml of growth medium and incubated for a further 
5 days. Cells were monitored daily for CPE. 
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2.5.4. Recombinant Baculovirus Growth 
Five ml of SF9 cells were seeded at 8 x 106 cells Iml, and incubated for 2 hours at 28°C 
with 1ml of the transfection mix or O.IMOI of recombinant baculovirus for preparation of 
high titred virus stock. The volume was made up to SO ml with growth medium and 
incubate at 28°C shaking at IISrpm for 4 days. Cells were pelleted at 1000RCF for IS 
minutes and the supernatant containing the virus harvested. For protein production the 
procedure was repeated as above using 3xl07 cells Iml in S ml for seeding and 3MOI or 
more of recombinant baculovirus. These cells were collected by centrifugation as above 
and prepared for protein purification. 
When using High S cells for protein production the procedure was repeated as above using 
Sml of Ix 107 cells/ml for seeding with SMOI of virus. 
2.5.5. Plaque Assay 
Six well tissue culture plate was seeded with Sf9 cells at 1 x 106 cellslwell in 2ml of 
growth medium and allowed to adhere for 30 minutes at room temperature. Media was 
removed and replaced with 1m! of fresh growth medium. Ten fold serial dilutions (10.1 to 
10.8) of the virus was made in 1 m! of growth medium and 100JlI of the diluted virus staring 
with the 10.3 dilution were added to the 1m! of media in duplicate wells, to give fmal 
dilution range of 10-4 to 10.9 of the virus. Virus was absorbed for 2 hours at 28°C. Media 
was removed and cells overlaid with 2ml of 3.2% Agarose type VII (Sigma) mixed 1:1 
with growth medium, to give a fmal concentration of 1.6% agarose. Once set. 1 ml of 
growth medium was added on top of the agarose. Cells were incubated at 28°C for 6 days. 
Plates were stained with 2m! of Neutral Red (Sigma) diluted 1 :20 with PBS (final 
concentration of 16Smg/l of neutral red) for 2 hours. The stain was removes and plates 
dried for 6 hours before the plaques were counted. 
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2.6. Analysis of Expressed Baculovirus Proteins 
2.6.1. SDS PAGE gel 
Protein samples were resolved by discontinuous SDS polyacrylamide gel electrophoresis 
(SDS PAGE). Prior to analysis cells were lysed with the appropriate lysis buffer; 1 %(v/v) 
nonident P-40 for mammalian cells or Ix Insect pop culture reagent for insect cells 
(Novagen). The required amount of sample was mixed to give a final concentration of Ix 
Nupage LDS sample buffer (Invitrogen) and Ix Nupage Sample reducing agent 
(Invitrogen) containing DTT and heated for 10 minutes at 100°C. The samples (l5-25Jll) 
were run on 10 or 15 well 4-12% Nupage Novex Bis-Tris acrylamide gels(1.5mm thick) 
(Invitrogen), for approximately 1 hour at 180V with 1 x MOPS or 1 x MES Buffer 
(Invitrogen) using the XCell SureLock Mini Cell electrophoresis equipment (Invitrogen). 
2.6.2. Western Blotting 
Proteins were transferred from SDS PAGE gel on to Hybond nitrocellulose ECL 
membranes (Amersham Biosiences) using the XC ell SureLock Mini Cell transfer 
equipment (Invitrogen), with 1 x Nupage transfer buffer (Invitrogen) and 10% Methanol per 
gel/membrane transfer. After transfer membranes were blocked for 1 hour at room 
temperature or overnight at 4°C in 25ml PBS containing 5% (w/v) dried skimmed milk 
powder. Membranes were then incubated with primary antibody diluted in PBS containing 
0.1 % (v/v) TWEEN 20 (VWR International) and 5% (w/v) dried skimmed milk powder for 
1 hour at room temperature. Membranes were washed 3 times for 10 minutes with PBS 
containing 0.1% (v/v) TWEEN 20. Membranes were incubated with secondary HRP 
conjugated antibody diluted in PBS containing 0.1 % (v/v) TWEEN 20 and 5% (w/v) dried 
skimmed milk powder for 1 hour at room temperature. Membranes were washed 3 times 
for 10 minutes with PBS containing 0.1% (v/v) TWEEN 20. Bound antibody was detected 
using the chemoluminescence (ECL) detection reagents (Amersham Biosciences). 
Membranes were wrapped and exposed to Hyperfilm ECL (Amersham Biosciences) for 1-
20 minutes. Film was developed manually using CD18 Developer and fixer (GRI limited.) 
2.6.3. Coomassie Stain 
Proteins run on SDS PAGE gels were visualised using Simply Blue Coomassie safe stain 
(Invitrogen). The gel was washed 3 times for 5 minutes with distilled water. Enough Safe 
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stain was used to cover the gel, and was incubated on a rocker for Ihour at room 
temperature. The gel was washed 3 times for 5 minutes with distilled water, and incubated 
in distilled water on a shaker overnight to destain. Gels were preserved using a gel drying 
solution Kit (Invitrogen) according to the manufacturers instructions. 
2.6.4. BioRad protein assay 
To quantitate total protein by a protein assay. The BioRad DC Protein assay kit was used to 
the manufacturers instruction. 
2.6.5. Immunofluorescence 
Transfected or infected cells were fixed by 80% ice cold acetone in PBS or 4% 
paraformaldehyde for 10 minutes. Cells fixed with paraformaldehyde were permeabilised 
with 0.25% Triton X-I00 (v/v) and washed 3 times for 5 minutes with PBS containing 
0.1% (v/v) TWEEN 20. Cells were blocked with 1% BSA (v/v) in PBS for 15 minutes, and 
washed as before. Cells were incubated with primary antibody diluted in PBS containing 
0.1 % (v/v) TWEEN 20 and 1% BSA (v/v) for 30 minutes at 37°C. Cells were washed as 
before. Cells were incubated with Secondary FITC conjugated antibody diluted in PBS 
containing 0.1% (v/v) TWEEN 20 and 1% BSA (v/v) for 30 minutes at 37°C. In some 
instances 0.01% Evans blu counterstain was included in the secondary antibody diluent. 
Cells were washed as before. In some instances 1 ug/ml DAPI Nuclear Stain(Roche) was 
incubated with the cells for 15minues at room temperature, and washed as before. 
Fluorescence was analysed using a Zeiss Axiovert 200 Inverted Microscope. Images were 
captured with a Zeiss AxioCam HRc and Axio vision software. 
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2.7. Protein Purification 
2.7.1. Preparation of cell lysate 
SF9 cells infected with recombinant baculovirus expressing the hMPV N protein were 
pelleted by centrifugation at 3000rpm for 10 minutes. The cells were resuspended in one 
fifth of the original culture volume with Ix Insect pop culture reagent for insect cells 
(Novagen) supplemented with Ix protease inhibitor cocktail set I (CalBiochem) and 
10units/mi of Benzonase Nuclease (Novagen) and incubated at room temperature for 15 
minutes. The cell lysate was clarified by centrifugation at 3000rpm for 10 minutes. The 
clarified supernatant was purified by Ni-NTA affmity column, or stored at -20°C. 
SF9 cells infected with recombinant baculovirus expressing the hMPV G-FL protein were 
pelleted by centrifugation at 3000rpm for 10 minutes. 
The cells were lysed by resuspending the pellet in either: 
• 1 x Insect pop culture reagent 
• 1%NP-40 
• 0.1% Triton X-I00 
• 2% Tween-20 
Each lysis reagent was supplemented with Ix protease inhibitor cocktail set I (CalBiochem) 
and IOunits/ml of Benzonase Nuclease (Novagen) and incubated at room temperature for 
15 minutes. The cell lysate was clarified by centrifugation at 3000rpm for 10 minutes. 
2.7.2. Ni NT A protein purification of the hMPV N protein 
The 6 x histadine Tagged hMPV N protein was purified using a Ni-NTA his bind resin and 
buffer kit (Novagen) under native conditions according to the manufacturers instructions. 
Purification required some optimisation of buffer conditions. 
Briefly; the lysed cell preparation (described in 2.7.1) was clarified by centrifugation and 
o 
applied to the Ni-NTA bind slurry and incubated on a shaker at 4 C for 2 hours. The slurry 
contained Ni-NTA sepharose beads and 10mM imidazole buffer. The mixture was then 
packed in to a column for the washing and elution steps. Unbound and non-specific 
proteins were removed using increasing concentrations of imidazole buffer. N-FL was 
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eluted using a 250mM imidazole buffer. Each of the fractions was collected and analysed 
by ELISA, Western blot and protein gel for purity of the purified eluted protein fragments, 
as described in section 2.6. 
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2.8. Generation of hMPV Specific Antiserum 
HMPV specific antiserum was raised against whole virus grown In cell culture, and 
baculovirus expressed recombinant hMPV nucleocapsid protein and attachment 
glycoprotein using female New Zealand White Rabbits. Summarised details of the antigen, 
prepared innoculum and inoculation schedule for each antiserum is provided in Table 2.2. 
An schematic of the inoculation and bleeding schedule for each antiserum is shown in 
Figure 2.1 below. 
Table 2.2: hMPV Specific antiserum raised and evaluated in this study. 
Antiserum 
Rabbit a-hMPV 
Total 
Rabbit a-hMPV 
N-FL 
Rabbit a-hMPV 
G (s)-Fc 
Immunogen 
hMPV infected RMK cell lysate approximately 1 x 105 cells/ml. 
Unknown amount of hMPV virus, assumed to be very low titre, no adjuvant 
was used. 4 x 0.25ml of the inoculum was injected at 4 points along the dorsal 
of the rabbit with a booster given on day 30 into the hind leg muscle. Terminal 
Bleed taken day 60. 
Purified baculovirus expressed hMPV N-FL 
100ng of purified protein 10mM Purified LPS 0.5ml incomplete Freund's 
adjuvant. 4 x 0.25ml of the inoculum was injected at 4 points along the dorsal 
of the rabbit.lOOng purified N-FL with 10mM LPS and saline was given as a 
second immunogen on days 21 and 40 into the hind leg muscle. Test bleeds 
taken days 35 and 55. Terminal Bleed taken day 60. 
Baculovirus expressed hMPV G(s)-Fc High 5 supernatant 
100ng of total protein from the cell supernatant with 10mM Purified LPS 0.5ml 
incomplete Freund's adjuvant. 4 x 0.25ml of the inoculum was injected at 4 
points along the dorsal of the rabbit. 100ng of total protein from the cell 
supernatant with 10mM LPS and saline was given as a second and third 
immunogen on days 21 and 40 into the hind leg muscle. Test bleeds taken days 
35 and 55. Terminal Bleed taken day 60. 
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Day 0 21 30 35 40 55 60 
I I I I I I I 
u-bMPV Total 
• • • • 
u-bMPVN 
• • • • 
u-bMPV G(s) 
• • • •• 
Key: - Bleeds Taken " Inoculations given 
Figure 2.1: Schedule of rabbit inoculations for the generation of hMPV specifc 
antiserum. (i) Rabbit a-hMPV Total was generated by Dr Joanne Stockton at the HPA 
Colindale. (ii) hMPV N-FL Specific polyclonal serum was raised against 100ng of hMPV N-FL 
mixed with purified lipopolysaccharide and incomplete Freund's adjuvant to form an emulsion. 
(iii) hMPV G(s) Specific polyclonal serum was raised against 100ng of hMPV G(s) Supernatant 
mixed with purified lipopolysaccharide and incomplete Freund's adjuvant to form an emulsion. 
2.8.1. Rabbit a-hMPV total 
The Rabbit a-hMPV total antiserum was prepared and provided by Dr Joanne Stockton, 
HP A Colindale. hMPV was isolated from a combined nose and throat swab collected in 
2001 as part of the Leicester study described in Chapter 3 and is an A subgroup virus but is 
a different strain to those used elsewhere in the study. The details describing the isolation 
of this strain are unavailable. The inoculum used to generate this rabbit serum is an hMPV 
infected RMK cell lysate of approximately 1 x 105 cells/ml. The lysate was prepared by lysis 
with distilled water, sonicated for 15 minutes and diluted 1:2 with saline. 4 x 0.25ml of the 
inoculum was injected at 4 points along the dorsal of the rabbit with a booster given on 
day 30 into the hind leg muscle. The terminal bleed was taken day 60, and the serum cross 
absorbed against RMK cells to remove antibody directed towards cellular proteins. 
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2.8.2. Rabbit a-hMPV N 
F or the hMPV nUcleocapsid protein the primary inoculation consisted of 100ng of purified 
N protein (For expression purification methodology of hMPV N see sections 2.5, 2.6 and 
2.7 and Chapter 5 for more detail) , with 10mM purified lipopolysaccharide and incomplete 
freunds adjuvant kindly supplied by Dr Henrick Chart to total volume of 1m1 and sonicated 
to form an emulsion. Four x 0.25ml of the emulsion was injected at 4 points along the 
dorsal of the rabbit. The following 2 booster inoculations given at 21 and 40 days 
contained 100ng of purified N and 10mM purified lipopolysaccharide. Saline was used to 
make the volume Up to Iml. 0.5 ml was injected in to each of the hind legs. Two test bleeds 
were taken on days 33 and 55. Terminal bleed was taken day 62. 
2.8.3. Rabbit a-hMPV G(s)-Fc 
The rabbit a-hMPV G(s)-Fc was raised against baculovirus expressed recombinant hMPV 
attachment glycoprotein High 5 cell culture supernatant. Cell culture supernatant 
containing 100ng of total protein was mixed with 10mM Purified LPS 0.5ml incomplete 
Freund's adjuvant kindly supplied by Dr Henrick Chart to total volume of 1 m1 and 
sonicated. 4 x 0.25ml of the inoculum was injected at 4 points along the dorsal of the rabbit. Two 
booster inoculations of the baculovirus expressed hMPV G(s)-Fc cell culture supernatant 
containing 100ng of total protein mixed with 10mM Purified LPS and made up to 1 ml with 
saline were given on days 21 and 40 into the hind leg muscle. Test bleeds taken days 35 and 55. 
Terminal Bleed taken day 60. The serum cross absorbed against High 5 cells to remove 
antibody directed towards cellular proteins. 
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2.9. ELISA Techniques 
2.9.1. ELISA Optimisation 
All optimisation steps were performed changing only one parameter at a time. A number of 
different coating buffers, antigen, primary and secondary antibody formulas and 
concentrations were tested as described in chapter 6. 
2.9.2. Antigen Preparation for ELISA 
Uninfected and hMPV N baculovirus infected cell lysate was prepared in one batch to 
provide enough antigen for the study. SF9 cells infected with recombinant baculovirus 
expressing the hMPV N protein were pelleted by centrifugation at 3000rpm for 10 minutes. 
The cells were resuspended in one fifth of the original culture volume with 1 x Insect pop 
culture reagent for insect cells (Novagen) supplemented with 1 x protease inhibitor cocktail 
set I (CaIBiochem) and 10units/ml of Benzonase Nuclease (Novagen) and incubated at 
room temperature for 15 minutes. The cell lysate was clarified by centrifugation at 
3000rpm for 10 minutes. Nucleoprotein positive and uninfected cell lysate were 
standardised to contain the same amount of total protein by gel analysis. 
2.9.3. Serological ELISA for the Detection of Human IgG Against hMPV 
Nucleoprotein. 
A 96 well U bottom Nunc Maxisorb ELISA plate (Fisher scientific) was coated overnight 
at 4°C with I00f.11 per well ofhMPV N positive Sf9 cell lysate or uninfected cell lysate (as 
described above) diluted 1 :200 with 20mMTris HCL (pH9.6) to give a final total protein 
concentration of 400ng/ well. Plates were washed 4x with PBS containing 0.05% TWEEN 
20 (v/v) using a Tecan Plate washer. Plates were incubated with I00f.11 of test or control 
serum diluted 1: 100 with PBS containing 0.5% (v/v) TWEEN 20 and 5% (w/v) dried 
skimmed milk powder for 1 hour at 37°C on an orbital Plate shaker (Edmund BUhler 
TiMix) at 600rpm. Each test serum or control serum was tested in duplicate against both 
the hMPV N SF9 cell lysate and uninfected cell lysate. Plates were washed as before and 
incubated with 100f.11 of Rabbit (X- Human IgG HRP conjugated antibody (Dako) at 1 :5000 
dilution with PBS containing 0.5% (v/v) TWEEN 20 and 5% (w/v) dried skimmed milk 
powder and incubated as before. Plates were washed as before and incubated in the dark 
with 100f.11 of TMB substrate (Europa Bioproducts Ltd M0701A) for 5 minutes. The 
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reaction was stopped with lOOfll of 0.5M HCL (VWR International). The Absorbance at 
450nm (reference 670nm) was measured using a 96 well Tecan Spectra Image plate 
reader. 
2.9.4. Correction and Data analysis 
Subtract the OD 450 value for the hMPV N negative cell lysate was subtracted from that of 
the N positive cell lysate to give the corrected OD450 Value. Each sample was tested in 
duplicate so the average corrected OD450 value was determined. Samples with an average 
corrected OD450 value below the OD450 Cut off value of 0.4 were negative for hMPV N 
IgG, while those at or above were positive. 
2.9.5. Statistical analysis 
Where appropriate statistical analysis was performed using the students t-Test. 
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2.10. Transient expression of the full length hMPV G protein in 
mammalian cells. 
2.10.1. Transfection 
The purified pTriex vector containing the full length hMPV G gene was transfected into 
293T I Vero cells using Lipofectamine 2000 (Invitrogen) according to the manufacturers 
instruction. 
96 well tissue culture plates were seeded with 5xI04 cells Iwell of 293T or vero cells in 
growth medium [Minimum Essential Medium (MEM) (lX) liquid containing Earle's salts, 
and 25 mM HEPES (Invitrogen) supplemented with a final concentration of 10% Foetal 
Bovine Serum (Invitrogen), 2mM Glutamax I (Invitrogen), 50J.1g/ml Gentamicin 
(Invitrogen), and Ix MEM Non- Essential amino acid solution (Sigma)]. And incubated 
overnight, or until 90% confluent monolayer's were formed, in a 37°c incubator with 5% 
C02. On the day of transfection the growth medium was removed and the cells washed 
three times with I00J.11 of transfection medium [Minimum Essential Medium (MEM) (lX) 
liquid containing Earle's salts, and 25 mM HEPES (Invitrogen) supplemented with a final 
concentration of 2mM Glutamax I (Invitrogen) and Ix MEM Non- Essential amino acid 
solution (Sigma)]. After washing I00J.11 oftransfection medium was dispensed per well. 
The transfection mix was prepared by diluting 0.2-0.8J.1g of the plasmid DNA (0.4J.1g was 
optimal) in 25J.11 of transfection medium. In a separate tube 0.5J.11 of the Lippofectamine 
2000 reagent was diluted in 25 J.11 of transfection media and incubated at room temperature 
for 5 minutes. The diluted transfection reagent was the added to the diluted plasmid and 
incubated at room termperature for a further 20 minutes. The entire 50J.11 of the transfection 
mixture was then added to each well of the 96 well plate containing the cells and 100 J.11 of 
the transfection media. The plate was incubated in a 37°c incubator with 5% C02 for 24-
72 hours. For those plates being incubated > 24 hours, after the initial 24 hours the media 
and transfection reagent were removed, and replaced with I00J.11 of fresh growth medium. 
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2.10.2. Immunofluorescence analysis 
Transfected cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilised with 
0.25% Triton X-I00 (v/v) and washed 3 times for 5 minutes with PBS containing 0.1% 
(v/v) TWEEN 20. Cells were blocked with 1 % BSA (v/v) in PBS for 15 minutes, and 
washed as before. Cells were incubated with Mouse a-6x histidine MAb diluted 1 :50 in 
PBS containing 0.1% (v/v) TWEEN 20 and 1% BSA (v/v) for 30 minutes at 37°C. Cells 
were washed as before, and incubated with a Rabbit a-mouse IgG FITC conjugated 
antibody diluted 1 :40. 1 ug/ml DAPI Nuclear Stain(Roche) was incubated with the cells for 
15minues at room temperature, and washed as before. Fluorescence was analysed using a 
Zeiss Axiovert 200 Inverted Microscope. Images were captured with a Zeiss AxioCam 
HRc and Axio vision software. 
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Table 2.3 CeU lines and Bacterial Strains used in this study 
Cell Line Comments Source 
LLC-MK2 Rhesus Monkey Kidney ATCC 
Epithelial Cells 
293T Human Kidney Epithelial ATCC 
cells transformed with 
adenovirus 5 DNA, 
expressing T7 promoter 
Hep- 2 HeLa contaminant - Human ATCC 
Adenocarcinoma Cervix 
Epithelial Cells 
HEP2V Hep-2 cells stably Prof. Rick Randal 
expressing SV -5 V protein. University of St Andrews 
A549 Human Lung Carcinoma ATCC 
Epithelial Cells 
BS-C-l African Green Monkey ATCC 
Kidney Epithelial cells 
VERO African Green Monkey ATCC 
Kidney Epithelial Cells 
RMK Primary Monkey Kidney Cambridge HP A 
Cells 
SF9 Insect cell line from Invitrogen 
Spodoptera frugiperda 
HIGH 5 Insect cell line from Invitrogen 
Trichop/usia ni 
TOP 10 Chemically competent E. coli Invitogen 
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Table 2.4 Vectors and Constructs used and generated in this study 
Plasmid Comments Antibiotic Source 
Resistance 
PCR -2.1-TOPO Linearised vector with 3' - thymidine Ampicillin! Invitrogen 
overhangs for T A cloning, covalently Kanamycin 
bound to Topoisomerase I 
PTriEx-2 Neo 3 system expression vector with a hybrid Ampicillin / Novagen 
CMV chicken J3-actin promoter for Neomycin 
mammalian cell expression, flanking polh Sulphate 
baculovirus sequences for homologous 
recombinanation and pI 0 promoter for 
expression in insect cells, and T7 lac 
promoter for expression in E. coli. A 
number of tags are available. 
PtriEx - human Same as PTriEx-2 N eo vector engineered Amplicillin Prof. Ian 
IgGFc to contain a carboxyl terminal human IgG Jones 
FC for fusion proteins when using the University 
engineered Sfi 1 sites. of 
Reading 
PTriEx-2 Neo- PTriEx-2 Neo vector with hMPV Ampicillin / This 
hMPVNORF Nucleoprotein ORF subtype A derived Neomycin Project 
from a clinical sample inserted with Notl Sulphate 
Bam HI sites with in frame amino 
terminal 6 x Histadine tag. 
PTriEx-2 Neo- PTriEx-2 Neo vector with hMPV Ampicillin / This 
hMPVN Nucleoprotein Fragment A inserted with Neomycin Project 
Fragment A Notl Bam HI with in frame amino Sulphate 
terminal 6 x Histadine tag. 
PTriEx-2 Neo- PTriEx -2 Neo vector with hMPV Ampicillin / This 
hMPVN Nucleoprotein Fragment B inserted with Neomycin Project 
Fragment B Notl Bam HI with in frame amino Sulphate 
terminal 6 x Histadine tag. 
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Plasmid Comments Antibiotic Source 
Resistance 
PTriEx-2 Neo- PTriEx-2 Neo vector with hMPV Ampicillin / This 
hMPVN Nucleoprotein Fragment C inserted with Neomycin Project 
Fragment C Not 1 Bam HI with in frame amino Sulphate 
terminal 6 x Histadine tag. 
PTriEx-2 Neo- PTriEx-2 Neo vector with hMPV Ampicillin / This 
hMPVN Nucleoprotein Fragment D inserted with Neomycin Project 
Fragment D Notl Bam HI with in frame amino Sulphate 
terminal 6 x Histadine tag. 
PTriEx-2 Neo - PTriEx-2 Neo vector with hMPV Ampicillin / This 
hMPVN Nucleoprotein Fragment F inserted with Neomycin Project 
Fragment F Notl Bam HI with in frame amino Sulphate 
terminal 6 x Histadine tag. 
PTriEx-2 Neo PTriEx-2 Neo vector with hMPV Ampicillin / This 
hMPVGORF Attachment Glycoprotein ORF subtype A Neomycin Project 
derived from a clinical sample inserted Sulphate 
with Not! Bam HI with in frame amino 
terminal 6 x Histadine tag. 
PtriEx - human PtriEx - human IgGFc vector with Ampicillin This 
IgGFchMPV hMPV truncated Attachment Project 
G(s) Glycoprotein ORF without the 
cytoplasmic/ transmembrane regions 
inserted with Not! Bam HI sites with in 
frame amino terminal 6 x Histadine tag. 
Bac IO:K01629 Plasmid encoding the entire genome of Kanamycin Prof. Ian 
(Referred to as AcMNV lacking an essential gene for Jones 
Bacmid) replication. Used for the generation of University 
recombinant baculovirus when co of 
transfected with pTriEx-2 Neo vectors. Reading 
PTMI-hMPVF PTMI vector with the hMPV F gene 2 Ampicillin L. Beasley 
Gene PCR2 PCR target cloned in frame with a T7 HPA 
target promoter Colindale 
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Table 2.5 Commercial/Non-Clinical Antiserum used in this study 
Antiserum 
Mouse anti 6 x histidine 
Rabbit anti mouse 
Immunoglobulins HRP 
Rabbit anti Mouse 
Immunoglobulins FITC 
Rabbit anti hMPV total 
Rabbit anti hMPV N-his 
Rabbit anti hMPV G( s) 
Rabbit anti hMPV N-his 
FITC 
Goat anti Rabbit HRP 
Comments 
A monoclonal antibody(lgG1) 
against five consecutive histidine 
residues. 
Source 
Novagen 
Peroxidase conjugated antibody for DakoCytomation 
the detection of Mouse 
Immunoglobulin primary antiserum 
for techniques such as ELISA or 
Western Blot. 
FITC conjugated antibody for the DakoCytomation 
detection of Mouse Immunoglobulin 
primary antiserum for techniques 
such as Immunofluorescence 
Polyclonal Rabbit antiserum raised 
against hMPV infected RMK cell 
lysate 
Polyclonal Rabbit antiserum raised 
against purified baculovirus 
expressed hMPV nucleoprotein 
Polyclonal Rabbit antiserum raised 
against baculovirus expressed 
hMPV G(s) Sf9 cell lysate 
FITC conjugated IgG Polyclonal 
Rabbit antiserum raised against 
purified baculovirus expressed 
hMPV nucleoprotein 
This study 
This study 
This study 
This study with Dr 
Dhan Samuels HP A 
Colindale 
Peroxidase conjugated antibody for Kirktengaard and 
the detection of Rabbit IgG primary Perry Laboratories 
antiserum for techniques such as 
ELISA or Western Blot. 
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Comments 
FITC conjugated antibody for the 
detection of Rabbit IgG primary 
antiserum for techniques such as 
Immunofluorescence 
Source 
DakoCytomation 
Rabbit anti Human IgG HRP Peroxidase conjugated antibody for DakoCytomation 
Rabbit anti Human IgG 
FITC 
Rabbit anti Human IgG 
Fab2HRP 
Human Serum Pool 
Human sera < 15 years 
Human sera > 15 years 
the detection of human IgG primary 
antiserum for techniques such as 
ELISA or Western Blot. 
FITC conjugated antibody for the 
detection of human IgG primary 
antiserum for techniques such as 
Immunofluorescence 
DakoCytomation 
Peroxidase conjugated antibody for Sigma 
the detection of human IgG F AB 2 
region of primary antiserum for 
techniques such as ELISA or 
Western Blot. 
Adult human serum submitted to the Respiratory Virus 
Respiratory Virus Unit, HP A, unit, HP A Colindale 
Colindale as part of routine 
influenza surveillance. The pool is 
made from adult sera negative fIT 
influenza IgG in 2001 
Colindale HPA (2001-2004) sera Respiratory Virus 
submitted to the HP A for serological unit, HP A Colindale 
investigation of influenza. 
Colindale HPA (2001-2004) sera Respiratory Virus 
submitted to the HP A for serological unit, HP A Colindale 
investigation of influenza. 
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Adult acute and Co lindale HPA (2001) sera Respiratory Virus 
convalescent RSV AlB sera submitted as part of investigation in unit, HP A Colindale 
to the cause of AR TI in particular 
hRSV ill community dwelling 
elderly> 65 years old (Chapter 3) 
Paediatric acute and Colindale HPA. Neonatal paediatric Respiratory Virus 
convalescent RSV AlB sera sera collected as part of a unit, HP A Colindale 
longitudinal cohort study of RSV 
infection in childhood (Althani, 
2004). 
Age stratified panel of sera < Colindale HP A. Sera from UK Immunisation and 
72 months children submitted to the HP A for Diagnosis Unit, 
investigated of rash illness HP A Colindale 
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Table 2.6 hMPV G Gene Sequencing Primers 
Primer Gene Position· Sense Sequence 5'-3' Source 
HMPVG6100F8 G 6100-6120 + TTT~TATTTTGAJV\AC This study 
HMPVLABRa L 7185-7204 AGATAGACATTAACAGTGGA This study 
HMPVGAF8 G 6233-6259 + GGGACAAGTAGTTATGGAGGT This study 
GAAAG 
HMPVGBFa G 6233-6259 + GGGACAAGTGGCCATGGAAGT This study 
AAGAG 
MI3Fb TOPO GTAAAACGACGGCCAG Invitrogen 
MI3Rb TOPO + CAGGAAACAGCTATGAC Invitrogen 
HMPVGAI 104PC G 6348-6365 + CCTAATAGGAATAACTAC This study 
HMPVGA 1 529Rc G 6789-6770 GCTGCTTGTGCGGAGAGTGG This study 
HMPVGA1332PC G 6574-6503 + GCAAGCTCACCAGAGACAGAA This study 
CC 
HMPVGA2 126pd G 6367-6387 + CTGAGTATAGCCCTCAATATC This study 
HMPVGA2 226Fd G 6467-6488 + CAATCCAAACTCACAGCATCC This study 
HMPVGA2 494Rd G 6754-6733 CCTTCGCTGTTGTCCGTGGTGG This study 
HMPVGB 1 126Fe G 6367-6384 + GCATGGCACTTAATATTTTCC This study 
HMPVG Bl 519Re G 6773-6757 GTTGGGTGCAGCTGTGC This study 
Footnotes: (a) Primers used for amplification of the hMPV G ORF, (b) primers located in the 
TOTO vector used for the first round of sequencing, (c) Primers used for the second round of 
sequencing for A 1 strains, (d) Primers used for the second round of sequencing of A2 strains, (e) 
primers used for sequencing of B 1 strains, (*) Sequence positions according to reference strain 
NL-OOI. 
Table 2.7 hMPV G Gene Cloning Primers 
Primer 
HMPVGBAMHIF8 
HMPVGBAMHI 
HMPVG (S) BACFb 
HMPVG (S) BACRb 
Gene Position· Sense Sequence 5'-3' Source 
G 6247-6267 + GGATCCTATGGAGGTGAAAG This study 
TGGAGAA 
G 6956-6937 
G 6406-6421 
G 6956-6937 
+ 
GGA TCCTGTT AACTAGTTTG This study 
GTTGTATG 
GGCCA TT A TGGCCA TACAA T This study 
GCAAGAJV\AC 
GGCCGAGGCGGCCACTAGTT This study 
TGGTTGTATGTTGTTGA 
Footnotes: (a) Primers used for amplification of G-FL for cloning in to the pTRiEx vector (b) 
Primers used for amplification of G(s) for cloning in to the pTRiEx vector, (*) Sequence positions 
according to reference strain NL-OO 1. 
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Table 2.8 hMPV N Gene Cloning Primers for the pTRiEX vector. 
Primer Gene Position * Sense Sequence 5'-3' Source 
HMPV N PRIMER A N 40-59 + GGATCCCATGTCTGTTCA This study 
PTRlEX AGGGATTCACC 
HMPV N PRIMER B N 520-502 GCGGCCGCCTTAGATTAT This study 
PTRIEX GGGTGTGTCTGG 
HMPV N PRIMER C N 520-538 + GGATCCCTTATTATGTGT This study 
PTRIEX AGGTGCC 
HMPV N PRIMER D N 880-859 GCGGCCGCCTTAACCTTG This study 
PTRIEX GACGGATACATG 
HMPV N PRIMER E N 880-899 + GGATCCCGAGTTAAAACA This study 
PTRIEX GGTCACAG 
HMPV N PRIMER F N 1225-1206 GCGGCCGCCTTACTCATA This study 
PTRIEX ATCATTTTGAC 
Footnotes: (*) Sequence positions according to reference strain NL-OOI. 
Table 2.9 pTRiEX Vector sequencing primers 
Primer 
TRIEXUP 
TRIEX2R 
POLH105 
FC-60R 
Sequence 5'-3' 
GTT ATT GTG CTG TCT CAT CA 
AA T TAC CAC ACC AGC CAC CAC CT 
ATA GTT GCT GAT ATC ATG GAG 
TTC AGG TGC TGG GCA CGG TGG 
Source 
NOVAGEN 
Dr P.Heinen HP A 
Dr P .Heinen HP A 
This study 
Table 2.10 hMPV PCR 2 Primers 
Primer Gene 
HMPVF283F F 
HMPVF575R F 
HMPVF3052F F 
Position * Sense 
3334-3353 + 
3645-3626 
3052-3071 + 
Sequence 5'-3' Source 
ATTGAAAA TCCCAGA This study 
CAATC 
TCTGTTGAA TTGACTG This study 
AAGC 
ATGTCTTGGAAAGTG This study 
GTGAT 
Footnotes: (*) Sequence positions according to reference strain NL-OO 1. 
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forhMPV 
Chapter 3 - hMPV Epidemiology 
3.1. Introduction 
The use of RT-PCR for the diagnosis of respiratory viruses is fast becoming the gold 
standard in diagnostic laboratories as it offers a number of advantages over conventional 
methods such as virus isolation in cell culture, and immunofluorescence (Dumler & 
Valsamakis, 1999, Tang, 2003, Tang et aI., 1997). 
Cell culture isolation is time consummg and is dependent on obtaining good quality 
samples with viable virus. This technique is also limited by the use of cell lines which, 
often, do not support the growth of many viruses. Growth of hMPV in tissue culture has 
proved to be difficult, with very few reports of successful laboratory isolation (Peret et aI., 
2002, van den Hoogen et aI., 2001). RMK and LLC-MK2 cells have been reported to give 
the best results, but requires incubation periods of up to 3 weeks often without cytopathic 
effect (CPE). The use of primary cell lines such as RMK which often provide the best 
opportunity for isolating a broad spectrum of viruses, however, is being phased out in part, 
due to ethical issues surrounding the use of such cell lines, but also the advancement in 
other technologies and the need for more rapid tests. 
Immunofluorescence is also frequently used in diagnostic laboratories, and while it is a 
simple technique that provides a rapid result it is not as sensitive as molecular techniques, 
results may be subjective and high throughput screening is labour intensive (Bellau-Pujol 
et aI., 2005). RT-PCR provides rapid clear cut results for high throughput screening and 
offers increased sensitivity and specificity over conventional assays. Taking these factors 
into account it is clear that molecular methods such as RT -PCR provides the best 
opportunity for the detection of hMPV. 
At the time of starting this thesis only two RT-PCR methods had been reported for the 
detection of hMPV. These targeted the L polymerase gene and Fusion gene (Jarrti et aI., 
2002, Peret et aI., 2002, van den Hoogen et aI., 2001). At the Health Protection Agency, 
Colindale, an RT -PCR targeting the F gene had also been developed and validated for the 
detection of hMPV and was used to generate much of the data presented in this chapter 
(hMPV PCR 1 )(Nicholson et aI., 2006). However, the increasing availability of sequence 
data means that such assays require constant evaluation and refinement to ensure they offer 
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the best opportunity for detecting all possible strains of the virus. Therefore, as reported 
in this chapter a second RT-PCR was developed, based on the more up to date sequence 
data available at the time (hMPV PCR 2). 
Being a newly identified human pathogen a considerable amount of data regarding hMPV 
epidemiology has been generated since its discovery. However at the start of this PhD 
knowledge ofhMPV epidemiology was very limited. As described in chapter 1 hMPV had 
been discovered in children with RTI that were negative for other respiratory pathogens 
(van den Hoogen et aI., 2001). An Australian study had also detected hMPV in 2 out of 
200 (1 %) samples obtained from children with an unknown cause of viral pneumonia or 
bronchiolitis (Nissen et aI., 2002) and in 40 out of 535 (7.4%) samples obtained from 
people in the general community, 38 of which were children (Howe, 2002). In the UK 9 
out of 408 (2.2%) samples from patients in the community with influenza like illness (ILl), 
negative for other viral pathogens were positive for hMPV, 8 of which were adults 
between the ages of20 to 75 years (Stockton et aI., 2002). 
Given the limited knowledge of hMPV it was vital that the appropriate tools where 
developed and applied to the relevant clinical samples to assess the prevalence of hMPV in 
the UK population. This data will help to determine the contribution hMPV makes to 
respiratory illness in the UK and identify the most at risk groups of infection. It is also vital 
for assessing the potential value of vaccine and or antiviral development. 
At the health protection Agency, Colindale the Respiratory Virus Unit has a number of 
studies in place for the surveillance of respiratory viral infections in different populations 
within the UK. 
The surveillance of both upper (tonsillitis, sore throat, otitis media, common cold, sinitus) 
and lower (ILl, Pneumonia, bronchitis, laryngitis) respiratory tract infections is 
coordinated by the Royal College of General Practitioners (RCGP) (Fleming et aI., 2005) . 
ILl is of a particular interest because of the severity of the disease. ILl is an acute lower 
respiratory tract infection described as an acute illness with high fever, dry cough and 
muscle pains with a duration of:-:;; 5 days appearing at the same time as several other cases. 
The seasonal trend of ILl is highly consistent with the detection of influenza which 
contributes enormously to respiratory illness over the winter months(Fleming et aI., 2005). 
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As such the Health Protection Agency, Colindale collaborates with the RCGP to monitor 
the incidence of influenza associated with ILl in the community (Ellis et aI., 1997). The 
incidence of RSV in this population has also been successfully monitored and has shown 
to playa more important role in the incidence of ILl than previously thought (Stockton et 
aI., 1998), however more than 50% of these samples test negative for both influenza and 
RSV each year (Zambon et aI., 2001). 
Surveillance of influenza and RSV in hospitalized children is also carried out in 
collaboration with The Leicester Royal Infirmary Children's Hospital; the only facility 
within the county providing inpatient pediatric care to a total popUlation of about 1 million 
inhabitants of all ages, including 68,000 children :::;71 months of age (Nicholson et aI., 
2003). 
The investigation of the prevalence of hMPV in the general population and hospitalised 
children, as well as others should provide a good overall picture of the extent of hMPV 
prevalence in people with RTI in the UK. Reported here is the development of a RT-PCR 
for the detection of hMPV in clinical samples and its application to an epidemiological 
study of hMPV in the UK. 
70 
---------------------------~-~-----
Chapter 3 - hMPV Epidemiology 
3.2. Aims 
The aim of the work reported in this section of the thesis was to design, optimise and 
validate a PCR specific for the detection of all four known subtypes of hMPV, able to 
detect virus from cl inical material such as nose and throat swabs. 
The second aim of this section of work is to determine the extent to which hMPV 
contributes to respiratory disease in the general community, hospitalised, elderly and 
immunocompromised populations throughout the winter months, by applying the 
hMPV PCR to clinical samples from patients presenting with influenza like illness or 
acute respiratory tract infection. 
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3.3. Development of detection methodology for hMPV 
3.3.1. Virus growth 
In order to provide positive control material for the assay it was necessary to culture the 
virus in vitro. Due to the fastidious nature of this virus a number of different cell lines 
under a number of different conditions were tested for their ability to support the growth of 
hMPV from clinical samples. Cell lysate material was tested using hMPV PCR 1, to 
determine whether hMPV growth was supported. 
3.3.1.1. Culture conditions Tested 
• Cell lines tested: LLC-MK2, HEP2, HEP2V, A549, Vero, BSC-1, RMK 
• Trypsin concentration: 0 - 2J.lg/ml 
• Temperatures tested: 33-37oC 
• Incubation Period: 3-21 days 
• Cell confluency at inoculation: 60-100% 
• Culture vessels: Flask or tubes - Stationary or rolling. 
3.3.1.2. Virus harvesting techniques tested 
• Cell scraping with and without sonication. 
• Mechanical smashing of cells using glass beads with and without sonication, 
• Freeze thawing 
3.3.1.3.Results of virus propagation 
Over 50 different clinical samples known to be positive for hMPV by RT -PCR1 were 
inoculated on to the different cell lines, under the varying conditions listed above. Only 
three clinical samples yielded growth ofhMPV in vitro that was detectable by RT-PCR. 
Virus growth occurred only in LLC-MK2 cells incubated at 37°C in the presence of 
1.5 J.lg/ml of trypsin. Propagation was limited to only 4 or 5 passages of the virus before it 
was no longer detectable by RT-PCR. Some CPE was observed with a couple of the 
isolates as illustrated in Figure 3.1, where cells became refractory and progressed to 
rounding up and detaching from the monolayer. However, generally no CPE was seen, and 
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viruses were blindly passed on to fresh cells. With the exception of cell line, and the 
presence of trypsin there appeared to be no advantage in particular to any of the above 
conditions tested, and therefore appeared to be more dependent on the quality of the 
clinical sample used. Immunofluorescence analysis of cell culture grown hMPV is shown 
in chapter 5 page 197. 
Uninfected LLC-MK2 Cells HMPV Infected LLC-MK2 Cells 
Figure 3.1: hMPV infected or uninfected LLC-MK2 cells with CPE 10 days post infection. 
3.3.2. HMPV Positive Control Material 
All hMPV positive control material used for molecular work, was generated in cell culture 
as described in Chapter 2 from a clinical isolate. The isolate came from a 4 month old 
male, hospitalised with bronchiolitis and upper respiratory tract infection. Sequence and 
phylogenetic analysis places this isolate as an Al subtype (Chapter 4). The control 
material used was passage 3 cell lysate grown in LLC-MK2 cells. It was not possible to 
quantitate the amount of virus present as the poor growth properties of the virus did not 
allow for quantitative assays to be developed. 
3.3.3. hMPV PCR 1 
hMPV PCR 1 developed by Dr Joanne Stockton at the Heath Protection Agency Colindale 
was currently in use at the start of this PhD and has been used to generate much of the data 
presented in this chapter. 
Nucleic acid extraction and cDNA synthesis was performed as described in Chapter 2. 
Details of this PCR are described in chapter 2 and can also be found in (Nicholson et al. , 
2006). Table 3.1 and Figure 3.3 shows the hMPV PCR primer sequences and positions. 
Table 3.1 : hMPV peR 1 primer sequences 
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Table 3.1 : hMPV peR 1 primer sequences 
Primer name Sequence 5' to 3' 
HMPVMF1499 GCGGCAATTTTCAGACAACG 
HMPVMF2175 ACATGCTGTTCGCCTTCAAC 
HMPVMF1897 CAGCAGCAGGGATCAATGTT 
HMPVMF2166 TCGCCTTCAACTTTGCTTAG 
Sense 
+ 
+ 
Position 
3663-3682 
4358-4339 
4061-4080 
4349-4330 
Footnotes: Primer positions are based on reference strain NLOO-l accession number AF371337 
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HMPVMF1499 HMPVMF2175 Position 4358-4339 
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--... 44---
HMPVMF1897 HMPVMF2166 
Position 4061-4080 Position 4349-4330 
Figure 3.2: Schematic representation of peR 1 target region and primer positions. 
Primer positions are based on reference strain NLOO-1 accession number AF3 713 3 7 
3.3.4. Development of hMPV peR 2 
Before the identification of SARS coronavirus as the aetiological agent of the SARS 
outbreak in 2003 (Fouchier et al., 2003), a number of other respiratory viruses were 
identified as possible causative agents, including hMPV (Chan et at., 2003, Chan et al., 
2004). As a result, more hMPV sequence rapidly became available which allowed the 
design of improved assays 
The F gene was selected for detection of hMPV due to the availability of sequence. Primers 
were selected based on sequence analysis, the ability to create primer pairs for both single 
round and nested PCR approaches, amplicon length melting temperature, GC content, 
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primer combinations were tested against laboratory grown material. Nucleic acid 
extraction and cDNA synthesis was performed as described in Chapter 2. 
Using standard PCR buffer conditions. For the first round 20 J ..d of hMPV cDNA was 
added to 80 /J.I of PCR mix (20mM Tris-HCL (pH 8.0), 50mM KCL, ImM MgCL2). For 
the second round PCR, 2 /J.I of the primary round was added to 48 J.lI of PCR mix with the 
addition of 0.2mM of each dNTP. An annealing temperature of 50°C was used. Both 
primary and secondary round products were visualised by agarose gel electrophoresis. All 
primer combinations tested yielded products of the expected size and conformation of the 
correct product was achieved by sequence analysis of the amplicon. The primer set chosen 
however had the greatest specificity in both the primary and secondary round of the PCR. 
Optimisation of the PCR buffer and cycling conditions was performed for each round of 
the PCR. The buffer components optimised included MgCb, KCL and Tris-HCL 
concentration and pH and was performed using the Stratagene PCR Optimisation Kit. For 
both the primary and secondary round the final buffer conditions where optimised to 
10mM Tris HCL, pH9.2, 1.5mM MgCb, and 75mM KCL. Optimisation of the annealing 
temperature was performed using a PTC 225 gradient thermocycler varying the anneal ing 
temperature over 12 increments from 45°C to 60°C . 
For the primary round PCR primer set the specificity and sensitivity of the PCR increased 
with annealing temperature. The optimal temperature was set at 58°C. At lower annealing 
temperatures extra bands and smearing were visible on the gel as decreased stringency 
allowed miss-priming elsewhere in the genome. For the second round primer set the 
optimal temperature was 51°C which give slightly greater sensitivity over the other 
temperatures tested. 
3.3.5. Summary of hMPV peR 2 optimised conditions 
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3.3.5. Summary of hMPV PCR 2 optimised conditions 
Table 3.2 Summary of hMPV PCR 2 optimised conditions. 
Variable Optimised condition 
First round PCR primer set 
Second round PCR primer set 
PCR buffer conditions 
HMPVF3052F & HMPVF575R 
HMPVF283F & HMPVF575R 
10mM Tris HCL 
1.5mMMgCh 
75mMKCL 
pH9.2 
Primary round PCR Annealing temperature 58°C 
Secondary round PCR annealing temperature 51°C 
Footnotes: For full description of protocol see chapter 2, Materials and methods. 
Table 3.3 hMPV PCRl primer sequences and positions. 
Primer name Sequence 5' to 3' Sense 
HMPVF3052F ATGTCTTGGAAAGTGGTGAT + 
HMPVF283F ATTGAAAATCCCAGACAATC + 
HMPVF575R TCTGTTGAA TTGACTGAAGC 
Position 
3052-3071 
3334-3353 
3645-3626 
Footnotes: Primer positions are relative to reference strain NLOO-I accession number AF371337 
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Vl 
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HMPVF3052F HMPV575 Position 3645-3626 
Position 3052-3071 
HMPVF283F 
Position 3334-3353 
Figure 3.3: Schematic representation of PCR 2 target region and primer positions. 
Positions based on reference strain NLOO-l accession number AF3 713 3 7. 
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To assess the specificity of hMPV PCR 2 eDNA generated from a number of other 
common respiratory viruses including; influenza HI; influenza H3; influenza B; and RSV 
A and B was tested. Nose and throat swabs samples, known to be either positive or 
negative for influenza RSV or hMPV where also tested (Figure 3.4). A small amount of 
low molecular weight smearing was observed in clinical samples however this did not 
result in the production of defined bands and did not interfere with interpreting the results . 
To evaluate the specificity of the PCR further products amplified from a number of 
different clinical samples where sequenced, all of which yielded hMPV sequence. 
M 1 2 3 4 5 6 7 - 8 9 10 11 12 13 14 - 15 16 17 18 + + M 
1000bp 
500bp 
Figure 3.4: A typical example of the hMPV peR on clinical material seen in this study. (M) 
100bp molecular weight marker numbered samples, combined nose and throat swab material from 
patients presenting to GP with ILl and submitted to the HP A for influenza surveillance. (-) 
Negative water controls (+) Positive control. Lane 2 shows a typical positive reading. 
3.3.7. hMPV peR 2 Sensitivity 
The absolute sensitivity of hMPV RT -PCR 2 in relation to the number of PFU of virus 
could not be determined due to difficulties in growing the virus in tissue culture. RNA 
transcripts of the F gene were therefore synthesised in vitro using the PTMI vector into 
which the relevant portion of the hMPV F gene was cloned (Provided by Laura Beasley 
and Dr Bermingham HPA Colindale generated from an A I subtype virus obtained from 
Dublin; Ireland). The vector was linearised using the Smal restriction site located 
downstream of the hMPV F gene. Transcripts were synthesised in vitro by T7 RNA 
polymerase under the control of the T7 promoter located upstream of the cloned hMPV F 
gene fragment. The plasmid DNA was removed by digestion with recombinant RNAse 
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free DNAse, and passed through a Qiagen RNAEasy clean up column. The quantity of 
RNA was determined by spectrophotometry and the number of copies of the transcripts per 
, ..11 determined using the calculations given in chapter 2 (2.3 .18). A 10 fold dilution series 
of the RNA transcripts was made, and used to generate eDNA, and tested by hMPV PCR 2 
(Figure 3.5). 
M 1 2 3 4 5 6 7 8 9 10 11 12 M 
IOOObp 
500bo 
B 
IOOObp 
500hn 
Figure 3.5: Analysis ofhMPV PCR 2 sensitivity using in vitro synthesised RNA transcripts. M is a 
molecular weight marker. (A) Lanes 1 to 9 are a 10 fold dilution series of the synthetic transcripts 
starting at 1:10 which contained lxlOlocopies of RNA. (B) Control of template digestion. A 10 fold 
dilution series starting 1: 1 0 of material which has undergone the whole transcription process, 
without the addition of reverse transcriptase to ensure that the DNAse digestion was complete and 
amplicons were not being generated as a result of DNA vector carry through. In both A and B lanes 
10 and 12 are negative controls and lane 11 is a positive PCR control. 
Results show that that the hMPV PCR 2 has a limit of detection of Ix 104 copies/ reaction 
of the RNA transcripts which equates to roughly 1.8xI06 copies/mt. Whilst in figure lOB 
no amplicons are generated with the exception of a slight smear in lane 1 indicating that 
there is no residual DNA vector left following DNAse treatment. There were however 3 
bands visible in the lanes containing transcripts the lowest of 311 bp being the expected 
amplicon size for the second round PCR. The highest MW band of approximately 700bp is 
also visible in the PCR positive control and is the correct size for the primary round 
product. The third fainter band of approximately 400bp is most likely to be a result of 
transcript degradation. 
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The plasmid itself was also applied to the PCR in a 10 fold dilution series, and the number 
of copies determined. Figure 3.6 shows that the hMPV PCR 2 was able to detect up to 
1 xl 04 copies of the vector which equates roughly to 1 x 106 copies 1m!. 
M - - 1 2 3 4 5 6 7 8 9 10 11 12 M 
Figure 3.6: Analysis of the absolute sensitivity of the by hMPV peR2. M is a molecular weight 
marker, lanes I through to 10 are a 10 fold dilution series of the vector starting from IxlO IO copies 
through to IxlOI copies per reaction. lane II is a negative control and lane 12 hMPV positive 
control. 
3.3.8. hMPV PCR 1 Versus hMPV PCR 2 
hMPV PCR 2 was compared with hMPV PCR 1 using cDNA from laboratory grown 
material to determine the relative sensitivities of the two assays. Figure 3.7 clearly shows 
that hMPV PCR 2 out performs hMPV PCR 1 in terms of sensitivity and specificity. For 
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PCR 1 there are a number of bands other than that of the expected size of 300bp present in 
lanes 5 through to 8. 
PCR2 PCR 1 
r---"'-"----" r---""------.." 
M 1 2 345 678 
Figure 3.7: hMPV peRl Vs peR 2. second round peR products generated from a dilution series 
(Neat, 1: 10, 1 :20 and 1 :40) of hMPV eDNA was analysed by DNA gel electrophoreses. Lanes 1 to 
4 contain hMPV peR 2 products. Lanes to 8 contain hMPV peR 1 products. (M) 100bp molecular 
weight marker. (1) hMPV peR 2 Neat eDNA. (2) hMPV peR 2 1:10 eDNA. (3) hMPV peR 2 
1:20 eDNA. (4) hMPV peR 2 (1:40) eDNA. (5) hMPV peR 1 Neat eDNA. (6) hMPV peR 1 1 :10 
eDNA, (7) hMPV peR 1 1 :20 eDNA, (8) hMPV peR 1 1 :40 eDNA. 
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3.4. Clinical Studies 
To address the question of the incidence of hMPV, and its contribution towards burden of 
respiratory illness in the community and other populations, clinical respiratory samples, 
mostly combined nose and throat swabs or nasopharyngeal aspirates (NP A), from defined 
clinical studies, were tested for hMPV, and other respiratory viruses by PCR. An outline of 
each of the clinical studies, target population, clinical setting, sample type and number is 
shown in Table 3.4. 
The samples were received and processed as described in chapter 2. Where influenza and 
RSV was tested as part of the national surveillance programme the remaining cDNA was 
stored at _20DC until testing for hMPV. When no cDNA was available nucleic acid was re-
extracted from the original sample. 
For hMPV testing either hMPV PCR 1 or hMPV PCR 2 were used. hRSV and Influenza 
were detected using the multiplex assay described elsewhere (Stockton et aI., 1998). 
Coronavirus, Rhinovirus and other Enteroviruses were detected in the Leicester Royal 
Infirmary study using assays developed at the HP A Colindale. 
Testing of samples for influenza and RSV was carried out as part of routine influenza 
surveillance by the Respiratory Virus Unit, HPA Colindale, who kindly provided the data 
for analysis. Coronavirus, Rhinovirus and Enterovirus data was kindly provided for 
analysis by Dr Hosler and Dr Lock of the Respiratory Virus Unit, HPA Colindale. All data 
analysis presented in this thesis was performed by myself. 
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-0 Table 3.4: Summary of studies used to assess the prevalence of hMPV in clinical cohorts in the UK . . -S 
C!) 
"'0 
.-0.. Study Study Cohort Age Winter Study Description Sample Sample HMPV ~ 
> Season Type Number PCR 0.. 
~ used 
..c 
I RCGP Community All Ages 2001- Royal College of General Practitioners NT 389 1 
M 
Acquired All 2002 Influenza surveillance scheme. General Swab 
'"'" C!) 
+-> Ages with ILl practitioners from England enrolled in the 0.. 
ro 2002 - 372 2 ..c scheme take samples from patients from the U 2003 general community presenting to them with 
2003 - influenza or influenza like illness. For the 655 2 
2004 investigation of influenza strain surveillance 
(Stockton et aI., 1998, Zambon et aI., 2001) N 00 
Leicester Hospitalised :::;5 2001- Children under the age of 5 years admitted to NPA 1 
Royal Children with Years 2002 the Leicester Royal Infirmary in the UK with 
Infirmary ARTI acute respiratory tract infections. (Nicholson et 510 2 2002 -
aI., 2003) 2003 
RCGP/ Community ~ 65 2001- Burden of disease caused by RSV in NT 264 1 
Aventis Acquired Years 2002 community dwelling elderly> 65 years old. Swab 
Elderly with 
ARTI 
Royal Hospitalised All Ages 2002- Surveillance of acute respiratory illness in NPA 134 2 
Free Immuno 2004 patients in the immunocompromised ward of 
compromised the Royal Free Hospital. 
with ARTI 
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The RCGP ILl index is the number of people per 100,000 of the UK population presenting 
to General practitioners with influenza or influenza like illness ( 
Table 3.4) and is a useful guide to the severity/ timing of ILl for the given year, and as 
such, has been included in the following analysis. 
Table 3.4: RCGP ILl Index and Influenza Activity. 
RCGP Index 
< 50 
50 - 200 
>200 
Category 
Baseline Influenza Activity 
Normal Influenza Activity 
Epidemic Influenza Activity 
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3.5. Community Acquired Infections 
1416 clinical samples (combined nose and throat swabs) submitted as part of the national 
surveillance program for ILl were tested prospectively for influenza and RSV, and 
retrospectively for hMPV. Samples were taken between October and March for 3 
successive seasons, 2001-2002 (Year 1), 2002-2003 (Year 2) and 2003-2004 (Year 3). 
Year 1 was analysed for hMPV using hMPV PCR 1 and year 2 and 3 using hMPV PCR 2. 
The total number of incidences of hMPV, RSV and Influenza over the 3 years is 
summarised in table (Table 3.5). In total only 43% of the samples were positive for either 
hMPV, RSV or influenza leaving the remaining 57% without identification of a possible 
aetiological agent. Overall, hMPV accounted for 4.8 % of the total number of samples 
(1l.2 % of those with a virus detected). The incidence of RSV is more than twice that of 
hMPV, and influenza almost 12 times that hMPV. 
The percentage ofhMPV infections increased from Yl to Y2 from 3.4% to 5.1%, which, 
in part, may be due to the introduction of hMPV PCR 2 in 2003. The percentage of hMPV 
was similar for Y2 and Y3. Influenza activity was similar for Yl and Y2, however, 
increased by more than three times in Y3 accounting for almost 38% of infections and is 
responsible for the increased samples number received that year. Incidences of RSV, 
increased dramatically in Y2 to over 25%, and then fell again in Y3 to levels lower than 
that ofhMPV. 
Table 3.5: Community Acquired infections 2001 :2004: Percentage of hMPV, RSV and Influenza 
cases detected. 95% confidence intervals calculated using STATA Version 8.2 (STATACorp, 
USA). 
Year Total No of hMPV RSV Influenza Unknown Dual 
Samples 0/0 0/0 % % Infections 
0/0 
01102 (YI) 389 3.5 6.2 19.2 70.9 0 
02/03 (Y2) 372 5.1 25.3 20.4 49.2 2.9 
03/04 (Y3) 655 5.3 4.1 37.7 52.8 l.5 
Total 1416 4.8 10.2 28.1 28.1 l.5 
95% CI 3.7-6.0 8.7-11.9 25.7-30.5 54.2-59.4 0.9-2.3 
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A total of 21 dual infections were identified over the three years and analysis of these is 
shown in Table 3.7. Eighteen were dual infections of hMPV with either RSV or Influenza. 
This accounts for 26.4 % the total number of hMPV positive samples. 
Table 3.6: Community Acquired Dual Infections. 
Dual Infection 
HMPV and RSV 
HMPV and Influenza 
RSV and Influenza 
3.5.1. Weekly Distribution 
Number of Samples (%, of Total) 
13 (0.9%») 
5 (0.3°;(1) 
3 (0.2%) 
The week by week analysis of the distribution of hMPV compared with RSV and influenza 
for the 3 seasons is shown in Figure 3.9. The distribution of the samples received 
throughout the 3 seasons is reflected in the RCGP index, and is similar in both Y I and 2 of 
the study with a peak in clinical activity between weeks 1-10. In Y3 , however the vast 
majority of illnesses occurred in the early part of the season between weeks 43-1 due to 
the earlier circulation of influenza that year. 
hMPV appeared at a fairly consistent rate throughout all 3 seasons, peaking slightly in 
week 50, weeks I and 3, and week 49 in YI , 2 and 3 respectively. The length of time that 
hMPV occurred through out the season varied from 15 to 24 weeks over the 3 years. 
hMPV activity appeared therefore to be unaffected by the shift in ILl in Y3. 
The RSV season started 8-10 weeks earlier than the influenza season in YI and 2 peaking 
in weeks I and 2 respectively. However, in Y3 the influenza season preceded that ofRSV 
by 7 weeks, reflecting the shift in ILl. The RSV season was not affected by this shift and 
peaked in week 2, which is consistent with the previous 2 seasons. The influenza seasons 
mirrored the RCGP ILl index over all 3 seasons peaking in week 3, 8 and 46 in YI , 2 and 
3 respectively. 
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Figure 3.8: Weekly distribution of community acquired hMPV, RSV and influenza infections over 
3 winter seasons. 2001-2002 (y 1), 2002-2003 (y2), and 2003-2004 (Y3). 
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3.5.2. Monthly Distribution 
The monthly distribution of hMPV, RSV and influenza over the thee seasons is shown in 
Figure 3.10. The largest number of samples were received in January for Yl and 2, and 
November for Y3 reflecting the trend of the RCGP ILl Index. hMPV was detected 
throughout all three 3 winter seasons with a peak incidence in December for winter seasons 
Yl and Y3, and January in Y2. RSV peaked in January in all 3 years, while influenza 
peaked in January, February and November in Yl, 2, and 3 respectively. 
300 60 
250 50 
100 
50 10 
o +-~-+~~~~~--~~~~~~~~~~~~~~~~+-~-+~~ o 
//////~~~////~~~////~~ 
300 60 
250 50 
100 
50 10 
Month 
"------"'V""----/ "------~----./ "--...... ----~-----~ 
Yl Y2 Y3 
_ Total Number of samples _ hMPV _ Influenza RS\ -RCGP III Index 
Figure 3.9: Monthly distribution of community acquired hMPV influenza and hRSV Infections 
over 3 consecutive winter seasons. 2001-2002 (y1), 2002-2003 (y2), and 2003-2004 (Y3). 
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3.5.3. Age Distribution 
The proportion of patients with hMPV, RSV or influenza infections for each age group of 
the community over the 3 winter seasons is shown in Figure 3.11, and the number hMPV, 
RSV and Influenza infections for each season shown in Figure 3.11. Over the 3 seasons the 
age of the patients ranged from 2 days to 99.2 years old, with an average age of 32.8 years 
reflecting the age distribution of the population sampled. All 3 viruses were detected in all 
age groups. Proportionally, hMPV was most prevalent in the 1-4 year age group accounting 
for 16.2% of all hMPV infections. hMPV occurred in roughly equal proportions in all age 
groups with the exception of infants <1 year old, where no hMPV cases were detected in 
Yl or 2 of the study. 
As expected the largest proportion of RSV infections occurred in infants < 1 year old, and 
decreased in older children and adults, however it increased again slightly with age in 
adults 35 years and up. Y2 of the study was the exception, where a majority of RSV 
infections occurred in adults between the ages of 15-44. 
Influenza infections also followed the expected trend for all 3 seasons occurring most 
frequently in school age children of 5-14 years old and decreased with age. Few influenza 
infections were detected in young children. 
100% 
80% 
60% 
40°A, 
20% 
0% 
<1 1-4 5-14 15-24 25-34 35-44 45-54 55-64 65+ Unknown 
Age (Years) 
Total • hMPV 0 RSV • Influenza 
Figure 3.10: Proportional age distribution of hMPV, hRSV, and influenza community acquired 
infections taken over 3 consecutive winter seasons (2001-2004). 
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Figure 3.11: Age distribution of total number of samples recieved, hMPV, hRSV, and influenza 
community acquired infections over 3 consecutive winter seasons. 2001-2002 (yl), 2002-2003 
(y2), and 2003-2004 (Y3). 
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3.5.4. Sex Distribution 
The sex distribution of hMPV, RSV and influenza infections in the community over the 3 
winter seasons is shown in Table 3.7. Overall just over 53% of the total number of samples 
were from female patients. The distribution of both hMPV and influenza infections is split 
at 500/0 between males and females. The majority (53.8%) of RSV infections, however, 
were detected in male patients. 
Table 3.7: Sex distribution of patients with hMPV, h RSV and influenza community acquired 
infections taken over 3 consecutive winter seasons (2001-2004). 
Sex hMPV RSV Influenza Total 
Number of Males 33 78 192 659 
% Grand 'rota I 2.3 5.5 13.6 46 .5 
0/0 of Males onlv 
.-
5.0 1 l.8 29.1 100 
%} 'rota! virus 48.5 53.8 48.2 
Number of Females 34 67 205 753 
% Grand Total 2.4 4.7 14.5 53.8 
% of r;'emales only 4.) 8.9 ' )'"" ') k I.~ 100 
0/0 'J'otal virus 50 46.2 -j ~ ).) 
Number Sex Not Known (SNK) 1 0 1 4 
(% Grand Tota l 0.07 0 0.07 0.3 
0/0 SNK only ,-~J 0 25 100 
(Yo 
'rota1 Virus 1.5 0 0.3 
Total virus 68 145 398 
Grand Total 1416 
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3.6. Hospitalised Children 
18 month study (200112003) 
A total of 1171 clinical samples (nasopharyngeal aspirates) were taken over an 18 month 
period from October 2001 to March 2003, to investigate the cause of respiratory illness in 
children,< 6 years old, hospitalised with ART!. The samples were tested prospectively for 
influenza and RSV, and retrospectively for hMPV. Yl (October 2001-July 2002) was 
analysed for hMPV using hMPV PCR 1 and Y2 (August 2002- March 20003) using hMPV 
PCR 2. Other respiratory viruses mentioned were detected using PCR assays developed at 
the HP A Colindale. 
The incidence of hMPV, RSV, influenza, coronavirus (CoV), rhinovirus (RV) and other 
enteroviruses (other than rhinovirus) (EV) is shown in Table 3.8. In total 57% of the 
samples had either 1 or more viruses detected leaving 43% without identification of a 
possible aetiological agent. Overall hMPV accounted for 5.7 % of the cases (9% of those 
with a virus detected). The percentage of hMPV infections increased from Y 1 to Y2 from 
4.4% to 7.1 % respectively, which, in part, may be due to the introduction of hMPV PCR 2 
in 2003. The incidence of RSV and RV infections were almost 4 times that of hMPV. As 
expected RSV was the predominant cause of infection in these children. Influenza was 
slightly higher that of hMPV and Other EV double, and again both viruses increase from 
Y 1 to Y2. Co V infections accounted for half the number of hMPV infections and, unlike 
the other viruses, the number of Co V cases decreased from Yl to Y2 by almost 50%. 
Table 3.8: Hospitalised children; 18 month Study: Percentage of hMPV, hRSV and influenza 
cases detected. 95% confidence intervals calculated using STAT A Version 8.2 (STAT ACorp, 
USA). (CV) Coronavirus, (RV) Rhinovirus and (EV) Other Enteroviruses except Rhinoviruses. 
Total hMPV RSV Influenza CoY RV EV Dual 
% 0/0 % % 0/0 % % 
01102 (Yl) 613 4.4 16.8 6.8 2.9 14.8 11.3 5.4 
02/03 (Y2) 558 7.2 24.9 7.9 1.6 22 .2 8.8 10.2 
Total 1171 5.7 20.7 '}') ! ._) . ., .. _.j 18,3 10.1 7.8 
9-% CI 
. =' ().- 4.4-7.2 18.3- 5.7-8.7 1.4- 11.3- 8 ., .~, - 6.1-9.2 
23.1 3.1 ..., - "> -) .. ) 11.8 
3.6.1. Dual Infections 
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3.6.1. Dual Infections 
A total of 88 dual infections were identified and in 2 cases there where 3 viruses (Table 
3.9). Of the hMPV positive samples 34% were dual infections, the largest number of which 
were with RSV. The greatest number of dual infections overall were with RSV and 
Rhinovirus. The contribution of each infection or dual infection to burden of illness is 
shown in Figure 3.12. 
Table 3.9: Number of dual infections detected in children hospitalised with ART! over the course 
of the 18 month study. 
Dual Infection 
HMPVandRSV 
HMPV and Influenza 
hMPV and Rhinovirus 
HMPV and other Enteroviruses 
HMPV, RSV and Influenza 
HMPV, RSV and other Enteroviruses 
RSV and Influenza 
RSV and Coronavirus 
RSV and Rhinovirus 
RSV and other Enteroviruses 
Influenza and Rhinovirus 
Influenza and other Enteroviruses 
Rhinovirus and Coronavirus 
0 .94 
0 .09 
0 .51 
Number of Samples 
11 
1 
6 
3 
1 
1 
4 
5 
28 
23 
3 
1 
3 
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ChMPVOnly 
• hMPV and RSV 
o hMPV and Influenza 
o hMPV and Rhinovirus 
• hMPV and Other Enterovirus 
hMPV RSV and Influenza 
• hMPV, RSV and Enterovirus 
ORSVOnly 
• Influenza Only 
• RSV and Influenza 
o Influenza and Rhinovirus 
• Influenza and Enterovirus 
• Coronavirus Only 
• Rhinovirus Only 
• Other Enterovirus Only 
• RSV and Coronavirus 
• RSV and Rhinovirus 
o RSV and Other Enterovirus 
o Rhinovirus and Coronavirus 
o Unknown 
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3.6.2. Seasonality 
The monthly distribution of hMPV, RSV and Influenza is shown in Figure 3.14 and the 
weekly distribution in Figure 3.13. The period studied spans 18 months from October 2001 
until march 2003, and includes 2 winter seasons and 1 summer. Samples were received for 
all months with the exception of August 2002 when respiratory virus activity is typically at 
its lowest. Based on the samples received the incidence of ARTI in children requiring 
hospitalisation reflects the RCGP ILl index for the community with the largest number of 
samples received in December 1 January for Yl and 2 respectively. 
hMPV was detected throughout the 18 months with the exception of October Yl and July 
and August Y2. hMPV activity occurred mainly during the winter months, peaking in 
February Yl and again in October Y2. In Yl hMPV season lasted from week 47 to 39, but 
was found predominantly in weeks 1 through 17. There was a small peak in hMPV 
activity in week 6, and one outlying hMPV case in week 26. In Y2 the hMPV season lasted 
from week 38 to 10, but occurred predominantly between weeks 38-50. 
In comparison RSV and influenza activity was more restricted to the winter periods. RSV 
appeared from November to April Y 1 peaking in December Y 1, and appeared again from 
September Y2 through to March Y2, peaking in November Y2. In Yl the RSV season 
lasted from weeks 42 to 17 and peaked in week 49. In Y2 the RSV season lasted from 
weeks 37 to 13 and peaked in week 47. 
Influenza was detected in November through to April 2001/2002, and again in October 
through to March 2002/2003, peaking in February 2002 and March 2003. In Yl the 
Influenza season lasted from week 50 through to 16 and peaked in week 5. and in Y2 from 
week 43. Very few influenza samples were detected until the second half of the season and 
was still on the increase by week 12 when the study ended. 
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Figure 3.13: Weeldy distribution of hMPV, RSV and Influenza from hospitalised children 
in relation to the ILl index. (A) Year 1 , and (B) Year 2. 
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Figure 3.14: Monthly distribution of hMPV, RSV, influenza and total number of samples 
collected from hospitalised children throughout the 18 moth period of the study related to the 
RCGP ILl index. 
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3.7. Community Acquired Infections in the Elderly 
A total of 264 clinical samples (combined nose and throat swabs) collected from October 
2001 to March 2002 as part of a study investigating the cause of ARTI in the community 
dwelling elderly were tested prospectively for RSV and influenza, and retrospectively for 
hMPV using hMPV PCR 1. The total burden of illness caused by hMPV, RSV and 
Influenza is shown in Table 3.10. In total only 12.5% of the samples were positive for 
either hMPV, RSV or Influenza, leaving 87.5% without identification of a possible 
aetiological agent. hMPV accounted for 4.5 % of the total number of samples (36% of 
those with a virus detected) and was the most commonly detected virus. No dual infections 
were identified. 
Table 3.10: Percentage of hMPV, RSV and influenza cases detected in the community dwelling 
elderly with ARTI over winter season 2000-200l. 
hMPV RSV Influenza Unknown Total Number of 
0/0 0/0 0/0 % Saml!les 
% of positive 4.5 3.8 4.2 87.5 264 
samples 
% of Sam pies 36.4 30.3 33 .3 
with Virus 
Detected 
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The sex distribution of hMPV compared with RSV and influenza is shown in Table 3.12. 
Overall 56% of the total number of samples were from female patients. One third of hMPV 
and Influenza infections were in females. In comparison more than two thirds of RSV 
infections were in females. 
Table 3.11: Sex distribution of patients with hMPV, RSV and influenza infections detected 
in the community dwelling elderly with ARTI over winter season 2000-2001. 
Sex hMPV 
Number of Males 7 
% Grand 'rota I 2.7 
(Xl of Males Only 7.7 
% 'rotal virus -8 ""I ), .. J 
Number of Females 4 
o;() (irand 'rota l 1.5 
% of F;'emalcs onlY 
.-
2.7 
~Io 'rotal virus 3" "' ,,),) 
Number Sex Not Known (SNK) 1 
%) Grand 'fotal 0.4 
% SNK only 4.00 
% 1'ota1 Virus 8 " , .~) 
Total virus 12 
Grand Total 
RSV 
3 
1.] 
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8.00 
18 I 
, .~ 
11 
Total 
91 
"'4 '7 ~, .! 
100 
148 
56.! 
100 
25 
9.5 
100 
264 
The weekly analysis of the distribution of hMPV, RSV and Influenza is shown in Figure 
3.16. The season spanned 23 weeks from weeks 44 to 14. hMPV appeared sporadically 
throughout the winter season from week 46 to week 10 with no apparent peek in incidence. 
In comparison, RSV was detected in weeks 47 to 6 and peaked in week 1. Influenza was 
detected in weeks 1 to 10 peaking in week 6. 
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Figure 3.15: Weekly distribution of the total number of samples received and hMPV, RSV, 
influenza infections detected in the community dwelling elderly with AR TI over winter season 
2000-2001. 
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3.8. Immunocompromised Patients 
A total of 134 clinical samples (nasopharyngeal aspirates) collected as part of a study 
investigating the cause of AR TI in hospitalised immunocompromised patients between 
November 2002 and March 2004. Samples were tested retrospectively for hMPV using 
hMPV peR 2. The patients studied were hospitalised at the Royal Free in London, and 
covered a range of immunocompromised conditions, the majority of patients having 
undergone bone marrow transplantation. All other investigations into viral or bacterial 
pathogens were carried out at the Royal Free Hospital of which no information was 
available. The total burden of illness for hMPV is shown in table 3.13. hMPV accounted 
for 8.2% of the total number of samples over the 2 years. 
Table 3.12: Percentage of hMPV cases detected in hospitalised immunocompromised patients 
with ARTI over winter 2 consecutive winter season 2002-2004. 
No of Samples 
0/0 Total No of Samples 
hMPV 
11 
8.2 
Unknown 
123 
91.8 
Total Number of 
Samples 
134 
100 
The monthly distribution ofhMPV is shown in Figure 3.16. Samples span from November 
through to March. hMPV was detected in all months with the exception of November with 
the largest number of cases occurring in December. 
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Figure 3.16: The monthly distribution of hMPV cases detected in hospitalised 
immunocompromised patients with ARTI over winter 2 consecutive winter season 2002-2004. 
100 
Chapter 3 - hMPV Epidemiology 
The age distribution of patients with hMPV infection is shown in Figure 3.17. There were 
similar numbers of samples for each age group, with the exception of the <1 year age 
group, which accounted for almost 30% of the samples. As such the largest number of 
hMPV infections was detected in children less than one year of age (2, 5, 6 and 8 months 
old) of which, one was a pre-term baby. The highest proportion, however, was in the 15-24 
year age group. The older patients with hMPV infections had all received bone marrow 
transplants. 
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Figure 3.17: The age distribution of hMPV cases detected in hospitalised immunocompromised 
patients with ARTI over winter 2 consecutive winter season 2002-2004. 
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3.9. Summary 
Table 3.14 summarises the key results by year of the different clinical studies described 
above. 
Year 1 includes 3 studies; community acquired ILl, AR TI in Hospitalised children, and 
ARTI in community dwelling elderly. The largest proportion of hMPV cases occurred in 
hospitalised children and the elderly. The largest proportion on hMPV infections in the 
community occurred in 1-4 year olds. The proportion of RSV in the community was 
greater than that in the elderly by more than 1 Y2 times. Influenza as expected, was most 
prevalent in the community ILl study with the smallest proportion was in the elderly 
cohort, where the uptake of influenza vaccine is considerably larger than the other cohorts 
investigated. 
Year 2 also included 3 studies; community acquired ILl, ARTI in Hospitalised children, 
and ARTI in Hospitalised immunocompromised patients .. The largest proportion ofhMPV 
cases were identified in patients hospitalised with compromised immunity, followed by 
hospitalised children. The largest proportion on hMPV infections in the community 
occurred in 1-4 year olds. No Information regarding the incidence ofRSV or influenza was 
available for the immunocompromised study, however, RSV occurred in roughly equal 
proportions in both the community and hospitalised children due to the severity of the 
RSV season. Influenza, consistent with Yl was most prevalent in the community. 
Year 3 included 2 studies; community acquired ILl and ARTI in hospitalised 
immunocompromised patients. Consistent with Y2 the largest proportion of hMPV 
infections occurred in patients with compromised immunity and the largest proportion on 
hMPV infections in the community occurred in 1-4 year olds. There was also a difference 
in the age groups in which hMPV peaked. In both Y2 and 3 of the immunocompromised 
study, adults had proportionally the highest number ofhMPV infections. 
Table 3.13: Summary of finding of the prevalence of hMPV in the different clinical 
studies investigated. 
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Year 
1 
01102 
2 
02/03 
3 
03/04 
Study Number 
of 
Samples 
Community 389 
Hospitalised children 613 
Community Elderly 264 
Community 372 
Hospitalised children 558 
Hospitalised 45 
Immunocompromised 
Patients 
Community 655 
H os pitalised 89 
Immunocompromised 
Patients 
hMPV RSV (%) 
(%) 
14 (3.6) 24 
(6.2) 
27 103 
(4.4) (16.8) 
12 10 
(4.6) (3.8) 
19 94 
(5.l1) (25.3) 
40 139 
(7.2) (24.9) 
5 -
(11.1) 
35 27 
(5.3) (4.1 ) 
6 -
(6.7) 
Influenza Other Dual 
(%) Virus Infection 
(%) (%) 
75 
- 0 
(19.8) 
41 178 33 
(6.7) (29.0) (5.4) 
11 
- 0 
(4.2) 
76 
-
11 
(20.4) (2.9) 
44 182 57 
(7.9) (32.6) (10.2) 
- - -
247 
- 10 
(37.7) (1.5) 
- - -
~-
No virus 
Detected (%) 
276 
(70.9) 
297 
(48.4) 
231 
(87.5) 
183 
(49.2) 
210 
(37.6) 
-
346 
(52.8) 
-
hMPV Peak 
Age 
1-4 
<6 
>65 
1-4 
<6 
25-34 
1-4 
15-24 
M 
o 
..... 
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3.10. Discussion 
3.10.1. peR Development 
The RT-PCR strategies adopted in this work are based on the detection of the fusion gene 
of the hMPV genome. hMPV PCR 1 was the original PCR developed at the HP A 
Colindale when hMPV was first identified; and as such was designed when limited 
sequences were available. HMPV PCR 2 was developed in this work when a greater 
number of sequences were available. hMPV PCR 2 was compared with hMPV PCR1 and 
was found to have a higher specificity and sensitivity, when tested using a cDNA dilution 
senes. 
3.10.1.1. Nucleic acid extraction 
The extraction method used in this work uses guanidine isothiocynate and guanidine 
hydrochloride. These are chaotrophic agents which disrupt the virion and cellular material 
by denaturing proteins, therefore also inhibiting any nuclease activity. Nucleic acid binds 
to the sepharose surface of magnetic glass beads due to the high chaotrophic salt 
conditions. Unbound substances including denatured proteins, membrane material and 
other PCR inhibitors are removed by gradually reducing the salt concentration. Purified 
nucleic acid is eluted at low salt concentrations and elevated temperatures. This method 
has been shown to be a sensitive method for extracting nucleic acid from clinical samples, 
and has been fully optimised and well validated at HP A Colindale and elsewhere for 
analysis of respiratory samples (Stockton et aI., 1998). 
3.10.1.2. Reverse transcription 
The cDNA synthesis method used in this work is based on random hexamer priming. 
Random hexamers prime reverse transcription by binding at multiple points along the 
template. It is a generic approach to generating cDNA and enables a variety of pathogens 
to detected be subsequently by PCR. Random hexamer priming is also useful for templates 
with difficult secondary structures or for fragmented RNA. Random hexamers have also 
shown to improve the transcription of 5' regions more efficiently (Promega, 2006). This 
method has been fully optimised and validated at HP A Colindale and elsewhere for the 
analysis of respiratory samples (Stockton et ai., 1998). There are drawbacks with using a 
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random hexamer approach in that it is non specific and all RNA species within the sample 
will be used as template for first strand synthesis therefore increasing the chances of non-
specific amplification by the PCR. Other options for RT priming are Oligo (dT), and gene 
specific primers. Oligo (dT) are more specific than random hexamers in that they prime at 
the poly A tail of mRNA species, therefore the complexity of the cDNA is less than with 
random hexamers. However only mRNA species are targeted, and not all RNA viruses use 
a poly A tailed message. Therefore Oligo (dT) is not optimal for clinical samples of this 
type, and may result in decreased sensitivity of the assay. Gene specific primers (GSP) are 
the most specific method of performing an RT by hybridising at a specific site at the 3 ~ 
terminus of the mRNA species. They are useful when there is a low abundance of 
transcripts and may be useful for producing longer cDNA species. However, GSP often 
fail to prime, and due to the specificity of the primer only the corresponding PCR may then 
be subsequently used. This is not ideal when a samples requires testing for multiple agents. 
3.10.1.3. peR 
In this study over 20 different primers (some of which were previously published)( Table 
3.15) were evaluated theoretically using the Oligo 6 primer design software (Molecular 
Biology Insights, Inc). 
Primers were selected based on sequence analysis, the ability to create primer pairs for 
both single and nested PCR approaches, amplicon length, melting temperature, GC 
content, primer length, repeats, 3' end stability, primer dimers and hairpins. 
This reduced the number of primers to 6 (Table 3.15), which were tested experimentally in 
all possible combinations as single and nested PCRs against laboratory grown material 
using the standard PCR conditions with an annealing temperature of 50°C. Products were 
all of expected size and sequencing confirmed the correct products were obtained. The 
primers chosen had the greatest specificity in the primary and secondary rounds of the 
PCR. A nested or hemi nested PCR approach was preferred due to the increased in 
sensitivity it offers. 
Biochemical optimisation of the both the primary and secondary round of the selected PCR 
was investigated. This included altering the concentration of Tris-HCL, MgCb, KCI and 
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the pH. The optimal annealing temperature for each round of the PCR was also 
determined. 
Table 3.14: Complete list of hMPV F gene Primers analysed theoretically using Oligo 
6 primer design software (Molecular Biology Insights, Inc). 
Footnotes: (i)*Primer positions are relative to reference strain NLOO-l accession number 
AF371337. (ii) The shaded primers were selected for experimental testing. 
Primer Sequence 5'-3' 
HMPVF2941F CTT GGC CAA GAG CTA CTA AC 
'*··RMBtt;~;id;52;It' •• j~~1it0m'1£r~~§![GXQtbTG Ami, 
'c_ ,,". '~:'M,:.:;,;:"."»<~»N.v",~", ,,.:''/'hl.'/,W,,.,,.,,,,,,,,,.:..$.:c .. · -'.""~M'if£,,,<p.{>i;":-'<V"'., n ,,,~,,,.:;';>.,»;C;>;, ;:eN .. ~:;"" ~, ".;, ..... ,.-~Z:l,'..0"';""", "':>~'-":''';;'>'-n' ,,"",.-:._ ». . -"_,,.,,.;':;;'::'" 
HMPV4390 F GAC CCA GTC AAG TTT CCT GAA 
RF1.g;r~r;.; r!p'i$i1r.~; ;;~r~#t·¥"" A!!:~AA TC:: 
HMPYF4734R 
HMPVF4651R 
HMPYFI622R-A 
HMPVF1622R-B 
HMPVF 1622R-C 
HMPVF4651R-A 
HMPVF4651R-B 
HMPVF4737R 
GGA GCC TTG CGA GAC A TT AT 
TAA TTA TGT GGT ATG AAG CC 
ACT ATG CGG TAT AAA ACC GC 
ATT ATG TGG TAT AAG ACA TT 
CTA ATT ATG TGG TAT GAA GC 
CTA ACT ATG CGG TAT AAA ACC 
CTA ATT ATG TGG TAT GAA GCC 
GCA CGG AGC CTT GCG AGA 
CAT 
LH' . 11. rn1: tiBt5'7" 5 -a~%il1!\Cl%,,;;1ki,ml5lri-:;ih;:PT~;ii43~I;A C~hliA' D 'P. r;?A'A' Grui&>, i~ >. ,'W.~~Y-!£;Jt§,:~ .. x:.~~;;:;;,~){~i001lSf[iMffit>&~1!W~  1, .. !t&\tJ~a~'Jfu#k.~~~~'!d;Ha'>'-M ,·,>".v,~Jirt~L~: 
HMPV 1499 GCG GCA A TT TTC AGA CAA CG 
HMPV 1897 CAG CAG CAG GAA TCA A TG TT 
HMPV 2175 ACA TGC TGT TCG CCT TCA AC 
H· Mr" 'ti'iPZ"t'1'o '6"":V,W\1\iftlh' 1i IT'lRiil!'*''C' ' " B;.rHm5'il"A·';'iiiAq~'Ti~G'T'AifVr. A' 0" 'HiS . ~~-!d~:~,,~ ~ ;~':~j:W1D(+' ,-:-,.l!~Sl~, .. v>.~.!J{{!~~, . ~ ~~*Z£~L!,: Aw. -::",?:jA;J: ' . .' *~0YC' 
MPVFl AGC TGT TCC ATT GGC AGC A 
MPVF3 GAG TAG GGATCATCAAGCA 
MPYF2 ATG CTG TTC RCC YTC AAC TTT 
MPYF4 GCT TAG CTG RTA TAC AGT GTT 
HMPV-Fl 
HMPV-F2 
3.10.1.4. 
A TG TCT TGG AAA GTG GTG 
TCT TCT T AC CAT TGC AC 
Sensitivity 
Sense 
+ 
, 
+. ) 
+ 
+ < 
+ 
+ 
+ 
+ 
+ 
Position* Source 
2941-2960 This work 
3052-3071:{ This work 
4390-4410 This work 
3334-3353, ' Thiscwork 
4753-4734 This work 
4670-4651 This work 
4668-4648 This work 
4668-4648 This work 
4671-4652 This work 
4671-4651 This work 
4671-4651 This work 
4757-4737 This work 
' 3",6,' .. 4 .... 5 .... ~. 3.·,.6'~(jj,t,·:.;:. Th·' " k 
, • . .• , . .•.• ,0.> .' , J~.i~9J ' ,'. 
3663-3682 Nicholson et aI. , 2006 
4061-4080 Nicholson et aI. , 2006 
4358-4339 Nicholson et al., 2006 
4349~4J3Q:!t N.ic,~()lson et al. , 2006 
4216-4234 Chan et al. , 2003 
4238-4256 Chan et al. , 2003 
4356-4336 Chan et aI. , 2003 
4335-4315 Chan et al. , 2003 
:3~7,d4~3:7 \ 1 er:J"t7NE1MSARS 
<:,'i/' _. ')' - ",. .. ,~~;~./v'":''' :.' . , 
. 4!~·3·-413~.~.~,, ~r~!£!sEJM SARS 
3052-3069 Boivin et al. , 2002 
3810-3794 Boivin et al. , 2002 
Due to the poor growth properties of hMPV in cell culture it was not possible to relate the 
sensitivity of the peR to virus infectivity by determining the number of pfu/ml of virus. 
Therefore in vitro transcripts were made of the target region of the hMPV F gene and 
applied to the RT -PCR in a dilution series. The PCR detected Ix 104 copies of RNA 
transcript! reaction and 1 x 104 copies of plasmid DNA. This appears to be rather 
insensitive for a nested RT-PCR where lxl03 copies of RNA should be easily detectable. 
The insensitivity of this PCR may be underestimated due to inaccurate calculation of RNA 
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copy number using a spectrophotometer, or RNA degradation. More sensitive and accurate 
methods of RNA quantification could be considered for future work. The presence of an 
additional band in the PCR products generated may also decrease the sensitivity. Further 
optimisation of buffer conditions, primer concentration, quantity of Taq polymerase and 
cDNA would also ideally have been investigated and would likely have improved 
sensitivity. Alternative targets could also have been investigated, however due to time 
constraints further optimisation was omitted. 
3.10.1.5. Specificity 
A wide range of other viral and bacterial pathogens may also be present in the clinical 
samples, along with human chromosomal material. To ascertain whether the presence of 
such genomes would interfere with the PCR, resulting in non-specific amplification, a 
number of clinical samples and samples known to contain a variety of these pathogens 
were tested in the PCR. Sequence analysis of the amplicons was also performed to confirm 
specificity. There was no cross reactivity observed with any of these, or with the clinical 
samples, with the exception of some low molecular weight smearing in some samples. All 
amplicons that were produced were of the expected size and sequence. Further 
improvements to assay design could be contemplated. With regard to the low molecular 
weight smearing observed in some samples the use of HOT START taq polymerase could 
be investigated. This utilises an immobilised Taq polymerase. The Taq is therefore inactive 
until the correct melting temperature is reached and the Taq is released. This prevents 
amplification of products which may occur before the optimal temperatures are reached, 
and has been shown to increase the specificity PCR. 
Since the initial reports of hMPV detection by RT-PCR a number of other conventional 
and real time RT-PCR assays have been reported, a summary of which is given in Table 
3.16. Some assays have targeted the L, M, or P genes, however a majority have targeted 
either the F gene, as in this work, or the N gene. Due to the proximity of the N gene to the 
3' promoter RT -PCR assays targeting this gene are likely to be more sensitive than those 
targeting other genes. The F gene was targeted in this work due to the availability of 
sequence at the time, future PCR development however should target the N gene. 
Real time PCR also offers many improvements in the sensitivity ofRT-PCR assays with as 
few as a 1000 copies/ml being readily detected (Kuypers et aI., 2005). Real time assays 
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also offer greater versatility in terms of turn around time, and reduced samples quantities, 
many also provide quantitative data. Future development of diagnostic PCR for hMPV 
would therefore ideally be based on a real-time format. 
Table 3.15: Summary of reported PCR methodologies for the detection of hMPV. (RT) Real time 
format, (C) Conventional format 
Target Position Publication Format Comment 
Gene 
N 104-1025 (Boivin et aI., 2003) RT GSP RT Step 
742-965 (Konig et aI., 2004) C 
490-807 (Xepapadaki et aI., 2004) C 
74-245 (Rohde et aI., 2005) RT 
993-1064 (Sumino et aI., 2005) RT 
389-1004 (Samransamruajkit et aI., C Nested 
556-814 2006) 
80-596 (Sarasini et aI., 2006) C 
40-766 (Gema et aI., 2005) C 
641-813 (Bouscambert-Duchamp et RT 
aI., 2005) 
97-1025 (Cote et aI., 2003) RT 
F 4216-4357 (Chan et aI., 2003) C Nested 
4238-4335 
39010-4566 (Esper et aI., 2003) C 
3704-4153 (Peret et aI., 2002) C 
3163-3443 (Esper et aI., 2004) C 
3647-4153 (Samransamruajkit et aI., C Hemi nested 
3704-4153 2006) 
3619-3686 (Kuypers et aI., 2005) RT A or B subtypes 
or 
3619-3693 
3626-4155 (Gema et aI., 2005) C 
3626-3767 (Ebihara et aI., 2004) C 
P-M 1864-2185 (Mackay et aI., 2004) CIRT 
1798-1878 (Agapov et aI., 2006) RT 
M 2630-2830 (Peiris et aI., 2003) C Detects both hMPV & 
APV 
2396-2598 (Mackay et aI., 2003) C 
L 11321-11490 (van den Hoogen et aI., 2003) C Dot blot 
hybridisation. 
1152-11486 (Samransamruajkit et aI., C Hemi nested 
11336-11486 2006) 
11288-11457 (Sarasini et aI., 2006) C 
7308-7857 (Cote et aI., 2003) RT 
Other methods used for the detection of hMPV in clinical samples include indirect IF or 
nasopharyngeal secretions (Ebihara et aI., 2005) and immunofluorescence of shell vial 
cultures (Landry et aI., 2005), however both these reports compared the IF assays to RT-
PCR and both proved RT-PCR to be more sensitive. A number of serological assays have 
also been developed for the detection of hMPV antibody as will be discussed in chapter 6. 
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Whilst these assays are useful tools for the assessment of seroprevalence, and other 
immunological investigations as well as confirmatory diagnosis if seroconversion in 
convalescent serum is measured, they cannot be readily used in the acute phase of illness. 
3.10.2. Sampling 
The optimal sample type for hMPV has not yet been determined. The samples investigated 
in these studies, nose and throat swabs, and NP As are the most typical samples for 
investigating acute respiratory tract infections. However, as hMPV has been shown to 
cause a broad range of illness other sample types should not be overlooked. Both hMPV 
and RSV have been found in middle ear effusions, conjunctival brushes, paranasal sinus 
tissue, BAL and sputum samples to name but a few. (Boivin et aI., 2002, Suzuki et ai., 
2005, van den Hoogen et aI., 2003) Recently, hMPV was also detected in the plasma of 
41 % of patients with hMPV positive nose swabs (Maggi et aI., 2003) and recovered from 
lung and brain material of a fatal encephalitis case of other wise unknown cause 
(Schildgen et aI., 2005). Investigations into the optimal sample types should be carried 
out. Each sample type, however, has its own bias and it is unlikely one sample type will 
suffice for all clinical presentations. 
Transit of the sample from the GP/ Hospital to the laboratory is also an important 
consideration. In the community study swabs were put into virus transport medium and 
sent by first class mail at ambient temperature to the laboratory arriving approximately 3 
days from when the sample was taken. It is possible a degree of sample degradation occurs 
during this time. The samples taken for the hospital study by comparison were couriered to 
the laboratory the same day, which, may contribute to the increase detection rate of hMPV 
in this study. Upon receipt, samples were aliquoted immediately, to avoid repeated freeze 
thawing. PCR aliquots were put in to guanidine based buffers to help preserve the sample. 
A portion of the original sample, however, was frozen without guanidine and used for 
virus isolation in cell culture. Repeated freeze thawing or long term storage of this sample 
may result in sample degradation, and reduce the recovery rates of virus in culture. This is 
particularly important for hMPV which is already a very fastidious virus to grow, and like 
RSV is thought to be sensitive to freeze thawing (Gupta et ai., 1996). 
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The majority of hMPV PCR testing was carried out on cDNA previously used for testing 
for other agents, and may well have undergone several freeze thaw cycles before hMPV 
testing was carried out. Again resulting in sample degradation which is not optimal for the 
detection of RNA. Monitoring of sample degradation could be achieved through the 
analysis by RT-PCR of housekeeping genes such as GAPDH or ~-actin. 
3.10.3. Epidemiology 
hMPV PCRs 1 and 2 were applied to clinical material from a variety of different clinical 
studies to determine the level of ILl or ARTI within different UK populations that can be 
attributed to hMPV infection. 
It is worth noting that the number of samples received from both the community and 
hospital study decrease by almost half in week 52, and is reflected in the RCGP ILl index. 
It is unlikely that this is due to a decrease in RTI during this time and more likely due the 
closure of GP surgeries, reduction in the postal service, and a reluctance to hospitalise 
children over the Christmas and New Year holiday. The incidence of hMPV, RSV and 
Influenza may therefore be under estimated for that period. 
Table 3.17 summarises the relevant published data on the detection of hMPV in various 
studies conducted on samples obtained in different study groups and different seasons. The 
publications have been grouped according to the main focus of the study population, but is 
not absolute, and is not intended to be an exhausted list of publications on hMPV 
epidemiology. 
Table 3.16: Summary of published addressing the prevalence and epidemiology ofhMPV. 
NL: Netherlands, UK: United kingdom, BRA: Brazil, USA: United States of America, 
SPA: Spain, GER: Germany, IND: India, CAN: Canada, JAP: Japan, ARG: Argentina, 
ITA: Italy, THA: Thailand, AUS: Australia, FL: Finland, CHI: China, HK: Hong Kong, 
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NOR: Norway, SA: South Africa, DEN: Denmark, GRE: Greece, FRA: France, IRE: 
Ireland, MEX: Mexico, ISR: Israel. A: Samples tested are negative for other respiratory 
pathogens. B: Co- infections with hMPV detected, N: A symptomatic or negative control 
group included. COPD: Cardio Pulmonary Disease, RD: Respiratory Distress, NS: Not 
Stated. Where spaces are blank, the relevant information was not reported. 
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Ii' PopuJati 9~@. 7f,a.l"~~~IrY; Y group x;;.v ;,, :iNdy penOCl J Number '/thMPV (;omment Peak age peak penOCl 
Commuhity van den Hoogen 2001 NL < 10 Yr- RTI 20 Years 68 7 (10%) A 4-74Yr ND 
Stockton 2002 UK III Oct 00- Mar 01 408 9 (2.2%) A >65Yr Dec 
Cuevas 2003 BRA Children- ARTI May and June 202 111 19(17%) B 
Esper 2003 USA < 5 Yr- UJt.RTI Oct 2001 to Feb 2002 296 19(6.4%) A 8.7Mo Jan- Feb 
Vicente 2003 SPA <3 Yr-ARTI Nov 01-Feb 02 147 6(4.1%) 7-20Mo 
Konig 2004 GER <3 Yr-ARTI Nov 99-0ct 01 83 15(18%) B 
Mullins 2004 USA Children-ARTI Aug 00- Sep 01 668 26(3.9%) 1-2Yr Mar-Apr 
Rao 2004 IND ARTI MAug03 26 15(19.2%) 
Williams 2004 USA Children -LRTI 25 years 248 49(20%) N 11-12Mo Dec-Apr 
Chano 2005 CAN Children-RTI Winter 01 1132 44(3.9%) BN Jan- Feb 
Sasaki 2005 JAP children-IU 02-03 & 03-04 RS 1498 84 (5.6%) Feb 
164( +RTI) & (+RTI) & 0(0%) (. 
Falsey 2006 USA >18 years - +1- RTI 158 (-RTI) RTI) N winter 
Williams 2006 USA Children- URTI 82-01 (20 years) 2384 18(5%) A Dec- May 
<5 Yr-ARTI( 
Community Galiano 2004 ARG bronchiolitis) 98-02 100 11(11%) A Spring 
& Bosis 2005 ITA <15 Yr - non respiratory Nov 02- Mar 03 1505 42 (2.8) B winter 
Hospital Kuypers 2005 USA ARTI Dec 02-May 03 719 52(7.2%) 7-12Mo Apr- May 
Robinson 2005 CAN children-ARTI Nov 02 -Dec 03 1079 42(3.9%) Jan- Apr 
Agapov 2006 USA Children Mar 02- June 04 3740 202 (5.4%) A <2Yr Feb - Apr 
<3 years - RTI-
Kaida 2006 JAP Encephalitus Jun 04-May 05 144 29(20.1%) Apr 
Saramaronsmurajit 2006 THA Children- LRTI Mar 01- Nov 03 220 12 (5.4%) 
Hospital Howe 2002 AUS Children- ARTI NS 525 40(7.6%) A 
3mo -16 y Expiratory 
Jartti 2002 FI Wheezing Sep OO-May 01 132 10(8%) B 
<5 
Bastien 2003 CAN ARTI Oct 01-Apr 02 445 66(14.8%) A years>50years 
Boivin 2003 CAN <3 Yr-ARTI DecOl-Apr 02 208 12(6%) <2yYr Mar- May 
Chan 2003 CHI SARS Mar-03 48 25(52.1%) SARS 
Falsey 2003 USA ARTIICOPD Winter 99-01 984 44(4.5%) N Young aduHs Feb 
Freymouth 2003 FRA Children- ARTI Winter 01-02 337 19(6.6%) A 3Mo-12Yr Dec- Jan 
Kuiken 2003 CHI SARS Mar-03 335 41(12%) SARS 
Maggi 2003 ITA Infants- ARTI Winter 00-02 75 & 15 21 (28%) & 2(3%) B 7.8Mo Jan- Jun 
Peiris 2003 HK <18Yr-ARTI Aug 01-Mar 02 581 32(5.5%) B 3-72 Mo Sring 
van den Hoogen 2003 NL ARTI Sep OO-Feb 02 681 47(7%) A 4-6Mo Dec-Jan 
< 2Yr- U/LRTI; 
Viazov 2003 GER Wheezing, RD Jan - May02 63 11(17.5%) B Jan- Apr 
Dollner 2004 NOR Children- ARTI Nov 02-Apr 03 236 50(21%) Nov - Jan 
Esper 2004 USA <5Yr-ARTI Nov 01-0ct 02 668 54(8.1%) A March 
FF 2004 SA Children -ARTI 137 18(5.8%) 
3mo-16 Yr- Expiratory 
Jartti 2004 FIN wheezing Sep OO-May 02 132 10(8%) B Epidemic 2001 
Kashiwa 2004 JAP children-LRTI Sep 02-Aug 03 27 16(59%) Apr-Jul 
Smuts 2004 SA <3 Yr-ARTI Apr-Aug 01 & 02 143 16(11.2%) B Winter 
von Ustow 2004 DEN ARTI 99-00 & 00-01 (Nov-May) 383 11(2.9%) B 
Xepapadaki 2004 GRE Acute bronchiolitis Nov - May (NS) 56 9(16.1%) B Feb - Apr 
Bouscambert 2005 FRA <24months- bronchiolitis Sep 01-Jun 02 94 8(9%) B Jan 
Carr 2005 IRE 48-72 Yr-RTI Sep 03- Mar 04 168 4(2.4%) A 
Ebinhara 2005 JAP Children- RTI Apr - May 04 48 11 (22%) A 
Noyola 2005 MEX <3 Yr-RTI 03-04 RS 323 34(10.5%) A Feb - Mar 
Rohde 2005 GER COPD Oct 99- Jun 04 130 3(2.3%) 
>18 years-Asthma 
Williams 2005 USA exacerbations Dec 99-Dec 03 101 7 (6.9%) Jan- May 
Jacques 2006 FRA Wheezing Sep 01-Jun 02 192 8(4%) 
AduHs-COPD 
MartineDo 2006 USA exacerbation Dec 02 -May 03 50 6(12%) 
Regev 2006 ISR <5 Yr- ARTI 388 42(10.8%) A Feb - Apr 
Sarasini 2006 ITA Children - ARTI Winter & Sprin g 03-04 306 40(13.1%) Feb - Mar 
Immunocomp Madhi 2003 SA Infants- +I-HIV; ARTI NS 196 14(7.1%) 
Kumar 2005 CAN ART~ Lung transplant 2001-2003 50 1 (2%) N 
Gema 2006 ITA UILRTI ~ung transplant Nov 01-May 04 128 60% BN 
McAdam 2004 USA <18 Yr-ARTI 00-02 1257 58(4.6%) B 3-24 Mo Jan -Feb 
Larcher 2005 AUS Children- ARTI Sep 03-Mar 04 265 43 (16.2%) Outbreak- Mar 
Martino 2005 SPA Adu«S-UILRTI Sep 99-0ct 03 512 19(4.6%) 
Rovida 2005 ITA ARTI Winter 01-02 208 12 (5.8%) B 
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3.10.3.1. Community Acquired Infections 
Combined nose and throat swabs submitted as part of the national surveillance program for 
ILl were tested prospectively for Influenza and RSV, and retrospectively for hMPV. 
Samples were taken between October and March for 3 successive seasons, 2001-2002 
(Year 1),2002-2003 (Year 2) and 2003-2004 (Year 3). 
hMPV was detected in all three winter seasons and over the 3 years was found in 
approximately 4.8% of the samples tested. There was an increase in the detection rate of 
hMPV between year 1 and 2 from 3.6% to 5.1 %, most likely due to the introduction of 
hMPV PCR 2 in the second year. The incidence of hMPV in years 2 and 3 of the study 
were around the same level with roughly 5.2% of the patients having detectable levels of 
hMPV. 
In comparison, the incidence ofRSV varied greatly over the 3 winter seasons, from 25.3% 
in Y2 to 4.12% in Y3. In year 3, the incidence of hMPV was greater than that of RSV 
(5.34% vs. 4.12%). In contrast, the level of influenza activity was similar for years 1 and 2 
of the study. However, in year 3 the incidence of influenza almost doubled accounting for 
over 370/0 of patient samples. The increase in the incidence of influenza was reflected in 
the RCGP ILl index, and accounts for the increased number of samples received that year. 
The detection rate reported for hMPV in the general community in other publications 
varies considerably from 2.5% to 20%. This reflects differences in the target population, 
illness, the length and timing of the studies and the relative sensitivities of the detection 
assays. The only other study which addresses the contribution of hMPV in community 
acquired ILl only targeted children in which 5.6% were positive for hMPV over two 
consecutive winters in Japan. 
Other community based studies targeted a broader range of respiratory illnesses i.e. ARTI, 
URTI, LRTI or RTI. Very few studies have targeted adults, or all ages of the population, 
and have focused mainly instead on the incidence of hMPV in children. One study which 
did address the incidence of hMPV in adults> 18 years of age with RTI showed hMPV 
was present in 3.40/0 of cases with RTI and 0% of healthy adults (Falsey et al., 2006). One 
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study which investigated the incidence ofhMPV in UILRTI in children showed hMPV was 
present in 5 and 120/0 of cases respectively(Williams et aI., 2004, Williams et aI., 2006). 
The age distribution of samples received reflected the normal age distribution of the 
population tested. hMPV was detected in all ages of the community in roughly equal 
numbers. Proportionally, to the total number of samples received, hMPV was most 
prevalent in the 1-4 year age group, as was observed for RSV. Influenza was also detected 
in all ages and was most prevalent in school age children of 5-14 years old. These finding 
supports published data ( 
Table 3.16). This data however shows that hMPV has the ability to cause ILl in adults 
leading to the requirement for medical consultation. 
Samples received from the RCGP community all ages study were taken only from patients 
presenting with influenza like illness. The overall incidence of hMPV in the community is 
therefore undoubtedly underestimated in this study. While it has been shown in this work 
and that of others that hMPV can cause influenza like illness in children and adults 
(Nicholson et aI., 2006, Sasaki et aI., 2005, Stockton et aI., 2002), a majority of healthy 
adults with hMPV infections are likely to have much milder symptoms (Boivin et aI., 
2002, van den Hoogen et aI., 2003). Furthermore, most adults with heavy cold or influenza 
like illnesses are less likely to attend the GP than children and infants. Therefore a large 
proportion of the general community with ARTI and ARTI's in general are 
underrepresented. To fully evaluate the burden of disease caused by hMPV in the 
community samples from patients with a much broader clinical picture need to be 
analysed. 
3.10.3.2. Community Acquired Infections in the Elderly 
Combined nose and throat swabs collected by GPs between October 2001 to March 2002 
as part of a study investigating the cause of ARTI in the community dwelling elderly were 
tested prospectively for RSV and influenza, and retrospectively for hMPV. 
hMPV was present in 4.5% of the cases investigated in the elderly study. Although the 
number of hMPV, RSV and influenza infections were roughly the same, it is interesting 
that while hMPV accounted for a larger proportion of infections in the elderly that year, 
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compared with the general community, the proportion of RSV and Influenza were 
considerably lower. While it was expected that few influenza cases were detected due to 
the higher uptake of the influenza vaccine in this age group (Fleming et aI., 2005) 
compared with the mean age of the community study, it is surprising that a larger 
incidence of RSV was not seen. This study highlights the important role hMPV plays in 
RTI in the community dwelling elderly and is consistent with a findings from a number of 
other reports that the elderly adults have an increased susceptibility to hMPV infection 
than younger adults (Falsey et aI., 2003, van den Hoogen et aI., 2003). Increased 
susceptibility to hMPV in this age group, may be attributed to waning immunity and 
increased incidence of underlying diseases such as COPD, may leave them more prone to 
infection. However the large proportion of cases in which these three viruses were not 
detected, is significant, and analysis of other viral and bacterial pathogens is required to fill 
this gap in our knowledge. 
3.10.3.3. Hospitalised Paediatrics 
Samples collected from children <5 years of age hospitalised with ART! were 
analysed for a range of common respiratory tract infections including hMPV. Over 
the 18 months of the study hMPV was detected in 5.70/0 of samples, which is 
slightly higher than the level of hMPV observed in the community and supports 
findings that children <5 years old are more susceptible to infection with hMPV 
than other age groups. As expected, RSV was the most frequently identified viral 
agent. There was an increase in the incidence of hMPV from 5% to 6.6% over the 
two winter seasons studied, and is again most likely due to the introduction of 
hMPV PCR 2 in the summer of 2003. Unfortunately the clinical data was not 
available for analysis, therefore comments cannot be made on the severity of the 
illness of children with hMPV versus RSV infections, however previously 
published work suggests that hMPV and RSV infections are clinically 
indistinguishable. hMPV, therefore, contributes significantly to the number of 
young children hospitalised each year with ART!. These results are comparable 
with those from published findings ( 
Table 3.16). 
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The incidence of hMPV in other studies varies considerably from 2.9-22% which is again 
dependent on the specific target groups, study size, timing and length of study, clinical 
picture and relative sensitivities of the detection assay used. Again most publications focus 
on children. Esper et at reported the presence of hMPV in 8.1 % of samples obtained from 
children <5 years hospitalised with ARTI in the USA that were negative for other viral 
pathogens (Esper et aI., 2004). Another report found hMPV in 10.8% of children < 5 years 
hospitalised with ARTI in Israel that were negative for other viral pathogens (Regev et aI., 
2006). In studies that looked at children < 3 years of age hospitalised with ARTI, hMPV 
was present in 11.2% of cases in South Africa (Smuts et aI., 2004), 10.5% in Mexico 
(Noyola et aI., 2005), and 6% in Canada with a greater percentage of cases occurring in 
children < 2 years of age (Boivin et aI., 2003). In Hong Kong hMPV was present in 5.5% 
of samples from children < 18 years hospitalised with ARTI, however the incidence of 
hMPV peaked in children between the ages of 3 -72 months (Peiris et aI., 2003). 
3.10.3.4. Imm unocom promised 
The incidence ofhMPV in the immunocompromised study accounted for 8.2% of the total 
number of samples received. This cohort had the highest percentage of hMPV of all the 
cohorts examined in this thesis, and supports evidence of a higher rate of hMPV activity in 
people with compromised immunity. Most of the samples received and hence hMPV 
positive cases were from children < 1 year old. hMPV was also identified in adults, all of 
which received bone marrow transplants. However it is also worth bearing in mind that 
this study encompass patients with a broader spectrum of respiratory illness not considered 
in the other cohorts, ranging from mild sniffles to severe bronchiolitis. As these patients 
were all hospitalised at the time of illness it is likely a majority of these infections were 
nosocomial, and highlight the importance of infection control measures especially in the 
immunocompromised wards. Unfortunately, there was no information available regarding 
the incidences of other pathogens, or clinical outcomes. 
A number of other reports have focused on, or addressed the question of hMPV in the 
immunocompromised population ( 
Table 3.16). One such study compared the incidence ofhMPV in RTI of otherwise healthy 
children, lung transplant recipients and immunocompromised children. hMPV was present 
in 14%, 25% and 2% respectively (Larcher et aI., 2005). Surprisingly however in infants 
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hospitalised with RTI that were either HIV positive or negative, hMPV was detected in 
9.1 % of HIV negative children but only 3.7% of HIV positive children. The authors 
however suggest this may be due to the greater importance of other pathogens in HIV 
infected individuals such as P. jiroveci which accounts for 450/0 of cases. Other respiratory 
viruses such as RSV, influenza and parainfluenza, have also been reported to occur less 
frequently in LRTI of HIV positive children compared to HIV negative children. However 
the relative risk of hospitalization in HIV positive children with respiratory viruses is much 
greater (Madhi et aI., 2003). 
3.10.4. Dual Infections 
In the RCGP community acquired and hospitalised paediatric studies dual infections were 
identified in 1.5% and 7.5% of the total number of samples respectively. There were no 
dual infections identified in the elderly or immunocompromised cohorts. As the hospital 
study investigated a larger variety of viral pathogens the increase in the rate of dual 
infection was expected. Overall, dual infections with hMPV accounted for 85% of all dual 
infections in the RCGP community, and 26% in hospitalised paediatrics. The percentage of 
hMPV dual infections alters considerably from 42% of all hMPV infections identified in 
year 2 to 28 % in year 3 of the RCGP community study. No dual infections were 
identified in year 1. Of the hospitalised paediatric hMPV cases 34% were dual infections. 
In both incidences the main co-pathogen of hMPV infections was RSV. The largest 
number of dual infections in the hospital setting were with RSV and either Rhinovirus or 
other Enteroviruses the three most commonly identified viruses in that study. 
From this investigation it is not possible to determine if both viruses identified in a dual 
infection are causing disease, or to what extent each virus is contributing to the disease 
symptoms. It is likely, however, that some symptoms are due to the presence of both 
viruses. It has been reported that children hospitalised with RSV infections are 10 times 
more likely to require ventilation/ mechanical support ifhMPV is also present (Greensill et 
aI., 2003), suggesting hMPV plays an important role as a co-pathogen. It would therefore 
be beneficial to investigate whether symptoms associated with dual hMPV infections are 
more severe or longer lasting than single hMPV infections. 
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Furthermore, it is not known for how long after infection the PCR is capable of detecting 
viral nucleic acid or for how long hMPV may persist. It has been reported that RSV has the 
ability to cause persistent infections which are associated with chronic wheezing and 
asthma in animal models (Bramley et aI., 1999, Dakhama et aI., 1997, Hegele et aI., 1994) . 
Recently, Alvarez and Trip et al have demonstrated hMPV persistence in mice. In that 
study genomic RNA was detected in the lungs of BALB/c mice 180 days post infection, 
with recoverable virus up to 60 days post infection despite the presence of neutralising 
antibodies and cytotoxic T cells (Alvarez et aI., 2004, Alvarez & Tripp, 2005). Whether 
hMPV can cause persistent infections in humans is yet to be investigated. However, if 
found to do so, the detection of genomic RNA may be possible long after the symptomatic 
phase of illness, and may not be associated with the ARTI under investigation. 
Further investigation of these points requires volunteer studies with sampling before, 
during, and after the symptomatic phase of illness, with detailed information as to the 
clinical picture and outcome. 
3.10.5. Seasonality 
The start and length of the hMPV seasons differed slightly over the 3 years of the 
community study. In year 1 hMPV was detected in November through to February, and in 
years 2 and 3 in October through to the end of March with peak incidence in December or 
January. The RCGP community studies are designed to target influenza! RSV activity 
which have well defined seasonal patterns and samples were therefore only collected over 
the winter months. Consequently this does not give the scope for determining the amount 
of hMPV activity over the summer period. 
The hospitalised paediatric study, in companson, looks at samples collected over 18 
consecutive months encompassing 2 winter seasons and one summer. The number of 
samples collected shows an increase in ARTI during the winter months but remains high 
through the summer with the exception of July and August when few/no samples were 
collected. hMPV appears from November through to June with a peak incidence in 
January/February. hMPV then reappears again in September through to March when the 
study ended, with a peak incidence in October, preceding the peek incidence in the 
community acquired study for that same year by a couple of months. 
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hMPV appears to have a seasonal pattern occurring primarily in the winter months, 
and therefore co-circulates with other seasonal respiratory viruses such as RSV and 
Influenza. Unlike RSV and influenza, hMPV continues to circulate throughout spring 
and early summer, and then reappears in late summer early autumn before the start 
of the RSV season. This is consistent with all the data produced about the seasonality 
of hMPV in temperate climates ( 
Table 3.l6) 
3.10.6. Other Comments 
The lack of negative (asymptomatic) control groups highlights one of the inherent flaws of 
these types of studies, as the incidence of asymptomatic infection is not measured. It is 
important to consider asymptomatic infections as any virus being shed may be a source of 
symptomatic infection in other individuals. With the exception of one study in which there 
were roughly equal proportions of hMPV positive young adults with or without RTI 
(Falsey et aI., 2003), little or no hMPV activity is reported to occur in asymptomatic 
control groups (Gerna et aI., 2006, Williams et aI., 2004). These studies however are 
limited and further investigation is required. 
It is also important to note that in a large proportion of samples, especially in the elderly 
study (87.5%), an aetiological agent was not identified. As most of these studies only 
examined in incidence of hMPV, RSV and Influenza, there is obvious scope for a much 
broader range or respiratory pathogens, both viral and bacterial, to be investigated. It 
should also not be forgotten that a number of so far unidentified pathogens may be 
responsible for a proportion of the ARTI observed and this undoubtedly deserves further 
attention .. 
The data presented in this chapter raises a number of questions relating to strain diversity 
and the potential of hMPV to cause repeated infections, as seen with RSV, and whether 
strains circulating in the paediatric population the same as those in older children and 
adults. Chapter 4 aims to address these points through sequence and phylogenetic analysis 
of the hMPV G protein. Serological analysis of the prevalence of hMPV antibodies in 
different populations or age groups would provide valuable information as the prevalence 
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of hMPV antibodies in these different groups, and their potential susceptibility to hMPV 
infection, especially when addressing the question of repeated infection. Presented in 
chapters 5 and 6 is the development of such an assay and its application to try and address 
some of these questions. 
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4.1 Introduction 
One of the important issues surrounding hMPV, as has been shown in chapter 3, and 
investigated further in chapter 6, is the ability of the virus to infect very young children, 
possibly at a time when maternal antibodies should be protective, as well as its ability to 
cause repeated infections throughout ones lifetime. This is similar to hRSV where 
incomplete immunity to the virus, and or genetic heterogeneity contributes to the virus's 
ability to evade host immune responses (Melero et aI., 1997, Sullender et aI., 1998, Zlateva 
et aI., 2005) It is therefore important to develop a thorough understanding of the extent of 
the genetic and antigenic variability in the different hMPV surface proteins, and to relate 
this to information regarding the timing of primary infection and re-infection relative to 
antibody levels. 
Phylogenetic analysis of the M, N, P, F, G and L genes ofhMPV show that there are two 
lineages of hMPV; A and B, each with at least 2 sub-lineages (AI, A2 and B1, B2) 
(Bastien et aI., 2003, Mackay et aI., 2004). It has recently been reported that an additional 
A sub-lineage (A3) may exist (Huck et aI., 2006). 
For RSV and other pneumoviruses the fusion (F) and attachment glycoprotein (G) are the 
major antigenic determinants, against which neutralizing antibodies are generated. 
The G protein ofhMPV is highly divergent with approximately 33% amino acid homology 
reported between lineages (Bastien et aI., 2004, Boivin et aI., 2004, Ishiguro et aI., 2004). 
The high serine and threonine content of the G protein is also another important 
characteristic and indicates that like the G protein of hRSV the hMPV G protein is also 
likely to be highly O-glycosylated (van den Hoogen et aI., 2002). These characteristics 
may aid the virus in evading pre-existing immunity by modifying epitopes. In contrast to G 
the F protein has been shown to be highly conserved showing 93-100% amino acid 
homology between lineages (Bastien et aI., 2003, Boivin et aI., 2004, Skiadopoulos et aI., 
2004). Analysis of the G protein would therefore provide more valuable information as to 
the diversity of the circulating stains and immune evasion strategies. 
Mutations in a protein may be brought about by nucleotide substitutions, insertions or 
deletions in its encoding gene, of which the two latter result in frame shift mutations. 
Frame shift may alter the appearance of the protein dramatically, and may result in 
premature termination. Nucleotide substitutions mayor may not alter the amino acid that is 
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encoded, or introduce stop codons. Where amino acid changes are brought about the nature 
of the amino acid substitution, its location within the protein and the involvement of that 
amino acid in the protein structure or function influences whether the mutation is 
detrimental or beneficial to the protein or has no effect. 
Due to the dependence of RNA virus replication on RNA dependent RNA polymerase, 
which lacks proof reading capabilities, mistakes! mutations introduced during replication 
cannot be corrected (Castro et aI., 2005, Drake, 1993, Drake, 1999). Any mutations that are 
incorporated are passed on to progeny virus, and a mixed population of viruses, a 
quasi species, is generated. The existence of quasispecies needs to be considered when 
designing a sequencing strategy for RNA viruses, and the extent of variation within a viral 
population can be addressed through the sequence analysis of clones. In general the 
majority species present in a sample is considered the strain type. 
The use of DNA sequencing to estimate the strain diversity of RNA viruses suffers from 
inherent complications due to enzyme induced errors. A comparison of 3 RNA 
amplification methods used for DNA sequencing showed that the use of MML V reverse 
transcriptase followed by a nested PCR with Taq polymerase gave the least errors when 
compared to a combined RT-PCR using a Tth enzyme or a nucleic acid sequenced based 
amplification (NASBA) method using AMV reverse transcriptase and T7 RNA 
polymerase. Furthermore this study showed that sequencing of cloned products also 
reduced error rates (Chadwick et aI., 1998). 
Phylogenetic analysis is only as good as the alignment upon which it is based. Multiple 
alignments are generated in three major steps. The first step is a pair-wise alignment in 
which each sequence is aligned with each of the other sequences in the dataset, starting at 
one end, and attempts to match all possible pairs using a scoring system such as a DNA or 
protein weight matrix. The Gonnet 250 protein weight matrix used in this work assigns a 
score depending on the amino acids present in each position of the alignment. Where 
identical amino acids are aligned the highest score is given, and where biologically distinct 
amino acids are aligned a low score is given. Other alignment parameters to be set include 
a gap opening penalty, which gives a negative score, where insertions and deletions occur 
resulting in the introduction of gaps in the alignment, and gap extension penalties for 
increasing the length of the gap. The alignment with the highest overall score has the 
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maximum likelihood of occurring and is used to construct a guide tree (step 2), from which 
the process is repeated (step 3). 
Sequence alignment and phylogenetic analysis of amino acid sequences is generally 
considered to be more biologically relevant when dealing with coding sequences, as is the 
case in this work. However it provides little information as to the changes occurring at the 
nucleotide level. Direct alignment of the nucleotide sequence also has an inherent flaw as 
gaps in the alignment are introduced where individual nucleotide bases have been inserted 
or deleted, therefore, translation of the consensus will result in an amino acid sequence that 
does not reflect the original sequence. In-frame nucleotide alignments however overcome 
these problems. 
In-frame nucleotide alignments are based on amino acid alignments which are utilised by 
software such as codon align to align the corresponding nucleotide sequences, introducing 
gaps of three nucleotides where amino acids have been inserted or deleted, therefore 
maintaining the open reading frame. Translation of the consensus sequence generated by 
this process results in an amino acid sequence which represents that of the original. 
There are three general ways of performing phylogenetic analysis once an alignment has 
been generated, maximum parsimony, distance and maximum likelihood. The maximum 
parsimony method produces phylogenetic trees which minimise the number of steps 
(mutations) required to generate sequence B from sequence A, and considers every 
position within the alignment. As such this method is highly time consuming and suitable 
for only a small number of sequences, or where there is a high degree of sequence 
homology. 
There are a number of available distance methods that can be used, the most common 
being the neighbour joining method. This method identifies the sequence pair within the 
alignment that has the smallest number of changes between them, and places them as 
neighbours on the tree then moves on to find the next closest sequence. This method has 
the advantage of being fast and is capable of dealing with a large data set. However it is 
biased by the most closely related sequences, and assumes equal rates of evolution are 
occurring throughout the sequence and between taxa (the molecular clock hypothesis). As 
such this method my give rise to an inaccurate account of evolutionary history. 
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The maximum likelihood method however allows for variation in rates of change and is 
therefore more suited for more distantly related or highly variable sequences, as is the case 
in this work. The maximum likelihood approach is similar to that of the maximum 
parsimony, in that it evaluates all positions within the alignment, and finds the tree with the 
greatest likelihood based on a model of evolution, and therefore has the draw back of being 
highly time consuming and computorally intense. The most appropriate evolutionary 
model for the data set under investigation was determined in this work using the model test 
application within the P AUP phylogenetic software. Model test analyses the dataset and 
selects a model which most closely represents the data under investigation from 
approximately 60 defined models, and provides estimates on the rates of substitution, 
transition, translation, additions and deletions, which are used as parameters in the 
phylogenetic analysis. 
A number of questions arise from the epidemiological data presented in chapter 3. What is 
the genetic diversity of the circulating hMPV strains? Do the same strains circulate in 
community and hospital populations, and at different time points? And what evidence is 
there that genetic diversity in the attachment protein contributes to antigenic changes and 
evasion from host immunity? This chapter aims to address these questions through the use 
of sequence and phylogenetic analysis of the highly divergent G gene ofhMPV. 
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4.2 Aims 
• To develop a sequencing strategy for the full length open reading frame of the 
hMPV attachment glycoprotein and apply it to clinical material in which hMPV has 
been detected using the F gene diagnostic PCR described in chapter 3. 
• To analyse the sequence data to determine the relationships of the hMPV strains 
circulating. 
• To analyse diversity between strains and formulate hypotheses about the functional 
properties of the hMPV G protein. 
125 
Chapter 4 -Strain Diversity 
4.3 Development of a Sequencing Strategy for the hMPV G 
ORF 
4.3.1 Gene amplification 
Primers were designed to amplify the entire length of the hMPV G gene. To avoid regions 
where large amounts of variation occurred and the need for extensively degenerate 
primers, forward primers were place primarily in the SH-G inter-genic and G start regions, 
and the reverse primers placed primarily in the large polymerase gene. 
Table 4.1 Primers investigated for use in the amplification of hMPV G ORF from clinical samples 
Primer Position * Sense Seguence 
1 HMPVSH5479 5479-5498 + GTG GGA TAA ATG ACA ATG AT 
F 
2 HMPVSHABF 5481-5500 + GGG ATA ART GAC AAT GAW AA 
., MPVSHI 5494-5511 + ATG AlA TCA TTA GAD A YV .) 
4 HMPVG6247F 6247-6266 + ATG GAG GTG AAA GTG GAG AA 
5 HMPVGABF 6233-6259 + GGG ACA AGT RGY YAT GGA RGT RAR AG 
6 HMPVGAF 6233-6259 + GGG ACA AGT AGT TAT GGA GGT GAA AG 
7 HMPVGBF 6233-6259 + GGG ACA AGT GGC CAT GGA AGT AAG AG 
8 MPVGIF 6235-6258 + GAG CAA GAA GTA ATG AAC RTG VIA 
9 MPVG5F 6242-6269 + TAGTTA TGIASA TGAAAGTGA TARAMA 
W 
10 HMPVG3F 6423-6445 + ATC TGA ATC AGA ACC TCM CAC MA 
11 HMPVG6100F 6100-6120 + TTT AAA AA T A TT TTG AAA AC 
12 HMPVG6260F 6260-6280 + TGG AGA ACA TTC GAA CAA TA 
13 HMPVG257F 6503-6523 + ACA CCA ACT CAA GCC CAC AGC 
14 HMPVG481F 6727-6747 + CAT TCT CCA CCA CGG GCA ACG 
15 HMPVG277R 6503-6523 GCT GTG GGC ITG AGT TGG TGT 
16 HMPVG501R 6727-6747 CGT TGC CCG TGG TGG AGA ATG 
17 HMPVG7056R 7056-7036 A TG GTG TTG TTG CCT TTT TG 
18 HMPVG6686R 6686-6666 GCC GGA CTT GTC ITT GTT CT 
19 HMPVG7085R 7104-7085 TGG TAT ATG GGC GAG TGT TT 
20 HMPVLABR 7185-7204 AGA TAG ACA TTA ACA GTG GA 
21 MPVGLRVI 7167-7192 CAG TGG ATT CAT TAA GIG GRT CSA T 
22 MPVGLRV2 7205-7227 CAT CIT TAA GTT ATA ARA GTC GWA 
GRYY 
Footnotes: (*) Primer positions based on reference strain NLOO-l. Schematic representation of 
primer positions is shown in Figure 4.1. 
Primers were tested in various combinations of single, nested and hemi nested peR 
approaches on hMPV positive control material grown in the laboratory using Taq DNA 
polymerase. Over 50 different combinations were tested many generating products of the 
incorrect size or non-specific bands. 
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Figure 4.1: Schematic representation of hMPV G primers evaluated for used in the G ORF sequencing strategy. For primer 
sequences and nucleotide positions, see Table 3.1. 
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An example of the some of the nested PCRs, which yielded the correct sized products, are 
shown in Figure 4.2. Products were sequenced and confirmed to be the correct target. 
M 2 3 4 5 M 
lOOObp 
500bp 
Figure 4.2: M is a mobility marker with base sizes indicated with arrows. Lane 1 contains the 
product amplified with primers hMPVG6100F and hMPVG6056R primary round, hMPVGABF 
and hMPVG7056R Secondary round. Lane 2 amplification product generated with primers 
hMPVG6100F and hMPVLABR primary round, hMPVGABF and hMPVG7085R. Lane 3 
amplification product generated with primers hMPVG6100F and hMPVLABR primary round, 
hMPVGABF and hMPVG7056R. Lane 4 amplification product generated with pnmers 
hMPVG6100F and hMPVG7085R primary round, hMPVGABF and hMPVG7085R. Lane 5 
Amplification product generated with primers hMPVG6100F and hMPVG7085R primary round, 
hMPVGABF and hMPVG7085R 
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The primer combinations, which were found to give the best amplification and sequencing 
results, are listed in Table 4.2. 
Table 4.2: Selected hMPV G Primers used for the amplification ofhMPV G ORF. 
Primer Sequence 5'-3' Gene Position Size 
* 
Primary Amplification 
HMPVG6100F TTT AAA AA T A TT TTG AAA AC SH-G 6100 1104 
HMPVLABR AGA TAG ACA TT A ACA GTG GA L 7204 
Secondary Amplification 
HMPVGABF GGG ACA AGT RGY Y A T GGA RGT RAR AG SH-G 6233 971 
HMPVLABR AGA TAG ACA TTA ACA GTG GA L 7204 
Footnotes: (*) Primer positions according to reference strain NLOO-l. F: Forward primer, R: 
reverse pnmer. 
Screening of the Primer sets was carried out usmg a non-proof reading DNA Taq 
Polymerase. Therefore, a range of proof reading Taq polymerases were investigated to 
determine which would be the optimal to use in this PCR. PCRs were set up according to 
the manufacturer's instruction, and the primary and secondary products analysed on a gel 
(Figure 4.3). 
M 1234567812345678 M 
971 
Figure 4.3: Determination of the optimal proof reading Tag polymerase. The lanes 1-8 in black are 
the primary round products, lanes 1-8 in Red are the secondary round products, amplified using (1 ) 
PFU Ultra, (2) PFU Turbo, (3) Expand, (4) Platinum Tag, (5) Platinum PFX, (6) AccuePrime PFX, 
(7) Platinum peR SuperMix, (8) DNA Tag Polymerase. 
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Results shown that none of the Taq polymerises tested produced primary round products 
that could be visualised on a gel. However, the secondary round products show that there 
were considerable differences between the different proof reading Taq polymerases. All 
produced the correct sized product with the exception of Expand. Platinum Taq gave the 
strongest result and was therefore chosen for analysis of clinical strains. 
4.3.2 Degenerate versus non degenerate primers 
Up until this point the chosen primer set included a degenerate forward primer in the 
second round of the PCR. A degenerate primer was used to enable amplification from both 
subtypes of hMPV. However, the use of degenerate primers is often not as sensitive and 
results in the non-specific amplification of nucleic acid when compared to non-degenerate 
primers. Therefore, the performance of the degenerate primer was compared to A and B 
subtype specific non-degenerate primers at the same site (Table 4.3) against clinical 
material known to be either positive or negative for hMPV by the F gene RT-PCR 
described previously. Any bands generated were sequenced using the amplification primer 
set to confirm the specificity of the primers; the results of which are summarised in Table 
4.4. 
Table 4.3: Comparison of degenerate and non-degenerate primer sequences. 
Primer 
HMPVGABF 
HMPVGAF 
HMPVGBF 
Sequence 5'-3' 
GGG ACA AGT RGY YAT GGA RGT RAR AG 
GGG ACA AGT AGT TAT GGA GGT GAA AG 
GGG ACA AGT GGC CAT GGA AGT AAG AG 
Subtype 
AandB 
A 
B 
Footnotes: Highlighted in Red are the degenerate bases in the hMPV G AB primer, highlighted in 
green are the bases selected for subtype specific detection. Degenerate bases R: A & G, Y: C & T. 
Results show that of the 13-hMPV positive samples identified by hMPV F gene RT-PCR, 
10 were also positive by one or more of the three hMPV G R T -PCRs tested. Overall the 
positivity rate using the hMPV G RT-PCR was 77%. The material used for this screening 
was the same cDNA material used for the initial F gene analysis. 
The 3 samples in which the G gene was not amplified were highlighted in red. Bands that 
were slightly smaller than the expected size were generated in 2 out of these 3 samples. 
Sequence analysis revealed these bands were human chromosomal material. 
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Overall the use of subtype specific primer sets yielded a larger number of positive results 
than the degenerate primer set. Highlighted in green are examples of the subtype specific 
PCR outperforming the degenerate primer set. 
Table 4.4: Summary of results comparing degenerate and subtype specific primers against hMPV 
positive and negative clinical samples. 
Primer Set 
Sample FGENE AD A B Sequence Optimal 
Number Result Primer Set 
p p p WP P A 
P P P WP P A 
P WP N WP P B 
P P P P P A or B or AB 
hMPV P P P N P A 
positive P P P N P A 
samples P P P N P A 
P N N WP P B 
P WP N P P B 
p WP N P P 13 
P N N N N* 
P N N N N* 
p N N N N* 
N N N N 
N N N N 
N N N N 
N N N N 
hMPV N N N N 
negative N N N N 
samples N N N N 
N N N N 
N N N N 
N N N N 
N N N N 
N N N N 
N N N N 
Footnotes: (P)= positive (N)= negative (WP) = week positive. (*) Samples positive by the F gene 
peR but not the G gene peR. All 3 primer sets used the same primers for the first round peR: 
HMPVG6100F, HMPVLABR the sequences of which are given in Table 4.2. For the 
second round the same reverse primer, HMPVLABR, was used in all three primer sets. 
Only the forward primer changed. AB: HMPVGABF, A: HMPVGAF, B: HMPVGBF, the 
sequences of which are given in Table 4.3. 
The primary round PCR was therefore followed by each subtype specific PCR, as outlined 
in Figure 4.4. 
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Generic primary round PCR using non 
degenerate primers HMPVG61 OOF and 
HMPVLABR 
A subtype specific second 
round PCR using primers 
HMPVLABR and HMPVGAF 
B subtype specific second round 
PCR using primers 
HMPVLABR and HMPVGAF 
DNA Gel Electrophoresis 
Figure 4.4: Amplification strategy for hMPV G ORF sequencing. 
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4.3.3 Cloning and design of sequencing primers 
Due to the high level of variation expected to be seen m this gene it is difficult to 
determine before hand which internal primers to use in order to generate full length 
sequence on both strands of the DNA. Therefore to overcome this problem and to improve 
the quality of the sequence generated the purified PCR product was cloned in to the TOPO 
TA vector. This allowed a first round of sequencing to be performed using the M13 
Forward and Reverse primers located in the vector, the data of which enabled choices to be 
made with respect to which internal primers should be used to generate further sequence 
data. 
The TOPO TA cloning vector is a commercially available vector that is supplied in its 
linear form, with thymidine overhangs at the 3' ends. Coupled to topoisomerase I, which 
mediates the ligation. 
BstX I £coR I 
Ec('JR V BslX I Not I XlJol Nsi l Xb8 1 
I 
17 Promoter 
At.;f--"c: ;., r;- ;:'(:r~ yj./'1 - ~'!v.: 
,!'C .A.. eTC A(;C AT il. AX 
( 
Comments for pCR~.1 -TOPO® 
3931 nucleotides 
pCR®2.1 .. TOPO® 
3.9 kb 
, Apal 
+ 
..... -::G '~ CA(' :'GG (Jv\ 1 .... :.... C 
;, :C ,It, C7C Ace C'~'~ 7 ';'":; 
Figure 4.5: pCR 2.1 - TOPO Map shows the features of pCR2.1 TOPO and the sequence 
surrounding the cloning site which is highlighted by a blue box. The M 13 forward and reverse 
primer positions are highlighted by red ovals. Taken from the Invitrogen TOPO TA cloning 
instruction manual Version P 051302 25-0184 
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This system allows the rapid cloning of purified PCR products that have the 
complementary adenosine overhangs at the 3' ends. Normally when a non-proof reading 
Taq-polymerase is used these 3' overhangs are added. However with a proof reading 
enzyme, they are removed. Therefore, the 3' adenosines were added to the ends of the PCR 
products, which were subsequently purified prior to cloning in to the TOPO vector, as 
described in materials and methods. 
TOP 10 E.coli were transformed with the ligated vector, and plated on to ampicillin 
selective agar. Positive colonies were selected through blue/white screening, and grown up 
in culture. The plasmid DNA was purified and the presence of the insert confirmed by 
restriction digest (EcoRI). Sequencing was performed using the M13 forward and reverse 
primers, which prime either side of the cloning site in the TOPO vector. This provided a 
near to full-length sequence of the G gene. Based on the first round of sequencing data 6 
additional primers were designed to generate overlapping sequences for both strands of the 
DNA, ensuring the full length of the gene was sequenced (See Chapter 2 Materials and 
Methods for primer sequences) 
4.3.4 Analysis of quasispecies 
Due to the nature of RNA genomes and the high degree of variation that occurs in the G 
gene especially, it is highly likely quasispecies exist within the same sample. Amplification 
by PCR is likely to amplify the major species present in the sample, or the one to which the 
primers bind most efficiently. Furthermore, the use of cloning may mean that the sequence 
obtained is not representative of the major species and may only represent a subset of the 
quasi species. Therefore to ascertain whether differences would occur between separate 
clones originating from the same sample, 2 clinical samples were randomly selected and 
the sequencing results from 5 separate clones from each sample were analysed for 
variation. Figure 4.6 shows the alignment results for 5 separate clones generated from each 
of the 2 samples. 
Results show that the sequences obtained from the separate clones are identical with the 
exception of one amino acid difference at position 77 in only one out of the 5 sequences 
obtained from sample A, and 2 amino acid changes at positions 21 and 217 in one out of 5 
of the sequences obtained from sample B. 
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The nucleotide mutation corresponding with the amino acid substitution at position 77 is 
sample A is an A to G transition at the 1 st position in the codon. There are also 2 silent 
mutations observed in sequences obtained from sample A; an A to G nucleotide change at 
position 57 at the third base of the codon in one sequence and another A to G transition in 
the stop codon in the third base position creating an A TG stop codon in another sequence. 
The nucleotide mutation corresponding with the amino acid substitution at position 21 in 
sample B is a C to T transition in the 1st position of the codon, and at position 217, a G to 
A transition also in the 1 st base of the codon. 
This indicates that quasi species exist and that while there are a few amino acid changes 
that may be missed on the whole the sequence data from one clone is likely to be a good 
representation of the majority species in the sample. 
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Figure 4.6: Sequence alignments of the full-length attachment glycoprotein from samples A and B, 
where 5 separate clones were generated from each sample. Red represents areas of identical amino 
acid. Orange where amino acid differences are present. 
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4.3.5 Analysis of clinical samples 
Nose and throat swabs from the community acquired and hospitalised paediatric studies 
identified as being positive for hMPV by the F gene RT -PCR were analysed with the 
hMPV G PCR excluding samples in which dual infections were identified. Wherever 
possible G was amplified from the same cDNA from which the initial F gene analysis was 
performed. However, for many of the samples there was insufficient cDNA available and 
therefore the original sample was re-extracted. An example of the hMPV G-A and G-B 
subtype PCR against clinical samples is shown in Figure 4.7. Results show that that there is 
often other non-specific bands generated, which appears to be greater with the hMPV G-
subtype B primer set, compared to that of subtype A. 
1-7 9 - 15 17 - 26 
Figure 4.7: Example of the hMPV G subtype A and B PCRS on clinical samples. M is the mobility 
marker, 1-7, 9-15, and 17-26 are all hMPV positive clinical samples. N indicates negative controls, 
P represents positive control samples. The Arrow represents the expected size of the product. 
Table 4.5 summarises the use of the sequencing strategy for the different study groups. 
Overall, of the 135 samples that were positive for hMPV, 103 were hMPV only infections 
(NB: Rhionviruses and coronaviruses were not investigated in the community study). All 
103 samples were analysed using the hMPV A and B G gene PCR for sequencing. Of these 
approximately 50% yielded bands of the correct or approximate size, and were cloned in to 
the TOPO vector and sequenced. Of these 30 were found to be the correct target. 
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Table 4.5: Summary of the hMPV G sequences obtain from this work. 
Season Study Total hMPVonly hMPV Sequence hMPVA hMPVB 
hMPV (%) (%) (%) (%) 
01-02 Community 14 14 (100) 7 (50) 7 (100) 0 (0) 
02-03 19 11 (57.9) 1 (9) 0(0) 1(100) 
01-02 Paediatric 27 26 (96.3) 11 (42.3) 11 (100) 0(0) 
02-03 40 24 (58.5) 10 (42) 10 (100) 0(0) 
Total 135 103 (76) 29 (30) 28 (96) 1(4) 
Footnotes: Each study group is broken down in to the two years in which samples were analysed 
for hMPV G sequence. Column 3 shows the number of hMPV positive samples detected in that 
group. Column 4 shows the numbers which were positive only for hMPV. Column 5 the number of 
full length G gene sequences obtained for that group. Column 5 and 6 the number of A or B 
subtype sequences obtained. 
The specificity of the primers was not evaluated in this study, however, Blast analysis of 
the sequence generated from some of the additional bands revealed that segments of the 
sequences shared homology with Homo sapien chromosome 10 (unspecified locus), and 
Human aldo-keto reductase (Family of enzymes that catalyse the NADPH-dependent 
reduction of a number of compounds) with E values of 7e-167 and 5e-51 respectively. In a 
crude nucleotide alignment performed using the DNA Star software megalign there was 
between 29 and 33% percent identity between the nucleotide sequences generated from 
these bands and the hMPV reference strains used in the phylogenetic analysis presented in 
this thesis. 
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4.4 Phylogenetic Analysis 
Amino acid alignments of the different data sets were created using Clustal X, and applied 
to CODON Align with the corresponding nucleotide sequences in order to create in-frame 
nucleotide alignments. The in-frame nucleotide alignments were subsequently used for the 
generation of maximum likelihood trees using the program PAUP (4.1 Ob). The criterion 
used for creating the trees was determined using the MODELTEST 3.7 (Posanda and 
Crandall 1998) application within PAUP (Table 4.6). This application compares different 
models of evolution and determines which model and criterion best fit the data set under 
investigation. Bootstrapping of maximum likelihood trees was impractical due to the large 
amount of computing time required. Maximum likelihood trees were therefore compared 
with bootstrapped neighbour joining trees. Where trees were congruent bootstraps are 
shown on the maximum likelihood trees. 
The maximum parsimony methods were not used in this work as it best suits closely 
related sequences. 
In-frame nucleotide alignments were used to calculate Transition: Transversion Ratios 
using the program PUZZLE, and Non-synonymous: Synonymous Ratios using the 
program MEGA 3.1. 
Figures 4.8 and 4.9 show the phylogenetic relationships of all the available hMPV full 
length G ORF sequences in neighbour joining trees. Figure 4.8 was created in DNAST AR 
and is based on the amino acid alignment presented in Figure 4.15. Figure 4.9 is based on 
the in frame nucleotide alignment created from figure 4.15 in codon align. All in-frame 
nucleotide alignments can be found in Appendix 2. Unfortunately due to time constraints 
bootstrap values were not generated for these two trees. Both figures however show clearly 
the division of strains in to 2 major lineages A and B, which are both further subdivided in 
to 2 sub-lineages AI, A2 and Bl, B2. 
Sequences generated in this study are highlighted in blue (strains from hospitalised 
children) or green (strains from community acquired ILl) .It is clear that all but one of the 
strains from this study belong to the A lineage. It is also clear that the strains from this 
work and that of others are all very closely related to one another, and the short branch 
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lengths indicate that very little accumulation of amino acid changes has occurred. There is 
therefore no difference between strains circulation in the community or those identified in 
hospitalised children 
The strains circled in yellow are outliers of the Al sub-lineage that show unusual 
mutations which alter drastically the amino acid sequence of the down stream protein, and 
are highlighted in yellow in figure 4.15. These may be naturally occurring mutations or 
may have arisen as a result of only having sequenced one clone. Where these sequences 
have been treated separately in further analysis they have been referred to as the Al 
outliers and have been discussed in detail later in this chapter. 
Figures 4.10 and 4.11 are maximum likelihood trees showing the close phylogenetic 
relationship of strains sequenced in this study from the community or hospitalised children 
respectively. Again it is apparent that very little antigenic drift is occurring in the G protein 
of these isolates. 
Figure 4.12 is a maximum likelihood tree of all the strains sequenced in this study, and is 
highlighted according to the year of circulation. This tree again indicates the same strains 
circulating during year 1 (2001-2002) of the community and hospitalised children's 
studies, phylogeneticaly very closely related to those circulating in year 2 (2002-2003) of 
the study. 
Figures 4.13 and 4.14 show again in maximum likelihood trees this time the phylogenetic 
relationships of A or B lineages respectively, and confirm that findings of the neighbour 
joining trees shown in figures 4.8 and 4.9. 
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Figure 4.8: Neighbour joining tree of all available full length G sequences based on the amino acid 
alignment presented in Figure 4.15. Reference Strains are highlighted in grey; Sequences from tills 
work are highlighted in (green) Hospitalised children, or (Blue) Community Acquired. Tree is mid-
point rooted for clarity. Created in DNA STAR. 
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f~162000 
If---- JMLEIC1011 
Figure 4.9: Neighbour joining tree of all available full-length G sequences based on in frame 
nucleotide alignment of the amino acid alignment in Figure 4.15. Reference Strains are highlighted 
in grey; Sequences from this work are highlighted in (Blue) Hospitalised children, and (Green) 
Community Acquired. Consensus tree based on 500 replicates 
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Figure 4.10: Maximum likelihood tree of samples acquired from the community. The tree is based 
on in frame nucleotide alignment generated in CODON Align from the corresponding amino acid 
alignment shown in appendix II. Reference strains are highlighted in grey. Boot strap values are 
based on congruent neighbour joining trees of 1000 bootstraps. 
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B 
NL 199GB1 100 
NL194GB2 
Figure 4.11: Maximum likelihood tree of strains from hospitalised children. Reference Strains are 
highlighted in grey. The tree is based on in frame nucleotide alignment generated in CODON Align 
from the corresponding amino acid aJignment shown in appendix II. Boot strap values are based on 
congruent neighbour joining trees of 1000 bootstraps. 
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Figure 4.12: Maximum likelihood tree of hMPV G full-length sequences generated in this study 
and colour coded according to the study year. YI = 2001-2002, Y2 = 2002-2003. Reference Strains 
are highlighted in grey. The tree is based on in frame nucleotide alignment generated in CODON 
Align from the corresponding amino acid alignment shown in appendix II. Boot strap values are 
based on congruent neighbour joining trees of 1000 bootstraps. 
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Figure 4.13: Maximum likelihood tree of all available Full-length G Subtype A sequences. 
Reference Strains are highlighted in grey; sequences from this work are highlighted in blue 
(Hospitalised children), green (Community Acquired). The tree is based on in frame nucleotide 
alignment generated in CODON Align from the corresponding amino acid alignment shown in 
appendix II .. Boot strap values are based on congruent neighbour joining trees of 1000 bootstraps. 
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Figure 4.14: Maximum likelihood tree of all available Full-length G subtype B sequences. 
Reference strains are highlighted in grey; sequences from this work are highlighted in blue 
(Hospitalised children), green (Community Acquired). The tree is based on in frame nucleotide 
alignment generated in CODON Align from the corresponding amino acid alignment shown in 
appendix II. Boot strap values are based on congruent neighbour joining trees of 1000 bootstraps. 
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The parameters used for the above phylogenetic analysis are displayed below. 
Table 4.6: Nucleotide substitution Rate matrix: Parameters used for Phylogenetic analysis. 
Group A-C A-G A-T C-G C-T G-T Invariable y 
sites Distribution 
Community 1.00 7.25 1.00 1.00 18.14 1.00 0.19 5.76 
Hospital 0.73 2.80 0.41 0.38 7.23 1.00 1.22 1.10 
This study 0.79 2.90 0.51 0.34 8.22 1.00 0.12 1.06 
All 
AliA 1.00 3.51 0.52 0.52 9.64 1.00 0.17 1.51 
All B 1.00 7.13 1.00 1.00 19.77 1.00 0.00 1.04 
Footnotes: values calculated using the Model Block Test application in the program PAUP. 
Columns 2 through to 7 show the relative proportions of change between the specified nucleotides. 
The table also shows the Proportion of Invariable sites and the Gamma distribution shape 
parameter. 
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TsITv Ratios 
Table 4.7: TslTv Ratios for the different datasets analysed. 
Group Ts/Tv Pyrimidine 0/0 0/0 A 010 C 0/0 G 0/0 T 
Ratio Tsl Purine Constant 
(No of Seq) Ts 
Community (12) 2.93 0.62 32.8 39.3 30.0 16.9 13.7 
Hospital (25) 2.49 0.65 29.0 38.7 30.4 16.9 14.0 
RVU All (33) 2.13 0.63 28.2 38.7 30.3 17.0 14.0 
All A (86) 2.23 0.66 36.1 38.5 30.5 17.0 14.0 
All B (20) 4.69 0.55 53.9 41.7 28.6 16.5 13.2 
All Al (58) 2.61 0.63 44.3 31.8 30.5 17.6 13.8 
All A2 (29) 2.42 0.72 35.3 39.3 30.6 15 .7 14.4 
All BI (6) 3.42 0.46 75 .6 42.7 29.3 16.9 11.2 
All B2 (14) 7.22 0.59 76.0 41.4 28.4 16.3 14.0 
Footnotes: Calculated in the program PUZZLE using the model of substitution: HKY (Hasegawa et 
al. 1985). (% constant) % of nucleotides constant in the multiple alignments. (% A/C/O/T) % of 
corresponding nucleotide bases in consensus sequence. 
The transition: transversion ratios calculated in Puzzle indicates that as expected there are 
generally more transitions than transversions occurring. There is a marked difference in the 
Ts/Tv ratios between A and B subtypes, with a greater number of transversion occurring in 
the A dataset suggesting that there is greater selective pressure on A subtypes than B, 
although this may be skewed by the larger number of available A sequences. However, 
analysis between the Bland B2 viruses show that transversions occurred far less 
frequently in B2 viruses than B 1, despite the larger number of sequences under 
investigation. There is very little difference in the Ts/Tv ratios between viruses sequenced 
in this study that were circulating in the community and those in-hospitalised children. 
The Pyrimidine Tsl Purine Ts ratios indicate that the majority of transitions are occurring 
between Purine bases A and G for all data sets. The results also indicate that the G gene is 
adenine rich, with adenosine residues occurring approximately 40% of the time. 
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4.4.1 Synonymous: Non-synonymous Ratios 
Table 4.8: Non synonymous: Synonymous ratios of the different data sets. 
Group dN dS dN/dS No ofSyn No of non 
Sites Syn sites 
(No of Seq) 
Community (12) 0.22 0.32 0.68 143 444 
(S F ' , ., J {{) ,U [ } f ' } ('"' } (\. . }..: , ~ ~ 7(" p, )} <3,(8 ) 
Hospital (25) 0.l7 0.24 0.71 137 426 
(SF:) (O,f)! ) (0 .0 I ) U) '71 U.! } (3 ,96 ) 
RVU All (33) 0.16 0.24 0.67 138 425 
(SE) (O,O1) (0.0 I } (3.gS) (3,) 1) 
All A (86) 0.10 0.15 0.67 142 436 
(SL) (0,00) (0.0 I) ~ 'L(4) ( ~ 9~ ), !) 
All B (20) 0.07 0.14 0.52 141 446 
(SE) (' ") { J ,{ U) 10 .(1) , ' (4.70 } {4 ~..." ". ·k! 
All Al (58) 0.05 0.08 0.61 142 436 
(SE) (0,00) (O.O\}} (4.20) (4,3 1) 
All A2 (29) 0.08 0.14 0.60 149 462 
(SF,) > ...... (O,(}O) (0.0 I) t:'['Oo) (:.L~8) 
All Bl (6) 0.04 0.09 0.43 141 461 
ST') ( , .'. (0,00) f (' C J' \) . ) } (4 .5 l ) (4.49) 
All' B2 (14) 0.03 0.06 0.472 157 499 
(SF ) {(UJO ) (0.00 ) ( 4.95) , , (4 ,75) 
Footnotes: Calculated using the program Mega 3.1 using the Nei-Gojobori method (p-distance) 
with 500 replicates. (dN) non-synonymous, (dS) synonymous, (dN/dS) nonsynonymous: 
synonymous ratio. 
The effects of nucleotide substitutions are classified as synonymous - silent mutations that 
do not alter the amino acid, and non- synonymous - mutations that do alter the amino acid. 
Table 7 shows the non-synonymous: synonymous ratios for the different data sets. In all 
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data sets the number of non- synonymous sites IS approximately 3 times that of 
synonymous sites. However, as would be expected, there is a greater number of 
synonymous changes occurring, which is most apparent in Subtype B viruses. The 
significance of this compared with A viruses has not been established, but does suggest 
there may be greater selective pressure on subtype A viruses. 
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Figure 4.15: Amino acid alignment of available sequences for hMPV G. The alignment was 
performed in Clustal X and imported in to DNASTAR Megalign for display purposes. The 
alignment has been filtered to hide amino acids that match the consensus (Majority are A I 
Subtypes). Sequences highlighted in blue belong to the Al subgroup. Sequences in yellow are the 
A I outliers. Sequences in White A2, Green B2, and Purple B 1. Across the top of the alignment the 
coloured histogram shows the consensus strength, with the most conserved positions in Red and the 
least conserved in dark blue. Amino acid deletion; (.) amino acids which match the consensus 
sequence of the alignment. Boxes highlight areas of interest. Blue box: Cytoplasmic and 
transmembrane regions of the protein. Green Box: Variable lengths at the carboxyl terminal. Red 
box: multiple insertion sites. Purple boxes: mutations resulting in change ofORF. 
4.4.2 Analysis of variation 
The amino acid alignment shown in Figure 4.15 highlights visually the extent of the 
variation that occurs in the attachment glycoprotein between, and within different subtypes 
of the virus. Highlighted in the coloured boxes are regions of interest. The blue box at the 
N-terminus of the protein shows the highly conserved cytoplasmic and transmembrane 
region. The green box at the carboxyl terminus highlights the variation in the lengths of 
the different proteins, and in red (residues 160 to 170), a possible insertion or deletion site 
containing multi basic residues in the B 11B2 subtype viruses. Purple boxes highlight 
potential changes in the ORF. 
The percentage nucleotide identity of the alignment is displayed in Table 4.9 and the 
corresponding amino acid homologies in table 4.10. The results show that A and B 
subtypes share between 28-38% amino acid identity and 53-61 % nucleotide similarity. 
Within A subtypes there is between 50-100% and 78-100% amino acid and nucleotide 
similarity respectively. Finally within B subtypes there are 65-99 %, and 65-99% amino 
acid and nucleotide identity respectively. The Al outliers are treated separately as to avoid 
potentially skewing results. What is also noticeable is that the amino acid variation is 
greater than that of the nucleotide, suggesting the nucleotide substitutions are advantageous 
for the virus. 
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Table 4.9: Percentage nucleotide identity within and between the different subtypes of the 
hMPV G protein. 
Group At A2 At Outliers Bt B2 
At 90.5-100 
A2 78.3-100 81.7-100 
AtOutliers 92.4-99.3 78.3-98.2 94.3-98.6 
Bt 54.4-58.2 53.7-58.2 54.6-58.2 94.1-98 
B2 55.1-60.7 55.4-59.5 55.0-60.7 80.2-85.8 99.2-91.4 
Footnotes: Determined using pair-wise distance matrices created in the DNAST AR Megalign 
Program. 
Table 4.10: Percentage amino acid identity within and between the different subtypes of the 
hMPV G protein. 
Group At A2 At Outliers Bt B2 
At 85.6-100 
A2 57.0-70.8 64.3-100 
At Outliers 60.9-78.8 50.0-62.7 71.0-97.9 
Bt 30.7-34.8 29.0-35.8 29.4-35.8 90.5-98.7 
B2 33.1-36.9 30.7-35.0 - 28.1-37.8 65.4-75.0 81.2-99.2 
Footnotes: Determined using pair-wise distance matrices created in the DNASTAR Megalign 
Program. 
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4.4.3 Bydrophilicity profiles 
To gain a better understanding of the effect of the amino acid differences on the potential 
structure, hydrophilicity plots of G proteins from the different subgroups were generated. 
All subgroups share a very similar hydrophilicity pattern with a region of hydrophobic 
residues at the N-terminus representing the cytoplasmic and transmembrane domains. The 
remaining two thirds of the protein is almost entirely hydrophilic, representing the 
exodomain. There is a small hydrophobic region in all subtypes between positions 104 to 
110, highlighted by the arrow, which may represent an internal structure of the protein. 
The similarity in the hydrophilicity profiles indicates that the amino acids that differ 
between subtypes share similar physical and chemical properties properties. 
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Figure 4.16: Hydrophilicity plots of hMPV G proteins from subgroups AI, A2, Bl and B2 
produced using the DNAST AR Protean program using the Kyte-Doolittle method (1982). 
Hydropathy values were assigned for all amino acids and were averaged over window of 9 amino 
acids. Circled in red is the multi basic site insertion noted in the B 1 strains. 
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4.4.4 Variation in protein length: Insertions and Deletions and Substitutions. 
One of the notable features of the hMPV G protein is the variation in the length of the 
protein between and within different subtypes of the virus (Figure 4.15). Premature 
terminations codons may occur as a result of frame shift mutation due to insertion or 
deletion or due to nucleotide substitution. The length variations for the different subgroups 
are summarised in Table 4.1l. The Al subgroup contains proteins of236 amino acids, the 
Al outliers are treated separately so as avoid potentially skewing results, and amino acid 
lengths in this group range from 193 to 235 amino acids in length. The variation in the 
length of this protein has important structural and functional implications. 
Table 4.11: Variation in the lengths of different G protein within and between subtypes. 
Group Length (aa) 
Al 236 
A2 208 - 228 
Al Outliers 193 - 235 
BI 202 - 232 
B2 223 - 241 
With the exception of the sequences highlighted in yellow in the amino acid alignment 
above the Al sequences have 2 different conserved protein lengths of 236 and 222 amino 
acids. Those with 222 amino acid lengths were all derived from one study, and only 
nucleotides 1-666 were deposited on gene bank. These sequences were not deposited with 
a publication and therefore it is unknown whether they represent the ORF of the strains 
that were sequenced or whether the sequencing method used stopped at position 666, 
therefore these should be disregarded when discussing gene length. 
Within the A2 subgroup there are 3 conserved protein lengths of 216, 218, and 228 with 
the exception of sequence JMLEIC 1011 generated in this study discussed below. In the 
B2 subgroup, all but one sequence from the Netherlands; NL 182 has a protein length of 
236 amino acids. Strain NL 182 is 17 amino acids shorter than the others and is a result of a 
C to T substitution at position 658. Within the B 1 strains 3 different protein lengths are 
noted. All but two consist of 232amino acids. Sequence NL199 from the Netherlands 
contains 226 amino acids, and is the result of a G to T substitution giving a TAG 
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termination codon. Sequence JM RCGP348034 generated in this study contains 203 amino 
acids as a result of a frame shift mutation due to a G nucleotide insertion at position 570 
leading to a premature TGA termination codon. 
The amino acid alignment in Figure 4.15 highlights in red and purple possible insertions or 
deletions resulting in a frame shift mutation which stand out in particular as they result in 
proteins whose carboxyl terminal look very different to related strains that do not contain 
the mutation(s). In all cases these mutations have lead to premature termination of 
translation resulting in the production of truncated forms of the G protein lacking the 
carboxyl terminal as mentioned above. 
The most notable is an insertion of 5 amino acid resides resulting in a multi basic region 
conserved in all the B 1 subtype viruses. Analysis of the nucleotide alignment of this 
region shows an insertion of 15 nucleotides resulting in an adenosine rich region that is not 
present in any of the virus strains from other subtypes. The inserted nucleotides and 
subsequent amino acids are shown in Figure 4.17. This region relates to a highly 
hydrophilic region in the hydrophilicity profile of the BIG proteins, as highlighted in 
Figure 4.16, and does not contain any glycosylation sites. 
::IC ~ AlA ~ AlA ~ GIG ~ AlA ~ AIG ~ AlA ~ A 
Figure 4.17: The inserted Adenosine rich nucleotide sequence at position 480-495 in the B 1 
subtype viruses and the corresponding Amino acids which result in the presence of a multi basic 
site within the B 1 Strains and amino acid positions 160-165 highlighted in Figure 4.15. 
The amino acid alignment in Figure 4.15 also boxes in purple a possible change in ORF in 
the A group sequences shaded in yellow, and A2 sequence JMLeic 1 0 11. 
Analysis of the nucleotide alignment of this region shows an insertion of 2 adenosine 
residues in sequence JMLeic 1 0 11 at position 458 and 459 following a run of 8 consecutive 
adenosine residues. This insertion results in a frame shift mutation, which consequently 
leads to premature termination at a TAG stop codon at nucleotide position 624. 
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An insertion of a single adenosine residue at position 456 occurs in sequences JMLeic21 0, 
l3, and 2392, following a run of6 adenosine residues. For sequences JMLeic21° and 2392 
this insertion results in a premature TAG termination codon at nucleotide position 708. For 
sequence 13 a premature TGA termination codon occurs at position 624. The difference 
between the two stop codons is due to a nucleotide substitution at position 624 in the 
JMLeic 13 sequence. It is not known without sequencing further clones or by population 
sequencing whether these are naturally occurring mutations, or whether these have arisen 
as a result of sequencing a single clone. 
A cytosine deletion also occurred in sequence JMLeic1627 at position 449. This deletion 
also occurred amongst a run of 7 adenosine residues, resulting also in a change of ORF that 
leads further downstream to a premature TGA termination codon at position 624. 
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4.4.5 Glycosylation 
The potential 0 (Figure 4.18) and N (Figure 4.19) linked glycosylation profiles of the 
different subtypes of G was also investigated due to the important role glycosylation is 
thought to play in the antigenicity of this and related proteins and its potential structure. 
The strains used for analysis are reference strains NL 1 OOGA 1, NL 1700GA2, NL 194GB2 
and NL199GB1. 
The results show that as expected the hMPV G protein is predicted to be extensively 
glycosylated with O-linked sugars. Overall serine and threonone amino acids (receptor 
sites for O-linked glycosylation) account for approximately 32% of all the amino acids in 
the G protein. In accordance with the hydrophilicity profiles of the protein the majority of 
glycosylation occurs in the hydrophilic ectodomain. The glycosylation potential of the 
small number of serine/ threonone amino acids present in the cytoplasmic and 
transmembrane regions fall below the 0.5 threshold, and are therefore unlikely to be 
glycosylated. Most notably in B 1 viruses there appears to be 2 distinct regions of 
glycosylation with the serine/ threonone amino acids around the 170 amino acid position 
showing a lower glycosylation potential than the remainder of the ectodomain. Less than 
8% of the potential O-linked glycosylated sites are conserved between all 4 subtypes. 
In contrast there is very little N-linked glycosylation with only 4- 5 predicted N- linked 
sites. The pattern of N-linked glycosylation varies considerably between subtypes with 
one conserved site occurring in the cytoplasmic- transmembrane region of the protein, and 
falls below the glycosylation potential threshold in A subtypes. Notably the glycosylation 
site found at position 52 is not present in the Bland B2 strains analysed. 
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Figure 4.18: Predicted O-linked Glycosylation sites using the NetOGlyc 3.1 Server available at 
http://www.cbs.dtu.dklservices/NetOGlyc/. Blue represents the potential of glycosylation at all 
possible glycosylation sites. Red indicates the threshold above which glycosylation at that site is 
considered highly likely to occur. Prediction, conservation analysis and structural characterization 
of mammalian mucin-type O-glycosylation sites K. Julenius, A. Melgaard, R. Gupta and S. 
Brunak. Glycobiology, 15:153-164, 2005. 
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Figure 4.19: Predicted N-linked Glycosylation sites using the NetNGlyc 1.0 Server available at 
http://www.cbs.dtu.dkJservices/NetNGlyc/. Blue represents the potential of glycosylation at all 
possible glycosylation sites. Red indicates the threshold above which glycosylation at that site is 
considered highJy likely to occur. Prediction of N-glycosylation sites in human proteins. 
R.Gupta, E.Jung and S.Brunak. In preparation, 2004 
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4.5 Discussion 
Reported here is the development of a sequencing strategy for the full-length open reading 
frame of the hMPV attachment glycoprotein, and its application to clinical material known 
to be positive for hMPV. Also reported is the phylogenetic and sequence analysis of the 
generated sequences to establish their relationship with each other and those deposited in 
the Genbank Sequence Database (See appendix 2). 
4.5.1 hMPV G RT-PCR 
The developed RT-PCR was designed to detect both subtypes of hMPV using sequences 
deposited on the Genbank Sequence Database. There are other published reports of primers 
which amplify the hMPV G gene or regions of it (Biacchesi et aI., 2003, van den Hoogen 
et aI., 2002). However most of those protocols require good quality samples for example 
isolates grown from clinical material, and as discussed previously it was not possible to 
culture hMPV from the clinical samples used in this study. Secondly many of the 
published primers were designed with fewer sequences, and many of the primers, 
especially those located within the gene would have been unsuitable due to the high level 
of nucleotide variation observed. 
The RT step as discussed in chapter 3 was based on a random hexamer approach. The peR 
itself was a hemi nested PCR incorporating a generic first round PCR followed by a 
subtype specific second round. The use of degenerate primers to capture both subtypes 
within the one PCR was investigated, but found to lack the sensitivity of the subtype 
specific second round PCR. A proof reading Taq polymerase was selected for this work to 
reduce any potential Taq polymerase errors, which may occur. 
In this study only 30% of the F gene PCR positive samples analysed were also positive 
using the hMPV G gene PCR, indicating the G gene PCR is not as sensitive as the F gene. 
A number of reasons may contribute to this. Firstly, the material used for this PCR was 
predominantly the same cDNA material used for the initial F gene analysis, or nucleic acid 
re-extracted from the original material. Long term storage and multiple freeze thaw cycles 
increase the likelihood of sample degradation. The monitoring of such degradation could 
be achieved through the detection of housekeeping genes such as ~-actin or GAPDH. The 
amplification of overlapping G gene fragments may also be another approach to generating 
hMPV G gene sequence where full length amplification of the gene may not be possible. 
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Secondly, the G gene primers designed using the limited number of hMPV G gene 
sequences available from the Genbank Sequence Database at the time, and as such it is 
likely that certain strain types were not amplified due to differences in one or more of the 
primer binding sites. The continually increasing availability of hMPV sequence will allow 
for the constant redesign and modification of primers to ensure the maximum numbers of 
strains are detected. 
Thirdly, the G gene primer set was cross-reactive with human chromosomal material 
which reduces sensitivity through competitive binding of the primers. The redesign of 
primers or the use of a gene specific RT step may improve specificity. Alternatively, 
DNAse treatment of the total nucleic acid preparation to remove genomic DNA or the 
specific extraction of RNA could also be considered. 
Fourthly, the differential expression of the F and G genes may result in different detection 
limits. As illustrated in chapter 1, the amount of mRNA transcribed for each gene depends 
on its proximity to the 3' end of the genome (Collins et ai., 2001). As the F gene is located 
closer to the 3' end of the genome than the G gene, it can be assumed that more F gene 
mRNA would be present in the sample than G. The possibility exists that either; vRNA, 
mRNA or both were being detected. If mRNA was detected this may provide an 
explanation for the observed differences between the two assays. 
Other differences that may influence the relative sensitivities of the two assays include the 
type of taq polymerase used, the processivity of the taq and the length of the amplicon, 
which for G was more than 3 times the length of that for F. 
4.5.2 Sequencing of clones 
The use of cloning in this sequencing strategy enabled hMPV G gene sequence from each 
sample to be generated, from which internal sequencing primers could be designed. The 
use of the TOPO T A cloning vector provided a fast and efficient cloning method, which 
did not require the use of restriction sites or blunt ended cloning which is often very 
inefficient. Sequence data generated from clones however has one inherent flaw, in that the 
species that is present in the clone may not be representative of the majority species in the 
viral population. Analysis of 10 different clones generated from 2 samples, indicated that 
quasispecies were present, but only one or two amino acid changes were observed in 2 of 
the 10 sequences indicating that a majority of the clones contained representatives of the 
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major species. The further analysis of clones should be carried out in order to address the 
level of variation within a viral popUlation. 
4.5.3 Analysis of strain diversity 
Despite the fact that the detection rate of hMPV G was not as good as would have been 
liked, the 30 sequences obtained in this work account for 30% of all the internationally 
available full-length hMPV G gene sequences to date. Analysis of these sequences together 
with those available from the Genbank Sequence Database is reported here (Appendix 2). 
As previously reported, phylogenetic analysis of G reveals that hMPV can be divided in to 
2 lineages A and B, each with two sub-lineages (A 1, A2 and B 1, B2) (Bastien et aI., 2003, 
van den Hoogen et al., 2004). Sequences from this study, which include samples from the 
community and hospital populations, were all A subtypes with the exception of 1 B strain 
detected in the community. Similar strains were found to circulate in both the community 
and hospital populations, which is not surprising, as the children investigated in the 
hospital study would most likely have acquired the infection whilst in the community. It 
was also noted that similar strains were detected in the different years of the study. This 
has also been noted in previous work by van den Hoogen et al (2004), who also reported 
that similar strains of hMPV were found to circulate in different countries (van den 
Hoogen et aI., 2004). Similar strains of hRSV viruses have also been isolated at different 
time points, and in different geographical locations (Cane & Pringle, 1995). 
Predominantly A strain viruses were recovered in this study which is reflected also in the 
distribution of all the available G gene sequences to date. It would be speculation to say 
whether this represents a predominance of A strains over B strains in this study given the 
number of samples which failed to generate sequence, or whether this represents 
differences in the sensitivity of different assays to the different subtypes. 
Analysis of the predicted amino acid sequences of the G ORF revealed a high level of 
sequence diversity within and between subtypes (28-38 % amino acid identity between Al 
and B 1). This level of sequence homology is slightly different to that previously reported 
for hMPV G using different subsets of these sequences as would be expected with an 
increased number of sequences. Most recently; Peret et al (2004) has reported 74-100% 
nucleotide and 61-100% amino acid homology within the A lineage. 77-99% nucleotide 
and 63-990/0 amino acid homology Within the B lineage, and 52-580/0 nucleotide and 31-
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acid variation, compared with nucleotide suggests that the amino acid changes that are 
occurring are advantageous to the virus and supports the view that this protein evolved 
under immunological pressure. 
This level of variation is greater than that observed in the hRSV for which 80-95% amino 
acid homology has been observed within subtypes, and 38% between subtypes(Garcia et 
aI., 1994, Johnson et aI., 1987). For Avian metapneumovirus a high degree of amino acid 
homology has been reported within subtypes (98.5-99.7 %), however between the A and B 
subtypes there is 380/0 amino acid homology (Juhasz & Easton, 1994). In another study 
looking at the variation in the G gene among avian metapneumoviruses an even greater 
level of sequence divergence was reported between the G proteins of the different 
metapneumovirus subtypes with only 5.6% amino acid identity between Band D, 7.2% 
between C and B, 10.1% between A and D, 12.60/0 between c and D, 13% between A and 
C , and finally 28.7% between A and D (Alvarez et aI., 2003). 
4.5.4 Selective pressure 
Despite the amount of variation observed the short branch lengths of the trees presented in 
this thesis indicate there was very little progressive accumulation of amino acid changes, 
also observed elsewhere (van den Hoogen et aI., 2004).While this relates to only the short 
time period for which hMPV isolates are available this contrasts with hRSV in which the 
accumulation of amino acid changes has been reported (Cane & Pringle, 1995, Woelk & 
Holmes, 2001, Zlateva et aI., 2004). 
The transition/ transversions (TsITv) and non-synonymous/synonymous (DnlDs) ratios 
provide some information as to the selective pressure acting on G. It has been reported that 
the lower the value of the TsITv, and the higher the value of the DnlDs ratios, the more 
evidence there is for positive selection (Hurst, 2002). This type of analysis has not yet been 
published for hMPV. 
This study found very little difference in the TsITv ratios between viruses circulating in the 
community and those in hospitalised children. This indicates that selective pressures are 
equal in both groups and supports the phylogenetic findings that similar strains where 
present in both populations. Of particular interest however was the marked difference in 
the TsITv ratios between A and B subtypes. A greater number of transversions were 
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selective pressure on A subtype viruses is occurring. Similarly transversions occurred more 
often in B 1 viruses than B2. 
As expected, there were a greater number of synonymous changes detected in all data sets 
investigated in this study. The greatest proportion of non-synonymous changes however 
occurred in A subtype viruses, indicating, as with the Ts/Tv ratios, that A subtype viruses 
may be under grater positive selective pressure, although the significance of this compared 
with B viruses was not established. 
Overall the results indicate that despite the large degree of variation observed, within and 
between subtypes, the hMPV G gene is under negative selection, as during the short time 
period over which these sequences were acquired there has been no accumulation in amino 
acid changes. More temporal data is therefore required to assess whether amino acid 
changes are acquired over longer periods of time. Furthermore this data does not rule out 
the possibility that particular sites or positions within the gene are under positive selection 
as shown for RSV (Cane & Pringle, 1995, Woelk & Holmes, 2001, Zlateva et aI., 2004). 
Both the TslTv and DnlDs ratios were determined from global alignments of the hMPV G 
sequences that included both conserved and variable regions of the gene. To identify 
whether different regions of the gene were under different selective pressures regional 
alignments comparing conserved and variable regions should be analysed. Furthermore to 
ascertain whether this type of selection is true throughout the entire hMPV genome TS/TV 
and DnlDs ratios should be calculated for different genes. 
The differences observed in the selective pressure of A and B subtypes, may be occurring 
for a number of reasons, although given the limited number of sequences available it is not 
possible to ascertain what is actually happening. Firstly; the increased selective pressure on 
A subtype viruses may be skewed by the greater number of A sequences analysed 
compared with B. Secondly; the greater level of selective pressure on A subtype viruses 
may also be an indication of the predominance of A subtypes over B. With a larger 
proportion of the population perhaps having experienced A subtype infections the pressure 
on A virus to evade host immune responses may be greater than B. Alternatively the 
immune response elicited by A subtype viruses may differ from that of B subtype viruses 
in such a way that greater pressure is put on A viruses to adapt. Further research however 
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is required before conclusions can be made as to the significance and interpenetration of 
these results. 
4.5.5 Mechanisms of change 
The Pyrimidine Tsl Purine Ts ratios indicate that the majority of transitions are occurring 
between the purine bases adenine (A) and guanine (G) in all data sets. This is consistent 
with the fact that approximately 40% of the gene is comprised of adenine bases and 
supports the view that this gene is constantly changing. 
The bias in the high frequency of AG transitions has also been shown for a number of 
other RNA viruses; in particular RSV (Martinez et aI., 1997), measles (Cattaneo et aI., 
1988, Wong et aI., 1991), and influenza (Suarez-Lopez & Ortin, 1994). One mechanism 
which may explain the high rate of AG transitions observed in RNA viruses, involves 
cellular adenosine deaminases (Martinez & Melero, 2002). These enzymes are thought to 
act on small dsRNA structures, such as those formed during transcription or replication. 
This enzyme converts adenine into inosine bases, which behave as guanine bases during 
base pairing (Schaub & Keller, 2002). Adenosine deaminases have been associated with 
the modification of cellular RNAs as well as hyper-mutational events within retrovirus and 
hepatitis genomes (Bass, 1997, Jayan, 2004, Schaub & Keller, 2002) 
The most notable mutations observed in the hMPV G gene sequence were additions or 
deletions of nucleotides which resulted in frame shift mutations. These mutations 
significantly altered the amino acid content and length of the resulting proteins. Variation 
in length is also frequently observed in the hRSV G protein (Rueda et aI., 1991). All the 
frame shift mutations observed in the G gene occurred in regions where runs of multiple 
adenine bases were present. This is a typical occurrence in adenosine rich templates and is 
thought to arise as a result of polymerase error due to a form of slippage at these sites 
(Hausmann et aI., 1996, Jacques et aI., 1994). 
It is not known however whether these mutations observed in the Al outliers group are 
naturally occurring or are as a result of sequencing only one clone. In study by Cane et aI, 
1993 it was demonstrated that frame shifting in the RSV G protein as a result of 
polymerase slippage at runs adenosine bases occurred in 14% of clones derived from 
mRNA, 58% of clones from genomic RNA, and 50% of clones generated from in vitro 
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transcripts (Cane et aI., 1993). Further analysis of these strains is required, either through 
sequence analysis of multiple clones, or by population sequencing. 
The possible insertion of 5 ammo acids in the hMPV G B2 subgroup provides an 
interesting point for discussion. Major changes in the RSV G protein due to insertions of 
up to 60 nucleotides have also been reported (Trento et aI., 2003) and provides another 
example of the drastic genetic alterations that can be tolerated in this protein. The insertion 
of these 5 amino acids into the hMPV B2 subtype G protein introduces a multi-basic site 
that is not present in the G proteins of the other hMPV subtypes. Multi basic sites in other 
viral proteins are associated with a protease cleavage, often required for protein activation 
and function; such as membrane fusion; for example in the influenza haemagglutinin or 
RSV and hMPV Fusion proteins (Bolt et aI., 2000, Nagai et aI., 1991, Stieneke-Grober et 
aI., 1992). The presence of such sites in hMPV or RSV G proteins however has not been 
previously reported. Whether the presence of such a site in the hMPV G protein plays a 
similar role would be an interesting point for investigation. 
4.5.6 Glycosylation 
The O-linked glycosylation potential calculated in this study was based not only on the 
presence of serine Ithreonine residues but also on the predicted secondary structure and 
accessibility of the sites. The observed potential for extensive O-linked glycosylation in G 
was expected, and is comparable to that of RSV (Garcia-Beato & Melero, 2000, Lambert, 
1988, Wertz et aI., 1989). The majority of the potentially O-linked glycosylated sites occur 
in the hydrophilic ectodomain; however, less than 8% are conserved between all 4 
subtypes. Furthermore, huge differences in the glycosylation potential of strains belonging 
to the same subtype were also observed (data not shown). For RSV G, variation in 
glycosylation has also been observed in the same strain grown in different cell types, and 
within the same cell type (Garcia-Beato et aI., 1996). Glycosylation therefore is likely to 
contribute further to the extensive heterogeneity of this protein. 
The high level of glycosylation is thought also to mask dominant immune-epitopes that 
may be present. However the analysis of the reactivity ofRSV monoclonal antibodies with 
un-glycosylated RSV G species indicates that antibody recognition is often dependent on 
the presence of oligosaccharide side chains (Garcia-Beato et aI., 1996, Melero et aI., 1997). 
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As a result of the high level of glycosylation at serine and threonine residues and a high 
proline content the G proteins of hMPV and RSV have been likened to mucins, a group of 
proteins produced by mucosal epithelial cells which are essential for the mucociliary 
clearance of foreign particles present in the respiratory tract (Jeffery & Li, 1997). 
Abnormalities in either in the quality or quantity of mucins may result in the development 
of pathological airways as seen in chronic bronchitis, asthma, COPD and cystic fibrosis 
(Fahy, 2001, Kim et aI., 1997). The similarity ofhMPV G proteins to that of its host's may 
confer an advantage to the virus in terms of evading host immune responses, and may also 
contribute to the development of mucociliary clearance dysfunction. Many other viral 
glycoproteins have also been reported to contain mucin like regions for example Ebola and 
Crimean-Congo hemorrhagic fever virus glycoproteins (Sanchez et aI., 2002, Yang et aI., 
2000). 
The role of glycosylation in host immune response evasion has been widely reported; 
however the role of glycosylation in influencing the structure of G should not be 
overlooked. It has been reported that the extensive glycosylation observed in mucins may 
provide support and rigidity to these proteins which would otherwise have fairly flexible 
structures and incomplete glycosylation has been associated with severe pathology due to 
alterations in mucin structure and function (Ciborowski & Finn, 2002, Kim et aI., 1997, 
Rose, 1992) 
4.5.7 Protein structure 
Secondary structure prediction of hMPV G indicates that a majority of the protein is 
comprised of turn and loop regions, with very little evidence for the presence of alpha 
helices. hMPV G is similar to that of RSV G, in terms of its hydrophilicity, and 
glycosylation profiles, however in terms of the tertiary and quaternary structure these two 
protein may differ significantly. 
The variation in the length of hMPV G suggests that the far carboxy terminal of the protein 
does not play any structural role. Variation in the length of G has also been reported 
previously (Bastien et aI., 2004, Ishiguro et aI., 2004, van den Hoogen et aI., 2004). As has 
variation in the length of RSV G (Martinez et aI., 1999, Melero et aI., 1997, Rueda et aI., 
1991 ). 
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A 3D structure of RSV G has been proposed (Melero et ai., 1997). However, the lack of 
sequence homology between hRSV and hMPV G makes 3D structure prediction ofhMPV 
G impossible using bioinformatic techniques. A number of noticeable differences between 
the two proteins also indicate these proteins may differ structurally. Differences include the 
presence of 4 cystine residues and a conserved region in the ectodomain of the RSV G 
protein both of which are not present in hMPV G. Firstly, the conserved region in RSV G 
is hydrophobic, and thought to confer an internal structure of the protein. Secondly, the 4 
conserved cystine residues contain side chains which form 2 disulphide bridges, stabilising 
the structure and creating a cystine noose. 
4.5.8 Protein function 
The fact that the hMPV G protein appears to tolerate such dramatic alterations in its amino 
acid content, length, and glycosylation profile calls in to question the role G plays in the 
hMPV replicative cycle. Recently Biacchesi, et al (2004) demonstrated using infectious 
clones that hMPV viruses lacking the attachment glycoprotein grow equally as well in 
vitro as wild type viruses. Growth however was somewhat restricted in vivo (Biacchesi et 
aI., 2004). Similar findings have also been reported for RSV in vitro; however deletion of 
G in vivo significantly inhibits virus replication (Techaarpornkul et aI., 2001, Teng et aI., 
200 I), indicating potential differences between the functions of these two proteins 
Amino acid variation and truncation of the protein at the carboxyl terminal suggests there 
is little structural or functional hindrance in mutational occurrences. It is unlikely therefore 
that this region of the G protein provides a structural or functional role, but may be 
associated with the immune evasion strategies of the virus. Indeed the highly strain specific 
nature of antiserum generated against the G proteins of different hMPV strains supports 
this (Bastien et aI., 2004). 
The function of G in receptor binding can be studied in a variety of ways through the use 
of chimeric viruses or retroviral pseudotypes carrying the hMPV G protein. Epitope 
mapping and the use of monoclonal antibodies or compounds to block receptor binding in 
different cell systems could be used to determine the regions of the protein involved in 
receptor binding. It may also be possible to use oligosaccharide micro array technology to 
identify possible oligosaccharide moieties with which protein may interact. 
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The central conserved domain of the RSV G protein is thought to represent a possible 
receptor site against which neutralising antibodies are directed. A CXC motif present in 
this domain has been shown to interact with the CXC3Rl chemokine receptor (Tripp et aI., 
2001). The lack of this feature in the hMPV G protein may contribute to the differences 
observed in the inflammatory responses generated against hMPV and RSV as mentioned in 
chapter 1. The lack of a conserved region in hMPV G may also account for the inability to 
measure a meaningful neutralising antibody response against the hMPV G protein. 
Furthermore a secreted version of the G protein is produced by RSV. It is thought this 
protein mops up antibodies targeted towards the G protein. It has also been demonstrated 
this protein retains its ability for receptor binding. It is possible a secreted form of hMPV 
G protein is also produced. 
4.5.9 Future Work 
The work presented in this chapter highlights many points for further investigation. What 
is the seroprevalence of hMPV in the community? What is the age of primary infection, 
and what does this suggest about the presence of maternal antibodies? What evidence is 
there for hMPV to cause repeat infections in the presence of antibody? What evidence is 
there that antibody recognition of G is affected by the large degree of variation observed in 
this gene, and the presence of glycosylation. 
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Recombinant baculovirus expression of the hMPV 
nucleocapsid protein 
Chapter 5 -Expression of hMPV N Protein 
5.1 Introduction 
Estimation of the burden of disease due to a particular pathogen requires reagents that 
enable the assessment of the serological response to the virus; such reagents include viral 
antigen and virus specific antiserum. This chapter describes the development of such 
reagents. 
Due to the limitations of producing antigen and antiserum with a virus that grows poorly in 
the laboratory, antigen was generated through the expression of hMPV proteins in a 
recombinant baculovirus expression system, against which hMPV specific antiserum was 
raised. 
There are a number of systems available for the expression of heterologous proteins each 
with their own inherent advantages and disadvantages. Prokaryotic expression systems are 
a fast and effective way of producing large amounts of protein; however, they lack a 
number of posttranslational modifications. Where conformationally correct and accurately 
modified proteins are required, as for this work, eukaryotic systems have an advantage. 
Such systems include the yeast 2 hybrid, SV 40, recombinant vaccinia, recombinant 
baculovirus and plasmid expression systems. 
Mammalian cell expression using a simple plasmid system that utilises transcriptional 
regulatory elements offers an advantage over other mammalian expression systems. It is 
simple, safe, and offers moderate levels of gene expression in a wide variety of mammalian 
cell lines without the potential interference and added complication of other viral proteins 
or helper viruses required in other techniques. Depending on the features of the chosen 
vector stable cell lines constitutively expressing the protein of interest can be established. 
The moderate levels of protein expression however, are often insufficient for producing the 
large quantities of protein required for antiserum production. 
The recombinant baculovirus expressIOn system is one of the most extensively used 
systems for heterologous protein expression and also offers the advantages of a eukaryotic 
system producing biologically active proteins, with correct folding, disulphide bond 
formation, oligomerisation and other posttranslational modifications similar to that of 
mammalian cells whilst producing a much higher level of protein expression compared to 
that seen in mammalian cells. 
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Baculoviruses are a diverse group of viruses found exclusively in insects and for decades 
have been manipulated and utilised in pest control and more recently exploited as a 
powerful tool for heterologous protein expression. The most commonly used virus for this 
purpose is Autographia californica nuclear polyhedrosis virus (AcMNV). 
The baculovirus replication cycle can be divided in to 2 phases, early and late. During the 
early phase virus particles are released from the infected cell by budding through the 
cellular membrane. During the late phase, however, viruses are occluded in crystalline 
protein structures comprised of the polyhedron protein. The generation of occluded 
viruses in an essential part of the natural replication cycle allowing the virus to survive in 
harsh conditions when released from the dying host and ensuring subsequent hosts are 
exposed to a large number of virus particles thus guaranteeing infection. During the 
occlusion process fibrillar structures composed of the pi 0 protein also accumulate and are 
thought to function in promoting cell lysis. These functions, however, become obsolete in 
virus passed in continuous cell culture, eliminating the need for the polyhedron and pi 0 
proteins. These proteins are both produced at very high levels at the very late stages of 
infection and therefore one or the other, or both, can be replaced with a heterologous gene 
of interest. The proteins will therefore be expressed under the control of the polh or pi 0 
promoters with no detrimental effect to the virus. 
However, the late expression of the proteins occurs when a majority of host cell protein 
synthesis has been shut off and therefore the efficiency of posttranslational modifications 
may decline later in infection resulting in the production of heterogeneous protein products 
that differ in the extent of their posttranslational modifications. Complex N-linked 
glycosylation may also differ slightly from that in mammalian cells as insect cells may 
substitute less complex oligosaccharides. 
There are numerous examples in the literature of proteins from related viruses being 
expressed in the recombinant baculovirus system; including the expression of pneumovirus 
nucleocapsid, fusion, small hydrophobic and attachment glycoproteins, which were 
successfully used for Immunoassay development and protein characterisation 
(Buraphacheep et aI., 1997, Levely et aI., 1991, Luo et aI., 2005, Pastey & Samal, 1998, 
Sullender & Britt, 1996). The formation ofRSV nUcleocapsid structures similar to those of 
RSV infected cells have also been observed by electron microscopy when expressed in the 
175 
Chapter 5 -Expression of hMPV N Protein 
baculovirus system (BheIla et aI., 2002, Meric et ai., 1994) indicating the correct folding 
and processing of the expressed proteins. 
The nucleocapsid (N) of hMPV shows a high level of amino acid sequence homology of 
approximately 95% between the A and B subtypes (Bastien et ai., 2003). Serological cross 
reactivity between A and B subtypes has also recently been reported (Hamelin & Boivin, 
2005). Phylogenetic analysis has shown that hMPV is more closely related to avian 
Pneumovirus C (APV C) than hRSV, with N amino acid similarities of approximately 89% 
and 43% respectively(van den Hoogen et aI., 2002). This relationship has also been 
demonstrated serologically with cross reactivity occurring between hMPV and APV C N, 
but not with that ofhRSV (Alvarez et aI., 2004). 
The N proteins of the pneumOVlruses are immunogenic, and are one of the most 
abundantly produced proteins during infection. Antibodies to N appear early in infection 
and predominate throughout (Buraphacheep et aI., 1997, Samal et aI., 1993, Westenbrink et 
aI., 1989). These combined characteristics therefore make N an ideal target for the 
development of immunoassays for the specific detection of hMPV antibodies. HMPV and 
N specific antiserum would also be extremely useful reagents for monitoring viral growth 
in cell culture, and as a diagnostic tool. N was therefore chosen for expression in the 
recombinant baculovirus system. 
This chapter describes the expression of the hMPV N protein and the generation, and 
evaluation of hMPV specific polyclonal antiserum as potential diagnostic or research 
reagents 
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5.2 Aims 
• Expression of the hMPV full length nucleocapsid protein (N-FL) and N fragments 
in the recombinant baculovirus system as an alternative to cell culture produced 
hMPV whole antigen. 
• Generate high titre hMPV specific polyclonal antiserum. 
• To evaluate the potential use of the antigen and antiserum as tools for the 
assessment of serological response. 
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5.3 Recombinant Baculovirus System 
The baculovirus 'Bacmid' vector used in this work was kindly provided by Professor Ian 
Jones from the University of Reading. The bacmid vector contains the entire genome of the 
prototype baculovirus Autographia cali/ornica multiple nucleopolyhedrois virus (AcMNV) 
with a deletion in the essential region of the polh locus without which the virus cannot 
propagate. The bacmid was linearised by restriction digest and co-transfected into SF9 
cells with one of the transfer vectors described below (Table 5.1). The transfer vectors used 
encode the essential sequence deleted in the bacmid vector and the gene of interest. 
Based on the expression of other paramyxovirus nucleocapsid proteins in the baculovirus 
system it was expected that the majority of the N-FL and N fragments would be expressed 
in the cytoplasm of the SF9 cells. 
5.3.1 Construction of Baculovirus Transfer Vectors 
The commercially available plasmid pTriEx-2 Neo (Novagen) was used as the baculovirus 
transfer vector, and mammalian expression vector for N-FL and N fragments 
The pTriEx-2 Neo vector is a multiple expression system capable of expressing in E.coli, 
Insect and mammalian cells. For expression in insect cells the vector contains the 
baculovirus pI 0 promoter, and transcription start sequence. Baculovirus sequence flanks 
the promoter and cloning site to permit the generation of recombinant baculoviruses. 
Expression in mammalian cells is mediated by a hybrid promoter composed of the CMV 
immediate early enhancer fused to the chicken ~-actin promoter. The vector also offers an 
N-terminal 6-histidine tag, utilised here for the detection and purification of the expressed 
hMPV proteins. 
The isolate UK324-02 was chosen as starting material, as it was one of the few clinical 
samples to grow in cell culture at a detectable level by RT -PCR. It originated from a 4-
year-old male diagnosed with bronchiolitis and upper respiratory tract infection in 2002, 
collected as part of the investigation into the cause of illness in children hospitalised with 
ARTI (Chapter 3). This isolate belongs to the Al subgroup ofhMPV (Chapter 4). 
RT -PCR on total nucleic acid extracted from the original clinical sample was used to 
amplify the full-length hMPV N (N-FL) and N fragments using primers containing the 
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appropriate restriction sites shown in Table 5.l and 5.2 and shown schematically in Figure 
5.2. The amplified PCR product was first cloned in to the pCR2.I-TOPO TA cloning 
vector as described previously, and positive clones analysed by restriction digest and 
sequencing of purified plasmid. The TOPO constructs and the pTriEx-2 Neo plasmids 
were digested with the appropriate restriction enzymes, the correct fragments gel purified, 
and ligated together using T4 DNA ligase. The ligated plasmid was transformed in to 
chemically competent E.coli and individual colonies screened by restriction digest, and 
sequencing of purified plasmid. Figure 5.3 shows the map of the resulting plasmids. 
To aid in the detection and purification of the expressed proteins each gene was cloned in 
frame with a 6-histidine tag, supplied in the vector. The tag was placed at the N-terminal of 
the proteins followed by a short linker and then the protein or protein fragment. The 6-
Histidine tag was placed at the N terminal to aid the ease of cloning, and also because it 
had the least effect on the structure of the protein when analysed using secondary structure 
prediction software. Figure 5.1 shows the predicted secondary structure, hydrophilicity plot 
and surface probability of the hMPV N-FL with and without the N terminal 6-histidine tag 
using DNAST AR protein prediction software. The results show that there is no difference 
in the predicted secondary structure, hydrophilicity or surface prediction plots between the 
two in the N region indicating that the tag and linker are not likely to have an effect on the 
folding, processing or solubility of the resulting protein. Furthermore the 6-histidine tag is 
strongly hydrophilic and therefore likely to appear on the surface of the protein allowing 
easy detection and purification. 
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Figure 5.1 Secondary structure protein prediction of the hMPV N-FL with and without the 6-
Histidine Tag and linker using DNAST AR protean. (A) Schematic showing the localisation of 
the Tag and linker, (B) secondary structure prediction of the N-FL without the 6-histidine tag, (C) 
Secondary structure prediction of the N-FL with the 6-histidine tag. u, p, Turn and coil regions 
were predicted using the Gamier-Robson method (Gamier et aI., 1978). Hydrophilicity plot was 
predicted using the Hydropathy - Kyte-Doolittle method (Kyte & Doolittle, 1982), and the Surface 
probability predicted using the Emini method (Emini et aI., 1985). 
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Primer Position * Sense Sequence 5'-3' 
hMPVN 40-59 + GGATCCCATGTCTGTTCAAGGGATTCACC 
Primer A 
hMPVN 520-502 GCGGCCGCCTTAGATTATGGGTGTGTCTGG 
Primer B 
hMPVN 520-538 + GGATCCCTTATTATGTGTAGGTGCC 
Primer C 
hMPVN 880-859 GCGGCCGCCTTAACCTTGGACGGATACATG 
PrimerD 
hMPVN 880-899 + GGATCCCGAGTTAAAACAGGTCACAG 
Primer E 
hMPVN 1225-1206 GCGGCCGCCTTACTCATAATCATTTTGAC 
Primer F 
Table 5.1: Primers used for the amplification of N-FL gene and N fragments for 
cloning into the pTriEX 2 Neo vector. 
Footnotes: (*) primer positions according to reference strain NLOO-I. Restriction sites for cloning 
are underlined. For schematic representation of primer location see Figure 5.2. 
o 1225 nt 
~----------------~---V-N--G-en-e-(-O-RF--)--------------~I 
520 880 
• • 
HMPV N-FL (1185 bp) 
• • 
• 
bMPV N Fragment A (480 bp) 
Primer A 
(position 40*) 
• • 
hMPV N Fragment C (705 bp) 
• 
hMPV N Fragment B (840 bp) 
• • 
hMPV N Fragment D (345bp) 
• • 
hMPV N Fragment E (360bp) 
...... 
Primer Bf Primer C 
(Position 520*) 
...... 
Primer Df Primer E 
(Position 880*) 
Primer F 
(Position 1225*) 
Figure 5.2: Schematic representation of N-FL and N gene fragments expressed in the 
recombinant baculovirus system and primer positions. The blue box represents the hMPV N 
gene ORF. (Black) N-FL, (Green) N Fragment A. (Maroon) N fragment B, (Blue) N fragment C, 
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(Grey) N fragment D, and (purple) N fragment E. The size of each N region amplified in indicated 
in base pairs (bp) below the coloured line. Primers are represented by red arrows with the name of 
the primer below and the nucleotide starting position. (*) starting primer positions according to 
reference strain NLOO-I. For primer sequences see Table 5.1 . 
Table 5.2 : Summary of the properties of the amplified hMPV N gene and gene fragments, transfer 
vector and expected protein size. 
Summary of properties 
Gene I Fragment N-FL A B C D E 
Forward Primer hMPVN hMPVN hMPVN hMPVN hMPVN hMPVN 
A A A C E C 
Reverse Primer hMPVN hMPVN hMPVN hMPVN hMPVN hMPVN 
F B D F F D 
Expected Size (bp) 1185 480 840 705 345 360 
Restriction Sites BamHIINot 1 
Expression Vector pTriEx-2 Neo 
Estimated 51 24.4 37.5 32.6 19.4 19.9 
Recombinant 
Protein Size (KDa) * 
Footnotes: (*) Protein size estimated from amino acid sequence using EditSeq, DNA Star Lasergene software. 
T7 Terminator 
Rabbit j3-Globulin 
Terminator 
pTriEX-2 Neo-
hMPVN-FL 
neo 
CMV-ie Enhancer & 
chicken j3-actin promoter 
T7 Promoter, lac operon 
pl0 
6x Histidine Tag 
hMPV Gene/ Gene Fragment 
Figure 5.3: Scbematic representation of tbe bMPV N-FL pTriEx transfer vector. Each 
construct contains a CMV ie enhancer and chicken J3-actin promoter for expression in mammalian 
systems (purple), a T7 promoter for bacterial expression (pale green), and the pi 0 promoter for 
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recombinant baculovirus expression (pale blue ):· ··-A··· 6~· hi~iid·i-~-~-··-t~g-·-(·iii~~k) ·· i-~--~~ailabl~' just 
upstream of the multiple cloning site. The position of the inserted hMPV gene is shown in red. The 
vector contains the Rabbit J3-globulin (green) and T7 terminator (dark blue). The constructs also 
contain the neomycin resistance gene for the selection of stable mammalian cell lines which 
operates under the control of the EMCV-derived Cap-Independent Translation Enhancer (CITE). 
Clone foreign gene into transfer vector 
• 
Prepare Bacmid DNA 
Propagate and purify vector 
containing the foreign gene 
Co-transfect into insect cells 
• 
.I 
Amplify recombinant virus 
• Produce recombinant protein 
• Harvest and purify recombinant protein 
Figure 5.4 Flow diagram showing the major stages involved in producing protein in the 
recombinant baculovirus expression system. Propagate the transfer vector containing the foreign 
gene using competent cells and purify plasmid DNA. Co-transfect the bacmid DNA and 
recombinant transfer vector into 819 insect cells. Amplify the resultant recombinant virus in 819 
insect cells. Use the amplified viral stock to produce protein. Purify your protein using Ni-NTA 
purification system 
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Antigen 
N-FL 
hMPV infected 
cells 
Source 
4-year-old male diagnosed with bronchiolitis 
and upper respiratory tract infection in 2002, 
collected as part of the investigation in to the 
cause of illness in children hospitalised with 
ARTI in the UK isolated in LLC-MK2 cells. 
Northern Ireland HPA (2004) investigation in 
to the cause of respiratory illness first isolated 
in RMK cells. Further propagated at Colindale 
HPA in LLC-MK2 cells by Dr Alison 
Bermingham. 
Lineage 
Al (UK324-02) * 
A I (NIl-04) and 
BI (NI2-04) 
Table 5.3: Details of the hMPV virus strains used as antigen in this chapter. 
Footnotes: (*) see Chapter 4 for positioning in phylogenetic tree and alignment described as hMPV 
G clone. 
Antiserum 
Rabbit a-
hMPV Total 
Rabbit a-
hMPVN-FL 
Source of 
antiserum 
Colindale HP A 
raised against an 
hMPV infected 
RMK cells lysate 
isolated by Dr 
Joanne Stockton. 
This study, raised 
against 
recombinant 
baculovirus 
expressed hMPV 
G(s)-Fc High 5 
cell culture 
supernatant 
Source of Antigen Lineage 
From child < 5 years A (UK24 1-0 I) 
collected as part of the 
investigation in to the cause 
of illness in children 
hospitalised with ARTI in the 
UK. 
Recombinant baculovirus A I (UK324-02) * 
expressed hMPV N-FL 
generated in this study. 
See table 5.3 for further 
detail. 
Table 5.4: Details of the hMPV specific rabbit serum used in this chapter. 
Footnotes: (*) see Chapter 4 for positioning in phylogenetic tree and alignment described as hMPV 
G clone. 
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5.4 hMPV N Recombinant Baculovirus Expression 
In order to make recombinant baculoviruses expressing the N-FL or N fragments the 
different transfer vectors were co-transfected with the linearised bacmid into SF9 cells and 
incubated for 6 days at 28°C. The supernatant from the transfected cells was removed and 
used to inoculate fresh SF9 cells to grow up viral stocks. The cell lysates were analysed by 
Western Blot to confirm expression of the recombinant proteins (Figure 5.5). 
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Figure 5.5: Western Blot analysis of co-transfected SF9 cell lysate of hMPV N Fragments A-E, N-FL, 
Bacmid only, lipofectin only and cells only controls harvested 6 days post transfection. Recombinant proteins 
were detected using a mouse a-6-histidine MAb (1:1000) and detected with a a-mouse IgG HRP conjugate 
(1: 1 0000) by EeL reagent and autoradiography. 
Western Blot analysis clearly shows that the 6 recombinant baculoviruses expressing the 
hMPV N fragments A-E and N-FL generate proteins of the expected size. In the lanes 
containing Fragments A and D higher molecular weight bands equating approximately to 
the correct size for protein dimmers are present. The different levels of expression are due 
to the fact the co-transfected cell lysate material was used for this blot and represents 
differences in the quality or amount of recombinant virus generated. 
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of virus, an example of which is shown in Figure 5.6. Typically recombinant baculovirus 
hMPV N-FL reached high titres of around 2xl08pfu/ml. However, the recombinant 
baculoviruses expressing the hMPV fragments A to E grew only to titres of 1 xl 06pfu/ml , 
more than 2 logs lower than that ofN-FL. 
Figure 5.6: Example of a recombinant baculovirus plaque assay. Sf9 cells were infected with a 
ten fold dilution series of recombinant virus from 10-4 to 10-9 and overlaid with 1.6% agarose. At 7 
days post infection cells were stained with neutral red and the plaques counted by eye. 
To determine the optimal MOl for expression and day and for harvesting the expressed 
proteins, suspension cultures of SF9 cells were infected at an MOl of 3, 5 or 10 and 1 ml 
removed from the culture flask every 24 hours over 5 days. The cells were pelleted and the 
lysate analysed by Western blot analysis to determine which time point yielded the largest 
amount ofN/ml of cells. The Western blot results for the time course assay ofN-FL at the 
optimum MOl of3 is shown in Figure 5.7. 
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Figure 5.7: Time course assay of hMPv N-FL expression in the recombinant baculovirus system. 
Expression of N-FL in SF9 cells taken every 24 hours post infection. The expressed protein was 
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detected using a mouse a-6-histidine MAb (l: 1 000) followed by a-mouse IgG HRP conjugate 
( 1 : 1 0000) with EeL reagent and autoradiography. 
The results show that at 24 hours post infection N-FL is already expressed at reasonable 
levels. 48 to 72 hours post infection gives the optimal level of protein expression, which 
decreases from this point onwards, as host cell machinery shuts down and cells undergo 
apoptosis. At 5 days post infection a doublet is visible on the blot, which may represent 
different N-FL species with different levels ofposttranslational modification. 72 hours post 
infection was therefore the optimal time for harvesting N-FL. 
Recombinant baculoviruses expressing hMPV N fragments A-E however did not grow as 
well with virus titres more than 2 logs lower than that achieved for recombinant 
Baculovirus hMPV N-FL. The level of expressed protein was also considerably lower; 
despite attempts at optimisation of the culture conditions through varying cell seeding 
density and MOl (Data not shown). An MOl of 15 or greater was required to generate 
detectable levels of expressed protein by Western blot and therefore without virus 
purification the volume of virus required was not feasible. Virus purification was not 
possible however, due to time constraints. 
187 
Chapter 5 -Expression of hMPV N Protein 
5.5 Purification of Recombinant hMPV N-FL 
The recombinant N-FL was purified under non-denaturing conditions to maintain the 
correct structure and conformation of the protein using a Ni-NTA Affinity chromatography 
system. The protein was purified in order to generate an hMPV N specific polyclonal 
antiserum. 
Sf9 cells were infected with recombinant baculovirus hMPV N-FL and incubated for 3 
days. Cells were collected by centrifugation and lysed. The lysed cell preparation was 
clarified by centrifugation and applied to the Ni-NTA bind slurry and incubated on a 
shaker at 4°C for 2 hours. The slurry contained Ni-NT A sepharose beads and 10mM 
imidazole buffer. The 6-histidine tag of the recombinant hMPV N binds to Ni2+ cations 
immobilised on sepharose beads by nitro acetic acid (NT A). The imidazole present in the 
buffer competes with other Ni2+ binding proteins and histidine residues to reduce the 
amount of non-specific binding to the beads. The mixture was then packed in to a column 
for the washing and elution steps. Unbound and non-specific proteins were removed using 
increasing concentrations of imidazole buffer. N-FL was eluted using a 250mM imidazole 
buffer. Each of the fractions was collected and analysed by ELISA, Western blot and 
protein gel (Figure 5.8 A, B and C) for purity of the purified protein fragments, and 
assessment of the purification procedure. 
The results show that there was still a large amount of N-FL present in the flow through 
that was not bound to the Ni-NTA beads suggesting the quantity of antigen used exceeded 
the binding capacity for the column size and quantity ofNi-NTA beads used. Only a small 
amount of hMPV N was removed from the column during the washing process and all 
non-specific, unbound protein was removed. A majority of N-FL was eluted in the first 2 
elution fractions, with very little N-FL present in the 4th fraction. The protein gel however 
shows a number of contaminating bands in each of the elution fractions, which are most 
evident in elution fraction 2. These extra bands are also visible by Western blot analysis 
using a mouse a-6-histidine MAb followed by rabbit a-mouse IgG HRP conjugate. It is 
possible therefore that the highest molecular weight contaminating band is an hMPV N-FL 
dimer and lower molecular weight bands degradation products, despite the use of reducing 
conditions in the gel. It should not be overlooked however that other contaminating 
proteins with a high affinity for Ni2+ binding might also be present in the protein 
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preparation, the binding of which was not inhibited with the current concentration of 
imidazole. 
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Figure 5.8: (A) Analysis of hMPV N-FL Ni-NT A protein purification. 96 well plates were coated with 1 00~1 
of the different fractions in 2 fold dilutions across the plate starting at 1:10 with IOmM PBS and incubated at 
3i>C for 15 minutes. Plates were blocked with 1 %BSA for 1 hour at 3i>C. N-FL was detected using the 
mouse a-6-histidine MAb at 1:1000 followed by Rabbit a-mouse IgG HRP conjugate with TMB substrate. 
The absorbance was measured at 420nm. Analysis ofN-FL Ni-NTA protein purification by. (8) Protein gel 
analysis with Coomassie stain (C) Western Blot analysis using mouse a-6-histidine Mab I: lOOO followed by 
rabbit a- mouse IgG HRP conjugate 1:2500, and detected using ECL reagent and autoradiography. 1 O~l of 
each of the purification fractions was analysed. (M) Marker, (1 ) Protein Extract, (2) Column flow through, 
(3) wash I, (4) wash 2, (5) Elution 1, (6) Elution 2, (7) Elution 3, (8) Elution 4, (9) positive control - N-FL 
SF9 cell lysate 
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By increasing the concentration of imidazole in the binding buffer to 20mM the amount of 
contaminating proteins were reduced (Figure 5.9). The amount of purified N-FL required 
for the rabbit innoculations required several batch purifications, and it is worth noting that 
there was a conciderable difference between the quantity and the purity of the purified 
protein preparations between batches. Thefore each batch was assessed by commassie 
staining of protein gels, and only the purest elution fractions pooled . 
...c 
Ol) 
::l 
e 
0 C"l ..:r 
... ...c ..... M 
0 ..... ..... N c: c: c: c: ~ ~ ...c ...c 0 .9 0 0 ~ 
..9 1a 1a . .;:: ..... . .;:: . .;:: ~ ::l ::l ::l ::l t.l.. ~ ~ @ @ @ @ 
J)' 
191 
64 
51 ..,-x.' 
" .... ,.-,.,~ ,. 
39 
28 
19 
14 
0 
..... 
CI:S 
<Il 
.Q 
...c "'ij 
b!l U 
::l ~ e N M ..:r 
...c 
... r-- ..... C"l c: c: c: c: > ... 0 
,9 ,9 ,9 0 0 ~ ~ ...c ...c '';:: ~ ~ ~ <Il <Il ..... ..... ..... ~ 0 CI:S CI:S ::l ::l ::l ::l ~ ~ ~ ~ @ @ @ @ ::r:: ~ 
120 
100 
80 
60 
50 
40 
30 
20 
Figure 5.9: Analysis of N-FL Ni-NTA protein purification with increased imidazole concentrations, (A) 
Protein gel analysis with Coomassie stain (B) Western blot analysis using mouse a-6-histidineMab 1 :1000 
followed by rabbit a-mouse IgG HRP conjugate 1:2500, and detected using ECL reagent and 
autoradiography. 
190 
Chapter 5 -Expression of hMPV N Protein 
.... _ .... _ .. _ .. _--.. _--_._ .... __ .... __ ._ .. _-----------. __ ._-_ ... -._------.-_ .. -._--_._--_._. __ .. . ........ _. __ ._ ...... __ . __ ... __ .... _ ...... _ .. __ ...... ---_ .._ .. -._ ......... _ .. __ .•. _ .............•.......... - .. _---.... _ ..... _------------
Analysis of the pooled purified protein prep by spectrophotometery and total protein assay 
gave an estimate of 0.74mg/ml of total purified protein. By Coomassie blue staining the 
proteins separated on a SDS PAGE gel along side a BSA standard marker (Figure 5.10) it 
was calculated using density analysis software that N-FL accounted for approximately 
6.5% of the total protein preparation and was the major species in the preparation, this 
equates to a concentration of 47.4J.1g/ml of the purified preparation. 
M 1 23456789 
191 
64 
51 +- N-FL 
39 
28 
19 
14 
Figure 5.10: Protein gel analysis of hMPV N-FL purified protein preparation. M is a mobility 
marker; lane 1 to 5 is a BSA standard of 120ng, 90ng, 60ng, 60ng and 30ng respectively. Lanes 6 
to 9 are different volumes of the purified N-FL preparation of 10ul, Sui, Sui and 2ul respectively. 
Gels were stained with Coomassie blue stain and analysed using a BioRad density imager and 
software. 
191 
Chapter 5 -Expression of hMPV N Protein 
5.6 Generation and Evaluation of hMPV Specific Antiserum. 
For this work hMPV specific antiserum was raised against hMPV virus or recombinant 
baculovirus expressed hMPV N-FL and evaluated for their use as potential research or 
diagnostic reagents (Table 5.5). 
Table 5.5: hMPV Specific antiserum raised and evaluated in this study. 
Antiserum 
Rabbit a-hMPV 
Total 
Rabbit a-hMPV 
N-FL 
Dav 0 
(l-hMPVNP • 
(l-hMPV Total . 
Immunogen 
hMPV infected RMK cell lysate approximately lx105 cells/ml. 
Unknown amount of hMPV virus, assumed to be very low titre, no adjuvant 
was used. 4 x 0.25ml of the inoculum was injected at 4 points along the dorsal 
of the rabbit with a booster given on day 30 into the hind leg muscle. Terminal 
Bleed taken day 60. 
Purified baculovirus expressed hMPV N-FL 
100ng of purified protein 10mM Purified LPS 0.5mJ incomplete Freund's 
adjuvant. 4 x 0.25mJ of the inoculum was injected at 4 points along the dorsal 
of the rabbit.IOOng purified N-FL with IOmM LPS and saline was given as a 
second immunogen on days 21 and 40 into the hind leg muscle. Test bleeds 
taken days 35 and 55. Terminal Bleed taken day 60. 
30 35 40 55 60 
• 1J • • 
• • 
• 
• 
Serum collection Primary inoculation Secondary inoculation for NP 
Secondary inoculation for Total 1J Tertiary inoculation for NP 
Figure 5.11: Schedule of rabbit inoculations for the generation of hMPV specifc 
antiserum. hMPV N-FL Specific poly clonal serum was raised against 100ng of hMPV N-FL 
mixed with purified lipopolysaccharide (LPS- prepared from Escherichia coli 0157 [kindly 
supplied by Dr Henrik Chart at the HPA ColindaleD and incomplete Freund's adjuvant to form an 
emulsion. Rabbit a-hMPV Total was generated by Dr Joanne Stockton at the HP A Colindale. Red: 
rabbit bleeds, Green: inoculation. 
The sera were analysed by ELISA, Western blot, and immunofluorescence to evaluate their 
use as potential diagnostic or research reagents. 
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5.6.1 Analysis of hMPV Specific Sera by ELISA against recombinant hMPV 
proteins 
The terminal bleeds for rabbit a-hMPV Nand a-hMPV Total were tested by ELISA in a 
dilution series against the baculovirus expressed N-FL in the SF9 cell lysate with 
uninfected cells as a measure of background reactivity (Figure 5.12). 
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-0 .5 
Primary Ab Dilution 
--- Negative Rabbit --a-NP Terminal Bleed Day 60 --Rabbit a -hMPV Terminal Bleed Day 60 
Figure 5.12: Analysis of hMPV specific rabbit sera by indirect ELISA against recombinant 
baculovirus hMPV N-FL infected or uninfected SF9 cell lysate. Error bars show +/- 1 Standard 
deviation. 96 well plates were coated with approximately 0.8~g of total protein of Baculovirus 
hMPV N-FL infected /uninfected cell lysate standardised by cell equivalence of 1.5x104cells per 
well diluted 1: 100 with 10mM PBS and incubated at 37°C for 30 minutes. Plates were blocked with 
5% milk for 1 hour at 37°C. The hMPV specific Rabbit sera were tested in a dilution series from 
1: 10 to 1 :500,000 followed by Goat a-Rabbit IgG HRP conjugate 1:2500 and detected using TMB 
substrate. The absorbance was measured at 420nm reference 620nm, and the negative cell lysate 
OD value was subtracted from that ofthe positive to give the corrected OD values. 
Results show that both the Rabbit a-hMPV N and rabbit a-hMPV total sera recognised the 
N-FL antigen, although it is clear that the rabbit a-hMPV total has a considerably lower N 
antibody titre than the rabbit a-hMPV N-FL with only 1: 10 to I: 100 dilutions reacting. 
The a-hMPV N-FL terminal bleed (Day 60) showed a high hMPV N antibody titre with 
dilutions of 1 :50,000 still being reactive. The pre-bleed rabbit serum (negative) was 
negative at all dilutions tested. 
Sera were tested by Western blot and immunofluorescence analysis at dilutions appropriate 
for the antibody titres determined by ELISA (Rabbit a-hMPV N-FL at 1: 100, rabbit a-
hMPV Total 1 :50). 
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5.6.2 Analysis of hMPV Specific antiserum by Western blot using reco~binant 
baculovirus expressed hMPV proteins 
Sera were tested against cell lysate or supernatant positive or negative for recombinant 
baculovirus hMPV N-FL (Figure 5.13). The molecular weight species recognised by the 
serum in comparison with mouse a-6 -histidine MAb is summarised in Table 5.6. 
Western blot analysis of hMPV N positive and negative SF9 Cell lysate taken 72 hours 
post infection shows that both the rabbit a-hMPV Total and rabbit a-hMPV N-FL 
recognise baculovirus expressed hMPV N-FL. While rabbit a-hMPV Total gives very little 
non-specific binding, the rabbit a-hMPV N-FL, at the dilution tested, also recognises a 
number of other species. These species however are not detected by the mouse a-6-
histidine MAb indicating that the extra bands detected by rabbit a-hMPV N-FL are likely 
to be due to cross-reactivity with cellular proteins as oppose to degradation products ofN-
FL. The hMPV N-FL (51KDa species) is however the predominantly recognised species 
and reactivity against the cellular proteins was reduced by cross absorption with uninfected 
SF9 cells, and further dilution of the serum. 
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Figure 5.13: Western Blot analysis of hMPV specific Rabbit serum. (M) Marker, (1) Baculovirus 
hMPV N-FL infected SF9 cell lysate (2) Uninfected SF9 cell lysate (A) Negative rabbit serum 
1 :50, (B) Rabbit a-hMPV Total 1 :50, (C) Rabbit a-hMPV N-FL 1 :250, (D) mouse a-6-histidine 
MAb 1: 1 000. All rabbit sera were detected with goat a-rabbit IgG HRP conjugate at 1 :2500 with 
EeL and autoradiography. 
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Table 5.6: Summary of molecular weight profile of the major species recognised by Mouse a-6-
Histidine MAb, rabbit a- hMPV Total, rabbit a- hMPV N-FL, and negative rabbit serum by 
Western blot analysis. 
Antigen Mouse a-6- Rabbit a- Rabbit a- Negative 
His hMPVTotal hMPVN- Rabbit 
FL 
N-FL cell lysate 51 51 51 Negative 
5.6.3 Analysis of hMPV Specific Sera by Immunofluorescence against recombinant 
hMPV proteins 
Sera were also tested against the recombinant baculovirus expressed hMPV proteins by 
indirect immunofluorescence ofhMPV N-FL recombinant baculovirus infected/ un infected 
SF9 cells grown on cover slips. Figure 5.14 shows the IF against baculovirus hMPV N-FL 
infected/ uninfected SF9 cells. Results show that both Rabbit a-hMPV N-FL and Rabbit a-
hMPV Total react specifically against the N with no background binding to uninfected 
cells (Rabbit a-hMPV N-FL having been cross absorbed). As reflected in the ELISA 
results the Rabbit a-hMPV N-FL serum gave a greater level of fluorescence relative to that 
of the Rabbit a-hMPV Total as the Ab different dilutions tested here do not fully account 
for the difference in hMPV N antibody titre between the two sera demonstrated by ELISA, 
and therefore a lower dilution of Rabbit a-hMPV Total should be used for optimal 
fluorescence. 
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hMPV N-FL Positive Un infected 
Figure 5.14: Indirect immunofluorescence analysis of hMPV specific antiserum against hMPV N-FL 
positive / negative SF9 cells. SF9 cells were grown on glass cover slips and infected with 3MOI of 
recombinant baculovirus hMPV N-FL. At 72 hours pi cells were acetone fixed. The rabbit serum was applied 
and detected using swine a-Rabbit IgG FITC conjugated Ab. Cells were counter stained with Evans Blue and 
visualised by fluorescence microscopy. (A) Mouse a-6-histidine 1 :50, (B) Rabbit a-hMPV N-FL 1 :25 , (C) 
Rabbit a-hMPV Total 1 :25, (0) Negative Rabbit Serum I :25. Rabbit serum was detected with Swine a-
Rabbit IgG FITC conjugate 1:40. Counter stained with Evans Blue. 
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5.6.4 Analysis of hMPV Specific Sera by Immunofluorescence against hMPV 
positive clinical isolate infected LLC-MK2 Cells 
LLC-MK2 cells were grown on glass cover slips and inoculated with 250J.lI of hMPV 
infected LLC-MK2 passage 1 cell lysate material (unknown quantity of virus). The hMPV 
clinical isolates used were obtained from patients with ARTI from Northern Ireland 
(Kindly set to us from the Belfast HP A) 1 type A and 1 type B virus was used. At 14 days 
post infection cells were acetone fixed. Rabbit a-hMPV N-FL and rabbit a-hMPV Total 
was applied and detected using swine a-rabbit IgG FITC conjugated Ab. An FITC 
conjugated rabbit a-hMPV N-FL IgG was also evaluated for its use as a direct 
immunofluorescent agent. The conjugate was kindly prepared by Dr Dhan Samuels at the 
HP A Colindale. Cells were counter stained with Evans blue and visualised by fluorescence 
microscopy (Figure 5.15). 
IF of hMPV infected/ uninfected cells showed that the rabbit a-hMPV Total antiserum 
recognised the hMPV infected LLC-MK2 cells while, unexpectedly the rabbit a-hMPV N-
FL serum did not. There was however, a low level of fluorescence against hMPV subtype 
A with the rabbit a-hMPV N -FL FITC reagent as a direct IF reagent. There are a number 
of reasons that may explain the lack of reactivity by the a-N-FL antiserum; the first and 
most obvious being that there are conformational differences between the baculovirus 
expressed N-FL, against which the sera was raised, and the N-FL expressed in mammalian 
cells during infection. It may be that in natural infection the N is complexed with other 
viral or cellular proteins or indeed nucleic acid, which masks its recognition by the 
antibody. Alternatively the rabbit a-hMPV N-FL antiserum may be predominantly against 
the 6-histitine tag. This could be assessed by cleaving the Tag off and reanalysing sera 
reactivity . 
With regard to the reactivity of the rabbit a-hMPV Total antiserum, this information in 
conjunction with the IF and ELISA data against the recombinant N-FL suggests that the 
majority of antibody in this serum is directed to hMPV proteins other than the N. 
Reactivity may also be affected by potential conformational differences between 
recombinant and natural N expression. 
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The results shown in Figure 5.15 were cells analysed at 14 days post infection. However 
analysis was also performed at 7 and 21 days post infection (data not shown). There was 
no difference observed between the time points. 
Uninfected Cells hMPVA hMPVB 
Figure 5.15: Indirect immunofluorescence analysis of hMPV specific antiserum against hMPV 
infected I uninfected LLC-MK2 cells (NIl-04 and NI2-04). (A) Rabbit a-hMPV N-FL 1 :25 , (B) 
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Rabbit a-hMPV Total 1 :25, (C) Rabbit a-hMPV N-FL- FITC 1 :25 , (D) Negative Rabbit Serum. 
Rabbit serum was detected with Swine a-Rabbit IgG FITC conjugate 1:40. Counter stained with 
Evans Blue. 
Figure 5.16: High Magnification ofhMPV infected LLC-MK2 cells with rabbit a- hMPV Total. 
Higher magnification images of hMPV infected LLC-MK2 cells (Figure 5.16) immuno-
stained with rabbit a-hMPV Total show that the viral proteins were cytoplasmically 
located. The cells have a speckled appearance, which is slightly more concentrated around 
the nuclear envelope. 
5.6.5 Analysis of Rabbit a-hMPV N-FL against N-FL expressed in mammalian cells 
To investigate further the reactivity of the rabbit a-hMPV N-FL antiserum against N-FL 
expressed in mammalian cells, human kidney cells (293T) were transiently transfected 
with the hMPV N-FL pTriEx plasmid. Expression of N-FL was analysed by 
immunofluorescence and western blot. For immunofluorescence cells were fixed with 80% 
acetone PBS or 4% paraformaldehyde and permeablised using 0.25% TritonX-100 at 24 
hours post transfection. Surprisingly immunofluorescence analysis of the transfected cells 
with the mouse a-6 histidine MAb, rabbit a-hMPV N-FL, rabbit a-hMPV Total, and a 
range of adult human serum known to be seropositive for hMPV N all yielded negative 
fluorescence results (Data not shown). By Western blot analysis however the 51 KDa 
hMPV N-FL was detected, by the mouse a-6 histidine MAb, rabbit a-hMPV N-FL, and 
rabbit a- hMPV Total antiserum (Figure 5.17) confirming the expression of the N-FL and 
confirming recognition of linear epitopes by these sera. The a- N-Fl serum however also 
recognises a doublet at approximately 70KDa, which is also seen in the negative serum. 
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The a- hMPV Total serum also recognises a number of other proteins which are not 
detected by the a-6-histidine or other rabbit serum. These bands are present in both the 
infected and uninfected cell lysate. Therefore these non-specific bands are likely to be due 
to cross reactivity with cellular proteins. The 5IKDa band size of the N-FL recognised 
here is the same size as that expressed in the recombinant baculovirus system which 
suggests that the post translational modifications are similar in both cell types. 
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Figure 5.17: Western blot analysis of hMPV N-FL transfected 293T cell lysate 24 hours post 
transfection. (A) Mouse a-6 histidine MAb 1: 1 000 detected with Rabbit a-Mouse IgG HRP 
1: 10000, (8) Rabbit a-hMPV N 1 :500, (C) Negative Rabbit 1 :50, (D) Rabbit a-hMPV Total 1 :50. 
A, Band C were detected with Goat anti Rabbit IgG HRP at 1 :2500. Against (1) hMPV N-FL 
transfected 293T cell lysate 1, (2) hMPV N-FL transfected 293T cell lysate 2, (3) 293T un-
transfected cell lysate. 
These data support conclusions that there may be differences between the baculovirus 
expressed N and that expressed in mammalian cells through transfection or hMPV 
infection. Detection of the N-FL by Western blot of the transfected 293T cell lysate 
however indicates linear epitopes are recognised by the rabbit a-hMPV N-FL serum. It 
may be that the levels ofN in the hMPV infected celllysatel transfected cells were too low 
for detection by IF. The fixation methods used for the detection of hMPV N-FL may also 
affect whether the protein is detected or no. When IF was performed in SF9 cells, cells 
were fixed with 80% ice-cold acetone, and worked well. This method was also used 
against hMPV infected and transfected mammalian cells, however results were negative 
for the a-N-FL rabbit serum. 4% paraformaldehyde was also tried on transfected cells 
followed by permeablisation with 0.25% Triton X-I 00 but again the results were negative. 
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5.6.6 Analysis of hMPV specific serum against hMPV infected and uninfected cell 
lysate and hMPV N expressed in the recombinant baculovirus system. 
To further assess the reactivity of the hMPV specific antiserum, they were tested by 
Western blot against 2 different hMPV strains isolated from the 2 Northern Ireland clinical 
samples used in Figure 5.15, and purified hMPV N-FL were analysed (Figure5.18). 
Panel A shows the results for rabbit a-hMPV Total. As shown previously this serum 
recognises the 51KDa band of the baculovirus expressed N-FL in lane 4. In this lane there 
is also a faint band at approximately 100-11 OKDa which may represent a dimeric form of 
N-FL, despite the use of denaturing gels. This band was also detected by the a-N-FL 
serum (Panel Blane 4); however, this was not detected by the a-6-histidine MAb (Data not 
shown) and therefore may just be an artefact. To determine if this is an N dimerised 
product a non-denaturing gel should also be run in parallel to confirm this result, as this gel 
system may therefore not be completely denaturing. 
Against the hMPV infected and uninfected LLC-MK2 cell lysate The rabbit a-hMPV 
Total (Panel A lanes 1-3) there were a number of bands recognised, which were more 
apparent in lane 3 that were not detected in the uninfected cell lysate in lane 1. This 
included a band at molecular weight of 43-45KDa, which was the correct size for either the 
native nucleocapsid protein or the fusion protein F 1 fragment. There was also a band at 
90KDa recognised in lanes 2 and 3 by the rabbit a-N-FL in panel B, and supports possible 
recognition of an N dimer. There are also 2 bands of approximately 90 and 100KDa in 
lanes 2 and 3, which may be glycosylated species of G. These bands differ in the intensity 
in which they are stained (weaker in lane 2), and size, with those in lane 3 having slightly 
larger molecular weights than those in lane 2. This may demonstrates possible size or 
glycosylation differences between the G proteins of the two different strains analysed. 
The rabbit a-hMPV Total (Panel A) also recognises 2 another bands in lanes 2 and 3, the 
first with the approximate molecular weight of 60-65KDa which is the correct size for the 
native un-cleaved precursor fusion protein, and the second is the lowest molecular weight 
band detected which may represent the fusion protein F2 fragment neither of these bands 
are recognised by any of the other serum, as expected. Bands are present in lanes 2 and 3 
which also correspond to the correct molecular weight for the P and M proteins. 
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Panel C is negative rabbit sera and as expected shows no or very little reactivity against all 
antigens. 
This analysis highlights the need for monoclonal antibodies against each of the hMPV 
proteins in order to confirm the reactivity of the antiserum. The analysis of different 
cellular fractions and the use of non-denaturing gels will also aid in addressing or 
confirming these findings. 
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Figure 5.18: Western blot analysis of various hMPV specific serum against recombinant hMPV 
proteins and hMPV infected cell lysate. Against (1) Uninfected LLC-MK2 Cell Lysate, (2) hMPV 
Cell Lysate -NIl-04, (3) hMPV Cell Lysate -NI2-04, (4) Purified recombinant N-FL. Table 5.2 
shows the expected hMPV protein sizes * un-glycosylated, **glycosylated. 
202 
Chapter 5 -Expression of hMPV N Protein 
5.7 Discussion 
Reported here is the use of the recombinant baculovirus system to express the hMPV 
nucleocapsid and the subsequent generation and evaluation of hMPV specific antiserum; 
required for the development of serological assays to further the investigation ofhMPV. 
Recombinant baculovirus expression of hMPV N-FL and N fragments 
The results demonstrate that the hMPV N-FL could be expressed efficiently in the 
recombinant baculovirus system. The expression of the N fragments, however, was not as 
straight forward. The recombinant baculoviruses expressing N fragments A-E grew less 
efficiently in cell culture producing viral titres 2 logs lower than that of N-FL. Despite 
attempts at optimising the conditions, the level of expression was also considerably lower. 
There are a number of reasons that may explain the low level of recombinant virus growth 
and or protein expression including the accumulation of defective virus particles. However, 
it is unlikely that this is the cause of the problem with these recombinant viruses, as the 
appropriate measures (use of the correct MOl of virus, and use of low passage number 
virus stocks) were used. Furthermore, newly constructed batches of these recombinant 
viruses also failed to propagate and express the N protein fragments at sufficient levels. 
The level of protein expression was different for each of the fragments, with fragments A 
and D being expressed in slightly greater quantities than the others. When analysed by 
Western blot, 2 bands of the expected size of the monomeric and potentially dimeric forms 
of protein fragments A and D were detected, while only monomeric forms were detected 
for fragments B, C and E. This may be evidence of instability of these truncated proteins, 
which enhances the rate degradation. Fragments A and D, therefore, may be more stable as 
they may have the ability to dimerise, hence the greater level of protein detected. 
There is evidence that multimericl dimeric forms of the N proteins of the Paramyxoviridae 
exist through the observation that the nucleocapsid proteins self assemble into capsid like 
structures when expressed in recombinant systems (Bhella et ai., 2002, Fooks et ai., 1993, 
Meric et aI., 1994), and the domains involved in N-N assembly have been mapped to the N 
terminus (Krishnamurthy & Samal, 1998, Nishio et aI., 1999). The presence of N dimers 
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~aYb~~-~ig-~ific~~tsiepi~··theasse~biY·~{the ~~~leocapsid. N o~=de~at~~i~i-p~otef;;gels, 
analytical ultra centrifugation sedimentation or size exclusion chromatography could be 
used to determine the presence of dimeric forms. The fact the potentially dimerised forms 
of the protein fragments were detected indicates that the denaturing gel system used in this 
study may not have been completely denaturing, and the addition of antioxidants to the 
running buffer may be required. 
To investigate whether instability is the cause of the low level of the N fragment 
expression the relative quantity of heterologous gene mRNA and protein expression could 
be determined by northern and Western blot analysis respectively and compared with that 
of other baculovirus proteins expressed under the same promoter. The level of protein 
expression relative to the mRNA can therefore be determined. The mechanisms involved 
in the targeting of proteins for proteolytic degradation in insect cells are yet to be 
determined. However, in other eukaryotic cells unbiquitination plays an important role in 
this function and therefore ubiquitation inhibitors could also be examined to see if protein 
stability is improved (Wilkinson, 2000). It has also been suggested that a homologue for 
cystine protease; V -cath, is expressed during the late phases of baculovirus infection 
causing protein degradation (Slack et aI., 1995), and that the presence of cysteine protease 
inhibitors could help to stabilise the expressed protein. 
The N fragments in their truncated form may also have a toxic effect on the cells resulting 
in decreased virus propagation and protein expression levels. Cellular toxicity of 
heterologous proteins has been documented previously in this system. 
This may be overcome by expression using the in vitro coupled transcription translation 
expression system as an alternative method for protein production and to help address the 
question of protein toxicity, as heterologous protein expression is not dependent on the 
growth of a virus and expression of the heterologous protein is not affected by the presence 
of other viral proteins. 
Problems associated with the solubility of the truncated proteins may also be involved and 
could be overcome by fusing the N fragments to a fusion protein such as the maltose 
binding protein or IgG Fc protein which have been shown to be useful for increasing 
protein solubility in recombinant systems (Sachdev & Chirgwin, 2000, Sugiura, 2003). 
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Purification of hMPV N-FL 
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Purification ofN-FL was required for the generation of a-hMPV N-FL specific antiserum. 
The purification system used was aNi-NT A resin system which took advantage of the 6-
histidine tag fused to the N-terminus of N-FL. Optimisation of the imidazole 
concentrations in the buffers used reduced the amount of contaminating proteins in the 
purified protein preparation. However, analysis of the preparation by densitometry 
indicated the presence of contaminating proteins, furthermore, the antiserum generated 
from this preparation cross-reacted with cellular proteins in Western blot analysis. This 
background reactivity was removed through cross-absorption. However, improvements of 
the protein purification techniques would be more efficient in the long term. 
Two-stage protein purification would be likely to give the best results. By taking advantage 
of the inherent properties of the N as a nucleic acid binding protein heparin affinity 
columns may be used for the first round of purification. Due to the poly anionic nature and 
structure of heparin it is able to mimic the overall binding properties of nucleic acid, and 
has been used for the purification or evaluation of many other proteins (Karger et aI., 200 I, 
Tseng et aI., 1999). Binding of hMPV N-FL to heparin has been demonstrated (data not 
shown), and provides additional evidence that the integrity of the N-FL was maintained. 
This first stage purification could then be followed by the Ni-NTA affinity 
chromatography as described previously to remove other contaminating nucleic acid, and 
heparin binding proteins which may be present. However, this 2-step approach is likely to 
result in a reduced yield of the purified protein. 
It was important to ensure the integrity of the N-FL was maintained in order for the antigen 
to be used efficiently for the development of serological techniques, and the generation of 
antiserum. Binding ofN-FL to heparin indicated that N-FL has maintained its nucleic acid 
binding function. Furthermore, the baculovirus expressed N-FL protein was recognised by 
the rabbit a-hMPV total antiserum in Western blot, IF and ELISA. However reactivity 
against N-FL was only week, whilst there was strong reactivity against hMPV infected 
cells. This may be as a result of low levels of hMPV N antibody in the serum, or more 
likely antigenic differences between native and baculovirus expressed N protein, or a 
combination of both. Therefore conclusions cannot be drawn as to whether antigenicity of 
the baculovirus expressed N-FL protein was properly maintained. As mentioned above 
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previous work by Meric et at has··sho;~·-ihat th~Np~ot~in of hRSV~xpressed i~ the 
baculovirus system forms nucleocapsid like structures, similar to those seen in RSV 
infected cells (Meric et aI., 1994). If more time was available analysis of SF9 infected cells 
expressing hMPV N-FL by thin section electron microscopy would have been used to 
ascertain if this was also the case for hMPV N-FL. 
At the later stages of baculovirus infection an N-FL doublet (50 and 51KDa) was visible 
by Western blot analysis. Although this was only observed in later time points, it does not 
exclude the possibility that doublets were present throughout, but were undistinguishable 
due to the quantity of antigen and exposure used. This may represent differences in the 
level of post-translational modification, the most likely being phosphorylation, although 
this was not investigated within the scope of this work. The use of metabolic labelling with 
p32 over a time course, and phosphorylation inhibitors in conjunction with Western blotting 
and mass spectrometry could be used to investigate if the N-FL is phosphorylated, to what 
extent, and whether the doublet is a result of a decline in phosphorylation. 
Alternatively this could be a cleavage product. It has been reported that the nucleocapsid 
proteins of many RNA viruses, including influenza and SV5 are cleaved by proteases 
present in the cell (Mountcastle et aI., 1974, Zhirnov & Bukrinskaya, 1981, Zhirnov et aI., 
1999). Ultimately analysis of the amino acid sequence of both species would address the 
question of whether the protein is cleaved or truncated versus differences in post 
translational modifications, and indicate where truncations may have been made before the 
use of protease inhibitors is investigated. Analysis of mRNA species by northern blot 
would also indicate whether the fragment is generated prior to translation. Furthermore, 
the expression of N-FL in a prokaryotic or in-vitro system could also be used to generate 
non-post translationally modified species for comparison. 
HMPV Specific antiserum 
High titred antiserum specific for hMPV is an essential tool for hMPV research. This 
chapter outlines the generation of hMPV specific antiserum: Rabbit a-hMPV total; rabbit 
a-hMPV N-FL and evaluates their reactivity against hMPV antigens in different assays. 
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Rabbit a-hMPV Total was raised against whole hMPV virus '~~li-" iy'~at~'~' A-s exp~~ted this 
antiserum recognises hMPV in infected cells by indirect IF, and as such would be a useful 
tool for monitoring the growth of this virus in cell culture. Although not evaluated here it 
may also be useful as a diagnostic IF reagent used directly on clinical samples. 
Anti-serum 
Antigen Analysis Mouse a-6- Rabbit a- Rabbit a- Rabbit a-
Preparation Histidine hMPVN- hMPV hMPVN-FL 
MAb FL Total FITC 
Recombinant ELISA +++ +++ + ND 
baculovirus ( 1: 1(00) (1 :50) ( 1:50) 
hMPVN-FL WB +++ +++ ++ ND 
(1 : 1(00) (1 :500) (l:50) 
IF +++ +++ ++ + 
( 1: ! 00) (1 :50) ] ,-) ( :L.) (1:20) 
hMPV WB NI) ++ NI) 
infected cells (1:100) (1 :50)* 
IF ND +++ +/-
(] :25) (1 :25)* (I :20) 
Transfected WB + + + ND 
hMPVN-FL ( 1:1000) (1: 1(0) (I :50) 
293T cells IF ND 
( 1:50) ( 1:50) (I :25) 
Table 5.7: Summary of hMPV specific antiserum reactivity against recombinant bMPV N-FL and 
hMPV infected cells! cell lysate. 
Foot notes: WB: Western blot analysis; IF: Immunofluorescence, (-) No antibody reactivity (+) Weak 
antibody reactivity, (++) moderate antibody reactivity, (+++) strong antibody reactivity . The values given in 
(brackets) represent the antibody dilution which was tested or yielded a positive result. (*) See also chapter 6. 
HMPV infected LLC-MK2 cells analysed with the rabbit a-hMPV Total antiserum by IF 
at high magnification showed distinctive signs of CPE; focal rounding of the cells, 
syncytium formation and cell destruction. Analysis was carried out over 3 time points of7, 
14, and 21 days pi however little difference was observed between them indicating that 
infection and CPE was not progressive. This may be due to the amount of inoculum used, 
which had an unknown quantity of virus. As 100% of the cells on the hMPV-infected slide 
were fluorescing it suggests that all the cells may have been infected upon inoculation or 
that the virus had spread to all the cells within the first 7 day time period. As CPE did not 
progress further it indicates the virus may have been inhibited in some way, perhaps by the 
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antiviral····~e~po~ses·of--ih~~eii:-·F·~rthe~investigatio~···o-i·-hMPV virus growth-~ho~id be 
carried out varying the quantity of inoculum, growth conditions and cell line. Recently 
Biacchesi et al (2005) have reported the recovery of hMPV from cDNA containing an 
enhanced green fluorescent protein, which has enabled improved virus yields to be 
obtained (Biacchesi et aI., 2005). This would be the ultimate tool of choice for 
investigating further the growth properties of this virus. 
The rabbit a-hMPV total antiserum also recognised a number of species in hMPV infected 
cell lysates analysed by Western blot. The species recognised correlate with the expected 
size of the N protein, a potential dimeric form of N, FO, F], P, M, and high molecular 
weight glycosylated species ofG. 
The a-hMPV total antiserum reacts specifically with the hMPV N-FL expressed in the 
baculovirus system by IF, ELISA and WB. The ELISA and IF data indicate that despite N 
specific reactivity the N Ab titre is relatively low. The very strong reactivity of this sera 
against whole virus therefore indicates only a small minority of Ab is targeted to the N, 
and a majority is against other hMPV proteins. 
As expected the rabbit a-hMPV N-FL antiserum recognises the hMPV N-FL expressed in 
the baculovirus system by ELISA WB and IF. However, there is little evidence to suggest 
it recognises the native N in hMPV infected or hMPV N-FL PTriEx transfected cells when 
analysed by IF but this may be due to relative concentrations of the protein. Western blot 
analysis of N-FL transfected cells was however positive. This indicates that there may be 
differences in the sensitivity of the two assays or that the fixation methods used in the IF 
were not optimal and alternative methods should be investigated. It may also be a 
possibility that a majority of the rabbit a-hMPV N-FL antiserum may in fact be targeted to 
the histidine Tag. Analysis of the antiserum against the expressed protein with the tag 
removed would address this question. 
In summary the hMPV N-FL has been successfully expressed in the recombinant 
baculovirus system, and purified for the production of hMPV N-FL specific antiserum 
which will be a useful tool for the development of hMPV N specific assays, however, 
further evaluation of its reactivity against native N is required. A rabbit a-hMPV Total 
antiserum was also evaluated for its reactivity against hMPV antigens, and has show to be 
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r~~~tiv~~g~"i~~t··both·th~···~~~omb·i~~~i·N=FL··and othe~hMPV··~~tige~~~~dhas proved itself 
a useful tool for immunofluorescence work. 
209 
Chapter 6 
Development of an assay to detect human antibodies to 
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6.1 Introduction 
The assessment of the seroprevalence of hMPV in the UK population is important for 
determining the populations most at risk of infection, the age of primary infection, the 
persistence of maternal antibodies, and identifying those to be targeted for potential 
vaccines. 
Serological findings indicate hMPV has been present in the human population for at least 
50 years, and by the age of 5 years nearly all children have been infected (van den Hoogen 
et aI., 2001). At the time of starting this work serological assays for hMPV consisted of 
immunofluorescence (IF) or ELISA against hMPV infected cell lysate (Boivin et aI., 2002, 
Ebihara et aI., 2004a, Ebihara et aI., 2003, Falsey et aI., 2003, van den Roogen et aI., 2001, 
Wolf et aI., 2003). These assays however are dependent on successful growth of hMPV in 
the laboratory and as a result are often not suitable for large scale epidemiological studies, 
and the assays have not been well validated for potential cross-reactivity with hRSV. 
Furthermore, results may be inconsistent and subtype specific biases may exist to the 
different hMPV proteins. 
Serological assays based on ELISAs have been developed for the detection of antibodies to 
APV, RSV and other members of the Paramyxoviridae. These assays have been developed 
using infected cell lysate but a number of assays based on recombinant proteins, including 
the matrix (M) and nucleocapsid protein (N) have also been developed and shown to be 
more sensitive and specific than whole virus approaches (Buraphacheep et aI., 1997, Gulati 
et aI., 2000, Gulati et aI., 2001, Samal et aI., 1993). 
Of the hMPV proteins the N, M and F proteins have been shown to be the most conserved 
between the 2 lineages of hMPV (Bastien et aI., 2003), which is in direct contrast with the 
G and SH proteins which are the most variable, and therefore better suited for the analysis 
of subtype or strain specific antibody responses. In 2001 a study showed that the N protein 
was better than M for the detection of antibodies to APV A, Band C (Gulati et aI., 2001). 
Recently sero-cross reactivity between the N proteins of hMPV A and B lineages has been 
demonstrated, and it was concluded that N proteins from either A or B lineages could be 
used for the serological analysis ofhMPV (Hamelin & Boivin, 2005). 
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The data presented in chapter 5 shows the successful expression of the hMP\TN-FL 
protein in the recombinant baculovirus system. Recognition of this recombinant protein 
with hMPV specific polyclonal antiserum by a variety of methods suggests this may be a 
suitable antigen for the development of an hMPV specific ELISA. 
Presented here is the use of the recombinant baculovirus expressed hMPV N-FL protein to 
develop a specific ELISA for the detection of human u-hMPV N antibodies, and the 
application of this ELISA to ascertain the seroprevalence of hMPV in the UK. 
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6.2 Aims 
• Design and optimise an ELISA based on the recombinant hMPV N-FL for the 
detection of hMPV specific IgG. 
• Apply the ELISA to clinical samples to assess the seroprevalence of hMPV in a 
panel of age-stratified serum from the UK. 
• Use hMPV reactive sera identified in the ELISA to map human antibody reactivity 
to the N. 
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6.3 Clinical Studies 
Table 6.1: Summary of human serum used in this study 
Human serum 
Pooled human sera 
Human sera :s 15 
years 
Human sera ~ 15 
years 
Adult acute and 
convalescent RSV 
AlB sera 
Paediatric acute 
and convalescent 
RSV AlB sera 
Age stratified panel 
of sera :s 72 months 
Source 
Colindale HP A (2001) pooled adult sera negative for reactivity 
against influenza antigens submitted to the HP A for serological 
investigation of respiratory illness. 
Colindale HPA (2001-2004) sera submitted to the HPA for 
serological investigation of influenza. 
Colindale HPA (2001-2004) sera submitted to the HPA for 
serological investigation of influenza. 
Colindale HP A (2001) sera submitted as part of investigation in to 
the cause of ARTI in particular hRSV in community dwelling 
elderly> 65 years old (Chapter 3) 
Colindale HP A. Neonatal paediatric sera collected as part of a 
longitudinal cohort study of RSV infection in childhood (Althani, 
2004). 
Colindale HPA. Sera from UK children submitted to the HPA for 
investigated of rash illness 
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6.4 HMPV N ELISA Development 
In order to develop an ELISA that can be used to detect antibodies to the hMPV N in 
human sera, a basic indirect ELISA was developed. The time required for generating the 
quantity of purified N-FL required for ELISA development was not feasible for the 
timescale of this work, therefore, hMPV N-FL positive cell lysate was used and 
background reactivity taken into account by using hMPV N-FL negative cell lysate. The 
blocking and coating buffer conditions and antigen/ antibody dilutions were optimised 
using Rabbit a-hMPV N-FL, Rabbit a-hMPV Total, Negative Rabbit serum, and human 
sera. All optimisation steps were performed changing only one parameter at a time starting 
with the standard ELISA conditions outlined below. The final optimal conditions are 
summarised in Table 6.2. 
6.4.1 Standardisation of the hMPV N-FL positive and negative cell lysate. 
As cell lysate was used as the antigen for this ELISA it was important that any background 
reactivity that sera may have had against cellular proteins was taken in to account. 
Therefore both N-FL Positive and Negative cell lysates were used. The OD450 value 
generated from the N-FL negative cell lysate was subtracted from that of the positive to 
give the corrected OD450 value. However, to do this accurately, the amount of protein 
used in the N-FL positive and negative cell lysate was standardised such that the amount of 
total protein for the negative cell lysate was the same as the amount of total protein used 
for the N-FL positive cell lysate. The starting material was initially standardised by a cell 
equivalence of 15x 1 06 cells/ml in the lysate. A total protein assay based on the Bradford 
protein assay method was used to measure the total protein, and the negative cell lysate 
diluted to give the same total protein content as the positive cell lysate (Figure 6.1). 
This data also shows that there is a total protein concentration of 0.8mg/ml of the cell 
lysate preparation. An attempt was made to determine the % of N-FL in the total cell 
lysate using coomassie stained protein gel, however due to the number of cellular proteins 
present the N-FL protein band could not be distinguished and therefore could not be 
quantitated. 
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BSA Standard protein concentration (MglMl) 
o 0.1 0 .2 0 .3 0 .4 0.5 0.6 0.7 0.8 0.9 1 
2 0.8 
.... 
8 I. 0.6 
! 
J 
CC 0.4 
0.2 
1:2048 1:1024 1:512 1:256 1:128 1:64 1:32 1 :16 1:8 1:4 1:2 
Antigen Dilution 
• BSA ~ NP Negative Cell Lysate - NP Positive Cell Lysate - Linear (BSA ) 
Figure 6.1: Total protein assay for the standardisation of the hMPV N positive and negative cell 
lysate. The Average OD720 values of the N-FL positive and negative SF9 cell lysate material in a 
2-fold dilution series plotted against a standard BSA curve with a known amount of total protein. 
The error bars indicate +/- 1 standard deviation. 
6.4.2 The standard ELISA conditions used as the basis for developing the hMPV N 
ELISA: 
96 well U bottom plates were coated overnight at 4°C with 100JlI of hMPV N-FL positive 
or negative cell lysate diluted 1: 100 in 10mM PBS pH7 to give approximately 0.8 Jlg of 
total protein/well. Plates were washed 4 times with 0.05% PBS Tween20 and incubated at 
3 fc shaking at 600 rpm for 2 hours with 100JlI of blocking reagent. Plates were washed 
and incubated as before for 1 hour with 100JlI of primary antibody diluted 1: 1 00 in 5% 
Milk in 0.05% PBS Tween20. Plates were again washed and incubated with 100JlI of 
secondary HRP conjugated antibody diluted 1 :2500 in 5% Milk in 0.05%PBST. Plates 
were washed for a final time and incubated in the dark with 100JlI of TMB substrate for 5 
minutes. The reaction was stopped with 100JlI of 0.5M HCL. The absorbance at 450nm 
(reference 670nm) was measured using a 96 well plate reader. The negative OD value was 
subtracted from the N positive CL value to give the corrected OD 
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Table 6.2: Summary of optimised conditions used for the hMPV N ELISA 
Condition 
Blocking Reagent 
Coating Buffer 
Dilution of Antigen for coating 
Ab diluent 
Primary Ab dilution 
Secondary Ab dilution 
Options 
5% milk in PBS 
20mM Tris-HCI pH 9 
1:200 
5% milk in 0.1 % PBS - Tween 20 
1:100 
1 :1000 
6.4.3 Determination of the optimal Blocking reagent 
To determine the optimal blocking reagent control sera were tested against antigen coated! 
uncoated plates blocked with either 1 % BSA or 5% Milk in 10mM PBS pH7 (Figure 6.2). 
Results show the corrected OD450 values for each of the sera. When 1 % BSA was used 
both positive control sera gave high OD readings in both antigen coated and uncoated 
plates. The addition of 1 % BSA in the primary antibody diluent eliminated this, although 
not entirely, indicating the sera are reactive against BSA. 
When 5% milk was used it gave good differentiation for both positive control sera between 
the antigen coated and uncoated plates, with no background binding in the uncoated plate. 
5% milk in 10mM PBS pH7 was therefore chosen as a blocking reagent for this ELISA. 
".5 
" 
3.5 
3 
0 
10 2.5 • Q 
0 
• aI 2 
• ~
• 1.5 > C 
1 
0.5 
0 
~.5 
\.. 
With Ag WithoutAg 
j 
'V 
Rabbit anti hMPV total 
1% BSA 
With Ag Without Ag 
'--~---- ---_/ 
- V 
Rabbit anti hMPV N 
Rabbit Sera 
. 1 % BSA with 1 % BSA in Diluent 
With Ag 
v 
Without Ag 
..I 
Negative Rabbit 
C5%Milk 
Figure 6.2: Blocking reagent optimisation. The corrected average OD450 values for Rabbit 0.-
hMPv Total, Rabbit o.-bMPV N-FL and negative Rabbit sera at 1: 100 against Ag coated! uncoated 
plates with 1 % BSA, or 5%milk as a blocking reagent. 
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6.4.4 Coating Buffer 
To determine the optimal coating buffer, plates were set up as described above with 20mM 
Tris-HCI pH 9, 10mM PBS pH7, or 10mM carbonate buffer pH9.6 as the coating buffer. 
Five % milk in PBS was used as the blocking reagent. A 10 fold dilution series of Rabbit 
a-bMPV Total, Rabbit a-hMPV N-FL, and negative Rabbit sera were tested (Figure 6.3). 
TIN ratios were calculated as the ratio of the 00450 values of the test sera divided by 
negative serum. 
The results show that Tris- HCL at pH9 gave the highest TIN ratios for the Rabbit a-
hMPV N-FL and Rabbit a-hMPV Total serum indicating the biggest difference between 
them and the Negative Rabbit sera. Tris-HCL was therefore selected as the optimal coating 
buffer for this ELISA. 
600 
500 
400 
~ 300 
z j:: 
200 
100 
o 
Rabbita-NP 
1:10000 
Primary Ab and Dilution 
• Carbonate • Tris-HCL • PBS 
1:1000 
Rabbit a-hMPV 
1:10000 
Figure 6.3: Coating Buffer optimisation. Tin ratio values for Rabbit a-hMPV Total, Rabbit a-
hMPV N-FL sera in a 10 fold dilution series were tested against hMPV N-FL positive and negative 
cell lysate with Carbonate, Tris HCL or PBS coating buffers, repeated in triplicate. 
6.4.5 Antigen dilution 
To determine the optimal Ag dilution hMPV N-FL positive and negative SF9 cell ly sate s 
were diluted with Tris-HCL in a dilution series ranging from 1 :50 to 1: 800. Plates were 
blocked with 5% Milk in PBS and tested with a dilution series of the rabbit control sera. 
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Shown below are the TIN ratios for Rabbit a-hMPV Total and Rabbit a-hMPV N-FL and 
sera in a dilution series (Figure 6.4). Results show that a 1 :200 dilution of the Ag gives 
the optimal results at all Ab and Ab dilutions tested (Figure 6.4). 
1200 
1000 
800 
: 600 
t:: 
400 
200 
o 
1:500 1 :10000 
Rabbit a-hMPV Total Rabbit a-N-FL 
Primary Ab and Dilution 
[]50 . 100 0200 0400 . 600 800 
Figure 6.4: Antigen Concentration optimisation. The TIN ratios for Rabbit a-hMPV Total, 
Rabbit a-hMPV N-FL and negative Rabbit sera in a dilution series against a range of hMPV N-FL 
positive and negative cell lysate dilutions. The OD value for the negative cell lysate was subtracted 
from the positive for each replicate (each was tested in quadruplicate) to give the corrected OD 
value. The average corrected OD value was then detennined. The TIN ration was calculated by 
dividing the corrected OD value for each test sera, by the corrected OD value for the negative 
rabbit sera. 
6.4.6 Primary and secondary antibody dilution 
Optimal primary and secondary Ab dilutions of the rabbit control sera were detennined by 
testing a range of primary antibody dilutions with 1: 1 000 and 1 :2500 dilutions of the Goat 
a.-Rabbit HRP conjugated secondary antibody (according to the manufacturers suggested 
range) (Figure 6.5). Rabbit a-bMPV Total was optimal when used at 1: 10 dilution, and is 
therefore a very low titre serum. However, a 1 :50 dilution also gave an expectable 00 
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value, and clear results against purified N-FL by Western blot (Chapter 5). A 1 :50 dilution 
of rabbit a-hMPV total was therefore chosen. Rabbit a-hMPV N-FL was optimal when 
used at a 1: 1 00 dilution. The negative rabbit serum gave similar results at all dilutions 
tested and therefore also used at 1: 100. The Goat a-Rabbit HRP conjugated secondary 
antibody was optimal at a 1: 1 000 dilution for all the primary rabbit serum dilutions tested. 
3.50 
3.00 
2.50 
~ 2.00 
o 
• ~ 1.50 
~ 
1.00 
0.50 
0.00 
-0.50 
1:10000 
Rabbit a-hMPV Total Rabbit a-N-FL Negative Rabbit 
Primary Ab and Dilution 
Secondary Ab Dilution 1: 1000 • Secondary Ab Dilution 1 :2500 
Figure 6.5: Control sera dilution optimisation. The corrected average OD450 values for Rabbit 
u-hMPV Total, Rabbit a-hMPV N-FL and negative Rabbit sera in a dilution series against the 
optimal hMPV N positive and negative cell lysate dilution. The OD value for the negative cell 
lysate was subtracted from the positive for each replicate (each was tested in quadruplicate) to give 
the corrected OD value. The average corrected OD value was then determined. 
6.4.7 Human Ab reactivity in the hMPV N ELISA and establishment of a "Cut Off 
Value". 
To determine whether human sera were reactive against the baculovirus N-FL in the 
ELISA, and if so determine the optimal dilution of sera to be used for routine testing and 
high throughput screening a panel of 5 different adult sera (expected to be positive for 
hMPV N IgG) were tested in a 10 fold dilution series and detected with Rabbit a-Human 
IgG HRP conjugated antibody at 1 :5000 the manufacturers recommended dilution (Figure 
6.6). 
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0 t---~~~~~~~----------~----------~--~ 
-0.5 
o 
....... Adult1 
..... Adult5 
100 1000 10000 
Primary Ab Dilution 
- Adult 2 Adult 3 - Adult 4 
..... Negative Rabbit - Rabbit anti N-FL 
Figure 6.6: Human Ab Reactivity and Dilution Optimisation. The corrected average OD450 
values for 5 adult human sera in a lO-fold dilution series against the optimal hMPV N-FL positive 
and negative cell lysate dilution. The OD value for the negative cell lysate was subtracted from the 
positive for each replicate (each was tested in quadruplicate) to give the corrected OD value. The 
average corrected OD value was then determined. Error bars show plus 1 Standard Deviation. 
The results show the mean 0D450 values for the sera at each dilution and indicate that all 
the adult sera tested were reactive against N-FL in this ELISA. The ideal dilution to be 
chosen should fall in to the linear part of the titration curve as this provides the greatest 
sensitivity. Therefore a dilution of 1: 1 00 was chosen. This is a convenient dilution to use 
routinely as only a small amount of sample is required and it is unlikely that background 
interference will occur. It also gives a clear distinction between positive and negative 
reactive sera, as illustrated in Figure 6.7. 
In order to establish the "Cut Off" for the assay, sera which are negative for hMPV N IgG 
needed to be identified. To do this serum from children aged 0-15 years that were 
submitted to the HPA Colindale for investigation in to Influenza like illness were screened 
in the hMPV N ELISA at a 1:100 dilution (Figure 6.7A). 
Figure 6.7 A displays the mean OD450 value of the human sera against both the N-FL 
positive (Blue) and N-FL negative (Red) celllysates (Standardise total protein). The results 
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sh~~- that there·i~··~~·ry· I ittl~··b~~kgro un d bind ingafthe ser~t·o··th~-~eg~ti~~-~~il---· lysate. 
What little background reactivity that does occur, however, is accounted for by subtracting 
it from the value obtained against the Positive cell lysate as described previously to give 
the corrected OD450 value. This is shown to be important for determining the true 
reactivity of the Rabbit a-hMPV N control sera, which has a high level of background 
binding to the N negative cell lysate. The horizontal black line represents the Cut Off value 
for this ELISA. 
To determine the Cut Off value a number of low and moderately reactive sera, highlighted 
in Figure 6.7A by green and yellow arrows respectively, were also tested at a 1:75 dilution 
by Western Blot Analysis against purified N-FL (Figure 6.7B). The seven sera with the 
lowest reactivity by ELISA were also non reactive by Western Blot and were subsequently 
selected as negative controls to calculate the "Cut Off' value for the ELISA. The Cut Off 
value was set at an OD450 of 0.4, which was placed between the lowest OD450 value for 
the serum which was reactive by western blot, and the highest OD value for the sera which 
was negative by western blot (Figure 6.7). 
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Figure 6.7: Identification of human negative serum and establishment of the cut off. (A) Shows the 
mean OD 450 values of paediatric sera reactivity against the N-FL positive and N-FL negative cell lysate, 
with the established cut off for the ELISA indicated. The samples highlighted by green and yellow arrows 
indicated the hMPV N-FL ELISA negative and positive sera analysed by western blot at a 1 :75 dilution (B) 
against approximately 95ng of purified N -FL. 
To ensure that sera were truly negative at lower dilutions with respect to the established 
"Cut Off" value, the same negative sera were also tested in a dilution series starting at 1: 10 
(Figure 6.8). Results show that all the sera were negative at all the dilutions tested with the 
exception of sample 36, which was weekly positive at 1: 1 0, although at this low dilution it 
is more likely to be background interference than a genuine reaction against N-FL. 
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Primary Ab Dilution 
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Figure 6.8: Conformation of Negative Buman Serum. The corrected mean OD 450 values of paediatric 
sera in a dilution series with previously identified negative reactivity against N by ELISA at a I: 100 dilution 
and Western Blot analysis. The OD value for the negative cell lysate was subtracted from the positive for 
each replicate (each was tested in triplicate) to give the corrected OD value. The average corrected OD value 
was then determined. Error bars show plus 1 Standard Deviation. 
6.4.8 hMPV N ELISA Specificity and analysis of sero- cross reactivity 
It was important that this assay was specific for the detection of hMPV N IgG. Therefore 
to evaluate whether there was cross reactivity with antibodies against other common 
respiratory viruses, in particular hMPVs closest human relative hRSV, rabbit sera raised 
against a number of different respiratory viruses including RSV were tested in the hMPV 
N ELISA at 1: 1 00 dilution ( 
Figure 6.9A). In addition, 22 pairs of acute and convalescent serum taken from infants 
during / following a primary RSV A or B infection were also tested at 1: 1 00 in the hMPV 
NELISA ( 
Figure 6.9B). Ideally to address this question fully the change in hMPV Ab titre between 
acute and convalescent RSV serum would be investigated, unfortunately due to the limited 
availability of the serum from these often very young children this was not possible. 
Primary RSV infections were previously identified in these individuals using a 
combination ofRT-PCR and RSV neutralisation assays (Althani, 2004). 
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Ais~:apan~i~ipaired ~dult serum take~ as part-of ih~~o~m~~itYd~~ljing elde~-iy-study 
described in chapter 3 were also analysed. These paired serum were taken following ARTI 
with hMPV, RSV, influenza or unknown aetiology and analysed at 1: 1 00 (Figure 6.10 A-
D). 
As can be seen in 
Figure 6.9A all the rabbit sera tested that were raised against other common respiratory 
viruses fell below the Cut Off value for the ELISA. Furthermore 
Figure 6.9B shows there was no increase in Ab reactivity observed when 22 pairs of acute 
and convalescent paediatric sera following primary hRSV AI B infections where tested in 
the ELISA. On average there was in fact a decrease in the OD450 value in the 
convalescent serum, perhaps representing a decrease in maternal hMPV N antibody titre. 
In addition to this Figure 6.10 A-D shows the corrected mean OD450 value for the 
individual acute and convalescent serum following hMPV, RSV, influenza or other 
infection, with the average values for each cohort. The results show that all the adult sera 
were seropositive for hMPV, as expected, however, only the hMPV data set showed an 
increase in OD450 values in the convalescent serum, with RSV and influenza remaining 
the same on average. Patients with otherwise unknown aetiology show a small decrease. 
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Figure 6.9: (A) The hMPV N ELISA reactivity of rabbit sera raised against a number of related respiratory 
viruses is shown as the corrected mean OD value in light blue, with the appropriate controls in red. (B) The 
hMPV N ELISA reactivity of 22 pairs of acute and convalescent primary RSV A or B infection sera from a 
paediatric population with the appropriate controls in Red. A yellow star highlights the average acute and 
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convalescent results for RSV AI B infections. A horizontal black line indicates the 0.4 cut off. The OD value 
for the negative cell lysate was subtracted from the positive for each replicate (each was tested in triplicate) 
to give the corrected 00 value. The average corrected 00 value was then determined. Error bars show plus 1 
Standard Deviation. 
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Figure 6.10: Analysis of sero-cross reactivity of acute and convalescent adult sera following (A) 
hMPV, (B) RSV, (C) Influenza, (D) Other viral infections, diagnosed by RT-PCR on 
corresponding combined nose and throat swabs taken during the acute phase of illness. Results 
show the corrected mean OD450 values for the acute (Blue) and convalescent (Red) serum at a 
I: 100 dilution performed in triplicate. Error bars indicate + I Standard deviation. The black 
horizontal line indicates the cut off for the assay. P values calculated using a paired 2 sample 
student t-test. P::;0.05 is considered significant. 
These fmdings support those previously published showing that sero-cross reactivity does 
not exists between hMPV and other common respiratory viruses including hRSV. There 
was no significant difference between the acute and convalescent sera from patients 
infected with RSV, influenza or other viruses, but there was significant difference in the 
on values obtained between acute and convalescent sera collected from patients with 
hMPV infections. The hMPV N ELISA is therefore specific for the detection of Human 
and Rabbit a-hMPV N-FL IgG. 
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6.5 Seroprevalence in Age Stratified Sera from the UK 
The assessment of the seroprevalence of hMPV in the UK population provides important 
information as to the age of primary infection, the age groups in which hMPV is most 
abundant, and who should be targeted for any potential hMPV vaccine regimes. 
To do this a panel of age-stratified sera ranging from cord (taken at the time of delivery) to 
adult (>15 years) were tested by ELISA at a 1:100 dilution. The sera from the under 15 
year olds were submitted to the HPA Colindale for investigation into the cause of unknown 
viral or rash like illness. The adult sera used were submitted to the HP A for investigation 
of influenza like illness. 
Figure 6.11 shows the percentage of positive samples in each age group. The results show 
that at the time of birth (represented by cord sera) 1000/0 of the samples tested were 
seropositive for hMPV. By the age of 6 months the number of positive samples decreases 
dropping to approximately 200/0 between the ages of 7 - 15 months. The percentage of 
positive samples then increased gradually from 16 months onwards. By the age of 6 years 
approximately 70 % of the samples were seropositive. This reaches 100% in the adult 
group. 
These results indicate that hMPV infections occur throughout infancy, as the rate of 
seropositivity does not completely decline. As with hRSV, infections of hMPV early in 
infancy may be masked by the presence of maternal antibodies. A majority of primary 
infections, however, occur from the age of 16 months onwards with 70% of the population 
seeing an hMPV infection by the age of 6 years. This data therefore suggests that there is a 
notable difference in the acquisition of primary infection between individuals. 
Furthermore this data indicates that by adulthood 100% of individuals have had an hMPV 
infection, yet data presented in chapter 3 shows that hMPV can cause sever influenza like 
illness in adults. This supports thinking that like RSV, hMPV has the ability to effectively 
evade host immune responses. 
229 
• > 
!: 
• 0 
Q. 
• at 
• 
-c 
• u 
~ 
• D. 
Chapter 6 - hMPV Seroprevalence 
110 n = 16 n =125 
100 
90 
80 
70 n = 40 
60 
50 n = 37 
40 
30 
20 
10 
0 
CORD 0-6 months 7-9 months 10-15 months 16-36 months 37-72 months >15 years 
Age group 
Figure 6.11: Sero prevalence of hMPV from a panel of age-stratified sera analysed by hMPV 
N ELISA. The percentage of positive samples is shown for each age group with n representing the 
number of samples tested in that group. 
In addition to this 10 pairs of paediatric sere taken 12 months apart were analysed in a 2 
fold dilution series in the hMPV N ELISA starting at 1 :32. Of these 6 pairs sero-converted 
with a 2 4-fold increase in antibody titre. 2 pairs showed no change in Ab titre, while a 
further 2 showed a decrease. 
Of those 6 that showed an increase in Ab, all were over the age of 16 months at the time 
the second sample was taken. This indicates that these individuals had had a primary 
infection with hMPVat some point over that 12-month period. Of the 4 that showed no 
change or a decrease in Ab titre all but one were under the age of 16 months at the time of 
the second sample, and as yet have not had a primary hMPV infection. The one individual 
which is the exception is patient number 7 who was 24 months old at the time the second 
sample was taken and infect shows an 2 8 fold decrease in Ab titre during that period. 
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Figure 6.12: The hMPV N reciprocal Ab titre of 10 Pairs of paediatric serum taken 12 months 
apart analysed in the hMPV N ELISA in a two fold dilution series starting at 1 :32. The table below 
shows the ages of the children in months at the time the first and second serum samples were taken. 
To investigate further whether hMPV can cause severe influenza like illness in adults with 
pre-existing hMPV antibodies, acute and convalescent serum samples taken from around 
100 community dwelling elderly patients with ILl were examined in the hMPV N ELISA. 
Of these, hMPV virus was identified in 12 of the corresponding combined nose and throat 
swabs by RT-PCR as described previously. The sera were tested in a 2 fold dilution series 
starting at I :32 along with a subset of acute and convalescent sera following RSV 
infections from the same cohort as a control. Figure 6.13 shows the reciprocal antibody 
titre of the acute and convalescent sera for these 24 individuals. 
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As expected from the seroprevalence -data- abov~-a-ll patients w~re positive--for hMPV N 
IgG at the time of infection. Of the 12 patients, which tested positive for an hMPV 
infection by RT-PCR, 5 show sero-conversion to hMPV following infection with a ~ 4-
fold increase in Ab titre. A further 4 patients have a 2 fold increase in Ab titre, while, one 
remains unchanged, and one shows a 2 fold decrease. Conversely, there is no change in 
hMPV Ab titre in individuals infected with hRSV, with the exception of RSV patients 9 
and 12 in which there is a greater than 4 fold decrease in Ab titre. 
The geometric mean titres of the acute and convalescent sera are 1290 and 3873 
respectively. This indicates a 3-fold increase in antibody titre overall following an hMPV 
infection in this group of adults. P values indicate this is a significant increase. In 
comparison the geometric mean titres for acute and convalescent sera following RSV 
infection are 2050 and 1625.5 respectively which indicates a 1.2 fold decrease in Ab titre 
overall. 
These findings support the above data by demonstrating the ability of hMPV to cause ILl 
in adults with pre-existing antibodies to hMPV and indicates that infection with hMPV 
results in an increase in hMPV N antibody titre in a majority of patients. A slight decrease 
in Ab titre following an RSV infection suggests that the increase is specific for hMPV and 
again indicates that there is no sero cross reactivity between hMPV and RSV. 
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Figure 6.13: The reciprocal antibody titre determined by hMPV N ELISA are shown for 12 pairs of 
acute and convalescent adult sera following hMPV or RSV infection and the corresponding geometric 
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mea n an tibodytitr~·~·-:-p···~aiu~;-;ere· c~fculaied -~sirig a~~=saiiiple -studefit--t~test~-Pg) .o5--is-co;~idered 
significant. 
6.5.1 Preliminary hMPV N Mapping 
Further analysis of the human IgG Ab response against the hMPV N protein was 
performed against the different N fragments expressed in the recombinant baculovirus 
system, as described previously by immunofluorescence. This was done to enable 
preliminary analysis as to which regions of the hMPV N are most readily recognised by 
human Abs (Figure 6.14). 
The results show that the hMPV N fragments A-E were expressed at roughly equal levels 
when analysed by the Mouse a-6-histitine MAb positive control serum (as in roughly the 
same number of fluorescing cells). The positive human serum was, as shown previously, 
reactive against the full-length hMPV N. It was also reactive against the hMPV N 
fragments D and E, and less so against fragment C and were virtually unreative against 
fragments A and B. The negative human serum was negative against the full-length hMPV 
N and each of the N fragments. A Similar pattern of reactivity was observed in western 
blot analysis of these fragments with Rabbit a-hMPV N at 1 :250 shown also in Figure 
6.14. 
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Figure 6.14: Preliminary mappmg of human Immune responses to hMPV N by 
Immunofluorescence. SF9 cells were grow on glass cover slips and infected with 3-40 MOl of the 
various recombinant baculoviruses, to ensure equal levels of protein expression for each of the 
hMPV N fragments. At 3 days post infection cells were acetone fixed and immuno-stained with 
human sera containing a high titre ofhMPV NAb, and a paediatric N negative serum diluted 1 :2), 
both identified by the hMPV N ELISA. The bound Ab was detected with Mouse a-Human FITC 
conjugate at 1 :40. As described previously each fragment contained an N terminal 6-histadine tag, 
and therefore a Mouse a-6-histitine MAb 1 :50 was used as a positive control 
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6.6 Discussion 
Reported here is the development and validation of an ELISA for the specific detection of 
human a-hMPV N antibodies, based on the recombinant baculovirus expressed hMPV N-
FL protein. Also reported is the application of the ELISA to produce the first data on the 
seroprevalence of hMPV in the UK, and evidence of repeated hMPV infections occurring 
in adults despite the presence of pre-existing hMPV antibodies. 
The results demonstrate that the recombinant baculovirus expressed hMPV N-FL protein 
can serve not only as an immunogen for the preparation of hMPV specific antiserum, as 
described in chapter 5, but also as an abundant source of antigen for the development of 
serological assays and the measurement of human antibodies to hMPV. 
The hMPV N protein was chosen as the appropriate antigen due to the low level of amino 
acid variation observed between the N proteins of hMPV strains belonging to the A and B 
lineages. Published findings of hMPV N sequence analysis shows that there is between 
98.3 -100% amino acid homology within lineages and 94.2 -95.9% between lineages 
(Bastien et aI., 2003, van den Hoogen et aI., 2002). A high degree of sero-cross reactivity 
between the N protein of viruses belonging to both lineages has also been demonstrated 
(Hamelin & Boivin, 2005). 
To evaluate the specificity of the N ELISA, antiserum raised against a number of other 
common respiratory viruses, including hRSV was analysed. The results presented here 
indicate that there is no sero-cross reactivity between hMPV and other human respiratory 
viruses, including hRSV, supporting previously published data (Alvarez et aI., 2004, van 
den Hoogen et aI., 2001). Work presented in this thesis provides further support of these 
findings as acute and convalescent paediatric sera taken from children with primary RSV 
infections showed no increase in the 00 value of the convalescent serum in the hMPV N 
ELISA. Unfortunately, due to the limited availability of the sera it was not possible to look 
for changes to antibody titre, which would have given a more accurate indication of any 
cross-reactivity that may have existed. Analysis of the hMPV N antibody titres of acute 
and convalescent RSV adult serum, however was investigated, and in fact showed an 
overall decrease in hMPV antibody titre in the hRSV infected patients. 
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Anaiy~i~'~fa' 'pa~~i"'~f"ag~='~tiatifi~d" ~~~afr~~th~"'UK sho~~"that-hMPV---i~-a""~~~mon 
childhood pathogen with approximately 70% of children being infected by the age of 6 
years which is consistent with recent published findings (Ebihara et aI., 2003, van den 
Hoogen et aI., 2001, Wolf et aI., 2003). At the time of birth sera collected from the cord is 
a good indication of the antibody status of the infant at that time. The data presented here 
shows that 100% of the population had antibodies to hMPV at the time of birth, and this is 
likely to reflect the presence of transplacentally acquired maternal antibodies. By the age 
of 7 months only 20% of the samples tested had antibodies to hMPV, which represents a 
decline in the maternal antibody levels. The percentage of individuals positive for hMPV 
antibodies remained at just below 20% until the age of 16 months when the rate of 
positivty began to gradually increase. Similar findings were observed by Wolf et at (2003) 
who analysed sera by IF ofhMPV infected cells (Wolf et aI., 2003). 
As positivity does not completely decline these results indicate that pnmary hMPV 
infections occur throughout infancy and like hRSV, infections occurring in very young 
children may be masked by the presence of maternal antibodies (Glezen et aI., 1981, 
Ogilvie et aI., 1981). 
In a vast majority of cases primary hMPV infections occur in children who are 16 months 
or older. By the age of 6 years approximately 70% of the cohort had had an hMPV 
infection. This data supports previously published findings carried out by other groups 
using IF, and other ELISA techniques (Boivin et aI., 2002, Ebihara et aI., 2004a, Ebihara et 
aI., 2003, Falsey et aI., 2003, Hamelin & Boivin, 2005, Leung et aI., 2005, van den Hoogen 
et aI., 2001, Wolf et aI., 2003). This data indicates that there is a wide range in the age at 
which children have primary hMPV infections and acquire immunity, however, when 
compared with primary hRSV infections, primary hMPV infections appear to occur in 
slightly older children, with a majority of individuals having experienced hRSV infection 
by the age of2 years (Ebihara et aI., 2004b, Glezen et aI., 1986). 
The data also suggests that children aged between 7-16 months could be targeted for 
potential hMPV vaccines regimes, without interference from maternal antibodies (Crowe, 
2001). Whilst vaccination at this stage will not benefit the estimated 200/0 of the 
population who experience hMPV infections early during infancy, it may benefit the other 
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86%~--Howe~ei:··d~bate"· exists, as with -··hitS":· as to theefff~acyoi~-a·~a~ci~~·-foithese 
viruses due to the level of variation that exists within the G glycoprotein (chapter 4), and 
the ability of hMPV to cause repeat infections. 
Analysis of sera from adults indicates virtually all adults have detectable levels ofhMPV N 
specific antibodies, as reported elsewhere (Falsey et aI., 2003, Hamelin & Boivin, 2005). 
However, the data presented in Chapter 3 demonstrates that a substantial number of adults 
experience severe hMPV infections. Furthermore, analysis of paired sera from adults with 
severe hMPV infections in this chapter demonstrates the ability of hMPV to cause repeated 
infections despite the presence of existing hMPV antibodies and that hMPV infections 
result in an increase in antibody titre in a majority of adults. 
In a recent study conducted by Hamelin et al (2005) recombinant nUcleocapsid protein 
expressed in E.coli was used to develop an hMPV specific ELISA. Their data 
demonstrated that children had higher antibody titres than adults, and suggested that adults 
may loose their antibodies to hMPV, or that they may fall below detectable levels for their 
assay (Hamelin & Boivin, 2005). The antibody titres of children and adults were not 
directly compared in this study and it would be an interesting angle to pursue in future 
work addressing the role of immunity in hMPV reinfection. These data highlight the need 
for more extensive research to be carried out on hMPV immune evasion mechanisms, the 
analysis of strains circulating in the community, the induction and longevity of neutral ising 
antibodies to hMPV and its different proteins. 
The data presented in chapter 4 shows that the hMPV G a major surface antigen, displays a 
very high degree heterogeneity, and it is postulated that this protein plays an important role 
in immune evasion, preliminary work looking at the antigenic analysis of hMPV G to try 
and address some of the questions raised throughout this work is presented in Chapter 7 
Analysis of post infection sera for its ability to neutralise virus will also provide a lot of 
information regarding the induction of immunity. Neutralising antibody levels cannot be 
measured by ELISA and instead requires functional assays such neutralisation or plaque 
reduction assays. Establishing such assays however may be problematic given the 
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diff;c~-ltiesa~~~c·iat~·d-~ith·g~~~·i~g··hMP'Ti~"th~Tab~·iat~rY: and th~o-~gh-·~~ii~atfo-n--o·f the 
assay is required. Recently, Biacchesi et al (2005) have reported the development of a 
microtitre neutralisation assay for hMPV based on the rescue of hMPV from cDNA 
(Biacchesi et aI., 2005). This will provide a useful tool of analysing overall neutralising 
antibody responses to hMPV. The contribution of the individual surface glycoprotein's of 
hMPV to neutralisation have also been investigated through the use of chimeric viruses. 
The published data indicates that a majority of neutralising antibody is targeted towards the 
F protein (Skiadopoulos et aI., 2006). However as yet only sera from experimentally 
infected animals have been evaluated in these assays and extensive evaluation of human 
sera reactivity should be conducted. 
Preliminary data of the human Ab reactivity to different fragments of the N was also 
presented. A majority of human Ab reactivity by IF and WB appeared to be targeted 
against fragments D and E which are located at the carboxyl terminal of the N protein. This 
however is very provisional data, and further investigation by Western Blot analysis and 
ELISA and F ACS, is required, and will provide not only immunologically relative 
information but can also infer information on the structure of the N. Previous work by 
Ryan et al used MAb mapping techniques to define the regions of paramyxiovirus 
nucleocapsids important for immunogenicity and nucleocapsid assembly. They found that 
for PIV3 and Sendai virus the carboxyl terminal of the N contained a majority of the 
antigenic sites (REF), which is consistent with the preliminary findings presented here. The 
identification of immunodominant epitopes may enable further refinement of immune-
assays targeted against the N through the use of peptides. 
In summary, reported here is a simple and specific ELISA for the detection of human 
antibodies to the hMPV protein, and its application investigate the seroprevalence of 
hMPV in the UK. Although not a useful tool for diagnosis of hMPV during the acute phase 
of illness, this ELISA may be useful as a confirmatory test during outbreak situations 
through the analysis of acute and convalescent serum, or for further investigation of 
seroprevalence. 
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7.1 Introduction 
The sequence and phylogenetic analysis of the hMPV attachment glycoprotein of 
circulating strains presented in chapter 4 raises some important questions regarding the 
structure, function and immunogenicity of the protein. 
The high degree of amino acid variation suggests that G plays an important role in the 
evasion of host immune responses. The analysis of human Ab reactivity in terms of cross-
reactivity, epitope mapping, neutralizing ability, and the effect of such Ab on the sequence 
diversity of G should all be addressed. 
In order to do so however the basic reagents such as an appropriate hMPV G antigen and 
hMPV G specific antiserum are required. This chapter details the development of such 
reagents through the expression ofhMPV G in the recombinant baculovirus system. 
There have been numerous examples of the attachment glycoproteins of closely related 
viruses such as RSV and APV, as well as the surface glycoproteins of other viruses, such 
as the influenza haemagglutinin being successfully expressed in the recombinant 
baculovirus system and used for the development of immunoassays and protein 
characterisation and vaccination (Buraphacheep et aI., 1997, Crawford et aI., 1999, Sugiura 
et aI., 2001). The major disadvantage of using the baculovirus system for a protein that is 
expected to be heavily glycosylated (Chapter 4) is that the glycosylation provided in the 
insect cells is different in its extent and nature compared to that in mammalian cells (Jarvis, 
1997). Work published by Sullender and Britt showed that the RSV attachment 
glycoprotein expressed in the baculovirus system had reduced levels of glycosylation when 
compared to RSV G expressed in mammalian cells. Despite this, the localisation and 
antigenicity of the baculovirus expressed protein was maintained reacting against both 
monoclonal antibodies raised against native G, and human polyclonal serum. Furthermore, 
they demonstrated that the inoculation of cotton rats with the recombinant G protein 
conferred protection against wild type RSV challenge (Sullender & Britt, 1996). These 
data therefore support the use of the baculovirus system for the immune-analysis of the 
hMPV attachment glycoprotein. 
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7.2 Aims 
• Expression of the hMPV G protein in the recombinant baculovirus system as an 
alternative to G purified from hMPV infected cells. 
• Generate high titre hMPV G specific polyclonal antiserum. 
• To evaluate the potential use of the G antigen and antiserum as tools for the 
assessment of serological response. 
• Investigation in to human antibody reactivity against the hMPV G protein, as 
provisional data for the investigation of the antigenic properties of the G protein. 
What is the prevalence of hMPV G antibody in the UK population? Are antibodies 
to G cross-reactive? What evidence is there supporting positive selection of 
mutations occurring in this protein? Is there evidence that glycosylation interferes 
with antibody recognition of this protein? 
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7.3 Recombinant Baculovirus System 
Two recombinant baculoviruses expressing hMPV G were constructed, the fi rst expressing 
the full length attachment glycoprotein (G-FL) containing a 6 histidine tag at the amino 
terminal, and the second, a secreted form of hMPV fused to the Fc fragment of human IgG 
containing a 6 histidine tag at the carboxyl terminal of the fusion protein (G(s)-Fc) (Figure 
7.2). 
For expressIOn of G-FL the commercially available plasmid; pTriEx-2 Neo; used 
previously for the hMPV N protein expression work, was used as the baculov irus transfer 
vector and mammalian expression system. 
For expression of G(s)-Fc a second transfer vector was used. This vector is based on the 
pTriEx vector system with the addition of the human IgG Fc fusion protein. The use of the 
Fc fragment as a fusion protein has been used previously and shown to aid in the 
expression of secreted proteins by improving cellular processing and increasing the 
solubility of the protein (Schutze et ai. , 2005, Sugiura, 2003) 
G-FL and G(s) were amplified by PCR from the same isolate used in the hMPV N work 
presented in chapters 5 and 6, using primers containing the appropriate restriction sites 
(Table 7.2 and Figure 7.1). PCR products were cloned in to the TOPO cloning vector, and 
subsequently sub-cloned into the appropriate transfer vector (Figure 7.2). 
Based on the expression of other membrane proteins in the baculovirus system, it was 
expected that G-FL would be expressed on the surface of the cell , and G(s)-Fc is secreted 
in to the cell culture medium. 
Table 7.1 Primers used for the amplification of the hMPV G gene and G(s) fragment for 
cloning into the pTriEX vector. 
Primer 
hMPVG BamHIF 
hMPV G BamH 1 StopR 
hMPVG (S) BacF 
hMPVG (S) BacR 
Position* Sense 
6247-6267 + 
6956-6937 -
6406-6421 + 
6956-6937 -
Sequence 5'-3 ' 
GGATCCTATGGAGGTGAAAGTGGAGAA 
GGATCCTGTTAACTAGTTTGGTTGTATG 
GGCCATTATGGCCATACAATGCAAGAAA 
AC 
GGCCGAGGCGGCCACTAGTTTGGTTGT 
ATGTTGTTGA 
Footnotes: (*) primer positions according to reference strain N LOO-I . 
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Table 7.2: Primers, restriction enzymes, and vectors used for the construction of pTriEx 
mammalian expression and baculovirus transfer vectors. 
Gene I Gene Fragment 
Forward Primer 
Reverse Primer 
Expected Size (bp) 
Restriction Sites 
Expression Vector 
Recombinant Baculovirus 
Expected Recombinant Protein Size 
(KDa) 
G-FL 
hMPVGBamH IF 
hMPVGBamH} STOPR 
726 
BamHi 
pTriEx-2 Neo 
Baeulovirus - hMPV G-FL 
32.8* 
G (S) 
hMPVG(S)BACF 
HMPVG(S)BACR 
562 
Sfi} 
PTriEx- IgG Fe 
Baeulovirus - hMPV G 
(s)-Fe 
50.6* 
Footnotes: (*) The molecular weight of the proteins was estimated for the non-glycosylated 
species from amino acid sequences using EditSeq, DNAStar Lasergene software. For primer 
sequences see Table 7.1. 
6247* 695R* 
~~ ____________________ WMP ___ V_G_G_e_n_e_(O_RF _ )__________________ ~~ 
• 
... 
hMPVGBamHIF 
(Position 6247*) 
hMPV G-FL 
(711 bp) 
• 
• 
hMPVG(s)BacF 
(position 6396*) 
hMPV G(s)-Fc 
(562bp) 
• 
• 
hMPVGBamHR 
(position 6958*) 
• 
• 
hMPVG(s)BacR 
(position 6958*) 
Figure 7.1: Schematic representation of the amplified hMPV G regions and primer positions. 
The blue box represents the hMPV G gene ORF. The black line represents G-FL and the green line 
O(s). The size of each G region amplified in indicated in base pairs (bp) below the coloured line. 
Primers are represented by red arrows with the name of the primer below and the nucleotide 
starting position for the primer. (*) starting primer positions according to reference strain NLOO-I. 
For primer sequences see Table 7.1. 
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A 
T7 Terminator 
Rabbit ~ Globulin Terminator 
B 
ori 
pTriEX- 2 Neo hMPV 
G-FL (8000bp) 
neo 
pTriEX- hMPV G (S)-Fc 
(8000bp) 
........ UtH "". I -.Ln'\.}Jll;;::>:>JUlI U 1 I UYlr Y U 
CMV ie Enhancer & chicke~ actin 
Promoter 
T7 Promoter/acoperon 
p10 Promoter 
6x Histidine Tag 
hMPV Genel Gene Fragment 
CMV ie Enhancer & chickeJ\ actin 
Promoter 
T7 Promoter/acoperon 
p10 Promoter 
hMPV Genel Gene Fragment 
Human IgG Fe Fusion Protein 
Rabbit~ Globulin Terminator 6x Histidine Tag 
Figure 7.2: Schematic representation of the hMPV pTriEx G-FL and G(s)-Fc constructs used 
as transfer vectors for generating the recombinant baculoviruses. (A) hMPV G-FL, and (B) 
hMPV G(s)-Fc. Each construct contains a CMV ie enhancer and chicken p-actin promoter for 
expression in mammalian systems (purple), a T7 promoter for bacterial expression (pale green), 
and the plO promoter for recombinant baculovirus expression (pale blue). 6x histidine tags (Black) 
are available in both vectors these are located just upstream of the multiple cloning site for G-FL 
and immediately down stream of the Fc fusion protein (blue) in the G(s) construct. The position of 
the inserted hMPV gene is shown in red. Both vectors contain the Rabbit p-globulin (green) and n 
terminator (dark blue). The G-FL construct also contains the neomycin resistance gene for the 
selection of stable mammalian cell lines which operates under the control of the EMCV -derived 
Cap-Independent Translation Enhancer (CITE). 
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i;bi~ ·~i.3: Det~ii~' ~f"the hMPV ~irus strai~~ -~sed as antigen in this ch~pter: 
Antigen 
G-FL and 
G(s)-Fc 
hMPY infected 
cells 
Source 
4-year-old male diagnosed with bronchiolitis 
and upper respiratory tract infection in 2002, 
collected as part of the investigation in to the 
cause of illness in children hospitalised with 
ARTI in the UK isolated in LLC-MK2 cells. 
Northern Ireland HPA (2004) investigation in 
to the cause of respiratory illness first isolated 
in RMK cells. Further propagated at Colindale 
HPA in LLC-MK2 cells by Dr Alison 
Bermingham. 
Lineage 
Al (UK324-02) * 
Al (NI-04) 
B 1 (NI2-04) 
Footnotes: (*) see Chapter 4 for positioning in phylogenetic tree and alignment described as hMPY 
G clone. 
Table 7.4: Details of the hMPV specific rabbit serum used in this chapter. 
Antiserum 
Rabbit a-
hMPY Total 
Rabbit a-
hMPY G(s)-Fc 
Source of 
antiserum 
Colindale HP A 
raised against an 
hMPV infected 
RMK cells lysate 
isolated by Dr 
Joanne Stockton. 
This study, raised 
against 
recombinant 
baculovirus 
expressed hMPY 
G(s)-Fc High 5 
cell culture 
supernatant 
Source of Antigen Lineage 
From child < 5 years A (UK241-0 1) 
collected as part of the 
investigation in to the cause 
of illness in children 
hospitalised with ARTI in the 
UK. 
Recombinant baculovirus Al (UK324-02) * 
expressed hMPY G(s)-Fc 
generated in this study. 
See table 7.3 for further 
detail. 
Footnotes: (*) see Chapter 4 for positioning in phylogenetic tree and alignment described as hMPY 
G clone. 
Table 7.5: Details of the human serum used in this chapter. 
Human serum 
Pooled human sera 
Positive human 
serum 
Negative human 
serum 
Source 
Colindale HPA (2001) pooled adult sera negative for reactivity 
against influenza antigens submitted to the HPA for serological 
investigation of respiratory illness. 
Colindale HPA (2001-2004) adult sera submitted to the HPA for 
serological investigation of influenza. 
Colindale HPA. Neonatal paediatric sera collected as part of a 
longitudinal cohort study of RSY infection in childhood (Althani , 
2004). 
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7.4 Recombinant Baculovirus Expression of hMPV G-FL 
The recombinant baculovirus expressing the full-length hMPV attachment glycoprotein 
(G-FL) was generated as described previously (Chapter 5). 
To monitor the expressIOn of hMPV G-FL immunofluorescence (IF) analysis was 
performed on SF9 cells grown on glass cover slips and infected with approximately 10 _ 
20 MOl of the recombinant baculovirus . Cells were fixed with acetone and the expressed 
protein was detected using a mouse a-6 histidine MAb ( 1: 50) followed by rabbit u - mouse 
IgG FITC conjugate (1 :40) and visualised by fluorescence microscopy (Figure 7.3). The 
results show expression of the hMPV G-FL protein in the infected cells. The level of 
expression was considerably greater in cells infected with 20 MOl of virus compared to 
those infected with an MOl of 10. 
A: Uninfected B: 10 MOl c: 20 MOl 
Figure 7.3: Immunofluorescence analysis of recombinant baculovirus hMPV G-FL. (A) 
un infected, (B) infected at 10 MOl, or (C) infected at 30 MOl of virus. Detected with mouse a -6-
histidine MAb (1 :50) followed by rabbit a-Mouse IgG FITC conjugate (1 :40. ) 
Initial analysis of the clarified cell lysate by western blot using the mouse u -6-histidine 
MAb failed to detect any protein. Therefore analysis of the different cell lysate fractions 
was carried out. SF9 cells were inoculated with recombinant baculovirus hMPV G-FL at 
an MOl of 5, 10, 20 or 40 in a shaker culture. Cells were harvested 3 days pi and lysed 
using insect pop culture reagent (Novagen) . The cleared cell lysate, and the cell debris was 
analysed by western blot. In accordance with the IF results G-FL was detected in cells 
infec ted with 10 or 20 MOl of virus (Figure 7.4) prote in expression was not detected at an 
MOl of 5 or 40 (data not shown). 
Lanes 1 and 2 conta in the eelilysa te supernatant, and were negati ve for G-FL. Lanes 3 and 
4 contain the ce ll debris, and are posi tive for G-FL, indicating the lysis or so lubi I i ation 
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~~~·· i~~·~ffi~·i~~t· t~· ~~i~~~~ ·· th~ · p~;t~i-~ f~~~th~~~II~ I a~~~~bran e~a t~r i~l~-Th i s result 
suggests that the expressed protein is targeted correctly within the cell to either the plasma 
membrane or within the endoplasmic reticulum or Golgi apparatus for which different 
detergent may be required for lysis. Two bands are vis ible in both lanes 3 and 4. The low 
molecular weight band (LMW) represents the correct size fo r the un-glycosylated species 
and the high molecular weight band (HMW) most likely representing various glycosylated 
species; a pattern typically observed for hMPV and RSV attachment glycoproteins, 
although the presence of glycosylation was not investigated in this work. 
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Figure 7.4: Western Blot analysis of different cell lysate fractions of SF9 cells infected with 
Baculovirus hMPV G-FL at different MOl. Mouse a-6 histidine MAb I : I 000 and Rabbit a-
Mouse HRP conjugate 1:2500. (1) hMPV G-FL cell lysate supernatant Mal 20, (2) hMPY G-FL 
cell lysate supernatant MIa 10, (3) hMPV G-FL cell debris Mal 20, (4) hMPV G-FL cell debris 
Mal 10, (5) Uninfected cell lysate supernatant, (6) Uninfected cell debris , (7) Purified hMPY N 
Positive Control. 
To improve the solubilisation of membrane proteins and determine the optimal day for 
harvesting the expressed G-FL protein, a time course assay was performed . SF9 cells were 
infected with 20 MOl of recombinant virus and samples collected every 24 hours. Cells 
were collected by centrifugation; freeze thawed and lysed using a number of different non-
ionic detergents, including 1 % NP-40, 0.1 % Triton X-100, and 2% Tween-20. The lysed 
cell preparations were clarified by centri fugation and analysed by Western blot analysis 
(Figure 7.5) . 
It was important that non-ionic detergents were used in order to prevent denaturation of the 
protein which would subsequently be used for antibody production and immunoanalys is. 
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Figure 7.5: Western Blot analysis of cell lysate supernatant taken from recombinant 
baculovirus hMPV G-FL infected SF9 cells at an MOl of 20 over a time course of 24, 48, 72 
and 96 hours post infection. (N) Recombinant baculovirus expressed hMPY N-FL used as 
Western blot positive control antigen. (A) Cells lysed with 1 % NP-40 and (B) cells lysed with 
0.1 %1\ Triton X 100. (C) Cells lysed with 2% Tween 20. Detected using a mouse a-6-histidine 
MAb followed by rabbit a-mouse IgG HRP conjugate. 
Results show that lysis using 20/0 Tween-20 released only very small quantities of G-FL 
from the membranous fractions, while cells lysed with 1 % NP40 or 0.1 % Triton X-IOO 
were successful at 24 and 48 hours pi . NP-40 yielded the largest amount of protein (Figure 
7.5 A) The species detected resulted in a smeared appearance that differed in size between 
the 2 time points and likely represents different levels of posttranslational modification 
(e.g. glycosylation). Compared with Figure 7.4 in which the membranous fraction was 
analysed there was greater heterogeneity in the size of the proteins analysed in Figure 
7.5.1n particular HMW species were more viable indicating species with a higher degree of 
O-linked glycosylation were present in this antigen preparation. 
In summary the hMPY full-length attachment glycoprotein was expressed at detectable 
levels in SF9 cells when a high MOl of recombinant hMPY G-FL baculovirus was used. 
The protein however was only separated efficiently from cellular material with NP40 
resulting in a protein preparation with a high degree of molecular weight heterogeneity. 
Due to the high MOl required in order to achieve detectable levels of baculovirus 
expressed G-FL, virus purification using a sucrose gradient was attempted but was 
unsuccessful (data not shown). The quantities of the expressed protein required for protein 
purification, and the generation of G-FL specific polyclonal antiserum based on purified 
G-FL was therefore considered unfeasib le. 
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7.5 Recombinant baculovirus expression of hMPV G(s) 
As discussed in chapter 4, the G protein of RSV is produced not only in the full length 
transmembrane form, but also in a secreted form in which the cytoplasmic and 
transmembrane regions of the protein are deleted. This arises due to initiation of translation 
at a second methionine codon in the same ORF, situated immediately after the 
transmembrane region. A second in-frame methionine codon is also present at a similar 
location in the G gene of hMPV. This suggests that a secreted version of hMPV G may 
also be produced during hMPV viral infection, although this is yet to be investigated. 
However, expression of a secreted version of G may overcome the problems associated 
with producing the large enough quantities of G-FL for antibody production. 
The secreted version of the attachment glycoprotein (G(s)) was generated by amplifying 
the region from the second methionine codon to the stop codon at the end of the ORF, 
therefore excluding the cytoplasmic and transmembrane regions of the protein (Figure 7.1). 
This protein was fused at the carboxyl terminal of the protein to the Fc fragment of human 
IgG to increase solubility and help maintain the correct folding and processing of the 
truncated G protein. 
Although work presented in chapter 4 suggests that the carboxyl terminal of G is unlikely 
to play an important role in the structure or function of the molecule, this has not been 
investigated further and mapping of the major epitopes of this protein is still yet to be 
reported. DNAST AR software was therefore used to assess how the presence of the Fc 
fusion protein might affect the secondary structure ofG (Figure 7.6). 
Results show that the IgG-Fc fusion protein appears to have little effect on the predicted 
secondary structure, hydrophilicity or surface probability profiles of the G region when 
compared to that of the G-FL over a range of different window sizes (5-20 amino acids). A 
recombinant baculovirus expressing a secreted version of the hMPV attachment 
glycoprotein with the IgG-Fc fusion protein was therefore generated. 
249 
--, 
\.-.lla.plt;r I -expressIOn 01 hM.PY l.j 
A 
G-FL 
r 
G(s) 
hMPV G(s)- Fe 
I 
Tm-Region 
[ I 
Cytoplasmc-Region IgG-Fe-Region fi y Hi<;ticiinp I 
~~------I------~ 
B A' • 
s! 
T! I I 1 ID-+-IIO 1 II I I o 1 III 1 1 I: 1:11 I I 1 1 I D-IJ--O I 1 lo--t--tO--1J-H 
c 
~:] 
:] 
c 
A • 
B 
T 
C 
.:] 
.... 5 
:] 
Figure 7.6: Secondary structure protein prediction of the bMPV G (window size of 9 amino 
acids). (A) Schematic showing the localisation of the IgG-Fc fusion protein and his Tag, (B) 
Secondary structure prediction of the truncated G protein with the IgG-Fc fusion protein and 6-
histidine tag. (C) Secondary structure prediction of the full length G without the fusion protein and 
tag. a, ~, Turn and coil regions were predicted using the Garnier-Robson method (Gamier et aI., 
1978). Hydrophilicity plot was predicted using the Hydropathy - Kyte-Doolittle method (Kyte & 
Doolittle, 1982), and the Surface probability predicted using the Emini method (Emini et aI. , 1985). 
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7.10.1 hMPV G(s)-Fc baculovirus time course assay 
Figure 7.7 shows a time course assay of hMPY G(s)-Fc expressed in High 5 cells. High 5 
cells are an insect cell line with a greater capacity for expressing secreted proteins 
compared to that of SF9 or SF21 insect cells. 
As with G-FL there were 2 major bands. The low molecular weight (LMW) band is the 
predicted size of the non-glycosylated hMPY G(s)-Fc fusion protein while the HMW band 
may represent an hMPY G(s)-FC glycosylated species although this has not been 
determined in this study. LMW species may also represent break down products of the 
hMPY G(s)-Fc protein. Results show that the protein was expressed at 24hpi and consisted 
of predominantly HMW species. At 48 to 96 hours pi equivalent amounts of the HMW and 
LMW species were produced. At 96 hours pi the size of the HMW species was slightly 
reduced, possibly indicating a reduction in the rate of posttranslational mod ifications. The 
amount of the LMW species increased over the 4 days. The optimal time for harvesting the 
expressed protein was therefore 72 hours pi . 
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Figure 7.7: Time course assay of hMPV G(s)-Fc expression. Western Blot analysis of hMPY 
G(s) supernatant taken from HIGH 5 cells :(A) uninfected (B) infected with 5 MOl of the 
recombinant baculovirus hMPY G(s)- Fc every 24 hours over 5 days. The expressed protein was 
detected using Rabbit a-Human IgG-Fc 1: 1 000, and Goat a -Rabbit IgG HRP conjugate 1:2500 
followed by EeL reagent and autoradiography. 
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7.10.2 Purification of G(s)-Fc 
Purification of hMPV G(s)-Fc could be achieved through the use of protein A affmity 
chromatography making use of the inherent properties of the Fc fusion protein, or via the 
Ni NTA affmity chromatography system used previously for the purification of N in 
Chapter 6. To assess the binding capacity of hMPV G(s)-Fc to protein A, 96 well plates 
were coated with supernatant from high 5 cells infected or uninfected with recombinant 
baculovirus hMPV G(s)-Fc. A 5 fold dilution series of protein A HRP conjugate was 
applied followed by TMB substrate. The OD was read at 450nm (Figure 7.8). 
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Figure 7.8: Analysis of bMPV G(s)-Fc binding to protein A. A 96 well plate was coated with 
100fli of recombinant Baculovirus hMPV G(s)-Fc High 5 infected / uninfected supernatant diluted 
I: 100 with IOmM PBS and incubated at 37°C for 30 minutes. Plates were blocked with 5% milk 
for I hour at 37°C. HRP conjugated protein A was applied in a 5 fold dilution series and detected 
with TMB substrate and the OD450 reading taken, and the negative 00 value subtracted from the 
positive to give the corrected OD value 
The results clearly show the binding of the hMPV G(s)-Fc protein to the protein A HRP 
conjugate. This indicates that the Fc fusion protein has maintained its functionality despite 
the presence of the hMPV G(s) protein. A protein A affinity chromatography system 
(hitrap Column) was therefore utilised for purification of the hMPV G(s) -Fc protein 
(Figure 7.9). 
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p~·i~·~····t~ purific~ti~~ ··ih·~ - High ·5 ··~~il culture supe~n~t~ni co~t~i~in-g th~ - h-MPV G(s)-Fc 
protein was applied to a buffer exchange column to exchange the cell supernatant for the 
20mM sodium phosphate binding buffer (pH7), recommended by the manufacturer and 
applied to the Protein A column. The column was washed with binding buffer and eluted 
using 0.1 M citric acid pH3. The different fractions were collected and analysed by western 
blot analysis and detected with Rabbit a-human IgG (1: 1000) followed by Goat a -rabbit 
IgG HRP conjugate. 
The results show that no protein was lost in the buffer exchange process (lane 2). However 
there was a large amount ofG(s)-Fc present in the protein A column flow through (lane 4), 
and in the first wash fraction (lane 5). There was no protein in the following washes or 
elution fractions (lanes 6-10) suggesting that the protein failed to bind to the protein A 
column. Analysis of the column flow through revealed that the pH of the protein in the 
binding buffer was correct and not affected in the buffer exchange process. 
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Figure 7.9: Analysis of hMPV G(s)-Fc protein A purification fractions. (A) Western blot 
analysis with rabbit a-human IgG 1: 1 000 followed by goat a-rabbit IgG HRP conjugate 1:2500 
detected with ECL reagent and auto radiography. hMPV G(s)-Fc high 5 cell culture supernatant 
was underwent a buffer exchange with 20mM sodium phosphate binding buffer (pH7) and applied 
to the Protein A column, washed with binding buffer and eluted using 0.1 M citric acid pH3 . 
Fractions were collected. (M) Marker, (l) hMPV G(s )-Fc cell supernatant, (2) Column exchange 
flow through, (3) hMPY G(s)-Fc in binding buffer, (4) protein A high trap column flow through, 
(5) wash I, (6) wash 2, (7) wash 3, (8) Elution I, (9) Elution 2, (10) Elution 3. 
Purification of hMPY G(s)-Fc using the Ni-NTA purification system also failed to bind 
protein efficiently and only small quantities of protein were eluted (data not shown). 
Following a number of failed attempts at purifYing the protein by protein A or Ni-NTA 
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affinity chromatography-under varied conditions, --"-ii"- wa;-de"cided -that hMPV G(s)-Fc 
antiserum would be generated using the crude cell culture supernatant. 
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7.6 Generation and Evaluation of hMPV Specific Antiserum. 
HMPV specific G(S)-Fc antiserum was raised against the recombinant G(s)-Fc protein and 
evaluated for its use as potential research or diagnostic reagent (Table 7.6). Antiserum 
against the hMPV G-FL protein was not generated, as the protein could not be produced in 
large enough quantities. The rabbit a-hMPV total antiserum discussed in chapter 5 was 
also evaluated for its reactivity against the recombinant baculovirus expressed G proteins. 
Both sera were analysed by ELISA, Western Blot, and Immunofluorescence to evaluate 
their use as potential diagnostic or research reagents. 
Table 7.6: hMPV Specific antiserum raised and evaluated in this study. 
Antiserum 
Rabbit a-hMPV 
G (s)-Fc 
-0 
....... 
;:l 
0 
'"0 
"'"t (") 
~ c 
ttl ~ ..... 
(l) 0 (l) ::s 0- Vl 
Dav 0 
a-hMPV • • G(s) 
Immunogen 
Baculovirus expressed hMPV G(s)-Fc High 5 supernatant 
100ng of total protein from the cell supernatant with 10mM Purified LPS 0.5ml 
incomplete Freund's adjuvant. 4 x 0.25ml of the inoculum was injected at 4 
points along the dorsal of the rabbit. 100ng of total protein from the cell 
supernatant with 10mM LPS and saline was given as a second and third 
immunogen on days 21 and 40 into the hind leg muscle. Test bleeds taken days 
35 and 55. Terminal Bleed taken day 60. 
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Figure 7.10: Schedule of rabbit inoculations used to generate hMPV specific antiserum. 
hMPV G(s) Specific polyclonal serum was raised against lOOng ofhMPV G(s) Supernatant mixed 
with purified lipopolysaccharide (LPS- prepared from Escherichia coli 0157 [kindly supplied by Dr 
Henrik Chart at the HPA ColindaleD and incomplete Freund's adjuvant to form an emulsion. Red: 
rabbit bleeds, Green: inoculation. 
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7.10.1 Analysis of hMPV Specific Sera against recombinant hMPV proteins by 
ELISA 
The rabbit a-hMPV G(s)-Fc and rabbit a- hMPV total serum were tested by ELISA in a 
dilution series against the baculovirus expressed hMPV G (S)-Fc protein using culture 
supernatant from recombinant baculovirus hMPV G(s)-Fc infected and uninfected high 5 
cells (Figure 7.11). 
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Figure 7.11: Analysis of hMPV specific rabbit sera by indirect ELISA hMPV G(s)-Fc. Error bars show 
+/- 1 Standard deviation. 96 well plates were coated with approximately 1 Jlg of Rabbit a-human IgG 
antibody and blocked with 5% milk. HMPV G (S)-Fc positive and negative supernatant (0.8Jlg of total 
protein) diluted 1:100 with lOmM PBS and incubated at 3'fC for 30 minutes, and plates washed with 0.1% 
Tween 20 in PBS. The hMPV specific Rabbit sera were tested in a dilution series from I : ) 0 to 1 :5000 
followed by Goat a-Rabbit IgO HRP conjugate 1:2500 and detected using TMB substrate. The absorbance 
was measured at 420nm reference 620nm, and the uninfected cell culture supernatant 00 value was 
subtracted from that of the infected to give the corrected 00 values. 
Results showed that the rabbit a-hMPV G(s)-Fc reacted strongly against the G(s)-Fc 
protein when used between 1 :20 and 1: 1000 dilutions. The rabbit a -hMPY total antiserum 
however did not react at all, even at the lowest dilutions tested. The negative rabbit serum 
was negative at all dilutions tested. 
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7.10.2 Western blot analysis of hMPV specific antiserum reactivity against 
recombinant baculovirus expressed hMPV G (S)-Fc. 
Rabbit a-hMPV G(s)-Fc and rabbit a- hMPV total at 1 :50 and 1: 1 00 dilutions 
respectively) were tested against baculovirus expressed hMPV G(s)-Fc antigen by Western 
blot, as shown in Figure 7.12. 
Results show that the Rabbit (X- hMPV G(s)-Fc antiserum recognises both the high and low 
molecular weight species at 70 and 50Kda respectively which corresponds with the MW 
species detected with the positive control antiserum; rabbit a-Human IgG-Fc (Figure 
7.110). The rabbit a-hMPV total antiserum also reacted against both the HMW and LMW 
species, although at much lower levels, and after a longer exposure. The molecular weight 
species recognised by each serum is summarised in Table 7.7. 
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Figure 7.12: Western Blot analysis of hMPV specific Rabbit serum against. (M) Marker, (+) 
Infected hMPY G(s)-Fc High 5 supernatant, (-) uninfected High 5 Supernatant 2dpi. (A) negat ive 
rabbit sera (l :50), (8) rabbit a- hMPY total (1:50), (C) Rabbit a -hMPY G(s)-Fc (1: 1 00), (D) 
positive control serum against Fc fusion protein : rabbit a-Human IgG-Fc (l: 1000). Primary 
antibody was detected with goat a-rabbit JgG HRP conjugate at 1 :2500 followed by ECL and 
autoradiography. 
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Table 7.7: Summary of molecular weight profile of the major species recognised by rabbit serum 
by Western Blot Analysis (KDa) .. 
Antigen Rabbit a- Rabbit a- Rabbit a-G(s)- Negative 
human IgG hMPV Total Fe Rabbit 
HMPV G-Fe 50 and 70 KDa 50 and 70 28, 50, 60 and Negati ve 
Supernatant (doublet) KDa 70 KDa 
Uninfeeted Negative Negative 80KDa Negative 
supernatant 
7.10.3 Analysis of hMPV Specific Sera by IF against recombinant hMPV G-FL 
and hMPV G(s)-Fc. 
The rabbit sera was also tested against the recombinant baculovirus expressed hMPY 
proteins G-FL and G(s)-Fc by immunofluorescence of recombinant baculovirus infected/ 
uninfected SF9 cells grown on cover slips (Figure 7.13). 
Results show a good level of recombinant protein expression for both G-FL and G(s)-Fc 
using the Mouse a-6- Histidine MAb (Figure 7.13A). Both Rabbit a-hMPY G(s)-Fc 
(Figure 7.13C and Rabbit a-hMPV Total (Figure 7.13B) react specifically against both the 
secreted and full-length G proteins. Rabbit a-hMPY G(s)-Fc did however show some level 
of cross reactivity with uninfected SF9 cells, was removed by cross absorption . 
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Figure 7.13: Indirect Immunofluorescence of baculovirus hMPY G or Baculovi rus hMPY G(s)-Fc infected 
or uninfected SF9 Cells with (A) Mouse a-6- Histidine MAb 1 :50, (B) Rabbit a -hMPY Total I :25 , (C) 
Rabbit anti hMPY G(s)-Fc 1 :50, and (D) Negative Rabbit I :25 detected using Swine a -Rabbit FITC 
conjugate 1:40. Cells were counterstained with Evans Blue and visuali sed by fluorescence microscopy. 
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7.10.4 The Analysis of hMPV G(s)-Fc specific serum against hMPV infected and 
uninfected cell lysate. 
To further assess the reactivity of the hMPY G specific antiserum, it was tested by Western 
blot against 2 different hMPV strains isolated from the 2 Northern Ireland clinical samples 
(Table 7.3) previously standardised by cell equivalence to 1.5 x 105 cells/lane on an SDS 
PAGE gel (Figure 7.14). 
Against hMPY virus the rabbit a-hMPY G(s)-Fc was unreactive with the exception of a 
single band at <20KDa in lanes 2 and 3, also recognised by the negative rabbit serum lanes 
2 and 3 suggesting this is likely to be non-specific binding. The rabbit a-hMPY total and 
negative rabbit reactivates were discussed previously in chapter 5, but were included here 
as controls. 
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Figure 7.14: Western Blot analysis of various hMPY specific sera against recombinant hMPY 
proteins and hMPY infected cell lysate. (1) Uninfected LLC-MK2 Cell Lysate, (2) hMPY Cell 
Lysate -1 , (3) hMPY Cell Lysate -2. (*) size of un-glycosylated species. Rabbit a-hMPY G(s)-Fc 
(I: I 00), negative rabbit (1 :50), rabbit a- hMPY Total (1 :50). Primary antibody was detected with 
goat a-rabbit IgG HRP conjugate at 1 :2500 followed by ECL and autoradiography. The virus 
strains used are detailed in Table 7.3 . 
260 
Chapter 7 -Expression of hMPV G 
7.7 Analysis of human antibody reactivity by indirect IF against 
recombinant baculovirus expressed hMPV proteins. 
As shown in chapter 6 human antibody reactivity against the baculovirus expressed hMPV 
N protein could be measured by ELISA and western blot analysis. Using the recombinant 
baculovirus expressed hMPV N protein as a positive control antigen the reactivity of a 
panel of human sera with known antibody status against N was tested against the 
recombinant hMPV G-FL protein by IF (Figure 7.15). 
Results show that the 3 sera identified as being strongly positive for hMPV N IgG by 
ELISA are also reactive against the N protein by IF. The serum identified as being negative 
by the hMPV N ELISA was also negative for the N protein by IF. In response to the hMPV 
G-FL antigen only serum number 2 appeared to give a convincingly positive result, while 
serum number 1 showed a very low level of fluorescence. Serum number 3 and the 
negative serum were both completely negative at 1 :40 (and 1 :20 dilution; data not shown). 
Figure 7.15: Indirect immunofluorescence analysis of a panel of hMPV N positive and 
negative serum against the hMPV N and full length attachment glycoprotein expressed in the 
recombinant baculovirus system. SF9 cells were grown on glass cover slips and infected with 
either recombinant baculovirus hMPV N-FL or recombinant baculovirus hMPV G-FL at an MOl of 
3 and 20 respectively. The MOl was pre-determined to ensure relatively equal levels of 
recombinant protein expression in terms of the number of fluorescing cells detected by the mouse 
a-6- histidine MAb (data not shown). At 3 days post infection cells were fixed with acetone and 
immuno-stained with human sera (1: 40) followed by mouse a-human IgG FITC conjugated 
antibody (1 :40) and analysed by fluorescence microscopy. Mouse a-6- histidine MAb (1 :50) was 
used as a positive control and detected using rabbit a-mouse IgG FITC conjugate (1 :40). See Table 
7.5 for details regarding the human serum. 
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7.8 Analysis of human antibody reactivity to hMPV G-FL and hMPV 
G(s)-Fc by ELISA and Western blot. 
The reactivity of a larger panel of human sera against the hMPY G-FL, and hMPY G(s)-Fc 
baculovirus expressed antigen was analysed in a dilution series by ELISA using the 
optimised conditions for the hMPY N ELISA described previously (Chapter 6). In each 
case the corresponding negative cell lysate or supernatant was used to subtract background 
reactivity (Figure 7.16). 
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Figure 7.16: Human Ab ELISA reactivity against recombinant hMPV G antigens: (A) hMPY 
G-FL and (B) hMPV G(s)-Fc. Antiserum was tested in a 2 fold dilution series from 1: 10 to 1 :80 
against the positive and negative antigen. Rabbit sera were detected with goat a-rabbit IgG HRP 
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conjugated antibody (1 :2500). Human sera were detected with Rabbit a -human IgG HRP (1 :500) 
in the case of G-FL and corresponding negative antigen. Human sera were detected with rabbit a -
human IgG Fab specific HRP conjugated antibody (1 :5000) for the G(s)-Fc and corresponding 
negative antigen. In both cases the OD value for the negative antigen was subtracted from the 
positive to give the corrected OD value. Each dilution was tested in duplicate. The corrected mean 
00450 values were plotted against the primary Ab dilution. Error bars indicate +/- 1 standard 
deviation. 
Results show that two human sera were reactive with hMPV G-FL, one corresponding with 
the human sera that was also reactive by IF, and the second a pooled adult human serum 
(components unknown), all the other sera were non - reactive or only yielded OD450 
results which were the same as a human hMPV N negative serum indicated by the arrow. 
There was no human sera reactivity against the hMPV G(s)-Fc antigen by ELISA (Figure 
7.168). Analysis of a selection of these sera at a 1 :75 dilution against the G-FL SF9 cell 
lysate by western blot analysis is shown in Figure 7.17. The reactivity of the rabbit a,-
hMPV Total antiserum was also analysed. 
12 
10 
80 
60 
~50 
L~40 
30 
20 
M- + + + + + + + + 
Figure 7.17: Western Blot analysis of human Ab reactivity to hMPV G-FL expressed in the 
Recombinant Baculovirus system. Human Sera were tested against hMPV G-FL negative (-) or 
positive (+) cell lysate and analysed with (1) mouse a-6-histidine MAb 1: 1 000, (2) Rabbit a-
hMPv Total 1:50, (3) Negative Rabbit 1 :50, (4) Negative Human 1 :75, (5) Positive Human 1 1 :75 
(6)Positive Human 2 1 :75 (7)Positive Pooled Human 1 1 :75 (8)Positive Pooled Human 2 1 :75. 
Human sera were detected with Mouse a-Human IgG HRP conjugate at 1: 10000. The control sera 
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were·· .. d~t~ .. ~t .. ~d ·~~···· .. d~~~~i·b~d .. ·······p~~~i~~;iy~···iii~t~······;~r~ exp~;~d t~-.. Eci---~~~trate and 
autoradiography.(*) serum reactive against G-FL by IF and ELISA. 
Previously shown to be reactive against G(s)-Fc by Western blot and IF and against G-FL 
by IF, the rabbit a-hMPV Total serum was negative against both G-FL and G(s)-Fc by 
ELISA. Figure 7.17 show this serum recognises both the HMW and LMW species of 
hMPV G-FL, although only faint bands are visible (circled in green) and the LMW species 
appears to be a slightly smaller size. There was no reactivity observed with the negative 
rabbit serum. 
The human antiserum analysed show a number of different MW speCIes that are 
recognised, most likely cross reactivity with cellular proteins. The two sera (track*6 and 7) 
which were reactive against hMPV G-FL by ELISA and IF appear also to recognise a 
species in the hMPV G-FL positive cell lysate that is slightly larger than the correct size 
for the LMW species ofHMPVG-FL (circled in red). The 50Kda ML glycosylated species 
is less well recognised which may be due to interference of Ab recognition by 
glycosylation, or differences in the transfer of highly glycosylated species. The human 
serum in track 6 also recognises a band at approximately 80KDa, circled in blue, which 
may be non specific binding, which corresponds with a very faint band recognised by 
mouse a-6 histidine MAb also circled in blue and may represent a species of G -FL with a 
greater level of O-linked glycosylation, however is this is the case, why is the 50KDa 
species not recognised? 
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7.9 Transient Expression of hMPV Attachment Glycoprotein in 
Mammalian cells 
The differences in the posttranslational modifications between insect and mammalian cells 
may account for the lack of reactivity of human Ab against the baculovi rus expressed 
hMPV G protein. The expression in a mammalian system will yield proteins that more 
closely represent those expressed during viral infection. Presented here is the transient 
expression of the hMPV G-FL protein to determine the ability of the protein to be 
expressed in mammalian cells, with the view to establishing continually expressing cell 
lines for the analysis of human Ab reactivity, cellular localisation and protein trafficking. 
The hMPV G-FL pTriEx vector was transfected into 293T and Vero cells (See section 
2.10). At 24hours post transfection the cells were fixed with 4% Paraformaldehyde and 
permeablised with 0.250/0 triton X-I00. Protein expression was visualised by indirect IF 
using the mouse a-6-histidine MAb followed by rabbit a-mouse IgG FITC conjugated Ab . 
The nucleus was stained with 0.1 ug/ml DAPI Stain. The stained cells were visualised by 
fluorescence microscopy. 
Figure 7.18: Different transfection efficiencies in (A) 293T cells and (B) Vero cells transiently 
transfected with hMPV G pTriEx 24hours post transfection. The expressed protein was 
visualised using a mouse a 6-histidine MAb followed by Rabbit a -mouse IgG FITe conj ugate . 
The nucleus was stained with DAP!. 
The results show that the hMPV attachment glycoprotein was expressed in 293T cell s, but 
not in Vero cells. 293T cells were therefore used for further expression work. They were 
however problematic in their own way, attaching loosely to the slide, with a tendency of 
rounding up . Therefore optimisation of the techniques and transfection conditions wa 
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included comparing glass versus perminox slides, different cell seeding densities, and 
different DNA: lipofectamine ratios in the transfection mix. 
To assess the localisation of hMPV G-FL in transfected cells at different time points, cells 
were analysed by IF at 24,48 and 72 hours post transfection (Figure 7.19). 
The results show that hMPV G-FL is expressed at detectable levels throughout the time 
course. At 24 hours post transfection the protein concentrated around the nuclear envelope, 
perhaps due to processing through the rough endoplasmic reticulum. At 48 hours post 
transfection the protein is detected throughout the cytoplasm, and is found in concentrated 
spots, at 72 hours post transfection the protein appears to be concentrated at the cell 
surface. It is worth noting however that this analysis was performed with a standard 
fluorescence microscope, and con-focal microscopy would give much more accurate 
information as to the localisation of the protein. 
IF analysis of transiently transfected cells expressing G-FL was carried out with rabbit and 
human sera known to be positive or negative for hMPV N IgG, all sera however yielded 
negative results (data not shown). 
Unfortunately due to time constraints the use of this vector for establishing constitutively 
expressing protein, and further analysis of Ab reactivity against the transfected G-FL 
protein could not be pursued. 
267 
Chapter 7 -Express ion of hMPV G 
Figure 7.19:hMPV G-FL transiently transfected 293T cells over time. The expressed protein 
was visualised using a mouse a 6-histidine MAb followed by a -mouse IgG F1TC conjugate. The 
nucleus was stained with DAP!. (A) 24-hours post transfection, (8) 48-hours post transfecti on, (C) 
48-hours post transfection, (D) 72-hours post transfection, (E) pTriEx empty vec tor 48-hours post 
transfection, (F) Cells Only at 48-hours 
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7.10 Discussion 
Reported here is the use of the recombinant baculovirus system to express the hMPV 
attachment glycoprotein and the subsequent generation and evaluation of hMPV G specific 
antiserum required for the development of serological assays to measure human antibody 
reactivity against G. This is followed by preliminary work demonstrating the ability to 
express G in a mammalian expression system. 
7.10.1 Recombinant baculovirus expression of hMPV G-FL 
The full-length attachment glycoprotein of hMPV was successfully expressed in the 
recombinant baculovirus system; however, a high MOl of recombinant baculovirus was 
required in order to achieve detectable levels of protein expression, making the large scale 
synthesis of protein required for antibody production impractical without successful 
baculovirus virus purification. The reasons for the low level of protein expression were 
not investigated within the scope of this work. However protein toxicity, complex post 
translational modifications, protein instability or degradation, or the need for chaperone 
proteins (e.g. co-expression with F and SH) may be involved. 
The hydrophilicity profile of hMPV G presented in chapter 4 of this thesis, and its 
similarity with that ofhRSV and APV indicates that hMPV G-FL is likely to be a type two 
transmembrane protein. Whilst problematic in terms of protein extraction and purification 
the difficulties initially experience with extracting G-FL from the cellular membrane 
material provides good evidence that the protein was targeted correctly within the cell to 
membrane organelles such as the endoplasmic reticulum, Golgi apparatus or plasma 
membrane. The localization of G-FL in insect cells was not investigated further but could 
be addressed in future work though the use of confocal microscopy using dual labelling 
techniques. 
Different detergents were investigated for their ability to solubilise G, and the findings may 
be useful for any future work where expression levels of hMPV G-FL are investigated or 
optimised and subsequent protein extraction and purification techniques are employed. 
Whilst ionic detergents such as sodium dodecyl sulphate (SOS) are extremely effective at 
solubilising membrane proteins, they are also denaturing. Since the ultimate aim of this 
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and antibody production or in structural studies the use of denatured protein would not be 
appropriate. Re-folding or renaturation of the protein may be possible by transferring it 
into a renaturing (non-ionic) detergent or lipid environment, this however is not suitable 
for all proteins and the removal of SDS can often lead to irreversible aggregation or 
precipitation of the protein. This technique however has been used successfully for the 
purification of a chimeric RSV GF protein expressed in the recombinant baculovirus 
system and analysis with a panel of monoclonal antibodies showed reactivity against both 
linear and conformational epitopes (Wells et aI., 1994). 
Non-ionic detergents are mild and non-denaturing as they break up lipid-lipid and lipid-
protein interactions rather than protein-protein interactions and are therefore used for 
isolation of membrane proteins in their biologically active form. However it is important to 
be aware that non-ionic detergents with short chains (C7-CI0) may often lead to 
inactivation of protein function and therefore non ionic detergents with intermediate length 
(CI4) or longer side chains should be used preferentially (Seddon et aI., 2004). A number 
of non-ionic detergents with long chains were therefore tested and Nonidet P-40 (NP-40) 
found to be more efficient than Triton-X-I00 and Tween20, which also solubilised G-FL 
although to a much lesser extent. Extraction with NP-40 and Triton-X-I00 however 
resulted in a high degree of molecular weight heterogeneity compared to that seen in 
membrane fractions and may be a result of increased protein degradation. 
Detergents solubilise membrane proteins by mimicking the natural lipid bilayer in which 
the protein is located. The ability of different detergents to solubilise membrane or 
transmembrane proteins is dependent on a range of variables including the critical micelle 
concentration of the detergent; temperature, pH, and the components of the target 
membrane. 
Membranes typically exist in a fluid state of loosely packed lipids, however it is well 
recognised that distinct membrane domains differing in composition, physical properties 
and biological functions also exist. This is due to certain lipids which have a greater 
propensity to pack together more tightly forming what is known as lipid rafts. Lipid rafts 
have been associated with signal transduction and protein sorting and are often more 
resistant to disruption with detergents (e.g. Triton-X-I00) (Schuck et aI., 2003). The 
association of the G, F and SH proteins of hRSV with lipid rafts has been well 
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with lipid rafts (Henderson et aI., 2002, Rixon et aI., 2004). Whether G alone (i.e. without 
F or SH) or indeed whether G in a recombinant system has the ability to associate with 
lipid rafts is unknown. The ability to solubilise G may therefore depend on the ability to 
disrupt these membrane domains. The association of G with lipid rafts can be analysed 
using IF, and electron microscopy. 
7.10.2 Recombinant baculovirus expression of hMPV G(s)-Fc 
In contrast; the expression of hMPV G(s)-Fc was much greater than that of G-FL. hMPV 
G(s)-Fc lacks the N-terminal transmembrane and cytoplasmic regions of the protein and is 
fused to the human IgG Fc region at the carboxyl terminal. The Fc fusion protein has been 
shown to aid in the expression of secreted proteins by facilitating proper processing and 
increased solubility. Bioinformatic analysis of the predicted secondary structure, 
hydrophilicity and surface probability revealed no detrimental effect of the addition of Fc 
to G(s). 
The hMPV G(s)-Fc protein was expressed and secreted into the supernatant of High 5 cells 
at very high levels when grown in suspension. Purification of G(s)-Fc using protein A 
columns however was not successful despite demonstrating the ability of the protein to 
bind protein A in an ELISA. This is likely to be due binding buffer conditions or to steric 
hindrance within the column. 
The hMPV G(s)-Fc supernatant was nonetheless used to raIse an hMPV G specific 
polyclonal antiserum which was then evaluated as a possible research or diagnostic tool. 
7.10.3 Molecular weight analysis and glycosylation 
Western blot analysis of both G-FL and G (S)-Fc expressed in the recombinant baculovirus 
system yielded 2 distinct bands of approximately 33 KDa and a smear from 40 to 55 KDa 
with the major species at 50 KDa for G-FL (Figure 7.4), and two major species of 45 and 70 
KDa for G(s)-Fc (Figure 7.7). The low molecular weight band for each recombinant 
protein represents the expected molecular weights for the proteins without post 
translational modification. The HMW bands are likely therefore to represent species that 
have undergone post translational modification the most likely glycosylation. The data 
presented in chapter 4 demonstrates that hMPV G has a high potential for O-linked 
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used for the expression work presented here contains 37 serine residues and 39 threonine 
residues which have the potential to be glycosylated with O-linked carbohydrates. 
Furthermore this protein contains 2 potential N-linked glycosylation sites which if 
glycosylated will give a predicted MW species of approximately 39-40 kDa for which a 
band is visible (Figure 7.4). Although the presence of glycosylation was not investigated 
within the scope of this work there has much work already published on the presence of 
glycosylation in the G proteins of hRSV and other pneumoviruses, in virally infected cells 
and in the recombinant baculovirus expression system. The pattern of molecular weight 
distribution seen in this work is consistent with that observed for the G proteins of other 
pneumoviruses and indeed hMPV. 
Expression of hMPV G in the baculovirus system has also been reported by Bastien et al 
(2004) (Bastien et aI., 2004). In that study the G protein from an A and B isolate was 
expressed yielding molecular weights of 38 to 80 KDa, with a major band at 50 KDa for 
the A subtype protein and a smear of 45 to 75 KDa, with the dominant species migrating at 
45 and 58 KDa for the B subtype protein. These observations correspond with the observed 
molecular weights for G-FL in this study, with slight differences being accounted for by 
the presence of the histidine tag used in this work and potential differences in the level of 
glycosylation due to heterogeneity in the number of potentially N- and O-linked 
glycosylation sites between different strains and potential glycosylation differences of the 
different cell lines used (SF9 cells in this study and SF21 cells used by Bastien et al 2004). 
Interestingly Bastien et al did not appear to observe any non-postranslationally modified 
protein (26 KDa) as observed in this study (33 KDa) but this may purely be due to relative 
levels of the different species. 
To investigate the presence and nature of glycosylation; glycosylation inhibitors such a 
tunicamycin and monensin, which inhibit N- and O-linked glycosylation respectively, 
could be used in conjunction with western blot analysis or radio labelling to investigate 
differences in the MW of the spices generated. These techniques have been used 
successfully by a number of investigators to characterise the glycosylation profiles of a 
number of glycoprotein's including the RSV G (Collins, 1990, Collins & Mottet, 1992, 
Wertz et aI., 1989). 
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The expression of G-FL in transfected mammalian cells was also successful. Over a time 
course increased levels of protein expression was observed and was optimal at 48 hours 
post transfection. The expressed protein was localised throughout the cytoplasm of the cell 
with concentrated areas of fluorescence (punctuate dots) which may represent 
accumulation in the endoplasmic reticulum and Golgi apparatus. At 48hours post 
trasnfection G appeared to spread into thin extensions protruding from the cell (Figure 
7.19). Confocal microscopy however should be employed to address more accurately the 
localisation of this protein in the cell. 
Expression of G in the mammalian expression system offers a possible advantage to the 
recombinant baculovirus system expressing proteins that more accurately represent the 
native protein; particularly in terms of post translational modifications such as 
glycosylation, which is known to be more limited in insect cells. Furthermore the use of 
the mammalian expression system to establish constitutively expressing cell lines would be 
a vital tool for studying the trafficking and localisation of this protein when combined with 
confocal microscopy and pulse chase experiments. 
Sullender and Britt (1996) conducted a study analysing the glycosylational differences of 
hRSV G expressed in insect cells and in mammalian cells. Their results showed that a 
greater level of glycosylation was observed in the RSV G protein expressed in mammalian 
cells. However despite the reduced level of glycosylation there was little effect on 
monoclonal antibody recognition of the baculovirus expressed protein. Furthermore the 
baculovirus expressed RSV G protein was used to raise neutralising antibody in cotton rats 
which protected the rats upon challenge with RSV, indicating that the baculovirus 
expressed RSV G proteins had antigenic and immunogenic features similar to that of the G 
protein expressed in mammalian cells. 
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"' 7jo~5 HMPV specific and human antibody~~~~ti~itY~g~'i~~t '''~MPV-G antigens 
Table 7.4 summarises the reactiv ity of the hMPV G specific polyclonal antiserum raised 
against hMPV G(s)-Fc (described in this chapter), Rabbit a- hMPY Total raised against an 
hMPY infected cell lysate (described in Chapter 5), and a panel of human serum with 
known antibody status against recombinant baculovirus expressed hMPY N protein 
(Chapter 5 and 6) against the different G antigens described above and hMPY itself. 
Table 7.8: Summary of hMPV specific antiserum reactivity against recombinant hMPV G 
antigens. 
Anti-serum 
Antigen Analysis Mouse a-6- Rabbit a- Rabbit a- Human 
Preparation Histidine hMPV hMPV antiserum 
MAb G(s)-Fc Total ** 
Recombinant ELISA + + NT) ++ 
baculovirus ( 1 : i 0(0) (I :20) (I :20) 
hMPVG-FL WB ++ +/- + ++ 
( 1 : 1 0(0) ( 1 : 1 (0) ( I • "0) I __ , (,,-IS' 1 , f ~ ) 
IF +++ + + + 
( 1:50) (1 :50) I ')-l :~)) (1 :40) 
Recombinant ELISA + ++ 
baculovirus U :IOOU) ( [:80) (t :2U) (i :20) 
hMPV G(s)- WB + +++ + ND 
Fc (l:IOOO) (1 :250) ( I :5f)} 
IF +++ +++ ++ ND 
( 1 :50) , 1 > "0) \ , ... / , (t :25) 
hMPV WB NA + Nt) 
infected cells (! : 1 on) ! '';;O)~' ( ,,/> 
IF N!\ ND + :\1) 
(1:25)* 
hMPVG-FL IF +++ !j) 
transfected ( I :50} ( [;50) ! '") - ) > / ( :_), 
mammalian 
cells 
Footnotes: WB : Western blot analysis ; IF: Immunofluorescence, (-) No antibody reactivity (+) 
Weak antibody reactivity, (++) moderate antibody reactivity, (+++) strong antibody reactivity, The 
values given in (brackets) represent the antibody dilution which was tested or yielded a positive 
result. (NA) not applicable, (ND) not done. (*) See also chapter 5. (**) two human sera only, the 
remainder were negative. 
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7.10.5.1 Rabbit a-hMPV G(s)-Fc 
The rabbit a-hMPV G(s)-Fc polyclonal antiserum raised against the recombinant 
baculovirus expressed G(s)-Fc protein, reacted strongly against the homologous protein by 
Western blot, IF and ELISA. It also recognised recombinant baculovirus expressed hMPV 
G-FL by IF and possibly by Western blot, although it is worth bearing in mind that both 
the recombinant proteins contain a 6-histidine tag against which this antiserum may be 
reacting and repeat analysis should be performed following removal of the tag. Rabbit a-
hMPV G(s)-Fc was not reactive against hMPV infected cell lysate by Western blot 
analysis or hMPV G-FL expressed in the mammalian expression system by IF, but this 
could be concentration dependent. 
Failure to recognise the G protein in hMPV G infected cell lysate, may be due to strain 
differences, although both belong to the A lineage, or more likely the relative level of 
hMPV G protein expression in the cell lysate preparation. Due to the position of the G 
gene in relation to the promoter at the 3' end of the genome, it may possible that the level 
of G protein expression in hMPV infected cells is below the detection limit. Levels of G 
protein expression could be monitored over the course of hMPV infection by quantitative 
RT-PCR targeting mRNA, or by northern blot analysis. 
This however does not explain the lack of reactivity with the mammalian cell expressed G-
FL protein in which the homologous strain was used. Although the work done was only 
preliminary and optimisation may yield a different result. This suggests that there are 
possible differences in the conformational epitopes of the hMPV G(s)-Fc protein against 
which the antiserum was raised and that of the G-FL protein expressed in the mammalian 
cells. This antiserum is therefore unlikely to be a useful reagent for further research or 
diagnostic use except against its homologous hMPV G(s)-Fc protein. 
7.10.5.2 Rabbit a-hMPV total 
It was demonstrated in chapters 5 and 6 that the rabbit a-hMPV total antiserum contains 
IgG that was reactive against the hMPV N protein expressed in the recombinant 
baculovirus system. It was also demonstrated in chapter 5 that this serum reacted 
specifically against hMPV infected cells by IF and Western blot analysis clearly reacting 
against proteins with the correct molecular weight for the N, P and FO proteins (Figure 
7.14). Against the recombinant baculovirus expressed hMPV G-FL and G(s)-Fc, this 
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antise~~~··~as"··~~a~ti~~··bY· IF, a~d··-W-~ste~~···bio·t-a~aiysi~~T~di~~ti"~-that--eithe~li-~e~r or 
conformational epitopes were recognised. By western blot both un-glycosylated and 
glycosylated species were recognised although at very low levels suggesting that either the 
a-G antibody level in this rabbit serum was quite low or there are only a few conserved 
epitopes in the G proteins of different strains. This does however suggest that at least to 
some extent the antigenicity of the G protein expressed in the baculovirus system was 
maintained. 
Surprisingly this antiserum failed to detect the hMPV G-FL protein expressed in the 
mammalian expression system by IF. It is unlikely that strain differences between the virus 
used to generate the antiserum, and that used in the expression work account for this lack 
of reactivity as the same strain was used for all expression work and this antiserum clearly 
recognises the baculovirus expressed G proteins by IF. These however were preliminary 
data and optimisation of protein expression levels in the mammalian system, fixation 
techniques and the IF assay itself may yield a different result. This antiserum may provide 
a useful tool for the analysis of antibody reactivity against hMPV G proteins although 
assay optimisation is required. 
7.10.5.3 Human antibody reactivity. 
A panel of human serum known to be either positive or negative for hMPV N IgG was 
tested against the different hMPV G antigens. 
By IF only 1 of the 4 sera positive for hMPV N IgG tested were reactive against the hMPV 
G-FL protein expressed in the baculovirus system. This same antiserum, plus an additional 
antiserum pool was also reactive against G-FL, but not G(s)-Fc by ELISA, suggesting there 
are possible conformational differences between G(s)-Fc, and that of native G and G-FL. 
Or that the majority of antibody is targeted towards the more conserved transmembrane and 
cytoplasmic regions of the G protein. 
By Western blot these same two sera appeared to be reactive against a species which is 
slightly larger than the expected size of the non-glycosylated hMPV G-FL protein species, 
and smaller than the glycosylated species. This is either non specific, or may be reactivity 
of the sera against a g species without the tag, but was not investigated further due to time 
constraints. In general however the human sera tested were not reactive against either 
glycosylated or un-glycosylated species. 
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Work published by Bastian et al (2004) shows the reactivity of polyc1onal guinea pig 
antiserum raised against two different hMPV isolates was analysed by western blot and 
immuno-precipitation of baculovirus expressed hMPV G proteins from the homologous 
virus. By western blot analysis both glycosylated and un-glycosylated species were 
recognised. Immuno-precipitation however demonstrated that this antiserum did not react 
with highly glycosylated species (Bastien et aI., 2004). This observation suggests that 
antibody to the glycosylated forms of G may be poorly induced, and that glycosylation 
may contribute to the interference of antibody induction and recognition of the G protein. 
The presence of glycosylation in the G protein of hRSV G has also been reported to have a 
similar effect on human antibody reactivity (Palomo et aI., 2000). Some hRSV epitopes are 
dependent on glycosylation, thus, if glycosylation is different in different cell types (even 
if both mammalian) then the antigenic profile of this protein can be changed (Garcia-Beato 
et aI., 1996). 
In further support of this hypothesis Skiadopoulos et al have reported; using a recombinant 
parainfluenza virus (rPIV) expressing the hMPV G protein; that G was only very weakly 
immunogenic and very little if any neutralising antibody could be detected in serum taken 
from hamsters infected with the recombinant virus, despite high levels of G protein 
expression. In contrast; the F gene expressed in the rPIV system was highly immunogenic 
and protective (Skiadopoulos et aI., 2006). This differ significantly to the findings of all 
other paramyxoviruses in which all the F and GIHIHN proteins examined to date induce 
protective antibodies (de Swart et aI., 2005, Martinez & Melero, 1998, Paterson et aI., 
1987, Schmidt et aI., 2001). 
It is clear from the work presented in this chapter that analysis of antibody reactivity to the 
attachment glycoprotein of hMPV will not be straight forward and a range of techniques 
need to be employed. It is likely given the large degree of strain diversity shown in chapter 
4 that the best results for breaking down antibody reactivity and mapping epitopes will be 
achieved using a homologous antiserum to the strain being analysed. While it is clear that 
the human antiserum reacted with the baculovirus expressed hMPV G-FL protein, the 
hMPV G(s)-Fc protein is unlikely to be of any benefit in further research or diagnostic use, 
and energies should be focused on improving the expression levels of hMPV G-FL. It does 
highlight the importance of maintaining the integrity of the protein. As more information is 
accumulated with respect to the structure and function of this protein demonstrating that 
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glycosylation profile, localisation of the protein within the cell, and antibody recognition 
can all be analysed. 
Given that apparent complexity of antibody reactivity against this protein the baculovirus 
expression system however should be treated with caution and its limitations kept in mind 
at all times. A mammalian expression system may therefore provide more reliable results. 
Although human antibody reactivity against the G-FL protein expressed in the mammalian 
expression system was not investigated within the time available for the completion of this 
work, the preliminary data presented in this chapter demonstrate that hMPV G can be 
successfully expressed in the mammalian cell expression system and paves the way for 
constitutive cell lines expressing the G protein to be established. 
It is clear that the G protein of hMPV is not a major immunogen and the amino acid and 
glycosylation heterogeneity of the protein is likely to contribute to the lack of antibody 
recognition seen in this work and that of others. Inclusion of G in any potential vaccine is 
therefore unlikely to yield any benefits. 
However data is some what contradictory in the respect that the large degree of amino acid 
variation observed in this protein (Chapter 4) indicates that the protein may be under 
positive selection, most likely via immunological pressure (although more temporal data is 
required to prove this), suggesting that many antibodies targeted to G may indeed be 
protective in order to drive these amino acid changes, however the data presented in this 
chapter and that of others suggests otherwise (Skiadopoulos et aI., 2006). 
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Chapter 8 - Concluding Remarks 
As with all newly emerging or identified viruses it is vital to understand the potential risk 
of the virus to human and or animal health by characterising any virally associated disease, 
establishing its epidemiology and pathogenesis, identifying those most at risk of infection, 
and evaluating whether vaccine and or antiviral drug development should be pursued. 
Since the discovery of hMPV by Dutch researchers in 2001, hMPV has been reported 
world wide, and is considered an important cause of respiratory tract infection in people of 
all ages, in particular infants, young children, the elderly and immunocompromised 
populations (Boivin et a1., 2003, Hamelin & Boivin, 2005, van den Hoogen et a1., 2001, 
van den Hoogen et a1., 2004, van den Hoogen et al., 2003) . At the start of this work in 
2002 very little was known about hMPV. The aim of this thesis was to contribute to the 
overall understanding of hMPV, by assessing its contribution to disease in the UK 
community, and the diversity of circulating hMPV strains through the development of a 
number of research and diagnostic tools and reagents. 
8.1. Prevalence of hMPV 
It has been demonstrated in this work and that of others that hMPV is responsible for a 
substantial proportion of ARTI in young children, and is a frequent cause of hospitalisation 
(Chapter 3). Serological evidence suggests that hMPV infections occur throughout infancy, 
although the majority of primary infections occur in children 16 months or older, with 
approximately 70% having been infected by the age of 6 years (Chapter 6). This is 
somewhat older that that seen for hRSV, where a majority of children will have been 
infected by the age of 2 years (Ebihara et a1., 2004), and may in part explain why the 
severity of disease associated with hMPV infection is generally considered to be milder 
than that of hRSV. Although not investigated within the scope of this work, the clinical 
manifestations of hMPV infection in young children appear to be clinically 
indistinguishable from those with hRSV, with the most common hMPV associated 
diagnosis being bronchiolitis, pneumonia and bronchitis (Boivin et a1., 2003, van den 
Hoogen et al., 2003). 
hMPV is also an important cause of community acquired ARTI in people of all ages, as 
illustrated by the sizeable number of hMPV infections identified in adults presenting with 
influenza like illness in this study (Chapter 3). HMPV infection in adults has also been 
associated with bronchitis, pneumonia, and exacerbations of asthma and COPD (Martinello 
et al., 2006, Rohde et al., 2005, Williams et al., 2005). The major risk factors appear to be 
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advancing age, underlying cardiopulmonary or immunocompromised conditions, and 
COPD. To date a majority of studies investigating hMPV have focused on children 
, 
however, it is important that further investigations are continued in order to define the role 
of hMPV in these adult populations, especially considering the demographic changes that 
have occurred over the past 30 years which have resulted in an ageing population. Since 
1971 to 2004 the percentage of people over the age of 65 years has increased from 13 to 
16% with people aged 85 and over rising from 7 to 12%. In contrast, over the same period 
of time the percentage of people under 16 years of age has fallen from 25 to 19%, and this 
trend is projected to continue. In addition life expectancy, has risen at a much faster rate 
than healthy life expectancy (expected number of years in good heath), and the number of 
years a person can expect to live in poor health has risen from 6.5 to 8.7 years for males 
and from 10.1 to 11.6 years for females from 1981 to 2001 (ONS, 2005). 
Given that people are living longer, and in poor health the significance ofhMPV, and other 
respiratory viruses in this group is likely to increase, and may contribute significantly to 
the number of elderly with ARTI seeking medical attention. Overall, however hMPV is 
less frequently associated with disease in adults compared to that of children; nonetheless, 
asymptomatic infections are rarely detected in either group. 
HMPV has a seasonal distribution, peaking during the typical respiratory virus season 
(winter and spring months in temperate climates, and late spring early summer in 
subtropical countries). In some studies, including this one, hMPV has also been reported to 
occur sporadically or circulate throughout the summer, although at a much reduced rate 
(Chapter 3). Peak circulation occurs at a time when many other common respiratory 
viruses (including hRSV, influenza, PIV, rhinovirus and coronaviruses) are also 
circulating, it is not surprising therefore that co-infections of hMPV with one or more of 
these viruses are often detected, the most common being hRSV (Chapter 3). 
Whether co-infection of hMPV is associated with a more severe clinical picture is yet to be 
established. While some groups have reported little or no difference in the severity of 
disease one group has reported increased severity of hRSV associated bronchiolitis in 
hospitalised children also testing positive for hMPV (Greensill et aI., 2003, Semple et aL 
2005). During the recent SARS coronavirus outbreak in 2003, hMPV was the most 
commonly detected co-pathogen (Kuiken et aI., 2003). In-vivo work in monkeys however 
demonstrated there was little difference in the severity of disease or the pathological 
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findings of monkeys infected with either SARS Co Valone or co-infected with SARS Co V 
and hMPV (Fouchier et aI., 2003, Kuiken et aI., 2003, Kuiken et aI., 2004). This study 
however was limited to only a very small number of animals and the multifactorial 
influences on respiratory tract infections should not be underestimated. 
It has often been observed that infection with one pathogen may lead to a predisposition to 
infection or increased severity of disease by another. More favarable environments may 
arise as a result of co-infection by a number of mechanisms, for example, weakening host 
immune repossess, enhancing viral replication by providing accessory proteins, or by 
maintaining cells in a particular stage of cell cycle. 
There is at present no in vitro evidence reported on the effect of co-infection in hMPV 
replication, but this could easily be studied using laboratory adapted strains of hMPV 
capable of replicating in the same cell lines as other viruses. The effects of individual viral 
proteins could be studied through the use of constitutively expressing cell lines or chimeric 
viruses. One such study conducted by Ph am et al (2005) constructed recombinant hMPV 
viruses in which either the N or P genes of hMPV where substituted with the homologous 
genes from APV. Both recombinant viruses replicated more efficiently in Vero cells, but 
were attenuated in vivo (AGM) when compared to parental hMPV. The authors postulated 
that the APV Nand P proteins may function more efficiently in Vero cells compared to 
that ofhMPV indicating possible interactions with cellular components. Alternatively APV 
Nand P may function more efficiently in context with other hMPV proteins compared to 
those of hMPV although the in vivo results contradict this hypothesis (Pham et aI., 2005). 
Whether enhanced replication is observed in the presence of hRSV N or P proteins would 
be interesting and more relevant in terms of addressing questions relating to possible 
mechanisms for enhanced disease during naturally occurring co-infections with these two 
VIruses. 
8.2. Detection 
It is clear from the data presented in this thesis that cell culture isolation of hMPV is very 
difficult and time consuming, and for studies such as the one reported here where the 
samples are often of poor quality and low viral copy number cell culture isolation is not an 
appropriate means of detection. Although a recent publication by Ingram et al (2006) 
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demonstrated the successful use of human bronchial epithelial cells (16HBE 140) for the 
isolation ofhMPV from clinical samples (Ingram et aI., 2006) . The poor growth properties 
ofhMPV nonetheless in part explain why the virus has not been identified until recently. 
Genetically modified cell lines may be used to improve the growth properties of hMPV, 
and may include cells constitutively expressing proteins such as a putative receptor, or as 
shown above, proteins from closely related viruses such as the APV N or P proteins which 
enhance replication, or alternatively knockout cells lacking the ability to produce antiviral 
interferons. One such cell line used this study was a HEP2 cell line which constitutively 
expressed the V protein from SV5 which antagonises the antiviral interferon pathway by 
targeting STAT for proteasome degradation. This particular cell line did not yield any 
isolates (Chapter 3), although it has since been shown that HEP2 cells do not support the 
growth of laboratory adapted strains of hMPV. An alternative cell line such as LLC-MK2 
cells which have been shown to support hMPV growth may therefore yield better results if 
genetically modified in a similar way. Other factors should also be investigated; for 
example, do interactions occur between cellular proteins and the components of the RNP? 
If so what are they, and can they be enhanced or eliminated to improve replication? 
Alternatively could hMPV replication be cell cycle dependent, and if so at which stages is 
replication most efficient? 
Currently RT -PCR is the most commonly used technique for the detection of hMPV and 
has proved to be the appropriate assay for the detection of hMPV in this work. It is should 
be kept in mind that continuous review of the primers used in such assays is vital to ensure 
all possible strain types are detected. 
Immunofluorescence usmg specific antibodies to detect virus in clinical samples is a 
frequently used technique for respiratory viruses in many diagnostic laboratories. Two 
polyclonal antibodies generated in this work against hMPV infected cell lysate and 
recombinant baculovirus expressed hMPV nucleocapsid protein have been evaluated for 
their reactivity. Although not yet formally evaluated the rabbit a-hMPV total antiserum 
has the potential to be used as a reagent for direct IF of clinical material. Although a 
number of studies have shown that immunofluorescence is not as sensitive as RT-PCR for 
the detection of hMPV this may nevertheless be a useful approach for diagnostic 
laboratories. 
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8.3. Seroprevalence of hMPV 
A recombinant baculovirus expressing the hMPV nucleocapsid protein (N) was generated, 
and proved to be a useful source of antigen for serological assays and the production of 
polyclonal antiserum (Chapter 5 and 6). This antigen was used successfully in an indirect 
ELISA format, and in western blot analysis and immunofluorescence. Data gathered using 
the ELISA to test a panel of age stratified sera, showed that the assay had good level 
sensitivity and specificity (Chapter 6). 
Although not useful as a diagnostic assay during the acute phase of infection, such an 
approach provides a useful tool for continuing research into the seroprevalence of hMPV 
in different populations, and may be used during outbreak situations or as a confirmatory 
test through the analysis of acute and convalescent serum. 
The seroprevalence data presented in Chapter 6 highlights the important point that hMPV 
infections frequently occur despite the presence of pre-existing hMPV specific antibodies 
and raises a number of questions concerning the acquisition and duration of immunity, and 
the ability of the virus to evade host immune responses. It is clear from the seroprevalence 
study that virtually all adults have detectable levels of hMPV specific antibodies, and yet 
hMPV infections in adults can lead to severe LRTI requiring medical attention, such as 
those seen with ILl in this study (Chapter 3 and 6). Infants and young children also 
experience hMPV infections at a time when maternal antibodies should be protective, as IS 
the case for hRSV (Chapter 3 and 6). 
These data demonstrate that, as with hRSV, immunity against hMPV is likely to be 
incomplete and therefore not protective against reinfection (Alvarez & Tripp, 2005). 
hMPV may also possess several mechanisms for evading host immune responses, although 
what these are is not yet clear, especially since hMPV lacks the non-structural genes found 
in the pneumoviruses. It is highly likely, however, that the attachment glycoprotein (G) 
plays an important role in evasion from antibody recognition as discussed later. 
Despite the apparent ability of hMPV to cause reinfections in humans, a number of studies 
using experimentally infected animals have shown that protection against challenge with 
homologous virus can be achieved, with partial protection against heterologous virus 
strains. This may represent differences between experimental and natural infection and also 
between natural host and laboratory animals. 
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The nature of the antibodies raised during infection in terms of their affinity, avidity, 
neutralising capabilities and longevity should be investigated. Neutralising antibodies can 
be easily measured throughout the course of infection and beyond through the use of a 
robust virus neutralisation assay. Affinity maturation and antibody avidity against hMPV 
or its individual proteins could be assessed through the use of displacement ELISAs 
performed in the presence of increasing concentrations sodium thiocyanate (NaSCN) 
which disrupts antigen-antibody interactions. 
However, it is not just antibody responses that should be considered, as discussed in 
chapter 1 of this thesis. Innate and cellular immune responses also play an important role in 
clearing viral infections. Alvarez et al has recently demonstrated that hMPV can persist in 
the respiratory tracts of experimentally infected mice for up to 60 days post infection 
despite the presence of neutralising antibodies. Persistence was associated with the delayed 
onset of CTL responses. Depletion of T cells or NK cells also resulted in increased levels 
of virus replication(Alvarez et aI., 2004, Alvarez & Tripp, 2005). Furthermore a number of 
studies have shown that hMPV is a poor inducer of inflammatory cytokines, compared to 
hRSV in both animals and humans (Domachowske et at, 2002, Guerrero-Plata et aI., 2005, 
Laham et aI., 2004). Whether these apparently dampened cellular responses contribute to 
the ability of hMPV to cause reinfections in not yet known, and at present a thorough 
investigation of innate and T cell responses to hMPV is still to be conducted. 
Analysis of T cell function can be performed in a number of ways. T cell proliferation 
assays can be used to measure the clonal expansion of T cells in response to antigen 
stimulation, and the cytolytic effects of T cells measured through the use of a chromium 
release assay, which measures the ability of T cells to lyse chromium labeled antigen 
expressmg cells. ELIspot assays can also be used to measure the release of specific 
cytokines. 
To fully evaluate several aspects of hMPV reinfection however, including, severity, 
frequency, and duration of illness, immunity, lineage, and strain type, studies on cohorts or 
individuals conducted over a number of years is required. 
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8.4. Variability of G 
HMPV G has a very high degree of nucleotide and amino acid variation (28-37% amino 
acid homology between A and B lineages) (Chapter 4).This is greater than that observed 
for hRSV, which is reported to be 38% between hRSV A and B subtypes). As with hRSV 
G the majority of mutations occur in the extra cellular domain of the protein with 
nucleotide insertions or deletions resulting in frame shift mutations which often drastically 
alter the appearance of the protein and may result in truncation. The extra cellular domain 
also contains an unusually high degree of O-linked glycosylation which may mask 
potentially immunodominant epitopes, the heterogeneity of this glycosylation may also 
contribute further to the variability of this protein. 
Given the short time period over which hMPV G gene sequence has been obtained thus far 
it is not possible to determine whether the variation observed in G is due to a selective 
pressure on the virus, such as immune pressure, or whether it represents a pool of viruses 
which, although they differ in this gene, are genetically stable. Evidence supporting either 
hypothesis can only be generated from accumulating temporal data and the comparison of 
synonymous/ non-synonymous ratios as in chapter 4. In vitro analysis can also be 
conducted. A number of studies have used polyclonal and monoclonal antibodies in hRSV 
cell culture systems and shown that amino acid mutations frequently arise and are often 
associated with developing resistance to neutralisation (Rueda et aI., 1991). Such 
techniques could be employed to investigate the effects of immunological pressure in the 
hMPV G protein. 
Phylogenetic analysis of G was used in this work to address the question of strain diversity, 
and has shown that whilst a large degree of variation exists within this protein, strains from 
different populations, countries and years are genetically very similar. Strains circulating 
within the UK are therefore genetically similar to strains circulating elsewhere in the 
world, as are strains circulating in the general community and hospitalised children. 
During any given year both A and B lineages co-circulate in the community. In one study, 
however, the predominant lineage switched from A to B over 2 consecutive years, but the 
severity of illness did not change (Agapov et aI., 2006). While the sequencing strategy 
used in this study identified viruses belonging predominantly to the A lineage, given the 
number of identified cases in which G sequence could not be obtained it is not possible to 
286 
Chapter 8 - Concluding Remarks 
---. 
ascertain, nor has it been established elsewhere, whether one lineage is predominant over 
the other, or whether one is associated with a more severe clinical picture. Whether 
infection with either subtype of hRSV is associated with a particular clinical outcome is 
still under debate and a number of contradictory findings have been published (McIntosh et 
aI., 1993, Papadopoulos et aI., 2004, Walsh et aI., 1997) 
It is clear that the sequencing strategy used in this study requires optimisation in order to 
increase the success rate of obtaining full length G sequence. However, the poor sample 
quality is likely to be a limiting factor in this work. Due to the difficulties of obtaining full 
length G sequence, in future work, fragment analysis of the hyper variable region of G 
could be used to generate phylogenetic data. Simple sub-typing of hMPV could be 
achieved by sequencing a more conserved gene, or better still by a primary diagnostic able 
to differentiate between subtypes. 
Another important feature of the hMPV G protein is the high frequency in which 
premature stop codons are observed in the carboxyl terminal of the protein suggesting this 
region of the protein is not important structurally. Furthermore the ability of hMPV to 
tolerate such dramatic mutations in this protein calls in to question the function of this 
protein and its role in receptor binding. It has been demonstrated by Biacchesi et al that 
full length clones in which the entire G gene is deleted are capable or replication in vitro, 
and in the URT of hamster models to levels comparable to that of wild type virus. 
Replication in the LRT however was somewhat inhibited (Biacchesi et aI., 2005, Biacchesi 
et aI., 2004). This suggests hMPV has alternative mechanisms for attaching to the host 
cell, most likely via the fusion protein. 
RSV strains also often contain premature stop codons in their attachment glycoprotein's, 
which supports the findings of this study and suggest the data is technically sound. In a 
study by Rueda et al (1991) several hRSV escape mutants arose as a result of 
immunological pressure following several rounds of growth in the presence of a number of 
different monoclonal antibodies specific for the hRSV G protein. Sequence analysis 
revealed that 5 out of the 7 escape mutants had nucleotide changes yielding premature stop 
codons which resulted in truncations of 11 to 42 amino acids in the carboxyl terminal of 
the protein (Rueda et aI., 1991). Variation in the length of the attachment proteins may 
therefore be a useful strategy for evasion of antibody recognition, and it would be 
interesting to perform similar experiments with hMPV. 
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8.5. Sero-reactivity of hMPV G 
Due to the potential involvement of G in immune evasion, attempts were made in this 
project to develop the tools for analysis of human antibody reactivity against this protein 
looking at the potential for sero-cross reactivity between the G proteins obtained from 
different hMPV isolates, and mapping the immunodominant regions (Chapter 7). 
A recombinant baculovirus expressing the full length G protein of hMPV was generated. 
The success achieved with the nucleocapsid protein however was not repeated. A high 
MOl of recombinant virus was required in order achieve detectable levels of protein 
expression, and the protein proved difficult to extract from the cellular membrane material. 
Attempts to optimise the level of protein expression were not very effective and the 
reasons for this low level of expression were not investigated further within the scope of 
this work. Instead a recombinant baculovirus expressing a truncated extra cellular domain 
of G fused to the Fc fragment of human IgG was generated. This protein was expressed in 
very high levels in both glycosylated and un-glycosylated forms. 
Reactivity of a panel of human sera with known antibody status for the hMPV N protein 
was analysed against both the hMPV G-FL and G(s)-Fc. Only 2 human sera were 
consistently reactive against the G-FL protein by ELISA, IF and western blot analysis. 
However no human sera were reactive against the hMPV G(s)-Fc protein suggesting the 
integrity of the protein was not maintained when fused to the IgG Fc fusion protein. 
Alternatively antibody reactivity may be targeted towards the membrane and cytoplasmic 
regions of the protein. This data indicates that hMPV G(s)-Fc is therefore unsuitable for 
use in immunoassays. In addition the polyclonal rabbit serum raised against this protein is 
also unlikely to be a useful diagnostic or research reagent. 
The lack of antibody reactivity by a majority of the human serum tested against hMPV G-
FL may not be surprising given the extent of amino acid variation observed (Chapter 4). 
Furthermore western blot analysis revealed that the human serum only reacted with the un-
glycosylated species of hMPV G-FL. the rabbit a-hMPV total antiserum however 
appeared to recognise both, although the glycosylated species was less well recognised 
than the un-glycosylated. The reasons for the difference between human and rabbit serum 
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is not known but this data is somewhat consistent with that published by Bastian et al 
(2004) where polyclonal guinea pig antiserum raised against hMPV infected cells failed to 
react with the highly glycosylated species of recombinant baculovirus expressed G protein 
by Immuno-precipitation (Bastien et aI., 2004). 
These observations suggest that antibodies to the glycosylated forms of G may be poorly 
induced, and that glycosylation may interfere with antibody recognition of the G protein. 
As demonstrated in chapter 4 a large degree of heterogeneity exists in the glycosylation 
profiles of G proteins from different strains of hMPV. This heterogeneity may further 
contribute to the lack of antibody recognition. However, it should also be kept in mind that 
differences between human and insect cell glycosylation may also contribute to these 
results and this data should be treated with caution. 
Beyond antibody recognition of hMPV G-FL by the rabbit a-hMPV total antiserum, and 
human antiserum, and its association with cellular membranes, we did not evaluate 
whether the integrity of G-FL was maintained. There are however numerous examples in 
the literature of other viral glycoproteins such as hRSV G and the influenza 
haemagglutinin being successfully expressed in the recombinant baculovirus system and 
used for the development of immunoassays, protein characterisation and vaccination 
(Buraphacheep et aI., 1997, Crawford et aI., 1999, Sugiura et aI., 2001). Work on the 
influenza heaemagglutinin in particular has demonstrated that the baculovirus system is 
capable of expressing biologically functional glycoproteins. The integrity of hMPV G 
could have been assessed through the analysis of the extent and nature of its glycosylation, 
its cellular localization and whether oligomerisation of this protein occurs. 
Due to the differences in glycosylation observed between insect and mammalian cells 
(Sullender & Britt, 1996).The expression of hMPV G-FL in a mammalian cell expression 
system was also investigated using a plasmid based expression system (Chapter 7). 
Although this was only preliminary work analysis by immunofluorescence revealed the 
protein was successfully expressed and it paves the way for the production of 
constitutively expressing cell lines which can be used for immunoassays, and analysis of 
protein trafficking and localisation within the mammalian cell. Recombinant vaccinia 
viruses have also been previously used for the expression of hRSV G (Feldman et ai., 
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2001, Murphy et aI., 1988, Wertz et aI., 1989), and may prove useful when larger 
quantities of mammalian expressed G protein are required. 
Another approach being undertaken is the construction of pseudo-retrovirus particles 
expressing the hMPV G and F proteins. This is being done in collaboration with Dr Nigel 
Temperton (Wohl Virion Centre, UCL) and is currently only in its early stages. It is hoped 
these constructs will offer the opportunity to develop assays for measuring neutralising 
antibodies targeted against the G and F proteins, as well as providing a means of 
investigating susceptible cell lines and putative receptors. 
8.6. Vaccine development 
At this point it is still debatable as to whether hMPV vaccine development is worthwhile. 
While hMPV is clearly an important pathogen, the most at risk groups of severe illness are 
infants or young children who are often too young for vaccination to be of any benefit. 
Furthermore the ability of hMPV to cause repeated infections in older children and adults, 
and infect infants at a time when maternal antibodies should be protective raises the 
question as to whether protective immunity can be achieved through vaccination when it is 
clearly not achieved through natural infection. Repeat infections with hRSV, however, 
generally follow a milder cause of illness (Glezen et aI., 1986) , vaccination may therefore 
serve to reduce the severity of disease rather than prevent it altogether. 
Furthermore, given that a suitable vaccine candidate for hRSV (a far more important and 
well characterised virus), is yet to be found, it is likely, due to the many similarities of 
these two viruses that hMPV vaccine development will be equally problematic, and is 
further hampered by the limited availability of data on the pathogenesis of hMPV in its 
natural host. A number of groups have already embarked upon the search for a suitable 
vaccine candidate for hMPV through the use of reverse genetics and the construction of 
chimeric viruses which may allow for the more rapid identification and production of a 
number of monovalent or perhaps more useful polyvalent vaccine candidates (Biacchesi et 
aI., 2005, Biacchesi et aI., 2004, MacPhail et aI., 2004, Tang et aI., 2005). 
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8.7. Summary 
The work presented in this thesis contributes to the overall understanding of hMPV, and is 
the largest study of its type conducted within the UK. This work demonstrates the 
importance of hMPV as a pathogen through the development and application of a number 
of research tools and diagnostics and investigation of viral protein expression in 
recombinant systems. Sequence analysis of the hMPV G highlights a number of potentially 
important characteristics of this protein which should be considered for vaccine 
development. Moreover this study highlights a number of key areas which could be the 
focus of future research. 
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Ethical Approval 
The respiratory and serum samples analysed in this work where from patients who were 
not recruited specifically for this project. The studies used in this thesis were set up long 
before the commencement of this PhD, and there was no involvement in the actual patient 
sampling or clinical study design. The work for this PhD project fully complies with all 
existing UK legislation and Health Protection Agency policies 
The Royal College of General Practitioners (RCGP) Clinical Surveillance of influenza 
like illness(ILI) :This is a surveillance scheme that has been running in England since 
1993 and has pioneered linked clinical-virological investigation for the presence of 
respiratory viruses (Influenza, hRSV, hMPV and others) in the community. Swabs and 
serum are taken as part of these schemes and the types of investigations are documented in 
several publications (Ellis et ai., 1997, Stockton et ai., 1998, Stockton et ai., 2002, Zambon 
et ai., 2001). 
As these samples are taken as part of normal diagnostic work up, ethical committee 
submission is not required for investigation of respiratory viruses. 
Leicester Paediatric study: This is a study of infant hospitalisation related to Influenza, 
hRSV , hMPV and other respiratory viral pathogens documented in several publications 
(Nicholson et ai., 2006, Nicholson et ai., 2003). As these samples are taken as part of 
normal diagnostic work up, ethical committee submission is not required for investigation 
of respiratory viruses. 
Royal Free Immunocompromised study: These samples where taken as part of normal 
diagnostic work up for the investigation of respiratory illness, ethical committee 
submission is therefore not required for investigation of respiratory viruses. 
Age Stratified Serum: These serum were submitted to the HPA for testing for MMR, 
Parvovirus B 19 or rash virus diagnosis and not necessarily for respiratory virus infection. 
The sera used however were residual and not destined for any other testing, due only for 
discard, data was provided anonymously with the only detail being the age of the patient at 
the time of sampling. The latest ethics guidance document from The Royal College of 
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Pathologists "Interim guidance on the use of clinical samples retained in the pathology 
laboratory" issued in Nov 2004 specifically identifies testing of residual material for 
validation of new tests as desirable and is exempt from requirements for specific ethical 
approval. 
Data Security 
The Health Protection Agency is fully compliant with Caldicott guidelines, which were 
laid out in the 1997 December report (Department of Health & Caldicott, 1997). The HPA 
is unreservedly committed to preserving medical confidentiality in all aspects of its work, 
both in direct contact with clinicians and patients, and in aggregating data for surveillance 
and research purposes. 
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hMPV G gene sequences used in the phylogenetic analysis data presented in chapter 4 
of this thesis. Sequences were down loaded from http://www.ncbi.nlm.nih.gov/ 
Strain Accession no Reference 
NLOOI(AI)* AF371337 (van den Hoogen et aI., 2001) 
NL 1700(A2)* AY296021 (van den Hoogen et aI., 2004) 
N1l99(BI)* AY296034 
NLI94(B2)* AY296040 
NLl96 AY296042 
NL202 AY296020 
NLl81 AY296022 
NLl82 AY296041 
NLl93 AY296023 
NLl95 AY296026 
NL900 AY296044 
NL901 AY296038 
NLIOOI AY296019 
NLIIOO AY296035 
NLl200 AY296036 
NL2101 AY296039 
NL2201 AY296029 
NL2301 AY296031 
NL2401 AY296030 
NL2901 AY296032 
NL293 AY296024 
NL296 AY296027 
NL301 AY296045 
NL302 AY296033 
NL393 AY296025 
NL396 AY296028 
NL401 AY296046 
NL501 AY296037 
NL697 AY296043 
UK501 AY296047 
BR201 AY296014 
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FL301 AY296016 
FL401 AY296015 
FL801 AY296017 
FL1001 AY296018 
CAN3402 AY574225 (Bastien et aI., 2004) 
CAN3402 AY574225 
CAN4002 AY574226 
CAN5802 AY574227 
CAN9702 AY574228 
CAN9783 AY574249 
CAN9875 AY297748 
CAN9980 AY574247 
CAN9981 AY574224 
CAN 16402 AY574229 
CAN18202 AY574230 
CAN18702 AY574231 
CAN18802 AY574232 
CAN19402 AY574253 
CAN19702 AY574234 
CAN20802 AY574235 
CAN21502 AY574236 
CAN21602 AY574237 
CAN21902 AY574238 
CAN 22702 AY 574239 
CAN 34702 AY 574240 
CAN 34802 AY 574241 
CAN 43202 AY 574242 
CAN 46402 AY 574243 
CAN 53202 AY 574244 
CAN 54702 AY 574246 
CAN 53402 AY 574245 
HMPV8099 AY 485250 (Peret et aI., 2004) 
HMPV 8397 AY 485223 
HMPV13200 AY 485232 
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HMPV 16200 AY 485033 
HMPV 17200 AY 485234 
HMPV 222001 AY 485236 
HMPV 232001 AY 485238 
HMPV 282001 AY 485239 
HMPV 292001 AY 485240 
HMPV 312001 AY 485241 
HMPV 332001 AY 485242 
HMPV 731998 AY 485243 
HMPV 741998 AY 485244 
HMPV 751998 AY 485245 
HMPV 761998 AY 485246 
HMPV 771998 AY 485247 
HMPV 781998 AY 485248 
HMPV 791998 AY 485249 
HMPV 811999 AY 485251 
HMPV 821997 AY 485252 
HMPV 1932002 AY 485235 
HMPV 2282002 AY 485237 
HMPV 8631602 AY 485254 
HMPV 8844802 AY 485255 
HMPV 8847002 AY 485256 
JPS03480 AY 530092 (Ishiguro et aI., 2004) 
JPSO 3191 AY 530094 
JPSO 3240 AY 530095 
JPSO 276 AY 530089 
JPSO 3176 AY 530090 
JPSO 3178 AY 530091 
Q01419 AY 327803 (Mackay et aI., 2003) 
Q01629 AY 327810 
Q01634 AY 327806 
Q01641 AY 327804 
Q01718 AY 327802 
Q01726 AY 327805 
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Q01729 
Q01799 
Q01225 
*Reference strains 
AY 327809 
AY 327807 
AY 327808 
Amino acid alignment of hMPV G protein sequences obtained from the Community 
Study 
299 
Majority 
JMRCGP558 
JMRCGP1400 
NL1700GA2 
JMRCGP9935 
JMRCGP336 
JMRCGP2184 
JMRCGP4661 
JMRCGP559 
NL100BA1 
NL199GB1 
RCGP348034 
NL194GB2 
Majority 
JMRCGP558 
JMRCGP1400 
NL1700GA2 
JMRCGP9935 
JMRCGP336 
JMRCGP2184 
JMRCGP4661 
JMRCGP559 
NL100BA1 
NL199GB1 
RCGP348034 
NL194GB2 
Majority 
JMRCGP558 
JMRCGP1400 
NL1700GA2 
JMRCGP9935 
JMRCGP336 
JMRCGP2184 
JMRCGP4661 
JMRCGP559 
NL100BA1 
NL199GB1 
RCGP348034 
NL194GB2 
Majority 
MEVKVENI~IDMLKARVK~RVARSKCFK~ASLILIGITTLSIALNIYLIINYTMQKNTSESEHHTSSSP 
I I I 
10 20 30 40 50 60 70 
I I 
· ..................................................... I .. T .......... P. 
· ..................................................... I .. T .......... P. 
· ..................................................... I .. T .......... P. 
.:.: .. :: :~::'::::':::':':'::':':::':::::':::::'.:.:'::' :~'::::':.::::: 
· ...•...• T •..•••....•....•.... T.. G 
.•....... T ••••••••.....•••...•••. ~:::::::::::::::::: :~::.::::::::::::: 
· .. R ......... F .. K1. .. IRS. R. YR .. T ..... L.A .. M .... F ... DHATLR.MIKT . NCANMPS 
... R ......... F .. KI ... IRS.R.YR .. T ..... L.A .. M .... F ... DHATSR.MIKT.NCANMPS 
· .. R ......... F .. KM ... IRS ... YR .. T ..... L . A .. M .... F ... D. A. L .. MTKV .. CVNMP . 
MESSKETPTVPTDNSDTNPGSQYPTQQSTEGSTLHFAASASSPETEPTSTPDTTSRPPFVDTHTTPPSAS 
, , , I , I I 
80 90 100 110 120 130 140 
I I I « , I « 
T .. N ... S. 1. 1. . P.r.. N .. H ....... SL .. YP. S. V. PS .... A ... G1. N. LSS .. RS .. Q .. G. 
T .. N ... S. 1. 1. . P.r.. N .. H ....... SL .. YP. S. V. PS .... A ... GI. N. LS ... RS .. Q .. E. 
T. PN .. AS. IS ... P.r.. S .. H ....... NP .. NP ..... PS .... A ...... N. LSS .. RS. AQ .. E. 
.•.• R •••••• M •••.••...•.•.••...••...•••••.••••..••.............••••. G •• 
..•. R ....•• M •.........•..•.....•... P ....•...........••.... L .......... . 
.... R ...... I ....................... S .................... L ............ . 
•.•• R •••••• M •••..•..••...•..••.•.•..••...•....•... S •••..•...•....••... 
•... R .... I.M ............... P ....•. Y ...•......•..•......•.............. 
.... R ............. SSP.H ........... Y ................... N .............. . 
A.P .. K .. MTS.AGPN.K.NP.QA .. WT .. N .. SPV.TPEGH.Y.GT.Q.S ... APQQTT.K .. A.LKST 
A.P .. KA.MTS.AGPS.K.NP.QA .. WT .. N .. SPA.TPEGH.Y.GT.Q ..... APQQTT.KY.AL.KST 
V.P .. K .. MTSAVDLN.K.NP.QA .. LAA.D .. SLA.T.EDHLH.GT.P ... A.VSQQTT.EY .. LLRST 
RTRTSPAVHTKNNPRISSRTHSPPWATTRTVRGTTTLRTSSTRKRPSTASVQPDSSATTHKHEEASPASP 
I I I I I I I 
150 160 170 180 190 200 210 
I I I I I I I 
· .KIN.T .. K .. ISSTV ... Q .. TRT.AKAATRA.A .. M ... GE .. T.T ... S ... T .. QN ... TGS.N. 
· . K. NST .. K .. ISST1. .. Q ... RT. AKA. PR .. AF ..... GE .. T. T ... S ... T. AQN ... TGS. N. 
· . K. K. T ... 1. .. NTA. S. Q ... RT .. KAI. RA .. F. M ... G ... T. TL .. S ... T .. QN ... TGS. N. 
..••...•....• L •.• P ...•...• M .............. 1 ........................• V •. 
.K •......•.•.•... P ........ M ...........•.• 1 •........................ V .. 
................. P.A ..................... I ...............•......... V .. 
••.••.••••••••••• P .•.•..•.............•....••••.•.•......•......... V •. 
....•••••.•..• K .• L ..•.•.. VM .. M •........•.•.•..•......•..•..... ···•···· 
· .K •.....•.•.•. T ........ R •...• A.R ..................... 1 ...... N ....... . 
NEQITQTTTE.KTI.ATTQKREKGKEN.NQTTS.AATQ.TN.TNQIRN .. ETITT.DRPRTDTTTQSSEQ 
NEQITQTTTE.KTT.ATTQKREKGKEN.NQTTS.AATQ.TN.TNQIRN.RRDNHNIRQ.QN 
NRQ.TQTTTE.KPTGATTKK-----E .. TRTTS.AATQ.LN.TNQT.YVREATTT .. RSRNSATTQSSDQ 
QTSASTARPQRKGMEASTSTTYNQTS-----
, I I 
220 230 240 
JMRCGP558 . A .... MQK 
JMRCGP1400 .A .... M 
NL1700GA2 .A .... MQN 
JMRCGP9935 
JMRCGP336 
· .... I ................... . 
· ........................ . 
JMRCGP2184 . A ....................... . 
JMRCGP4661 .......... G .............. . 
JMRCGP559 ..................... LQFKLS 
NL100BA1 
NL199GB1 
RCGP348034 
· ..... T. I ... SV .. N ........ . 
T.R.TDPSSPPHHA 
NL194GB2 T.Q.ADPSS.PHHTQK .. T .... TDTSSPSS 
Amino acid alignment of hMPV G protein sequences obtained from the hospitalised 
Children's study 
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Majority 
JMLEIC72 
JMLEIC2564 
JMLEIC506 
JMLEIC4292 
JMLEIC399 
JMLEIC1294 
NL1700GA2 
JMLEIC1011 
JMLEIC1758 
GBaculo 
JMLEIC552 
JMLEIC138 
JMLEIC125 
JMLEIC37 
JMLEIC492 
MEVKVENIRTIDMLKARVKNRVARSKCFKNASLILIGITTLSIALNIYLIINYTMQE 
I I I I I NTSESEHHTSSSP 
• . . . . . . .. . . ..•..................................... I KT S P 
......... A..................... ·I·KT······· " . 
....................... P 
.....•... A..................... I·KT·········· . 
. . . . . . . . . . . . . . . • . . . . . . P • 
..•..... . A..................... ·I·KT·········· . 
. . . • . . . . . . . . . . . . . . . . . . P • 
........ . A................... ·I·KT·········· . 
......................... P 
......... A...................... I·KT········· 'p' 
o •••••••••••••••••• 
· ........ A ........................................ '" I' KT' ......... p' 
......... A ........................................ :::·I·KT··········p· 
" ........ " . 
· ................................................................... " .. 
· ................................................................... " .. 
· ................................................................... " .. 
· ................................................................... " .. 
· .................................................................... . 
•••••••••••••••••••••.•••••.•..••..•••.•.•••.•••..•.••.. G •••.•.•...... 
· .................................................................... . 
JMLEIC2294 .......... V .......................................................... . 
JMLEIC55 
JMLEIC417 
· .................................................................... . 
· .................................................................... . 
NL100BA1 ................................. V ................... K .. K ............ . 
JMLEIC2392 ............. S ........ 0 ••••••••••••••••••••••• 0 ••••••••••••••••••••••• 
JMLEIC210 
JMLEIC13 
JMLEIC1627 
NL199GB1 
NL194GB2 
Majority 
JMLEIC72 
· .................................................................... . 
· .................................................................... . 
· .................................................................... . 
· .. R ..... A ... F .. KI ... IRS. R. YR .. T ..... L.A .. M .... F ... DHATLR.MIKT. NCANMPS 
· .. R ...•. A ... F .. KM •.. IRS ... YR .. T ..... L . A .. M .... F ... D. A. LK. MTKV .. CVNMP . 
MESSRETPTVPMDNSDTNPGSQYPTQQSTEGSTLHFAASASSPETEPTSTPDTTSRPPFVDTHTTPPSAS 
I I I I I I I 
80 90 100 110 120 130 140 
I I I I I I I 
T .. NK .. S. T. 1. . PG1. .N .. H ....... SL .. YP. S. V .. S .... A ... G1.N. LS ... RS .. Q .. E. 
JMLEIC2564 T .. NK .. S. 1. 1. . PG1. . N .. H ....... SL .. YP. S. V .. S .... A ... G1. N .LS ... RS .. Q .. E. 
JMLEIC506 T .. NK .. S. 1. 1. . P.r.. N .. H .•.. P .. SL .. YP. S. V •• S .... A ... G1.N .LSS .. RS .. Q. oK. 
JMLEIC4292 T .. NK .. S. 1. 1. . P.r.. N .. H .... P .. SL .. YP. S. V .. S .... A ... G1. N .LSS .. RS .. Q .. K. 
JMLEIC399 T .. NK .. S. 1. 1. . P.r.. N .. H .... P .. SL .. YP. S. V .. S .... A ... G1. N. LSS .. RS .. Q .. K. 
JMLEIC1294 T .. NK .. S. 1. 1. . P.r.. N .. H .... P .. SL .. YP. S. V .. S .... A ... G1. N. LSS .. RS .. Q .. K. 
NL1700GA2 T.PNK.AS.IST .. P.I .. S .. H ....... NP .. NP ..... PS .... A ...... N.LSS .. RS.AQ .. E. 
JMLEIC1011 T .. NK .. S. 1. 1. SP. 1. . N .. H ....... SL .. YP. S. V. PS .... A ... G .. N .. S ... RS .. Q .. E. 
JMLEIC1758 ................................ A .................................... . 
GBaculo 
JMLEIC552 
JMLEIC138 
JMLEIC125 
JMLEIC37 
JMLEIC492 
JMLEIC2294 
JMLEIC55 
JMLEIC417 
NL100BA1 
JMLEIC2392 
· .................................................................... . 
....................................................... . L ............ . 
· ........ I ................................. , .............. , .. 0 •• •••••• 
......... 1 .......... P ........... A .................... · .. ·············· 
................................... S .. P ....................... ·.·· 0 ••• 
· .......•................................................. L .......... . 
· .................................................................... . 
. , ......... I ...................... YS ............... ··················· 
P P YS ......................... I ...... T. · . . . . . . . . . . . .. ..... . ........... . 
.......... . T ...... SSP.H ........... Y .............. ···· .N ......... ·.···· 
• ••••••••••••• , •• , ••••• , •••••••••• , •••• " •• , ••• 0 •• S .................. . 
JMLEIC210 ..... S.V ............ S ............. ······ 
JMLEIC13 
......... I' . . . . . . . . . . . . . . . . . . . . . .................................. V. 
· . . . . . . .. . ..................... . 
JMLEIC1627 AE S ... S ........... ·········· .L ......... ·· 
NL199GB1 ~:~:~~: :~~~TA~~~:~:N~:Q~: :~~: :~:.SPV.TPEGH.Y.GT.Q.S ... APQQTT.K .. A.LKST 
NL194GB2 V.P.KK .. MTSAVDLN.K.NP.QA .. LAA.D .. SLA.T.EDHLH.GT.P ... A.VSQQTT.EY .. LLRST 
301 
Majority 
JMLEIC72 
JMLEIC2564 
JMLEIC506 
JMLEIC4292 
JMLEIC399 
JMLEIC1294 
NL1700GA2 
JMLEIC10ll 
JMLEIC1758 
GBaculo 
JMLEIC552 
JMLEIC138 
JMLEIC125 
JMLEIC37 
JMLEIC492 
JMLEIC2294 
JMLEIC55 
JMLEIC417 
NL100BAl 
JMLEIC2392 
JMLEIC210 
JMLEIC13 
JMLEIC1627 
NL199GBl 
NL194GB2 
Majority 
JMLEIC72 
JMLEIC2564 
JMLEIC506 
JMLEIC4292 
JMLEIC399 
JMLEIC1294 
NL1700GA2 
JMLEIC10ll 
JMLEIC1758 
GBaculo 
JMLEIC552 
JMLEIC138 
JMLEIC125 
JMLEIC37 
JMLEIC492 
JMLEIC2294 
JMLEIC55 
JMLEIC417 
NL100BAl 
JMLEIC2392 
JMLEIC210 
JMLEIC13 
JMLEIC1627 
NL199GBl 
NL194GB2 
RTKTSPAVHTKNNPRTSPRTHSPPRATTRTVRGTTTLRTSSTRKRPSTASVQPDSSATTHKHEEASPVSP 
i I I I I 
· .R .......... L.I ........ L.M .............. 1 ........................... . 
............. L.I ........ W.M .............. 1 ........................... . 
· .R .......... L.I.S ...... W.M .............. 1 ........................... . 
• .R ..••..••••.. I.S ...... W.M ... A ..•....•.•........•..............•.•... 
· .R ..................... W.M .............. I ........................... . 
· .R .......•.... 1 ........ W.M .................................. '" ..... . 
•••• " T •••• , ••• I. '" •••• W •• " •••••••••••••••••••••••••••••••••••••• M •• 
• .R •••••••••••••••••• F •• W ••••••••••••••••••••••••• A ••••••••••••••••••• 
· .R •.•.•••..•••...... L .• W.M ............................. T ......••..•. L 
•••.•.•••.••.•.•• S ••.••••..•.. A.R ..................... 1 .••..• N •••.• A •• 
.. R ........ KQSKDK.QNTF.TMGNDKDGPWDHHSPHKQHK.KTVHSISPTRQQRNNPQTRRSK.SE. 
.. R ........ KRSKDK.QNTF.TMGNDKDGPWDHHSPHKQHK.KTVHSISPTRQQRNNPQTRKSK.SE. 
· .R ........ KQSKDKLQNTF.TMGNDKDGPWNHHSPHKQHK.KTVHSISPT 
......... K.TTQGQA.EHVPHHGQQQGRSTEPPLSAQAAQE.DRPQHQSN.TAAQQSTNTKKQVQ 
NEQITQTTTE.KTI.ATTQKREKGKEN.NQTTS.AATQ.TN.TNQIRN .. ETITT.DRPRTDTTTQSSEQ 
NRQ.TQTTTE.KPTGATTKK-----E .. TRTTS.AATQ.LN.TNQT.YVREATTT .. RSRNSATTQSSDQ 
QTSASTARPQRKGMEASTSTT-NQT------
I I I 
220 230 
.A .... MQN.HTNIARPN 
.A .... MQN.HTNIARPN 
.A .. N.M 
.A .. N.M 
.A .. N.M 
.A .. N.M 
.A .... MQN 
•••• , •••••••••••••••• H ••• S 
••••••••••••••••••• " Y ••• S 
• •••• I •••..•.••.• " •. Y .•. S 
••••••• , ••••••••••••• Y ••• S 
•• " ••••••••••••••••• Y ••• S 
., .... '" ..•.••.... , .H .•. S 
• ••••• T ••••••••• , •••• Y ••• S 
., •••••••• G •••••••••• Y ••• S 
• ••• G •••••••••• T ••• ,. Y ••• S 
· .••.•..••..•..• , .. , .H •.. S 
· ..... T. I ... SV .. N .... Y ... S 
ANICKHSKTT.E.YGGQHINNIQPN 
ANICKHSKTT.E.YGGQHINNIQPN 
240 
T.R.TDPSSPPHHA 
T.Q.ADPSS.PHHTQK .. T .. Y.TDTSSPSS 
302 
Amino acid alignment of sequences generated in this study from the community and 
hospitalised children's studies. 
Majority 
JMLEIC72 
JMLEIC2564 
JmRCGP1400 
JMRCGP558 
JMLEIC506 
JMLEIC4292 
JMLEIC399 
JMLEIC1294 
NL1700GA2 
JMLEIC1011 
JMLEIC2294 
JMRCGP466 
GBacu10 
JMLEIC1758 
JMLEIC552 
JMRCGP993 
JMLEIC138 
JMLEIC125 
JMLEIC492 
JMRCGP336 
JMRCGP2184 
JMLEIC37 
JMLEIC55 
JMLEIC417 
JMRCGP559 
NL100BA1 
JMLEIC2392 
JMLEIC210 
JMLEIC13 
JMLEIC1627 
NL199GB1 
RCGP348034 
NL194GB2 
Majority 
JMLEIC72 
JMLEIC2564 
JmRCGP1400 
JMRCGP558 
JMLEIC506 
JMLEIC4292 
JMLEIC399 
JMLEIC1294 
NL1700GA2 
JMLEIC1011 
JMLEIC2294 
JMRCGP466 
GBacu10 
JMLEIC1758 
JMLEIC552 
JMRCGP993 
JMLEIC138 
JMLEIC125 
JMLEIC492 
JMRCGP336 
JMRCGP2184 
JMLEIC37 
JMLEIC55 
JMLEIC417 
JMRCGP559 
NL100BA1 
JMLEIC2392 
JMLEIC210 
JMLEIC13 
JMLEIC1627 
NL199GB1 
RCGP348034 
NL194GB2 
MEVKVENIR~IDMLKARVK~RVARSKCFK~ASLILIGITTLSIALNIYLIINYTMQENTSESEHHTSSSP 
10 20 30 4~ 5~ I 
I I I I 60 70 
, I 
...................... 
. ...................... . 
· .............................. . 
. ................................ . 
· ........................................ . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . 
......................... 
· ......................... . 
•.••.•.. A .••.••.. 
................................... 
. ............................................ . 
.................... 
. ............................ . 
· ......................................... . 
· ........................ " 
...................................... 
.................................... 
· ................................... . 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
••••••••••••••••••••••••••••••••••••••••••••••••• G ••••••••••••• 
· ......................................... . 
· ......................... . 
...................................... 
••.••.••••.•••••.•••. T •..••••.•••.••.•••.•••••• G •••••.....••• 
• •••••••••••••••.••••....•••••..• V .••.•.•...••••••••• K .• K .••.••.•....• 
· ............ S ....................................................... . 
· .................................................................... . 
.................................................. 
· .................................................................... . 
· .. R ..... A ... F .. K I ... IRS. R . YR .. T ..... L . A .. M .... F ... D HAT L R . M I KT . NC ANM P S 
.. R ..... A ... F .. K I ... IRS. R . YR .. T ..... L . A .. M .... F ... D HA T SR. M I KT . N CANM P S 
· .. R ..... A ... F .. KM ... IRS ... YR .. T ..... L. A .. M .... F ... D. A. LK. MTKV .. CVNMP. 
MESSRETPTVPMDNSDTNPGSQYPTQQSTEGSTLHFAASASSPETEPTSTPDTTSRPPFVDTHTTPPSAS 
iii I I I I 
80 90 100 110 120 l30 l4( 
I « , I I I I 
T .. NK .. S.T.I .. PGI .. N .. H ....... SL .. YP.S.V .. S .... A ... GI.N.LS ... RS .. Q .. E. 
T .. NK .. S.I.I .. PGI .. N .. H ....... SL .. YP.S.V .. S .... A ... GI.N.LS ... RS .. Q .. E. 
T .. N K .. S . I. I .. P . I. . N .. H ....... S L .. Y P . S . V . P S .... A ... G I . N . L S ... R S .. Q .. E . 
T .. NK .. S.I.I .. P.I .. N .. H ....... SL .. YP.S.V.PS .... A ... GI.N.LSS .. RS .. Q .. G. 
T .. NK .. S.I.I .. P.I .. N .. H .... P .. SL .. YP.S.V .. S .... A ... GI.N.LSS .. RS .. Q .. K. 
T .. NK .. S.I.I .. P.I .. N .. H .... P .. SL .. YP.S.V .. S .... A ... GI.N.LSS .. RS .. Q .. K. 
T .. NK .. S.I.I .. P.I .. N .. H .... P .. SL .. YP.S.V .. S .... A ... GI.N.LSS .. RS .. Q .. K. 
T .. NK .. S.I.I .. P.I .. N .. H .... P .. SL .. YP.S.V .. S .... A ... GI.N.LSS .. RS .. Q .. K. 
T . P N K . AS. 1ST .. P . I .. S .. H ....... N P .. N P ..... P S .... A ...... N . L S S .. R S . AQ .. E. 
T .. N K .. S . I . I . S P . I .. N .. H ....... S L .. Y P. S . V . P S .... A ... G .. N .. S ... RS .. Q .. E. 
...................................... 
· •.•.•..•.•......•..................•..........•.. S •.••.......•....••. 
...................................... 
· ....... , ...................... . A ...... , ... " ...... , ................. . 
· •.•.•....•.•..•....••.•...•.••.•.........•.........•.•. L ..•......•..• 
• •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• G •• 
· ........ I ........................................................... . 
. • • . . . I ...•..•... P ....•..•... A ..........•...•...••..•.....••....... 
· ......•••.••••.....•.....•..•...•........•..•......•.•... L .....•...•. 
• .....•.••.•.••..•...•.....•.....•. P .......••......•...•.. L •....••.•.. 
..•...•• I ••..•..•......••..••... S ..•••.......••..••.• L ••.....•.•... 
· ••....••.••••..•.......•..•....••. S .• P ..•........•.•................• 
:::::::::::~::~:::::~:::::::::::::~~:::::::::::::::::::::::::~::::::~: 
• ••.•..•• I ••.••.•••.••...•• P .•••.. Y •••••..•.•.••...••••••••.•.•.••...• 
.......... T ...... SSP.H ........... Y .......... ········ .N ......... ······ 
· ................................................. S .................. . 
:::::::::~:::::::::::::::::::::::::::~::::::::::::~:::::::~::::::::>: 
........... AE ...... S ..•••••••• · . K A LKST 
A P KK MTSTAGPN K NP QA WT .. N .. SPV.TPEGH.Y.GT.Q.S ... APQQTT .... •• • • •.•• • TT KY AL KST 
A. P . KKA. MT STAG P S . K . N P . QA .. WT .. N .. SPA. T PEG H . Y . G T . Q ..... A P QQ TT . E Y· L ~RS T 
V.P.KK .. MTSAVDLN.K.NP.QA .. LAA.D .. SLA.T.EDHLH.GT.P ... A.VSQQ ... 
303 
Majority 
JMLEICn 
JMLEIC2564 
JmRCGP14 00 
JMRCGP558 
JMLEIC506 
JMLEIC4292 
JMLEIC399 
JMLEIC1294 
NL1700GA2 
JMLEICIOll 
JMLEIC2294 
JMRCGP466 
GBaculo 
JMLEIC1758 
JMLEIC552 
JMRCGP993 
JMLEIC138 
JMLEIC125 
JMLEIC492 
JMRCGP336 
JMRCGP2184 
JMLEIC37 
JMLEIC55 
JMLEIC417 
JMRCGP559 
NLIOOBAl 
JMLEIC2392 
JMLEIC210 
JMLEIC13 
JMLEIC1627 
NL199GBl 
RCGP348034 
NL194GB2 
Majority 
JMLEIC72 
JMLEIC2564 
JmRCGP1400 
JMRCGP558 
JMLE1C506 
JMLE1C4292 
JMLE1C399 
JMLEIC1294 
NL1700GA2 
JMLEICIOll 
JMLE1C2294 
JMRCGP466 
GBaculo 
JMLEIC1758 
JMLE1C552 
JMRCGP993 
JMLE1C138 
JMLEIC125 
JMLE1C492 
JMRCGP336 
JMRCGP2184 
JMLEIC37 
JMLE1C55 
JMLEIC417 
JMRCGP559 
NLIOOBAl 
JMLE1C2392 
JMLE1C210 
JMLEIC13 
JMLEIC1627 
NL199GBl 
RCGP348034 
NL194GB2 
RTRTSPAVHTKNNPRTSPRTHSPPWATTRTVRGTTTLRTSSTRKRPSTASVQPDSSAT 
I I I THKHEEAS PVS P 
· .••••..•••.•.• I .••••.••.• M ....•••••....•.......•...•......••..•••••.• 
• K •••••.•..•••• I ••.•••.•.. M .••..••••..•.. I .•....•.•.•..••••.....•....• 
· .............. I ... A ..................... I ........................... . 
· •...•.••..•.••.•••••••... M •..•........•. I ••.....•.....•.••.....•••••• 
• .•............•..•.. F .•....••..........•......... A ..•...•••••••.•••.. 
· ••.....•..•.••.••••• L •••. M •..•.••.•.....•..•.....•••••• T .•••••.•••.• L 
· ............. K I . L ....... VM .. M ..................................... A .. 
· .K .............. S ...... R ..... A.R ..................... 1 ...... N ..... A .. 
.......... . KQSKDK.QNTF.TMGNDKDGPWDHHSPHKQHK.KTVHS1SPTRQQRNNPQTRRSK.SE. 
........... KRSKDK.QNTF.TMGNDKDGPWDHHSPHKQHK.KTVHSISPTRQQRNNPQTRKSK.SE . 
.......... . KQSKDKLQNTF.TMGNDKDGPWNHHSPHKQHK.KTVHSISPT 
· .K ...... K.TTQGQA.EHVPHHGQQQGRSTEPPLSAQAAQE.DRPQHQSN.TAAQQSTNTKKQVQ 
NEQITQTTTE.KTI.ATTQKREKGKEN.NQTTS.AATQ.TN.TNQIRN .. ETITT.DRPRTDTTTQSSEQ 
NEQITQTTTE.KTT.ATTQKREKGKEN.NQTTS.AATQ.TN.TNQIRN.RRDNHNIRQ.QN 
NRQ.TQTTTE.KPTGATTKK-----E .. TRTTS.AATQ.LN.TNQT.YVREATTT .. RSRNSATTQSSDQ 
QTSASTARPQRKGMEASTSTT-NQT------
I i I 
220 
.A .... MQN.HTNIARPN 
· A .... MQN. HTNIARPN 
.A •.•. M 
· A .... MQK 
· A .• N. M 
· A .. N. M 
.A .. N. M 
• A .• N. M 
· A .... MQN 
230 
• .•.•..••• G •••.•..••. Y .•• S 
· •...•..•• G •.••.•.•.• Y •.• S 
· .••••••.•••••.•.•.•. Y .•. S 
• •.•.•..••.•.••...•.• H ••• S 
· ••.. I ..••.......•... Y ... S 
• ...• I •••..•.•••..... Y •.• S 
• •••••.••..••••.••••• Y •.• S 
· •••••••••••••••.•.•. Y .•. S 
• ••••. T •••••••••••••• Y ••• S 
• •••••.••.••••••••.•• Y ••. S 
· A ...•.••••.•.••..•.. Y ... S 
• •••.•••.••.••.••.•.• H ••• S 
• ••• G •••.•••••• T ••••• Y •.• S 
• .•.••••••.•••••••.•• H .•• S 
· .................... LQFKLS 
· ..... T. I ... SV .. N .... Y ... S 
ANICKHSKTT.E.YGGQH1NN1QPN 
ANICKHSKTT.E.YGGQH1NNIQPN 
T.R.TDPSSPPHHA 
240 
T.Q.ADPSS.PHHTQK .. T .. Y.TDTSSPSS 
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Amino acid alignment of all hMPV subtype B G protein Sequences 
Majority 
NL501 
NL1200 
NL199Bl 
NLllOO 
hMPV332001 
RCGP4B0341 
NL900 
UK501 
hMPV74199B 
hMPV73199B 
hMPV77199B 
hMPV7B199B 
NL401 
hMPV76199B 
CAN99BO 
hMPV75199B 
CAN9B75 
NL697 
NL194B2 
NL1B2 
Majority 
NL501 
NL1200 
NL199Bl 
NLllOO 
hMPV332001 
RCGP4B0341 
NL900 
UK501 
hMPV74199B 
hMPV73199B 
hMPV77199B 
hMPV7B199B 
NL401 
hMPV76199B 
CAN99BO 
hMPV75199B 
CAN9B75 
NL697 
NL194B2 
NL1B2 
Majority 
NL501 
NL1200 
NL199Bl 
NLllOO 
hMPV332001 
RCGP4B0341 
NL900 
UK501 
hMpV74199B 
hMpV73199B 
hMpV77199B 
hMpV7B199B 
NL401 
hMpV76199B 
CAN99BO 
hMpV75199B 
CAN9B75 
NL697 
NL194B2 
NL1B2 
...•.•..•......•. 1 ......• R.. . I H R I .L 
....................... '" .. 1. T.N .A .... 
................. 1 ....... R..... H R I 
..................... '" " .T.N.A .... 
................. I ....... R...... H R IT 
.. " •••. '" '" ..•••. '" " •• N .A •.• S 
.•.••.•.•••.•••.. 1 .•••.•. R ••..•...••.........•....•• H .•. R .• I.T N A S 
................. 1 ....... R··············· ........... H ... R .. I.T:N:A:::S 
................. 1 ....... R .......................... H .. SR. IT N A S 
.... '" 
· .................................................................... . 
· ............................................................. " ..... . 
· .................................................................... . 
• .•••••.•..•••••••••.••••..........•.••.•.•.••.•..••.•••• K .•.•••••••.• 
• ••••••••••••••••••••••••••••••••• " '" • '" • '" •••••••••••••• G •••••••• 
· ................................................................ " .. . 
...................................... S ............... KS.T .. R ........ . 
· ..•....•....•...•................... S ......•........•. S .........•..•. 
· •................................... S ................. S •••.....•.•... 
• .....•..........•.•.•............••. S ......•.......... S ...••......•.• 
• • A •••••••••••••••••••••••• H ••••••••• S •• P ••••• TL .... H •• S •••••••••••••• 
· .................................................................... . 
•..•••••.•.••.•••.••.•.•••..•••.••••.••••..•.•••....•• M .•.•••••.••.••• 
• ..••.••. T •.•••••••• " .••..•••..••••. " . '" ••...• " •••. F ••.•.•••• A •••• 
VEPSKKTPMTSAVDPNTKPNPQQATQLTTEDSTSLAATLEDHLHTGTTPTPDATVSQQTTDEHTTLLRST 
I I I Iii i 
BO 90 100 110 120 130 14 
« « , I I I , 
A ... R ...... TAG ............ w ... N ... P ... P . G ....... Q ... T . AP ..... K .. A. PK .. 
A .......... TAG ............ w ... N .. FP ... S . G ....... Q ... T. AP ..... K .. A. PK .. 
A .......... TAG ............ w ... N ... PV .. P. G. PY .... Q. S. T. AP ..... K .. AP. K .. 
A .......... TAG. S . E ........ w ... N ... P ..... S. PY .... Q ... I . AP ..... K .. A. PK .. 
A .......... TAG. S .......... w ... N ... P ..... G. PY . E .. Q ... T. AP ..... KY . A. SK .. 
A ..... A .... TAG. S .......... w ... N ... P ... P. G. PY .... Q ... T. AP ..... KY. A. PK .. 
• ••••••••••••• S ••••••••••••••••••••••••••• P ••••••••••••••••••••••••••• 
• •••.•.••.•.•• L •.••.••••.•.•..•••.••••..•. P •.•.••.••.•.•.••••.••.•.••• 
· .•...•.•..•.• L ...•..............•...•.......•...........••........•.• 
• ...........•. L ..... " ..... " . " ......... , ...........•..............•. 
· •••••••••••.• L ••.•••.•.••.•••.••.•••••.•..•••.••...•.• F •.•.••.••••••• 
· .•........•.. S ................... P ................................•.. 
• .•..•.•.••••. L .•.....•.••...•.•.. P ..•.. G •....•.•.•••...•.•••••...••• , 
· •...•.•....•...........•...........•. P ..................•.......... PI 
• •••••••••••••••••••••••••••••.••••••• P ••••••••••••••••••••••••••••• PI 
· ................................................................. , .. . 
.••••.•.•.•• A ••.•.•....•.•.•.•••....•...•....•.•.•.•.•..••••.••••••••• 
............. . L ... L ................... S.G.P .......................... . 
· ............. L ............ AA ••••••••• S ••••••••••••••••••••••• Y ••••••• 
........... T .. SS.G ..... T .. W ••••••••••• S ........... L ........ P.K ... P ... . 
NRQTTQTTAEKKPTRATTKKETTTR-----TTSTAATQTLNTTNQTSNGREATTTSARSRNNATTQSSDQ 
Iii Iii i 
150 160 170 lBO 190 200 21 
I I I I I I « 
· E. 1 .. A. T ... T .. E .. QRREKGKENTNQ ......... T ..... IR. AS. TI ... D. P. TDS ..... E. 
· E. 1. ... T ... T ..... QRREKGKENTNQ ......... T ..... IR. AS. T I ... D. P. TDS ..... E. 
· E . 1. ... T ... T 1. ... Q . RE KGKENTNQ ......... T ..... 1 R . AS . T 1. .. D . P. T DT ..... E. 
· E. I .... T ... T ..... Q. REKEKENTNQ ......... T ...... R. AS. TI ... D. P. IDT ...... . 
· E. 1. ... T ... T .... PQRRKKGKENTNQ ......... T ..... IR. AS. T1. .. D. P. ID1. .... E. 
.E.I .... T ... T ..... Q.REKGKENTNQ ......... T ..... IR.A.RDNHNIRQTQ. 
· ......................... . ----- .......................................... . 
................................ . ----- ............................................... .. 
· ................................... .. ----- ...................................................... .. 
· .................................... .. ----- .............................................................. . 
......................................... 
----- ................................................................ .. 
· ......................................... .. 
_____ ...•...•...•...•.•....•..••... S •....••. · 
..................... . 1 .. ----- ....................................... . 
· ....................................... .. 
----- ................................................................ .. 
· ....................................... .. 
----- ................................................................... .. 
........................................... 
----- ............................................................. .. 
........................ . ----- .......................... :::: :~::: :~::: 
....... AT ..... G •••••••••• ----- ••••••••• P ••••••••••••• ••• 5 
_____ ............... YV. . . . . . . . . . .. . .....•. 
....... . T ..... G.......... ., R T I ..... D ...... E. 
G T IA NQ----- ......... F ............ . .. ............ ............. .. ...... .. 
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Majority 
NL501 
NL1200 
NL199Bl 
NLllOO 
hMPV332001 
RCGP480341 
NL900 
UK501 
hMPV741998 
hMPV731998 
hMPV771998 
hMPV781998 
NL401 
hMPV761998 
CAN9980 
hMPV751998 
CAN9875 
NL697 
NL194B2 
NL182 
TTQAADPSSQSQHTQKSTTTTYNTDTSSPSS 
iii
220 230 240 
I I 
'" .T .... PAH.A.G.AKPK 
· .R.T .... PPH.A.G.AKPK 
· .R.T .... PPH.A 
· .R.T .... PPH.A.SGAKPK 
· .R.TE.GFPPH.ARRGAGPR 
•..•• E ••...•....••...•....•. L .• 
..... E.N .................... L .. 
· .... " ................ I .. F ... . 
· ...................... I ...... . 
.............. K ..•............. 
..................... H .....•... 
•.....•..•....•..•... H .....•..• 
•..••.•.•...•....•..• H •........ 
...•.•.••..•••....••• H ........ . 
I .•... S ... PH ........ A ...... F .. . 
.......... PH .................. . 
.N.TT ..... PH.A 
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Amino acid alignment of all hMPV subtype A G protein Sequences 
Majority MEVJ<VENIR~Ir.HLKAR~KCrn,w'LILIGIT7LSIALNIYL7INYTMQENT~ESEHllTSSS~SSRET~S~0YP'l'QQS~STLY~PE'l'EPTS'f 
10 20 30 40 50 60 70 80 90 100 110 121 
JHLEIC2392 
JHLEIC210 
JHLEIC13 
JHLEIC1627 
BR201 
GBaculo 
JMLEIC1758 
CAN9702 
JHLEIC552 
JMRCGP993 
NL1001 
hMPV312001 
hMPV292001 
hMPV282001 
hMPV232001 
hMPV132 000 
JMLEIC138 
JHLEIC125 
JMLEIC492 
JMLEIC4920 
JMRCGP336 
JMLEIC2294 
JMRCGP466 
JMLEIC37 
CAN46402 
JPS03180 
JMLEIC55 
CAN 4 002 
CAN2l602 
JMRCGP2184 
FLlOOl 
JMLEIC4l7 
001726 
......... : ••• S ••••• : .................................................................. '" : ......... : •••• H .••• : ......... : 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••.••••••••••••••••••••••••••••••••••••• HS.V •••••••••••• 
............................................................................... r. ....................... H ••••••••••••••• 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••.••••••••••••••••••••••• AE •••••• S •••••••••••••• HS •••••••••••••• 
.•...•••••....•• S .......•••••.... V •.........••..••... K .. K ..• ··· ...•.........•.•.. T ....•. SSP.H •......•....••.•..••••..••. 
•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• H ••••••••••••••• 
.•••...•.....•.....••..............•.•...••..........•.............. ·••·············· .....•••••...•••. A.H •.•.•.•••..•••. 
•••••••••••••.•••••••••••••••••••••••••.••.••••..••••.•••..••••..•.•••.••.•..••. S ..••.••.••••••.••••.•••.•••••••••••.••• 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••.••••••••••••••••••••••••••••••• H ••••••••••••••• 
••••••••• A •••••••••••••••.•••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• H ••••••••••••••• 
.......................................................... ••• .... ••••• .. ••• .... • .. • ..................... H ............. .. 
...•....•...•.•.•........•••••..•.............•.............•........•••......••. 1. •...........••••••..• H ••••••••••••••• 
•••••••.....••••••••••..••..•....•••...•..••.•..•••..•..•••••....•.•••.•....•..•. 1 .•..•.••.••..•.••••••• H ••••••••••••••• 
................................................................................. I ...................... H .............. . 
..•••......•...........•.......•.•..••...........•.......•.......•.....•......... 1. .......••...•.....••• H ••••••••••••••• 
........................................................ ·········•······· .. ·····.I. ..................... H ............. .. 
:;~!;~~Ol ::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ..•..•.............••.. ~::::::::::::::::::::::::::::::::::::::: 
001718 . .. . ... .. .. .. ... .. .. .. . .. .. . .. .... . .. .... . ....... ..... ....... ................... yp 
EEm::':::::::::::::::::::::::::::::-::-::-::-::::-:::::::::::::::::YHHHH:r:::::::::::::::::::::HHj:::: 
CAN43202 .•........•........••.•....••.•.................•.... ····· .. · .. Y ................... Y ................ D .... P ............ .. 
CAN34 02 ............................................................ · .. Y ................... Y ................ D .... P ............. . 
CAN2l902 ...................••................•.•..............••..... ··Y ......•............ Y .•......•..•.... D •••• P •......•..•.•• 
CANl9402 ............................................................... Y Y ............ D .... P ............ .. 
CAN'lB802 ...... . , ......•.......................................•............................•.. L 
~~~;559 ::::::::::::::::::::::::::::: :;:::::::::::::::::::::::: :~:::::::::: :::~:::::: ::~:::: ::::: ::::::: :~: :::: ::::::::::::::::: 
001225 . .. . .... . .. ... . . .. .. .. . .. ... .. .. .. . ...... . ...... . .. ... .. . ..... . 
001634 •..•.••.....••.•..........••.•..••.••...•......•...•.•. '~::::::::::::::::::::::::::::::::::::::::::::::::::::::: ••. : ... . Q01641 ........................................................ . .......... . 
~m: :::::::::::::::::::::::::::::::::::::::::::::::::::: :~: I::::::::::: -:::: _:: ::: :;::::: :;;L:::::: _:::- :::::::: ::: ::; 
NL001A1 ....•..............•.••..•....•.• v.......... K K T .SSP.H ...........•••............. 
~~rl :::::::::::::::::::::::::::::::: :~:::::::::::::: ~ ~~ ~~;~~;~ ~~ ~ ~~ ~~ ~~ ~ ~ ~ ~~ ~ ~~ ~~ ~~ ~ ~~~~~~~ :~~~:;:::::::: :::: :::::~::::::::: 
FL801 ................................. V.............. I KT P T NK .S.I.I .. P.I. .N .. H ....... SL ... P.S.V.PS .... A .. 
JMRCGP1400 ......... A ............................................ I'KT'" .....•. p' T' :NK: .5.1.1. .P. I. .N •• H •.•.••. SL ••. P.S.V.PS .... A •• 
....•.. .......••... SL P S V PS A CAN58 02 ......... A...................................... I KT P T NK .5.1.1 .. P.I. .N .. H....... ...... .. .. .. 
CAN34702 .....•... A .......................... ···•·· .. ·•·•· .... · I' KT····· .. ··· p' T' :NK: .5.1.1. .P. I. .N •. H ....... SL ... P.S.V.PS .... A .. 
CAN34802 ......... A ....................... T .................... I' KT::::::::: :P: T: .NK .. S. I. I. .P.I. .N .. H .•....• SL ... P.S.V.PS .... AA" 
19702 A C V.................... . T I PGI N H SL P S.V .. S .... .. CAN ......... .......... ............ I KT ..... S .. P.T .. NK .. S. ... ........... .... A 
JHLEIC72 ......... A.Y············· .. • .. ··•···· .... ····•··· .... · 1 •KT .. P T .NK .. S.I.I .. PGI..N .. H ....... SL .•• P.S.V .. S .... .. A ................... ............ N H SL P S.V.PS .... A •• JHLEIC2564 ......... .......................... I KT .......... P.T .. NK .. S.I.I..P.I.. .. ....... .... S A 
JMRCGP558 ......... A ....................... ··•······ .. ······· .. · I' KT P T .. NK .. S. I. I. .P.I. .N .. H .... P .. SL ... P.S.V ..... 'A" 
JHLEIC506 ••••....• A ••...•........•.•..••..••..••..•...•...••.•. I·KT·········· p' T .. NK .. S. 1.1 •. P. I. .N .• H ..•. P •. SL .•. P.S.V .• S ••. 'A" 
.... ........... H P SL PSV S ." JHLEIC399 ......... A ......................................... I KT .P.T .. NK .. S.I.I..P.I..N ............... S .. · A 
JHLEIC1294 •.•...... A ....••.........•..••.... ·•·········•······· ·I·KT········· PT •. NK .. S.I.I. .P.I..N .. H •... P •. SL ..• P.s.v··
s
" "A" 
........... P SL PSV • JPS03240 ..••..... A ..................... ·•··•········ .... ····· 'I'KT G P T .. NK .. S. I. I. .P.I..N .. H...... .. •. ·T·P·S .... . 
........... .......... N H NP NP V ....... .. JPS03187 ......... A............ ............ .......... HI KT .P.T .. NK.AS.IST .. P.I. ............. T PS 
hMPV172000 ..•••.... A ............. C ....................... ~ .... ·I·KT .. · .. ·· .. P T .• NK.AS.IST .. P.I..N .. H ....... NP •. NP.V. ·PS .. ·s;,. .. 
hMPV162000 ........• A ...................... P .. T ................. I' KT····· .. ··· P:T .. NK.AS.IST .. P.I. .N •. H ....... NP •. NP ..... PS'" A" 
NL302 ....•..•• A ••..•.•.•..•...••••...........•........••... I' KT·········· P T .• NK.AS. 1ST •• P. I. .N •• H •.....• NP •• NP •. ·V .. PS···· A" 
.... ....... ........... PIN H NP NP ........ .. CAN16402 ......... A ..................... •• .......... • I KTS P T .. NK.AS.IST.. • .. .. ....... .. p PS A 
CAN9783 ..••....• A ...................................... ::::: :I:KT.:::::::: :P: T.PNK.AS.IST .. P.I. .S .. H ....... NP •• N .: :~:PS::: :A:: 
NL1700A2 .••••...• A ........................ ••• .... ••• .. •• I KT .PP.T •• NK.AS.ISTGS .. I. .N .. H ....... NP •• :. v PS A 
CAN22702 •..•••.•• A ....... M .................................... I' KT .. ··· .. · PP. T .. NK.AS. ISTGS .. I. .N .• H ....... NP .• NP'" v' PS .. ·· A" 
CAN20802 •...••.•• A •... , .. M •......•.•••..••.••..•.•••••......•. I·KT····· ...• PP. T •. NK.AS. ISTGS .. I. .N .• H •..•.•• NP. 'NP' "V'PS" "A" 
A ..... ·· ......... N H NP......·· .. CAN21502 ......... A ....... M .................... · ........ I KT PP.T .. NK.AS.ISTGS .. I.. .. ....... .. PT V PS A 
CAN18202 ..••....• A ..... V.M ................. ···········•·•····· I' KT··· .. ·· ... P.T .. NK .. S. ISI .... I. .N •. H ....... SLL"SNP . 'v' ps'" 'A" 
.... .. .. ......... ......... S I I PIN H ...... S.. .... • ... .. NL396 ......... A...... .. .... ...... ...... .... .. ......... I.KT .......... P. T .. NK .......... ,. ..SP .. NP ... V. PS .... A .• 
NL393 ......... A ....... M ........................ · I KT .......... P.T •. NK .. S.I.I..P.I. .N .. H ..... SP NT V.PS •••• A .. 
NL181 ......... A .................. ··•·••· .. ·· .. •···· .. · .~ ... I' KT ............ T .. NKG.S.I.T .. P.I. .N .• : ....... SL" p' s·v.PS .... A .. 
NL193 AV ...................... V .............. '''I'KT P T NK .. s.I.I.SP.I..N ............. . 
JMLEIC1011 :::::::: :A. : : .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .... .. .. .. .... . .. 
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Majority 
JMLEIC2392 
JMLEIC210 
JMLEIC13 
JMLEIC1627 
BR201 
GBacu10 
JMLEIC1758 
CAN9702 
JMLEIC552 
JMRCGP993 
NL1001 
hMPV312001 
hMPV292001 
hMPV282001 
hMPV232001 
hMPV132000 
JMLEIC138 
JMLEIC125 
JMLEIC492 
JMLEIC4920 
JMRCGP336 
JMLEIC2294 
JMRCGP466 
JMLEIC37 
CAN46402 
JPS03180 
JMLEIC55 
CAN4002 
CAN21602 
JMRCGP2184 
FL1001 
JMLEIC417 
001726 
hMPV222001 
CAN54702 
CAN3402 
PDTTSRPPFVDTHTTPPSASRTRTSPAVHTKNNPRISSRTHSPPWATTRTVRGTTTLRTSSTCVDC 
I I I I ""","STASVOPDSSATTHKHEEAsPVSPOTSAS 
130 140 150 160 1 ;0 1~0 I I I ~GHEASTSTT-NQTS-
I I I I I I 1~0 200 210 220 I 
5 •••.••.•..••••.•••.••••••••••• KQSKDKPQNTF.TMGNDKDGPWDHHSPHKQHK I I 230 
.KTVHSISPTRQQRNNPOTRRSK I I 
S ••.•.•••••••.••••••••.•••••••. KRSKDKPQNTF TMGNDKDG=.~HHSPHKQHK .SE.ANICKHSKTT E Y~~NNI~ 
• "nu .KTVHSISPTRQQRNNPQTRKS . • ........... ""' .. 
••.••••.••••••.•• • V •.•••.....•• KQSKDKLQNTF.TMGNDKDGPWNHHSPHKQHK.KTVHSISPT K.SE.ANICKHSKTT.E.YGGOHINNIQPN 
..••..•• L •..••.••••.•• K ••••.• K.TTQGQAPEHVPHHGQQQGRSTEPPLSAOAAQE 
•••• N ..•••..•.••.•..•• K .•••••...••. T •••••••• R ..... A.RNHHSPHKQHK:~~~~~TAAQQSTNTKKOVO 
CAN21902 .••..•.••.•...••.•.••••.••.•..••....• L ..•.••.••..•..•..••.•.••••.•..•.........•••••.••.•..•.••..• • .•••.••••.••• Y ••.• 
CAN19402 .....•.•.••.••...••.••..•..•....••.•. L ..•..••..•..••.•...•...•••..••..........••••••• •.•·•.··•··•·•••·•·•••••• .Y •••• 
CAN18802 ..................................... L .................................................. ·• ........ •· ........... Y .. .. 
001729 .•••..•....•..•..•.•••..• R .•.•••. L .•• L •..•.... M •••.•.••.•••..•.•..•....•........••.••.•.••.. ·· •• ••·••· 
JMRCGP559 •••••..••.•.••..•.•.••.••..•.•..•• K •. L •••.••• VM .. M ...•••.•..•..•..••...••.....•.••••.•• A •.•...•..••••.•.••••••• LOFKLS 
001225 •.••....•.••..•..•.••.•.••.••.••.• K .•....•..• VM .. M ..•..•...•.........•..•..•.•••. · •• · •• A ••.•..•.••••.• 
001634 ••.••.•.••..•••..••••..•.•..••••.• K .• L .••.••. TM •. M ..••••..•.•.....•..•....•..•..• •••• •. A •..•.•.•..•••• 
001641 .•.•••••..•..•.••.•..••••.••••••. LK .• L .••.•..• M •• M ••.•..•..•.••••..•••..........•.••••. A ••••••.•.••.•• 
001799 •..••.•..•..•••..•..•.••••.•.••.. L ..• L •.•..•.. M .. M .•••••••....•..•....•••.••..••• · •• V •. A •••..•••.••••• 
001629 •..•..••.•••..••••..•...•••.•.••. L •.. L .•••..•• M .• M ••..•.•.••...•.•...•..•..•.••...••••. A ..•.•••.•..•.• 
001419 ••.••.•.. A •..•...••.••.••.•..•.•.•.•• L ••••.•.••.. M .••••.••...•..•.••. L ..••..••...••.•.• A •..•..•.•• L ..• 
NL001A1 ..•• N ..•••••..••••.•.. K •.••••...•.• T .•....•• R ••.•. A.R •.•..•.•..•.....••••• I ..•.•• N •.•.• A .•....•. T. I .•• SV .• N •.•. Y •••• 
CAN9981 ••.. N •.•.••.• , ...••.•• K •..•.••••.•. T •.•..••. R .•..• A.R •..••••. , ....•••••.•• I. ••..• N •.. , .A .••••.•. T. I. •. SV .• N •.•• Y •••. 
FL401 .... N ................. K ........................... A.R ................. A ... I. ..... N ..... A ........ T.T ... SV .. N .... Y .. .. 
FL301 ••.. D ..•....• , .•. " .•• K •.•...••..•.• , .•......•.•.• A.R ...••...••.......•... I ...... N •.. , .A .•...•.• T.T ... SV .. N ...• Y •.•. 
FL801 •••• D .•.•.•••.....••.• K .•.•• , •.••••...• " .•••. , .•• A.R •.•.••. , .•••..•. '" .• I. •.••• N •.. , .A ••.•.•.• T.T ..• SV .• N ..•• Y •••• 
JMRCGP14 00 .GI.N. LS ••. RS •• 0 .• E ... K.NST •. K •. ISSTI. .. 0 •.• RT .AKA.PR •• AF •.• , .GE .. T. T .•. S •.. T .AON ... TGSAN .• A •.•. M 
CAN5802 .GI.N.LS ..• RS •• 0 •• E ••• K.NST •• K •• ISSTI. •. 0 ••. RT .AKA.PR .. AF .•.•. GE •• T. T ..• S. " T .AQN ... TGSAN •. A ...• M 
CAN34702 .GI.N .LS •.• RS •• 0 •• E ••• K.NST •• K .• ISSTI. •. 0 •.• RT .AKA.PR •• AF •.•.• GE .• T. T ••• S. " T .AON ... TGSAN •• A •.•. M 
CAN34802 .GI.N.LS .•• RS .• 0 •• E ••• K.NST •. K •• ISSTI. .• 0 .•. RT .AKA.PR .• AF ..... GEK. T. T ... S •.. T .AON •. , TGSAN •• A •..• M 
CAN19702 .G •• N .LS.A.RS •• 0 •. E •.• K.NST .• K •. ISSTI. .• 0 •.• RT . AKA. PR •• A •.•••• GE •. T. T ... S .• , T .AON ••. TGSAN •• A .... M 
JMLEIC72 .GI.N.LS ••. RS •• 0 .• E ••• K.NRT •• K •• ISSTV •.• 0 ••• RT .AKV.PRA.AP ••.•• GE •. T. TP ..•.•. T •• ON ... TGSAN •. A .... ~.HTNIARPN 
JMLEIC2564 .GI.N .LS ••• RS •• 0 •• E •.• K.NRT •• K •• ISSTV ••• 0 •.• RT .AKV.PRA.A ..•••. GE •• T. TP ••••.• T •. ON ••• TGSAN •• A •••. M~ .HTNIARPN 
JMRCGP558 .GI.N. LSS •• RS •• O •• G ••• KIN.T •• K •. ISSTV ••• 0 •• TRT .AKAATRA.A .• M •.• GE .• T. T .•. S ..• T •• ON ••. TGSAN •• A .... MQK 
JMLEIC506 .GI.N.LSS •• RS •• 0 •• K ••. K. T. T •• KR. I.STV •.• 0 •.• RT .AKA.PRA.AF •.•.• GE •• T .•.•. SN •. T .. ON ..• TGSAN •. A •• N.M 
JMLEIC399 .GI.N .LSS •• RS •• 0 •• K ••• K. T.T •. KR. I. STV ••• 0 ••• RT .AKA.PRA.AF •..•• GE .. T .•. " SN .. T •. ON •.• TGSAN •• A •• N.M 
JMLEIC1294 .GI.N.LSS •• RS •• 0 •. K ••• K. T.T •• KR. I.STV .•• 0 •.• RT . AKA. PRA.AF .•.•. GE •• T •••.• SN .• T •. ON •.• TGSAN .• A •• N.M 
JPS03240 .GI.N .LSS •• RS .• 0 •• K.K.N. T. T .• KR. I.STV ..• 0 ••• RT • AKA. PRA.A .•.•. , GE •. T. T ••• SN .. T •• ON .•• TGSAN •. A .• N.~ 
JPS03187 • SI.N. LSS •• RS •• 0 •• K .•. N. T.T •• KR. I.STV •• KO •.• RT .AKA.PRA •• F .•••• GE •• T. T ... SN •. T •. ON ••• TGSAN •• A •• N.M~ 
hMPVl72000 •••• N.LSS •• RS .AO •• E ••• K.KST •.• R •.• STA.S .0 ••• R ••. KAI.RA •. F .M •.• E •.• T. TL •• Y .•• T •• ON .•• TGSAN •• A •••• M 
hMPV162000 ..•• N .LSS •• RS .AQ •• E ..• K.KST .•• R •.• STA.S .0 .•. R ••• KA1 .RA .• F .M .•. E •.. T. TL •. Y. " T .• ON ••. TGSAN •• A. V •• M 
NL302 •••. N.LSS •• RS. VO •• EN •• K.KLT ••• R •• LSTA.S .0 ••• R ••• KA1 .RA •.•• M •.• GR •• T. TL .• S ••. T •. ON ... TGSAN •• A •.•. M~ .HTNNIKPN 
CAN16402 •.•• N.LSS •. RS.AO •• EN •• K.N.TA •• R ••• STA. S.O •• 0R.A.KA1 .RA •••. M .•. GR .. T. T .•• S •.• T .• ON •. , TGSAN •• A .... M~.HTNNIKPN 
CAN9783 ••.• N.LSS •• RS .AO •. E ••• K.K. T •.• R ••• STA.S .0 .•• R .•. KA1 .RA •. F .M ... G •.. T. T .•• S ... T •. ON ••• TGSAN •• A.V .• ~ 
NL1700A2 •••• N .LSS •• RS.AO •• E ••• K.K. T ••• 1. .• NTA.S .0 ..• RT •• KA1 .RA •• F .M .•. G •.• T. TL •. S ••. T .. ON ... TGSAN •• A •.•• M~ 
CAN22702 •••• N.LSS .• RS.AQ •• E ••• K.NLT ••. S •.. STA.S .O.O.R ••• KAIPRA.AF .M •.. G ••. T. TL .• S ..• T .• ON.G. TGSAN.RA .. G.VOD 
CAN20802 •••• N .LSS .• RS.AQ •• E .•. K.NLT ••• S ••• STA.S .O.O.R .•. KAIPRA.AF .M •.• G ••• T. TL •. S .•. T •• ON.G. TGSAN .RA .. G. VQD 
CAN21502 .••• N.LSS •• RS .AQ •• E ••• K.NLT ••. S ••• STA.S .O.O.R •.• KAIPRA. VF .M .•. G •.. T. TL •• S .•. T .. ON.G. TGSAN .RA •• G.VQD 
CAN18202 •••. N .LSS •• RS.AQ •• E ••• K.NLT ••• S ••• STA.S .O.O.R ••. KAIPRA. VF .M •.• G .•• T. TL •• S ••. T •. ON .G. TGSAN.RA •• G. VOD 
NL396 S ••• N.LSS •• RS •• 0 •• E .• A •. K.T •• K •• I. STV ••• 0 •• LR ••• KA.LRA.AF .M ... GEG. T. T •.• S •.. T •. ON ••• TGSAN •. A .... ~.HTNIAJ(PN 
NL393 •••• N .LSS •• RS •. 0 •• E •.• K.KLT •• K •• I.STV ••• O.SIR ••• KA.LRA.AF ••••• GE •. T. T .•• S •.• T .• ON ..• TGSAN •• A .... M~ 
NL181 .••• N.LSS •• RS •• 0 •• E ••• K.K. T ••••••• STV .•. 0 •. LR .•. KA.LRA.AF •••.••.•• T. T •.• S •.• T .• ON •. , T .SAN •• A .... MQS .HTNNII<PN 
NL193 .••• N. LSSA.RS •• 0 •• E ••. K.KLT .••••• LSTA ••• 0 ••• R ••• KA.LRD.AFH .••• G •.• T. T ••. SG .. T •. ON ••• T .SSN •. A .... MQP.O'l'NNTI<QII 
JMLEIC1011 .G •• N •• S ••• RS •• 0 •• E ••• K.NST •• K.KTSOVQFLE ••• HHGQQ. RRSPEPPPFARAAQEKDQPQHQSSLTT. POP. IMKKOV 
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